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Abstract 
 
Primary Intracerebral haemorrhage is a severe form of stroke 
with poor prognosis attributed to haematoma characteristics. 
High blood pressure is present during the acute phase of 
intracerebral haemorrhage and associated with poor outcome 
in part through expansion of haematoma.   
 
Data from the ‘Efficacy of Nitric Oxide in Stroke trial’ (ENOS) 
was used to analyse the performance characteristics of 
qualitative and quantitative descriptors of intracerebral 
haematoma. The results showed that formal measurement of 
haemorrhage characteristics and visual estimates are 
reproducible. Intracerebral haemorrhage volumes measured 
using the modified ABC/2 formula were significantly lower 
compared to standard ABC/2 and computer assisted semi-
automatic segmentation. 
 
In 629 patients with intracerebral haemorrhage presenting 
within 48 hours, the effect of blood pressure lowering with 
transdermal glyceryl trinitrate was assessed. Glyceryl trinitrate 
lowered blood pressure, was safe but did not improve 
functional outcome. In a small group of patients treated within 
6 hours, glyceryl trinitrate improved functional outcome.  
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Analysis of 246 patients with acute intracerebral haemorrhage 
from ENOS was undertaken to assess whether there were any 
differences in functional outcome among those who continued 
prior antihypertensive drugs during the immediate stroke 
period compared to those assigned to stop temporarily for 7 
days. The results were neutral indicating that there was no 
benefit in those who continued treatment. 
 
Data of 1,011 patients with intracerebral haemorrhage in 
hyperacute trials from the VISTA collaboration showed 
differences in baseline characteristics and functional outcomes 
among patients from various ethnic backgrounds.  
 
A systematic review was updated to assess the effect of 26 
randomised controlled trials that aimed to alter blood pressure 
within one week of acute stroke. The results showed that 
blood pressure reduction did not improve functional outcome 
irrespective of stroke type. When examined by time, 
treatment within 6 hours appeared to benefit but the number 
of patients were small and more studies are needed. The 
analysis also showed that continuing prestroke 
antihypertensive drugs in the immediate period after stroke 
did not benefit and might be harmful.   
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In summary, this thesis provides new information on 
parameters used to estimate intracerebral haematoma, 
relationship between management of blood pressure and 
outcomes after haemorrhagic stroke. The work supports 
testing of whether very early blood pressure lowering after 
ictus is beneficial as is being undertaken in ongoing 
randomised controlled trials. Adjusting for ethnic differences 
may further identify patients in whom treatment may confer 
measurable advantage. 
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Chapter 1 - Background 
 
 
1.1 Introduction 
 
‘Stroke’ as a condition includes a range of clinical and 
etiological syndromes. It is defined as a ‘ rapidly developed 
clinical sign of focal or global disturbance in cerebral function, 
lasting more than 24 hours or until death with no apparent 
cause other than of vascular origin’.1 This includes cerebral 
infarction, intracerebral and subarachnoid haemorrhage but 
excludes transient ischaemic attack, subdural and extradural 
haemorrhage and infarction or haemorrhage due to infection 
or malignancy. If the symptoms resolve in less than 24 hours, 
for epidemiological purposes the syndrome is defined as a 
transient ischaemic attack (TIA). Most TIA’s resolve within 60 
minutes.2 The cut-off point of 24 hours is useful and valid 
when there is no permanent damage to brain tissue or retina.3 
 
Stroke is a worldwide condition and is the third most cause of 
death after heart disease and cancer.4 In the UK, stroke 
accounts for 11% of all deaths.5 Nearly 150,000 patients are 
affected in the UK every year. Stroke costs the UK around 
£8.2 billion a year and the estimated cost for treating each 
patient is around £30,000 in the first five years.6 Survivors 
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can be severely disabled and heavily reliant for self-care. 5 In 
a population based study, two-fifth of stroke survivors after 
five years were more disabled than they were few months 
after stroke.7  
 
1.2 Incidence and prevalence 
 
Incidence is defined as the number of first strokes occurring in 
a population per unit time. The incidence of stroke and TIA 
combined exceeds incidence of acute coronary syndrome.8 
Stroke can occur at any age. In developed countries, one in 
every 20 adults (>14 years) is affected by stroke.9  
 
The risk of stroke increases with age with most patients aged 
above 65 years.  With increase in each year, the risk of fatal 
and non-fatal stroke increases by around 10% in men and 
women.10 This is due to effects of ageing on the vascular 
system. Men are at a higher risk of compared to women. One 
in every four men and one in five women aged 45 can expect 
to have a stroke if they lived upto their eighties.11  
 
The risk of dying from stroke is higher in women.12 This is due 
to the higher age of onset of stroke in women and longevity.13 
The incidence and prevalence vary according to geography 
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and ethnicity.14, 15 A higher incidence of stroke in blacks is 
probably due to poor control of hypertension and small vessel 
disease.15-17 
 
Prevalence of stroke is the number of all individuals affected 
by stroke at a particular time and can be derived from stroke 
registers.18 With developments in stroke prevention such as 
antiplatelets, antihypertensive agents and lipid lowering 
agents, the number of survivors has increased in the last few 
years. One year after a stroke, 30% of patients will have died, 
30% are independent and 40% will be dependent for self-
care.19 One in six people who survive a first-stroke will have a 
recurrent stroke over the next five years, so strategies for 
secondary prevention should be initiated soon after the index 
event.20 
 
1.3 Stroke subtypes and classification 
 
Eighty-five percent of acute stroke is ischaemic, ten-fifteen 
percent is haemorrhagic and five percent includes sub-
arachnoid haemorrhage. In blacks, the incidence of primary 
intracerebral haemorrhage (ICH) is higher.16 
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The only reliable method used to differentiate between 
ischaemic and haemorrhagic stroke is by scanning the brain 
using computerised tomography (CT) or magnetic resonance 
imaging (MRI). Further subclassification is useful and has 
implications with regards to prevent recurrent stroke. In 
addition, very early identification of different subtypes is 
useful when therapy such as thrombolysis in large vessel 
occlusion is guided by the classification.   
 
1.3.1 Oxford Community Stroke Project (OCSP) 
Classification  
 
The Oxford Community Stroke Project (OCSP) classification 
defines four subtypes according to clinical presentation.21, 22 It 
is based on characteristic pattern of symptoms attributed to a 
vascular territory and has prognostic significance. This 
approach has the advantage that it is performed by the 
bedside and classifies patients even when brain imaging is 
normal.23  
 
1.3.1.1 Total Anterior Circulation Syndrome (TACS) 
 
This is defined by a combination of higher cerebral 
dysfunction, homonymous visual field defect and ipsilateral 
motor and or sensory deficit. These are consistent with middle 
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cerebral or anterior cerebral artery (ACA) infarction or 
haematoma in the lobes. Prognosis is poor with 39% dead in a 
month and 60% at one year.21  
 
1.3.1.2 Partial Anterior Circulation Syndrome (PACS) 
 
A PACS is caused by occlusion of one of the branches of the 
middle cerebral or anterior cerebral artery or a lobar 
haemorrhage.22 
PACS consists of one of the following: 
 2 out 3 of TACS syndrome  
 Higher cerebral dysfunction 
 Monoparesis 
 
Risk of recurrence is very high but prognosis is better than 
TACS; 15% are dead and 30% independent at one year.21 
 
1.3.1.3 Lacunar stroke (LACS)  
 
LACS is usually due to an infarct in upto 90% of cases.24, 25 
 
Each of the five classical lacunar syndromes has a distinct 
sympton complex. Symptoms may be suddenly, progressively 
or in a fluctuant manner. If severe hemiplegia alternates 
repeatedly with normal function, the phenomenon is called 
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‘capsular warning syndrome’.25 Occasionally, cortical infarction 
or haemorrhage can mimic lacunar infarcts, but true cortical 
signs (dysphasia or inattention) are always absent. 
 
 Pure motor stroke or hemiparesis; most common 
lacunar syndrome; 33-50% of cases (affecting the face, 
arm or leg on one side). The lesion usually occurs in the 
posterior limb of the internal capsule, pons and corona 
radiata. 
 Ataxic hemiparesis; second most frequent lacunar 
syndrome; usually affects the leg more than arm. Hence 
it is also known as homolateral ataxia or crural paresis. 
The lesion is in one of the posterior limb of the internal 
capsule, pons, corona radiata, red nucleus and lentiform 
nucleus.25 
 Dysarthria/clumsy hand; the main symptons are 
dysarthria and weakness of the hand in particular when 
writing. The lesion may occur in the pons, anterior limb 
or genu of internal capsule, corona radiata, basal 
ganglia, thalamus or cerebral peduncle. 
 Pure sensory stroke marked by persistent or transient 
numbness, tingling, pain, burning or unpleasant 
sensation on one side of the body. The location of the 
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lesion may be in the contralateral thalamus, internal 
capsule, corona radiata or midbrain. 
 Mixed sensorimotor stroke; this syndrome involves 
hemiparesis or hemiplegia with ipsilateral sensory loss. 
The lesion occurs is the thalamus and adjacent posterior 
internal capsule or lateral pons. 
 
Thirty percent of patients affected by lacunar stroke are 
dependent at one year.21 
 
1.3.1.4 Posterior circulation stroke (POCS)  
 
This is defined by any of 
 
 Ipsilateral cranial nerve palsy with contralateral motor 
deficit  
 Bilateral sensory or motor deficit 
 Disorder of conjugate eye movement 
 Cerebellar dysfunction 
 Isolated hemianopia22 
 
The lesion may be an infarct or haemorrhage including the 
occipital lobe, brain stem or thalamus. Risk of stroke 
recurrence is high with 19% dead at one year.21 
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Following brain imaging, patients are further classified as 
infarction (TACI, PACI, LACI and POCI) or haemorrhage 
(TACH, PACH, LACH and POCH). 
 
1.3.2 Trial of Org 10172 (TOAST) classification 
 
The Trial of Org 10172 (TOAST) system is used to categorise 
ischaemic stroke based on clinical features and results of 
investigations.26 This is as follows: 
 
1.3.2.1 Large-artery atherosclerosis 
 
Large-artery atherosclerosis accounts for 50% of ischemic 
stroke. Atherosclerosis is a chronic inflammatory disease of 
large and medium size arteries.  Atherosclerotic plaques 
consist of cholesterol rich necrotic core surrounded by smooth 
muscle cells and fibrous tissue. Atherosclerosis can cause 
problems through two mechanisms. The atheromatous plaque 
may rupture, exposing its centre to platelets and the 
coagulation pathway is activated. This may cause arterial 
blockage at the site of thrombus or cause emboli to travel 
distally. Secondly, the large plaque may cause narrowing of 
the artery, which may result in ischaemia of distal tissue. This 
causes conditions such as stroke, myocardial infarction or an 
ischaemic limb. 
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Advancing age, male sex, lipid abnormalities, cigarette 
smoking, hypertension, diabetes mellitus, heavy alcohol 
consumption and obesity increase the risk of atherosclerosis. 
Other factors that are also associated include increased serum 
homocysteine levels, hormone replacement therapy, 
haemostatic factors and family history. 
 
1.3.2.2 Cardio-embolism 
 
Cardio-embolism accounts for about 30% of ischaemic stroke. 
This includes patients when arterial occlusions occur either 
due to vegetation, fibrin debris or platelet aggregates that 
originate from the heart. Cardiac arrhythmia, in particular 
atrial fibrillation (AF) is the commonest cause of cardio- 
embolism. In patients with non-valvular AF, the absolute risk 
of stroke increases is 5% per year.27, 28 Also, thrombo-
embolism can occur in the presence of damaged myocardium, 
after myocardial infarction. Less common causes of stroke in 
this category include patients with prosthetic heart valves, 
mitral regurgitation, mitral valve prolapse and tumours in the 
heart. 
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1.3.2.3 Small vessel disease 
 
Small vessel disease accounts for 20% of all stroke. The 
precise mechanism in small vessel disease that causes stroke 
is not clear.24 It is thought that stroke is due to 
microatheroma and thrombosis of a single, deep perforating 
vessel in the internal capsule, basal ganglia or thalamus.24 The 
risk factors for lacunar stroke may be different from large 
vessel stroke with diabetes and hypertension most common; 
cigarette smoking, excess alcohol consumption are less 
common.29  
 
1.3.2.4 Stroke of other determined etiology 
 
The majority of ischaemic strokes can be classified in one of 
the previous categories. Rarely, stroke can occur in patients 
who are young and have no obvious risk factors. Amongst 
these are causes including vasculopathies, inherited errors of 
metabolism and genetic disorders. 
 
1.3.2.5 Stroke of undetermined etiology 
 
In some patients, no clear cause for stroke can be determined 
despite extensive diagnostic evaluation. It is thought that 
stroke occurs from an unknown cardiac source, paradoxical 
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embolism or non-occlusive atherosclerotic plaque in the aortic 
arch, cervical or vertebral arteries.30 These strokes are 
classified as stroke of undetermined etiology or cryptogenic 
stroke. 
 
1.4 Diagnosis  
 
Stroke is a clinical diagnosis and recognition in the acute stage 
is important for the following reasons: 
 It enables to exclude ‘stroke mimics’ such as migraine, 
epilepsy, anxiety, hypoglycaemia, posterior reversible 
encephalopathy syndrome (PRES) and rare 
presentations such as cognitive behavioural disorders. 
 Next, it helps to plan acute interventions such as 
thrombolysis or surgical evacuation of haematoma. 
Some subtypes of stroke caused by proximal intracranial 
artery occlusion may be appropriate for endovascular 
intervention. 
 Localisation helps to direct further investigations and 
follow up.  If a cardioembolic cause is suspected, tests 
such as echocardiogram or 24-hour holter monitoring 
will be performed. In contrast, cardiac investigations 
may be limited if a lacunar etiology is presumed. 
 It allows the clinician to anticipate and treat 
complications related to a stroke subtype, such as brain 
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stem compression with hydrocephalus related to primary 
intracerebral haemorrhage. 
 Last, making the correct diagnosis will lead to the 
appropriate secondary intervention. 
 
All patients who have had a stroke or TIA should have full 
blood count, clotting screen, electrolytes, glucose, lipid profile 
and 12 lead electrocardiogram. Further tests depend on age, 
risk factors, and possibility of recovery. Younger patients are 
more likely to have an identifiable cause of stroke and may 
need serological, immunological, genetic and thrombophilia 
screening. 
 
1.4.1 Diagnostic Imaging 
 
Current guidelines recommend that brain imaging should be 
undertaken as soon as possible but immediately (within 1 
hour) if any of the following apply:  
 Indications for thrombolysis or early anticoagulation 
 Decreased level of consciousness 
 Unexplained progressive or fluctuant symptons 
 On anticoagulants or known bleeding disorder 
 Papilloedema, neck stiffness or fever 
 Severe headache at onset of symptons31, 32 
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Even in those patients without these indications, immediate 
scanning improves outcomes and has shown to be cost-
effective.31 
 
In patients with TIA, brain imaging should be performed if the 
vascular territory or pathology is not clear.33 Scanning, 
preferably diffusion-weighted MRI should be done urgently in 
‘high risk’ patients with an ABCD2 score of 4 or more, or with 
two or more TIA’s in a week.33  
 
Computed Tomography (CT) or Magnetic Resonance Imaging 
(MRI) is vital to differentiate between ischaemic and 
haemorrhagic stroke since treatment differs for the two 
types.31 The posterior fossa of the brain is better visualised on 
MRI scan and in such patients, the imaging of choice. 34 MRI 
identifies a broader range of acute and chronic 
cerebrovascular pathologies such as anatomy, cerebral blood 
flow, perfusion, old or new lesions and hence, may replace CT 
in the future to aid decisions about acute intervention and 
further management.35 
 
A number of infarcts may not be detected with CT in the early 
phase, and as such a normal CT does not exclude the 
diagnosis of ischaemic stroke. 36 Diffusion weighted MRI 
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imaging is more sensitive than non-contrast CT to identify 
early ischaemic changes identified as bright lesions and is 
especially useful in patients with minor stroke symptons. 
Combined multimodal parenchymal, perfusion or angiography 
with CT or MRI is useful to identify tissues at risk of infarction 
that is salvageable (an estimate of the ischaemic penumbra) 
and may respond to recanalisation therapy even beyond three 
hours after onset of stroke.34, 37  
 
Both CT and MR imaging can detect intracerebral 
haemorrhage accurately in the early stage.38 39 CT scanning is 
used as first line because it is cheap, quicker to perform and 
readily available.34 In comparison with MRI, claustrophobic 
patients or those with pacemakers in situ tolerate CT scans 
better. Upto a week, CT is reliable in detecting haemorrhage 
and after this the haemorrhage loses the white hyperdense 
appearance to a dark hypodense appearance. MRI has an 
advantage over CT scan in detecting micro bleeds, indicative 
of underlying vascular disease and a risk factor for recurrent 
lobar ICH.38 After haemorrhage, haemosiderin, which is a 
breakdown product of haemoglobin is stored indefinitely in 
macrophages and can be detected months or years after the 
initial event by gradient-recalled echo MRI.40 
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The ‘hyperdense artery’ (MCA) sign and the ‘dot’ sign 
associated with acute embolic occlusion may be identified on 
CT scan as increased attenuation of the proximal portion of 
the MCA or its distal branches in the sylvian fissure.41, 42 In 
acute intracerebral haemorrhage, the ‘swirl’ sign is sometimes 
seen on nonenhanced CT scans as a heterogenous collection 
of clotted blood (hyperattentuating) and a small ‘swirled’ 
configuration of non -clotted blood, which appears 
hypoattentuating.43 Recent studies have indicated the 
presence of ‘spot sign’ as a predictor of haematoma 
enlargement in the acute phase.44 45, 46 It is visualised as 
small enhancing foci of ‘bright spots’ depicting active 
bleeding.44, 47  
 
Both CT and MR angiography are useful in detecting arterial 
rare causes of stroke such as dissection or vasculitis. Catheter 
angiography may be considered in patients with subarachnoid 
haemorrhage, abnormal calcifications, blood in unusual 
locations such as sylvian fissure and isolated intraventricular 
haemorrhage (IVH) to investigate for underlying aneurysm or 
arteriovenous malformation.48  
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1.5 Primary and secondary stroke prevention 
 
Prevention of stroke may be primary- in individuals with no 
previous history of stroke or transient ischaemic attack (TIA), 
and secondary prevention in those who have already had such 
an event. The key to stroke prevention is identification of risk 
factors both by a patient and the clinician treating the patient. 
Non-modifiable risk factors include age, sex, ethnicity and 
family history. Modifiable risk factors include hypertension, 
diabetes, hyperlipidemia, atrial fibrillation, smoking, obesity 
and carotid disease. Each of these modifiable risk factors are 
discussed in the following sections. 
 
1.5.1 Lifestyle 
 
Considerable benefit in lowering risk is noted upon smoking 
cessation and should be recommended for all patients with 
stroke or TIA.49 As compared with nonsmokers, cigarette 
smokers have a two to three time risk of both ischaemic and 
haemorrhagic stroke after control for age, blood pressure, 
coronary artery disease and other risk factors.50 The 
proportional risk increases with the number of cigarettes 
smoked per day.51 Passive smoking also increases the risk of 
ischaemic stroke.50 Treatment options for smoking cessation 
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include counselling, nicotine replacement, antidepressants 
such as bupropion or nortriptyline and the partial nicotinic 
acetylcholine receptor agonist varenicicline.52-54  
 
Daily alcohol consumption in small or moderate amounts is 
protective against total and ischaemic stroke whereas heavy 
consumption (more than 60 gm) is associated with increased 
risk of both ischaemic stroke (OR 1.64, 95%CI 1.39-1.93) and 
intracranial haemorrhage (OR 2.18, 95% CI 1.48-3.20).55 A 
diet with increased content of fruits and vegetables, reduced 
intake of sodium, increased intake of potassium and low 
content of saturated fat lower blood pressure and therefore 
may benefit reducing risk of stroke.56 Vascular risk factors 
such as hypertension, diabetes, hypercholesterolemia are 
more in common in obese individuals effecting a three fold 
increased risk of ischaemic stroke.57 Weight reduction 
targeting a body mass index 18.5 to 24.9 kg/m2 results in 
better control of these factors and lower the risk of stroke.57 
 
1.5.2 Antihypertensive therapy 
 
Although few treatments have created ethical dilemmas as 
profound as managing blood pressure in acute stroke, 
hypertension treatment in the context of primary and 
secondary prevention is robust and has most impact amongst 
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all modifiable risk factors.51 In primary prevention, 
antihypertensive treatment lowers systolic and diastolic blood 
pressure and reduces the risk of stroke.58 In comparison to 
the older antihypertensive agents (blockers, diuretics), 
treatment initiated with newer blood pressure lowering drugs 
(CCB’s, ARB’s) lower the incidence of stroke.58  
 
In two large trials enrolling patients with a history of 
cerebrovascular disease, the use of Indapamide both alone or 
in combination with Perindopril was effective in lowering blood 
pressure and significantly reduced recurrent stroke.59, 60 The 
HOPE study showed that in patients, particularly at high risk of 
fatal or nonfatal cardiovascular events, lowering blood 
pressure with Ramipril was safe and effective in reducing the 
risk of stroke (32%), myocardial infarction (20%) and 
cardiovascular death (26%).61 A systematic review of all trials 
(excluding one study) revealed that blood pressure lowering 
reduced the odds of recurrent stroke by nearly 25%.58 Current 
guidance recommends lowering and maintaining blood 
pressure below 130/80, except in those patients with bilateral 
carotid stenosis for whom a systolic target in the range 130-
150 is appropriate.33 After a stroke or TIA, treatment should 
be initiated before hospital discharge or at 2 weeks whichever 
is earlier. The algorithm to treat is based on classifying 
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patients with essential hypertension into low and high renin 
subgroups.62 More than a single drug is usually required to 
achieve good quality control.63 
 
For patients, younger than 55 years and not of African or Afro-
Caribbean origin, the first choice initial therapy is with an ACE 
inhibitor or an ARB blocker.32 In those aged 55 years and 
over, or of Afro-Caribbean ethnicity of any age, treatment 
should begin with a long acting calcium channel blocker or 
thiazide class diuretic.63  
 
1.5.3 Antiplatelet therapy 
  
Antiplatelet therapy decreases stroke incidence in patients at 
high risk of atherosclerosis and in those with known 
symptomatic cerebrovascular disease. In primary prevention 
without previous disease, aspirin is of uncertain value whereas 
in secondary prevention, aspirin given within 48 hours of 
onset of presumed ischaemic stroke reduces the risk of 
recurrent ischaemic stroke and increases the odds of making a 
complete recovery (OR 1.06, 95% CI 1.01 to 1.11).64, 65 Two 
randomised controlled trials comparing the efficacy of 
combination therapy using aspirin and dipyridamole than 
aspirin alone showed sufficient evidence to prefer the 
combination regimen over aspirin alone for the primary 
  
37 
 
composite end point of death from all vascular causes, non-
fatal stroke, non-fatal myocardial infarction or major bleeding 
complication.66, 67  
 
In preventing stroke recurrence, combined therapy of aspirin 
and dipyridamole does not differ in effect when compared to 
another antiplatelet agent, clopidogrel (ADP receptor 
binder).68 When clopidogrel is added to aspirin, the short- 
term benefits of lower vascular events were offset by a higher 
risk of bleeding in three trials but not seen in a recent trial 
performed in China.69-72 Current guidelines in the UK 
recommend clopidogrel at a dose of 75 mg daily for patients 
with ischaemic non- cardioembolic stroke or TIA and in those 
intolerant to clopidogrel, aspirin 75 mg daily and dipyridamole 
200 mg twice a day.33  
 
If two antiplatelet agents are superior to one, then intensive 
triple antiplatelet treatment may be better still in the acute 
phase; this concept was recently tested in a large trial and the 
results showed increased risk of bleeding with triple therapy.73  
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1.5.4 Anticoagulation 
 
Atrial Fibrillation (AF) increases with age, causes ~15% of all 
strokes and is associated with strokes with higher morbidity 
and mortality when compared with non-AF related ischaemic 
stroke.51, 74 
 
Evidence shows that in patients with nonvalvular AF 
comparing adjusted-dose warfarin and no treatment, the 
absolute reduction in annual stroke decreases from 4.5% in 
control patients to 1.4% in patients randomised to warfarin.57 
Also, the efficacy of aspirin is substantially weaker than that 
for warfarin.75 Warfarin is known to be relatively safe, with an 
annual rate of major bleeding of 1.3% compared to 1% for 
patients taking aspirin or no treatment.51  
 
Experts recommend commencing anticoagulation with warfarin 
immediately following a TIA once haemorrhage is excluded 
whilst treatment should be deferred for atleast 7 days after 
minor stroke.76 Once initiated, INR should be maintained 
between 2.0-3.0 for optimal effect.77 For patients where 
treatment with warfarin is proven impractical or poorly 
controlled, or results in an allergy or intolerance, a direct 
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thrombin inhibitor (such as dabigatran) or factor Xa inhibitor 
(such as rivaroxaban or apixaban) should be used.33  
 
There is no evidence supporting stroke prevention using 
treatment with anticoagulation in those patients with 
ischaemic non-cardioembolic stroke.78 
 
1.5.5 Carotid endarterectomy 
 
Carotid endarterectomy (CEA) reduces the risk of stroke in 
patients with recent symptomatic stenosis.79 Analysis of data 
from three trials involving 6092 patients shows that CEA is 
highly beneficial in those patients with 70-99% stenosis (ARR 
16.0%) without near-occlusion and of some benefit in those 
with 50-69% symptomatic stenosis (ARR 4.6%).80 The results 
do not recommend surgery in patients with near-occlusions.  
Benefit from surgery is greatest when performed within two 
weeks after the last symptomatic event.80 By comparison, 
meta-analysis has shown that carotid stenting is no more 
effective than CEA in symptomatic patients and therefore not 
recommended.81, 82   
 
1.5.6 Lipid lowering therapy 
 
Although observational studies have not shown an association 
between cholesterol levels and stroke incidence, trials using 
  
40 
 
statins have found reduction in risk of stroke associated with 
lowered lipid levels.83-85 In one of these studies involving 
patients with a previous stroke or TIA, Atorvastatin used at a 
dose of 80 mg demonstrated an absolute risk reduction of 
2.2% and significantly lowered LDL cholesterol of 53% from 
baseline.86 There were more incidence of haemorrhagic 
strokes in those treated with Atorvastatin and suggests a 
possible association between low cholesterol levels and brain 
haemorrhage.87 Therefore, careful consideration should be 
given when administering statins to those patients who may 
have had a haemorrhagic stroke. In comparison, for patients 
with ischaemic stroke or TIA unless contraindicated, treatment 
should be initiated with Simvastatin at a dosage of 40 mg 
daily.33  
 
1.6 The role of hypertension in the pathophysiology of 
acute stroke 
 
Hypertension is the commonest risk factor in the development 
of ischaemic and haemorrhagic stroke.88 The relationship 
between BP and stroke risk is linear, continuous and 
independent, with the risk increasing continuously above a BP 
of 115/75 mm Hg.89 Patients with hypertension are 3 to 4 
times more likely to have a stroke than normotensives.90 In 
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particular, a 2 mm Hg rise in systolic BP in middle age is 
associated with a 10% increased risk of stroke.90  
 
Increase in both systolic and diastolic components of BP are 
associated with stroke and treatment reduces the risk of first 
and recurrent stroke.58 In addition, high pulse pressure, an 
indicator of arterial stiffness and defined as the difference 
between systolic and diastolic blood BP is associated with 
reduction in cerebral blood flow and a 20% increase in risk of 
stroke.90, 91 
 
Of recent, variability in blood pressure has been recognised as 
a risk factor for stroke.92 In patients with TIA, visit-to-visit 
variation in systolic BP is more predictive of stroke risk than 
mean systolic BP.92 Also, within drug- class effects on 
variation in blood pressure may account for differences in 
preventing risk of stroke;93 calcium-channel blockers, non-
loop diuretics are effective in lowering BP variability whereas, 
angiotensin-converting enzyme (ACE) inhibitors, angiotensin-
receptor blockers and beta blockers increase BP variability.93 
 
Several mechanisms have explained the contribution of 
hypertension in acute ischaemic stroke. High intraluminal 
pressures lead to extensive alteration in the endothelium and 
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smooth muscle function in the cerebral vasculature.94 As a 
result, increase in permeability of the blood brain barrier 
causes local or widespread cerebral oedema. With endothelial 
damage, blood cell- endothelial interaction is altered, 
promoting leucocyte adhesion and thrombus formation. In 
addition, longstanding hypertension accelerates 
atherosclerosis, which causes cerebral infarction related to 
stenosis and embolism from intra and extracranial blood 
vessels, the aorta and the heart. The causal mechanisms of 
hypertension in lacunar stroke are unclear because of 
methodological inconsistencies and lack of pathological 
studies.95, 96 Perivascular oedema and thickening, arteriolar 
wall inflammation and disintegration is common, whereas 
vessel occlusion is rare.96, 97  
 
1.7  Cerebral blood flow and cerebral autoregulation 
1.7.1 Cerebral blood flow 
 
The brain is vulnerable to any vascular insult, as it requires a 
constant supply of oxygen and glucose to meet its high-
energy demand.  
 
Cerebral blood flow (CBF) depends on the cerebral perfusion 
pressure (CPP)- which is the difference between the mean 
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arterial pressure (MAP) and intracranial or central venous 
pressure (CVP) whichever is the highest.  
 
The absolute level of CBF is the same in healthy normotensive 
individuals and in patients with uncomplicated essential 
hypertension i.e. around 50 ml/100 g/min. This varies from 20 
ml/100g/min in white matter to 70 ml/100g/min in grey 
matter and decreases by approximately 0.5% every year.98  
 
1.7.2 Cerebral autoregulation 
1.7.2.1 Mechanisms 
 
Cerebral Autoregulation (CA) can be defined in terms of 
arteriolar calibre changes as blood pressure or perfusion 
pressure varies.99, 100 Under normal circumstances, these 
changes regulate cerebral blood flow between mean arterial 
pressure of 60 to 150 mmHg.101 
 
CA is regulated by several mechanisms including intrinsic 
myogenic vasomotor responses, arterial oxygen and carbon 
dioxide levels, metabolites such as adenosine, nitric oxide, 
endothelin and neurogenic control, in particular the 
sympathetic system related to extrinsic innervation of 
parenchymal arteries and intrinsic innervation of intra-
parenchymal arterioles.102, 103 
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Chronic hypertension stimulates the growth of smooth muscle 
within the intracranial vessels. The altered thickness enables 
the vessels to tolerate a higher intraluminal pressure 
protecting the blood brain barrier and shifting the cerebral 
autoregulation curve to the right. The increased resistance can 
compromise collateral blood flow in the ‘border zone’ regions 
or to an area distal to an occlusion thereby increasing the risk 
of ischaemic events.104   
 
1.7.3 Cerebral blood flow and metabolism in acute 
stroke 
 
As an initial response to focal ischaemia, intracranial 
resistance vessels dilate to increase CBF. After maximum 
threshold of vasodilatation is achieved, further decrease in 
CPP results in a fall in CBF. In the initial period, oxygen 
delivery to the brain is maintained by increasing the extraction 
fraction from the blood.105 As CBF falls, oxygen extraction is 
increased and functional consequences of reduced CBF occur 
when oxygen extraction fraction (OEF) is maximal.106, 107 
When CBF falls below a critical level (approximately 10-
12ml/100 gm/min) irreversible neuronal injury occurs.108 
 
In the acute phase just after infarction, CBF is extremely low 
or even absent in the centre of the lesion.109 In the periphery, 
exists a ‘penumbra’ region, trying to maintain perfusion by 
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extracting more oxygen from the blood. It implies that if blood 
flow is restored to this region within a specific duration, tissue 
recovery is possible.105 Therefore treatment such as 
thrombolysis will be most effective when given early.110, 111 
Once the clot material is lysed, ischaemia is followed by 
hyperaemia but invariably the tissue involved is irreversibly 
lost.106 In the days following infarction, CBF again decreases, 
and adapts itself to the lower or even absent oxygen 
consumption of the lesion.106  
 
A cerebral haemorrhage forms a haematoma and in its 
surroundings, areas of ischaemia and hyperaemia similar to 
infarction.109, 112 Three phases of perihaematoma blood flow 
and metabolism are known to occur after ICH.102, 113 The acute 
hibernation phase occurs within the first two days.102 In this 
phase, there is decrease in CBF and metabolism mainly in the 
ipsilateral perihaematoma region and contralateral 
hemisphere. During the subacute reperfusion phase, areas of 
normal, low and hyper-cerebral perfusion occur in the peri-
haematoma region. The normalisation phase is observed after 
14 days when normal blood flow is restored except in necrotic 
tissue.114  
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1.8 Hypertensive response after acute stroke 
 
For the use in estimating its prevalence, the acute 
hypertensive response is defined as ‘systolic BP>=140 mm Hg 
or diastolic BP of >=90 mm Hg demonstrated on 2 recordings 
taken 5 minutes apart within 24 hours of sympton onset’.115  
It is observed in upto>80% of patients in the immediate 
period after both ischaemic and haemorrhagic stroke.115 In a 
large portion or atleast in some of these patients, the acute 
hypertensive response is a reflection of poorly controlled or 
undetected long-standing high BP; however, in most cases, BP 
falls to pre-stroke levels over the first week.116, 117 The 
prognostic effect is shown in a systematic review which 
revealed that patients with stroke and high initial BP suffered 
a 1.5 to 5 fold increased risk of death or dependency.118 
 
Although the strength of the relationship between acute stroke 
and high BP is well established, the precise mechanism that 
causes elevated BP is not known. In acute stroke, elevated 
intracranial pressure, decreased parasympathetic activity, 
direct injury to the prefrontal and insular cortices and 
pathways to the nucleus solitarius in the medulla and effects 
of neurotransmitters can cause hypertension.119-123 In 
addition, stress from hospitalisation, headache, urinary 
retention and concomitant infection may increase sympathetic 
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drive and circulating inflammatory cytokines and contribute to 
increase in BP. 123, 124 
 
1.9 Blood pressure and outcome in acute stroke 
 
Analysis of data from 10,892 patients revealed that both high 
SBP and DBP were associated with combined death or 
dependency in both ischaemic stroke and ICH.125 Among 
patients with acute stroke, a U- shaped relationship was found 
between baseline SBP and both early death, late death and 
poor outcome.126 In multivariable analysis, high systolic BP 2 
to 24 hours after thrombolysis was significantly associated 
with worse outcome and as a categorical variable showed a 
linear association with symptomatic haemorrhage and a U-
shaped association with mortality and independence with 
systolic BP 141 to 150 mm Hg associated with most 
favourable outcomes.127 It is not clear why high BP is 
associated with poor outcome in acute ischaemic stroke; 
explanations include severe cerebral oedema and early 
recurrence of stroke.128 In patients with ICH, worse outcomes 
with high BP is probably due to a single or combination effects 
of the following: excessive perfusion pressure, worsening 
cerebral oedema, haemorrhage expansion, increased ICP and 
aggravated ischaemia in the penumbra region.103, 129 
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When considering the available evidence, low blood pressure 
in the immediate stroke period is also associated with poor 
outcome. 
 
Concomitant presence of sepsis, cardiac failure or factors 
directly relating to the stroke such as low blood pressure in 
those with larger strokes causing worsening of ischaemia in 
the penumbra may explain why low BP is associated with poor 
outcome.115, 130  
1.10 Lowering blood pressure in acute stroke 
 
Hypertension is associated with poor outcome and is present 
in approximately 80% of patients with acute stroke.125  
Cerebral autoregulation is dysfunctional in acute stroke and 
therefore cerebral perfusion may be fully dependent on blood 
pressure.99 The dilemma whether to treat blood pressure in 
acute stroke is balanced between epidemiological data which 
suggests that blood pressure lowering is likely to be beneficial 
and countered by pathophysiological evidence that lowering 
BP may reduce cerebral blood flow (CBF). In addition, deciding 
which antihypertensive agent to use is not clear as different 
antihypertensive medications have been tested in acute 
stroke, with different effects on blood pressure and clinical 
outcomes.  
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A systematic review of thirteen trials (1325 participants) using 
different antihypertensive drugs was performed to assess 
whether blood pressure should be altered actively during the 
active phase in both acute ischaemic and haemorrhagic 
stroke.131 The results showed that angiotensin converting 
inhibitors, angiotensin receptor antagonists, -receptor 
antagonists, calcium channel blockers, and glyceryl trinitrate 
lowered both systolic and diastolic blood pressure while 
phenylephrine, increased it.131 Functional outcome and death 
were not significantly altered by any of the drug classes used 
to alter blood pressure. 
 
A meta-regression of 13 drug classes analysing the 
relationship between the change in BP and functional outcome 
revealed no positive association.132 No significant effects of 
any single antihypertensive class were seen in the study. 
Lowering SBP in order of 8-14 mm Hg reduced the combined 
odds of early death or dependency, although the CI’s were 
wide and compatible with an overall benefit or harm.132 The 
results support the rationale for ongoing clinical trials lowering 
BP in acute stroke133, 134 and in the meanwhile the approach is 
to treat each patient on an individual basis. Guidelines usually 
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recommend more active intervention in ICH in comparison to 
ischaemic stroke.135  
 
Lowering blood pressure in patients with acute stroke is 
recommended only if there is a hypertensive emergency with 
one or more of the following complications: 
 Hypertensive encephalopathy 
 Hypertensive nephropathy 
 Hypertensive cardiac failure or myocardial infarction 
 Aortic dissection 
 Pre-eclampsia/ eclampsia 
 Intracerebral haemorrhage with systolic blood pressure 
above 150 mm Hg within 6 hours of onset33 
 
Approximately 50% of all patients with acute stroke are taking 
blood pressure lowering medications, and it is unclear whether 
pre-existing antihypertensive therapy should be continued or 
discontinued temporarily during the acute phase, this is the 
subject of two RCT’s one stopped and the other recently 
completed.136, 137  
 
1.11 Acute treatment of stroke 
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Acute stroke care begins in the community with patient 
recognition of  ‘stroke warning signs’ of sudden weakness; 
sudden speech difficulty; sudden visual loss; sudden dizziness 
and sudden, severe headache.138 Early management 
performed by paramedics includes urgent triage, stabilisation 
and transfer to a stroke-ready hospital. A useful tool to 
enhance recognition of stroke by the paramedics is the FAST 
test (Face, arm, speech) which shows good agreement with 
physician assessment even allowing time for evolution of 
deficits.139 
 
1.11.1 Stroke Unit care 
 
All patients with stroke should be treated in a designated 
specialist stroke unit.33 Patients with acute stroke who 
received specialist inpatient stroke unit care have significant 
reduction in death after one year (OR 0.86, CI 0.76- 0.98) and 
the combined outcome of death or dependency (OR 0.82, 95% 
CI 0.73-0.92).32 Care should be provided by a coordinated 
multidisciplinary team offering rehabilitation in a discrete ward 
setting.140 
 
1.11.1.1 General Measures 
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All patients with acute stroke regardless of etiology should 
receive supportive care with maintaining oxygen saturation, 
fluids, antibiotics and ensure that temperature remains within 
normal limits. Maintaining physiological homeostasis may 
improve outcome in stroke patients, which suggests the need 
for close monitoring and treatment of any dysequilibrium.141 
Management of hyperglycemia may be important with poor 
outcome seen in those patients with high glucose levels. No 
evidence at present exists to support aggressive glucose 
lowering 142 and guidelines suggest maintaining blood glucose 
between 4 and 11 mmol/l.33  
 
Measures should be undertaken to prevent complications after 
stroke such as pneumonia, pressure sores with proper 
assessment of swallowing, positioning and continence. There 
is a high risk of venous thromboembolism following stroke and 
is a major cause or morbidity and mortality. Analysis of nine 
trials involving 3137 patients suggests that treatment with low 
molecular weight heparin or heparinoid after acute ischaemic 
stroke lowers the occurrence of deep vein thrombosis 
compared with standard unfractionated heparin; more data is 
needed on the effects on critical outcomes, including death 
and haemorrhage.143 Data from a large international trial 
(2518 patients) revealed that thigh- length graduated 
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compression stockings failed to prevent deep vein thrombosis 
and were associated with increase in skin ulcers and necrosis 
and therefore not recommended.144 
 
The Clots in Legs or Thromboembolic diseases after Stroke 3’ 
(CLOTS 3) trial tested routine care plus intermittent 
pneumatic compression with routine care versus avoidance of 
intermittent pneumatic compression in 2876 patients who 
were admitted within three days of stroke onset.145 The study 
showed a significant reduction of symptomatic deep venous 
thrombosis (DVT) or DVT detected using duplex ultrasound in 
patients allocated to IPC than those allocated to avoid their 
use (OR 0.65, 95% CI 0.51-0.84).145 The results therefore 
support the use of intermittent pneumatic compression in 
patients admitted with acute stroke and poor mobility. 
 
1.12 Treatment of acute ischaemic stroke 
1.12.1 Aspirin 
 
Two large clinical trials have assessed the role of aspirin. The 
Chinese Acute Stroke trial (CAST) used 160 mg of aspirin 
within 48 hours of the onset of suspected stroke in 21,106 
patients and the International stroke trial treated 19435 
patients with unfractionated heparin 5000 units daily, aspirin 
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300 mg, both or neither. Taken together, the results showed 
that aspirin started early in hospital within 48 hours produces 
a definite benefit, with about 9 fewer deaths or non fatal 
strokes per 1000 patients in the first few weeks and 13 fewer 
dead or dependent per 1000 after some weeks or months of 
follow up. 146, 147 Aspirin therapy was associated with a small 
but definite excess of symptomatic intracranial haemorrhages, 
but this risk was offset by the reduction of recurrent ischaemic 
stroke.65, 147 Current guidelines recommend that all acute 
ischaemic stroke patients, should as soon possible, but 
certainly within 24 hours, be given aspirin 300 mg orally if 
they are not dysphagic or aspirin 300 mg rectally or by 
nasogastric tube if not able to swallow.32 Thereafter, aspirin 
300 mg should be continued until 2 weeks, at which time 
definitive long-term antithrombotic treatment should be 
initiated.32 
 
1.12.2 Intravenous Thrombolysis 
 
Intravenous thrombolysis was the first proven effective 
medical intervention in acute ischaemic stroke.148 
Thrombolytic drugs help to re-establish blood flow to the brain 
by dissolving the clots, which block the flow. t-PA is an 
enzyme found naturally in the body that converts, 
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plasminogen into plasmin to dissolve a blood clot. 
Recombinant t-PA is licensed for treatment of acute ischaemic 
stroke in the early hours after symptom onset. Administration 
of intravenous r-tPA at 0.9 mg/kg may result in clot lysis and 
restore blood flow to the ischaemic penumbra and limit further 
neuronal death. Successful treatment could mean the patient 
is more likely to recover from their stroke. Meta-analysis of 
twelve trials involving 7012 patients (including the very 
elderly, diabetics with previous stroke) comparing r-tPA with 
no treatment revealed that r-tPA administered within 6 hours 
found significant increased odds of being alive and 
independent at six months (OR 1·17, 95% CI 1·06-1·29) and 
the benefit greatest in patients treated within 3 hours (OR 
1·53, 95% CI 1·26-1·86).111 This was in spite of significant 
increase in death within 7 days (OR 1.44, 95% CI 1.18-1.76) 
the main cause of which was symptomatic intracranial 
haemorrhage (OR 3.72, 95% CI 2.98-4.64).111 The results 
strengthen the evidence to treat with r-tPA as early as 
possible after acute ischaemic stroke and patients older than 
80 years achieve similar benefit to those aged 80 years or 
younger.105, 149 Current guidelines recommend intravenous r-
tPA in patients presenting within 4.5 hours of symptons.33  
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Treatment with ‘standard dose’ 0.9 mg/kg r-tPA is associated 
with risk of intracerebral haemorrhage particularly higher 
among Asians150 and a lower dose of 0.6 mg/kg in a recent 
trial did not show non-inferiority in reducing death or 
dependency after acute ischaemic stroke.151 The primary 
outcome defined by the modified Rankin scale of 2 (mild 
disability) to 6 (death), occurred in 53.2% of patients who 
received the low dose and 51.1% in those who received the 
standard dose (OR 1.09, 95% CI 0.95-1.25).151 Although 
significantly few rates of intracerebral haemorrhage were 
observed in those treated with low-dose alteplase compared to 
those in the standard-dose group,151 the study did not report 
on vessel occlusion or rates of recanalisation. 
 
1.12.3 Endovascular therapy  
 
Of recent, studies have been performed testing alternative 
methods of restoring blood flow with intra-arterial 
thrombolysis with r-tPA, mechanical clot disruption or retrieval 
in acute ischaemic stroke.152-155 The concepts were driven by 
the need to find treatment options in patients who present 
beyond 4.5 hours or with contraindications to intravenous t-PA 
(e.g. recent major surgery or active bleeding). Moreover, 
evidence suggests that the rates of recanalisation can be 
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incomplete in proximal anterior circulation artery occlusions 
after treatment with r-tPA alone allowing the risk of 
permanent infarction and significant neurological deficit.156-158 
As a result, multiple randomised trials were launched to 
identify patients based on CTA confirmed proximal occlusions, 
presence of collateral circulation and salvageable penumbra 
based on imaging criteria.153-155, 159-163 Whether one approach 
is superior to another is unclear, but five recent trials (MR 
CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, REVASCAT)159-163 
demonstrated efficacy of intra-arterial therapy in patients with 
persistent ICA or M1 occlusions treated within 6 hours (except 
REVASCAT <8 hours). In all studies, there were no significant 
differences in 90-day mortality or symptomatic intracranial 
haemorrhage. Although the odds ratio (favouring good 
outcome range from 1.8 to 3.8) may be exaggerated given 
the total number of patients included in the trials, the results 
along with recent meta-analysis164, 165 demonstrate that 
endovascular therapy is beneficial in patients with large vessel 
ischaemic stroke. 
 
1.12.4 Decompressive surgery in ischaemic stroke 
 
Malignant MCA infarctions constitute between 1% and 10% of 
all supratentorial ischaemic strokes and those patients show a 
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progressive deterioration of consciousness due to severe brain 
swelling over the first 24-48 after stroke onset, reduced 
ventilatory drive and may require intubation.166  
 
The aetiology is mostly caused by thrombosis or embolic 
occlusion of the internal carotid artery or proximal middle 
cerebral artery.167 Anatomical variances that predispose an 
individual to a malignant MCA infarction include an atresia or 
hypoplasia of parts of the ipsilateral circle of Willis and 
insufficient number of vessels available to maintain collateral 
circulation.168 
 
In selected group of patients aged<60 years with space-
occupying unilateral malignant middle cerebral artery 
infarctions, trials have shown that decompressive surgery by 
hemicraniectomy (DHC) can improve outcome and survival.166, 
169 Clinical tools that may be useful to identify such patients 
include those with severe neurological deficit National 
Institutes of Health Stroke Scale (NIHSS) score>20 if 
dominant hemisphere is involved and between 15-18 in 
infarction of the non-dominant hemisphere, thrombus at 
terminal internal carotid artery, symptoms of nausea and 
vomiting, elevation of white blood cell count, early 
involvement of >50% of the MCA territory on CT, infarct 
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volume of greater than 145 ml on diffusion weighted MR 
scanning and concomitant involvement of both anterior and 
posterior cerebral artery territories.170-172  
 
It is recommended that surgery should be undertaken early 
within 48 hours; the procedure involves opening of the skull 
and removal of a bone flap (of atleast 12 cm) to allow the 
oedematous brain to swell outward, thereby preventing 
midline shift and herniation.169, 173 
 
A systematic review of 16 trials (382 patients) in quality of life 
in survivors after hemicraniectomy revealed that most 
patients and caregivers (77%) were satisfied and would again 
consent again for the procedure.173 This was in spite of 
moderately severe disability (47% had mRS Score 4) and 
moderate to severe depression in patients at one year follow 
up.173  
 
1.13 Neuroprotection 
 
The theory of neuroprotection supports benefit using 
pharmacological intervention in the pathophysiological cascade 
between the occlusion or bleeding of a cerebral artery and 
irreversible neuronal death.174  
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Neuroprotective drugs appear to be effective in animals, at 
present not successful in humans. This may have occurred for 
a number of reasons: inadequate studies, benefits were 
smaller than predicted from the animal studies and 
unexpected toxicity.175 Some agents are relatively simple to 
administer, whereas others may require infusions to be 
maintained over several days.110 
 
Preliminary evidence suggests that treatment with cooling 
therapy, ancrod, pro-urokinase, thiazolidinediones, edaravone 
(free radical scavenger) and citicoline may be effective in 
patients with acute ischaemic stroke. 110, 176-179 Other agents 
e.g. aptiganel, nimodipine, tirilazad, lubeluzole, 
corticosteroids, ifenprodil, magnesium, piracetam, 
pentoxifylline, vinpocetine, selfotel have shown to be toxic or 
ineffective.180 Although considerable research has been 
undertaken in this area, 110, 181-184 no neuroprotective drug as 
yet been found to have sufficient favourable benefit to be 
licensed for clinical use.110  
 
1.14 Primary Intracerebral Haemorrhage 
 
  
61 
 
Intracerebral Haemorrhage (ICH) occurs when a blood vessel 
within the brain parenchyma ruptures and causes 
accumulation of blood in the brain tissue. ICH causes 10-15% 
of all strokes in Caucasians with incidence rising sharply with 
age.185 A higher risk of ICH is observed in Blacks and tends to 
affect younger men compared to women.16  
 
ICH may be due to two main arteriopathies: hypertension and 
cerebral amyloid angiopathy.186, 187 Other causes include the 
use of antiplatelet agents, thrombolytics, anticoagulants 
particularly when the levels are above therapeutic levels, 
excess alcohol consumption, tumours, vascular malformation, 
drugs abuse (cocaine, heroin, amphetamines and cannabis)188 
and inherited bleeding disorders. In addition, cerebral 
reperfusion syndrome is a rare cause of ICH and can occur 
upto several weeks after revascularisation procedures 
including carotid endartrectomy and angioplasty or stenting.189  
 
Hypertensive bleeds tend to occur in the deeper areas of the 
brain including the basal ganglia, pons, thalamus and 
cerebellum whereas cerebral amyloidosis tends to occur in the 
lobar regions.186 
 
In chronic hypertension, degenerative changes from 
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hypertrophy to hyalinisation occur in the vascular wall. Excess 
or lack of collagen leads to arteriolar occlusion, dilatation or 
both.187 Eventually breakdown of the vascular wall occurs with 
bleeding as collagen has no contractile capability and unable 
to withstanding stress from high blood pressure.  
 
Pathophysiologically, cerebral amyloid results from impaired 
removal of beta-amyloid protein from the brain interstitial fluid 
and Virchow-Robin spaces resulting in its accumulation 
between the media and adventitial layers. As a result, the 
walls of blood vessels become weaker, form microaneurysms 
and in combination with chronic perivascular inflammation 
leads to vessel breakdown and haemorrhage.190  
ICH is a devastating stroke, with a fatality of approximately 
40% in the first month.191 Significant determinants of 
mortality at 30 days include age>80 years, ICH volume, 
infratentorial location of haematoma, hydrocephalus, Glasgow 
coma scale, and intraventricular haemorrhage (IVH).192  
 
A simple ICH score derived using clinical and radiological 
parameters may be used and relates to poor outcome.193 The 
ICH score calculates the sum of individual points assigned as 
follows: GCS score 3 to 4 (=2 points), 5 to 12 (=1), 13 to 15 
(=0); age ≥80 years yes (=1), no (=0); infratentorial origin 
  
63 
 
yes (=1), no (=0); ICH volume ≥30 cm3 (=1), <30 cm3 (=0); 
and intraventricular hemorrhage yes (=1), no (=0).193 Higher 
scores suggest worse prognosis. 
 
1.15 Antithrombotic and anticoagulant-related 
intracerebral haemorrhage 
 
The evidence that ICH expansion and poor outcome relate to 
antiplatelets is countered by no increase in haematoma 
volume or worsening outcome in human and animal studies.194 
The reasons for these differences may be attributed to the 
following: inclusion or exclusion of posterior fossa bleeds 
which may undergo limited expansion from anatomical 
restrictions, choosing different haematoma measurement 
techniques, defining haematoma expansion, the variety of 
antiplatelet agents used at different doses, reliability of 
antiplatelet use and differences in anti-aggregant activity and 
resistance.195 Although tested in small studies, platelet 
dysfunction related to aspirin may be associated with 
haematoma expansion, intraventricular haemorrhage and poor 
outcome.196-198 
 
Anticoagulant use has been mostly studied in relation to 
warfarin use and studies are awaited with the newer 
anticoagulants. The risk factors associated with warfarin-
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related ICH include the following: age, hypertension, 
concomitant use of antiplatelets, intensity of anticoagulation, 
leukoaraiosis and amyloid angiopathy.199-201 Most warfarin 
related ICH occurs with INR in the therapeutic range 202 with a  
2-fold increased risk of ICH observed in each 0.5 increase in 
INR above 4.5.192 In addition, elevated INR caused by warfarin 
increases haematoma growth (OR 6.2), with enlargement 
continuing longer than in patients not taking warfarin.203 When 
compared to spontaneous ICH, haematomas related to 
warfarin tend to have larger initial volumes, less oedema, 
impair thrombus formation and associated with greater 
mortality.204, 205  
 
1.16 Haematoma expansion in acute intracerebral 
haemorrhage 
 
Haematoma expansion or growth is thought to occur from a 
single vessel that ruptures and continues to bleed.102, 189 This 
is easy to conceptualise when explaining haemorrhage 
expansion from a single vessel in the first few hours after 
rupture. However, it is difficult to relate to this model in cases 
where haematoma expansion occurs several hours 
afterwards.190 
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Based on a neuropathological study, it is postulated that 
haematoma expansion may occur several hours later 
facilitated by secondary mechanical shearing of neighbouring 
blood vessels caused by the spreading initial haemorrhage.206 
Three findings add support to this theory. First, haemorrhage 
volumes tend to occur in a bimodal distribution either as 
‘micro bleeds’ or large ‘macro bleeds’ which may represent 
two separate haemorrhagic events.207 Second, genetic data 
has shown that possession of the apolipoprotein E allele 
predisposes to increased break down of capillary walls and 
haematoma expansion in lobar ICH.208 Therefore, it may be 
derived that this allele increases the tendency of the vessel to 
rupture and cause bleeding. Finally, multiple ‘spot signs’ have 
been observed within a single haematoma209 suggesting 
simultaneous bleeding from shearing of the surrounding 
vasculature rather than a persistently bleeding vessel.190 
  
ICH haematoma can enlarge up to 24 hours, with maximal 
expansion occurring within the first 6 hours.210, 211 
Determinants of haematoma expansion include anticoagulant 
use, larger size, irregular shape, heterogeneous density, 
reduced platelet activity, vascular injury with systemic 
inflammation (increase in serum interleukin 6, tumour 
necrosis factor-alpha, matrix metalloproteinase-9 and cellular 
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fibronectin levels), possession of apolipoprotein E 2 (APOE 2) 
allele and extravasation of contrast into the haematoma.212-214  
 
Elevated SBP is associated with haematoma expansion and 
poor outcomes; however the cause -and -effect relationship is 
not known.215 Lowering blood pressure may not be harmful 
with studies showing reduced metabolism (‘tissue 
hibernation’) and preserved autoregulation in the 
perihaematoma region during the acute phase.216-218  
 
Only ICH size and IVH are potential targets to intervention as 
intracerebral expansion of the haematoma and intraventricular 
extension may occur as a result of the dynamic properties of 
the haematoma.195 However, based on a study that showed 
that IVH is a consequence of haemorrhage enlargement and 
size,219 it may be derived that the single most modifiable 
target becomes limitation of haematoma expansion. Several 
large trials testing therapies aimed at preventing haematoma 
expansion are in progress, including blood pressure reduction, 
haemostatic agents and surgical intervention.133, 220, 221 The 
search for factors that attenuate haematoma expansion 
continue as it is identified as the principal cause of 
neurological deterioration during the acute phase and 
associated with poor outcome.211 
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1.17 Defining Haematoma Expansion (HE) 
 
At present, there is no clear consensus defining haematoma 
growth.214 
The majority of studies assessing haematoma expansion have 
used CT as imaging modality, mainly because of its 
widespread use and easy availability.31, 222 Varied definitions 
used for expansion are based on thresholds when expansion is 
visible on CT scans including 40% relative volume increase or 
an absolute volume increase of 12.6 ml, 33% relative 
increase, combination of 50% relative increase and 2 ml 
absolute increase, 20 ml absolute increase and a combined cut 
off 33% relative and 12.5 ml absolute increase.212, 223 An 
absolute increase of 6 ml was used in CT angiography studies 
examining haematoma enlargement.194, 224 
 
A cohort study of 531 patients with ICH was performed to test 
how different definitions of HE compare in their ability to 
predict poor outcome and assess if relationships between HE 
and poor outcome were dependent on the definition of poor 
outcome used.223 The results revealed that all definitions 
independently predicted outcome; positive predictive values 
(ranged from 68 to 78%) increased with higher growth cut-off 
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but were offset by lower sensitivity (<50%). Absolute growth 
cutoff of 12 mls or more were more predictive than relative 
when mRS 5-6 or 6 was defined as poor outcome.223 The 
results suggest the following: absolute growth may be more 
clinically relevant than relative growth; HE appears more 
predictive of severe than moderate outcomes and therefore an 
outcome based on death or severe disability may be more 
sensitive to detect intervention in trials involving haemostatic 
treatment.211, 222, 225  
 
1.18 Perihaematoma oedema and metabolism 
 
As the haematoma spreads, brain oedema occurs in the 
immediate vicinity of the clot with maximal expansion within 
the first day as a result of both blood brain barrier disruption 
and the local generation of osmotically active substances.226, 
227 The exact nature of oedema is not clear -serum from 
haematoma contraction, vasogenic substances from disruption 
of capillary membranes or cytotoxic components resulting 
from compromised microvascular perfusion or structural 
damage. It is suggested that brain damage is from the 
enlarging haematoma compressing and causing ischaemia of 
the perihaematoma regions.228 On the other hand, studies 
have disputed this. A positron emission tomography (PET) 
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study analysing perihaematoma ischaemia in 19 patients 
within 22 hours after haemorrhage onset, revealed that 
cerebral metabolic rate of oxygenation (CMR02) and oxygen 
extraction fraction (OEF) was reduced to a greater degree 
than cerebral blood flow (CBF).229 Similar results were 
confirmed with diffusion-weighted (DWI) and proton magnetic 
resonance spectroscopic imaging.230 A histological study 
evaluating brain metabolism in patients with ICH and control 
patients, revealed that mitochondrial dysfunction suggesting 
tissue hibernation and not ischaemia was the cause for 
reduced oxygen utilisation.231  
 
The prognostic value of relative perihaematoma oedema 
volume which is the ratio of absolute oedema volume and 
haematoma volume is unclear with studies reporting 
contrasting results in relation to outcomes.232, 233 
 
1.19 Intraventricular haemorrhage 
 
Intraventricular haemorrhage (IVH) can be primary arising 
from within the ventricle or a lesion close to the ventricles. 
Such causes include trauma, aneurysm, arteriovenous 
malformation and tumours involving the choroid plexus.234 
Factors promoting IVH growth include older age, location of 
lesion, larger baseline ICH volume, mean arterial pressure 
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greater than 120 mm Hg and presence of IVH at baseline.234, 
235 Bleeding sites in the deeper areas of the brain near the 
ventricles including the putamen, thalamus, caudate and 
cerebellum extend early into the ventricles, whilst bleeding 
sites further from the ventricles cumulate blood before 
mechanical pressure and size of the haemorrhage forces 
extension of blood into the ventricles.236  
 
The rupture into the ventricles causes damage to the reticular 
activating system resulting in decreased level of consciousness 
that is prolonged by a larger volume of blood and longer 
duration of exposure.237 Ventricular blood causes blockage in 
flow of cerebrospinal fluid causing life threatening acute 
obstructive hydrocephalus which in turn contributes to mass 
effect and further reduces cerebral perfusion.238  
 
Determinants of poor outcome in patients with IVH include 
increasing age, baseline lower level of consciousness, initial 
larger baseline ICH volume, IVH volume more than 20 ml, IVH 
growth and presence of IVH at baseline or 24 hours.235-237, 239 
 
1.19.1 Scoring systems of Intraventricular 
Haemorrhage 
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Three scoring systems have been developed to estimate 
severity of IVH on CT scans.240-242 The Graeb score adds a 
maximum score of 4 for each lateral ventricle and a score of 2 
for the third and fourth ventricle when filled with blood and 
fully expanded to produce a total score of 12.240 By 
comparison, the modified Graeb score allocates scores for 
separate ventricular compartments to reflect selective regional 
accumulation of blood and extra points for expansion of each 
ventricle.241 The maximum score is 32. The IVH score 
assumes that in comparison to the lateral ventricles, the third 
and fourth ventricles contribute less to the ventricular volume 
and in the presence of hydrocephalus, the ventricular volume 
increases through expansion.243 The score ranges from 0 to 23 
and grades each lateral ventricle with a maximum score of 3 
when mostly or completely filled with blood and the third and 
fourth ventricles receive a score of 1 each when partially or 
wholly filled with blood.243 Hydrocephalus is coded 1 when 
present. IVH volume in ml is calculated from the IVH score 
using logarithmic transformation [IVH volume = eIVHS/5].195, 
243 Amongst these scales, the Graeb score is the only system 
which has been validated in relation to clinical outcome.244 
 
1.20 Methods for estimating haematoma volume 
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Whilst there is no standard method for measuring all ICH 
volumes, literature considers computer-assisted volumetry to 
be reliable for parenchymal haemorrhages.245, 246 Although 
observers can be trained to use software, accuracy in 
measurement depends on software type and slice 
thickness.247-249 Moreover, studies have shown that volume 
calculation using computer-assisted methods are also time-
consuming and reliant on radiological expertise.249, 250  
 
The ABC/2 formula is the most widely used bedside method 
for estimating ICH volume and values can be obtained in less 
than a minute.251 However researchers have questioned the 
reliability as it was shown in small studies to underestimate or 
overestimate volumes in regular and irregular shaped 
haemorrhages.250, 252-254 In a small study involving 
haemorrhages related to anticoagulation, haemorrhage 
volume using ABC/2 overestimated volumes by nearly 15% in 
irregular and >32% in separated haemorrhages.250 However, 
in this study CT images obtained were of large slice thickness 
and this is likely to have introduced measurement errors.250 In 
the same study, increasing the denominator to 3 (i.e. ABC/3) 
revealed better correlation with computer assisted 
volumetry.250 These findings are important as haematoma 
volume has been identified as a predictor of haematoma 
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growth, which in turn is an indicator of acute neurological 
deterioration. Although the formula ABC/3 has not been 
validated since,253 the impact of error using the ABC/2 formula 
needs further investigation as every millilitre of haematoma 
volume counts in relation to clinical outcome.255  
 
1.21 Management of intracerebral haemorrhage 
 
ICH is a medical emergency and delays in treatment can 
result in worse outcome. Rapid diagnosis and intensive 
monitoring is important, as early deterioration is common in 
the first few hours.256 More than 20% of patients suffer a 
decrease in GCS of more than >=2 points between paramedic 
evaluation and assessment in the emergency department.256 
Within the first hour of presentation to a hospital, 15% of 
patients have a further decrease in GCS of >=2 points.256  
 
To-date, definite treatment for ICH is lacking.135 Potential 
treatment options include stopping or slowing the initial 
bleeding, removing haematoma from the parenchyma or 
ventricles and managing complications such as raised 
intracranial pressure and lowered cerebral perfusion. 
Endotracheal intubation and mechanical ventilation may be 
indicated in the unconscious patient or in those with 
deterioration of consciousness.257, 258 Further brain supportive 
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therapy may involve intra-arterial lines to monitor 
administration of vasoactive drugs, assessing intracranial 
pressure with catheters inserted into the brain parenchyma, 
treating acute hydrocephalus with drains and managing 
seizures with antiepileptics.135, 257  
 
1.21.1 Medical management  
 
It is recommended that patients with any of the following are 
unlikely to require surgical intervention and be treated 
medically initially:  
 
 Small deep haemorrhages 
 Lobar haemorrhage with no evidence of hydrocephalus 
or rapid deterioration in neurological state 
 Large haemorrhages in those with significant co-
morbidity before stroke onset 
 Supratentorial haemorrhage with Glasgow coma scale 
less than 8 unless this is attributed to hydrocephalus32 
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1.21.1.1 Blood pressure management in intracerebral 
haemorrhage 
 
Two theories have caused uncertainty in managing BP in acute 
ICH; first, the perihaematoma region might suffer ischaemia if 
the blood pressure is lowered precipitously and on the other 
hand, acute elevation in blood pressure may promote 
haematoma growth.124 A complicating factor when deciding if 
and when to treat is that evidence that is available does not 
show definite benefit to lowering BP and the risks and benefits 
may vary with the type of agent used. This is reflected in the 
number of drugs that have been assessed including labetalol, 
nicardipine, candesartan, esmolol, enalapril, hydralazine, 
nitroprusside and nitroglycerin.   
 
Based on epidemiological data suggesting poor outcome with 
high BP in ICH118 and the results of experimental studies that 
failed to demonstrate the presence of ischaemic penumbra,216, 
259 two trials tested the feasibility in lowering BP in acute ICH. 
 
INTERACT (Intensive blood pressure reduction in acute 
cerebral haemorrhage trial), was an open labelled trial in 404 
patients, with no definite indication or contraindication to 
treatment randomised to early intensive lowering of BP (target 
systolic BP 140 mm Hg; n=203) or standard guideline-based 
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management of BP (target systolic BP 180 mm Hg; n=201).260 
Participants with lower levels of consciousness (GCS 3-5) were 
excluded and enrolled patients had mean volumes of 12 ml 
(guideline) and 14 ml (intensive). The primary efficacy 
endpoint was proportional change in haematoma volume at 24 
h; secondary efficacy outcomes included other measurements 
of haematoma volume.260 From randomisation to 1 h, mean 
systolic BP was 153 mm Hg in the intensive group and 167 
mm Hg in the guideline group (difference 13.3 mm Hg, 95% 
CI 8.9-17.6 mm Hg; p<0.0001); from 1 h to 24 h, BP was 146 
mm Hg in the intensive group and 157 mm Hg in the guideline 
group (10.8 mm Hg, 95% CI 7.7-13.9 mm Hg; p<0.0001).260 
A significant reduction was observed in the proportional 
haematoma growth between the intensive group (13.7%) and 
the guideline group (36.3%) at 24 h.260  
 
The Antihypertensive Treatment of Acute Cerebral 
Haemorrhage trial (ATACH) tested the feasibility of three 
levels of systolic blood pressure reduction with intravenous 
nicardipine-170 to 200 mm Hg (n=18), 140 to 170 mm Hg 
(n=20) and 110 to 140 mm Hg (n=22) in patients with 
supratentorial intracerebral hemorrhage treated within 6 hours 
after symptom onset.215 Other important outcomes included 
neurologic deterioration within 24 hours and serious adverse 
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events within 72 hours. The results demonstrated that it was 
feasible to intensively lower blood pressure and importantly no 
significant adverse events were observed.215  
 
INTERACT-2 was a natural follow on and tested intensive with 
guideline lowering of blood pressure in 2839 patients 
predominantly from China with various antihypertensive 
agents (such as diuretic, calcium channel blocker, ACE 
inhibitor, Beta-blocker, Angiotensin II receptor antagonist) 
admitted within 6 hours of stroke onset.261 The mean 
difference in systolic blood pressure at 1 hour after treatment 
initiation was 14 mm Hg (150 mm Hg vs 164 mm Hg). At 90 
days, the trial was neutral in its primary outcome of modified 
Rankin scale (mRS)>2; however key secondary outcomes 
were positive including shift analysis of mRS and quality of life 
after stroke.261  
 
Although INTERACT 2 provided optimism for lowering blood 
pressure in treatment of intracerebral haemorrhage, it equally 
generated more questions: What next? Are the results 
applicable to a population non-Chinese? Do single agents 
work? Will earlier treatment targeting haematoma expansion 
further improve outcomes? Although no clear answers can be 
given to these questions yet, four recent studies 
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heterogeneous in their design, patient population, time of 
treatment initiation and testing various agents provide 
important information.137, 262-264  
 
In the Controlling hypertension and hypotension post-stroke 
trial (CHHIPS), hypertensive patients with ICH were 
randomised to lisinopril, the mixed alpha/beta-receptor 
antagonist labetalol or placebo within 36 hours. The results 
showed that neither the primary outcome (death or 
dependency at 2 weeks) nor early neurological deterioration 
was significantly altered using either agent or route of 
administration.262 SCAST (Scandinavian Candesartan Acute 
Stroke trial) tested a specific question whether oral 
candesartan given within 36 hours for 7 days was beneficial in 
acute stroke.263 In 274 patients with ICH, blood pressure was 
lowered to a modest level at 5 mm Hg but associated with a 
non-significant higher risk of vascular events (hazard ratio 
1.36, 95% CI 0.65-2.83, p=0.41) and significantly worsening 
in functional outcome at 6 months (common odds ratio 1.61, 
95%CI 1.03-2.50, p=0.04).265 ENOS was larger than SCAST 
and in a partial-factorial design tested BP lowering in 4,011 
patients with glyceryl trinitrate (GTN) within 48 hours of 
symptom onset with SBP thresholds at 140 mm Hg and 220 
mm Hg.137   
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Two trials tested the agents GTN and lisinopril in earlier time-
windows (pre-hospital/ultra-acute setting).264, 266 In both 
studies, paramedics were able to identify suspected stroke 
patients, obtain consent and administer BP lowering 
treatment. It is difficult to draw any definite conclusions as the 
trials were performed in a small number of patients. 264, 266  
 
1.21.1.2 Haemostasis 
 
The concepts of haemostatic intervention were based on 
observations that substantial ongoing bleeding occurred in 
patients with ICH in particular during the first few hours after 
onset and directly linked to poor outcome.211, 267  
 
For patients with ICH related to anticoagulants, the 
recommendation is to reverse the INR as rapidly as 
possible.268 A single agent, protamine sulphate reverses 
heparin anticoagulation.268 Conversely, several alternative 
measures are available to counteract the effect of warfarin 
including vitamin K, fresh frozen plasma (FFP), prothrombin 
cell complex (PCC) and recombinant factor V11a (r-FVIIa).  
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Vitamin K is usually administered in combination with FFP or 
PCC as it takes several hours as a single agent to correct 
INR.269 FFP acts quicker than Vitamin K. Nevertheless, its use 
is limited by the risk of allergy, transfusion reactions, long 
duration to administer (with the potential for continuing 
haematoma enlargement), incomplete haemostasis (factor 1X 
level may remain low) and risk of cardiac failure (large volume 
in constitution).195, 270 In comparison, PCC’s contain high 
concentration of coagulation factors II, VII, IX and X and can 
be rapidly administered in small volumes. The lower risk of 
thromboembolism with PCC’s is offset by rapid correction of 
INR.271  
 
A retrospective study of anticoagulant related ICH comparing 
PCC alone or in combination with FFP or Vitamin K showed 
those who received PCC had rapid correction in INR and 
reduced haematoma growth.168 Despite lack of evidence on 
clinical outcomes in a recent trial comparing PCC versus 
FFP,272 neurovascular society experts recommend PCC in rapid 
correction of INR in anticoagulation related ICH.268  
 
r-FVIIa contains a single coagulation protein and therefore not 
effective in reversal of warfarin anticoagulation. r-FVIIa fails to 
reverse bleeding even if the INR is normal273 and not able to 
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restore thrombin generation.274 With the additional risk of 
systemic thrombosis and possible need for repeated dosage 
the use of this drug becomes limited. Hence, neurovascular 
society guidelines do not recommend use of r-FVIIa.268 
 
In patients with ICH not taking anticoagulants, early therapy 
with r-FVIIa (40, 80 and 160 gm) as a haemostatic agent 
was tested in the proof-of-concept dose escalation FAST 
trial.275 r-FVIIa has been shown to induce haemostasis in 
patients with haemophilia, and profuse bleeding caused by 
surgery or trauma.276 It acts by generating a tight 
haemostatic plug through increased thrombin generation. For 
the nearly 400 patients in FAST, mean treatment time was 
167 minutes after symptom onset.275 Proof -of -concept was 
achieved with a reduction in ICH haematoma volume by half 
in the r-FVIIa group whereas a 29% increase was seen in the 
placebo group.275 In addition, secondary outcome of mortality 
was significantly lower at 18% in the pooled treated group.277 
The larger FAST III trial randomly assigned 841 patients with 
spontaneous intracerebral haemorrhage to r-FVIIa (20 and 80 
gm) or placebo.278 In spite of reduction in ICH volume for the 
80 gm group (11% versus 26%), no significant differences in 
outcome were observed among the three groups those 
randomised to treatment and placebo (24% in the placebo 
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group, 26% in the group receiving 20 gm of r-FVIIa and 29% 
in the group receiving 80 gm).278 In addition, there was a 5% 
increased in number of arterial occlusive events in those 
treated with r-FVIIa.278 Possible explanations for the observed 
results include low mortality (19%) in the placebo group, 
increase in IVH in patients receiving r-FVIIa (38% versus 
29%) and increased frequency of thrombotic complications in 
those receiving r-FVIIa (8% in comparison to 4%). A post hoc 
analysis identified a subgroup of patients who may benefit 
from r-FVIIa: patients aged <=70 years with baseline ICH 
volume <60 ml, IVH volume <5 ml and those treated within 
2.5 hours after ictus.279 Incorporating markers of ongoing 
bleeding might delineate further those who may benefit from 
r-FVIIa; this aspect is currently being assessed in two ongoing 
RCT’s- STOP-IT and SPOTLIGHT.280, 281 
 
The newer anticoagulants which act by direct inhibition of 
thrombin or factor Xa are likely to be seen more in the setting 
of ICH because of increasing use, greater efficacy over aspirin 
and safety profile than warfarin, advantage of not requiring 
regular monitoring and higher incidence of atrial fibrillation in 
the elderly.282, 283 With the exception of dabigatran,284 no 
antidote is available to completely neutralise the anticoagulant 
activity of other agents, 285 suggesting patients taking these 
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might be at greater risk of ongoing bleeding, haematoma 
expansion and mortality. However, partial control of 
haemorrhage may be achieved using greater concentration of 
factor X and thrombin in PCC’s than FFP or r-FVIIa.195 
 
The decision of reintroducing anticoagulation after warfarin 
related ICH in those taking warfarin for prevention of 
cardioembolic stroke associated with chronic AF or prosthetic 
heart valves is complex with the balance between the risk of 
ischaemic stroke and recurrence of ICH. At present, limited 
data is available assessing the recurrence rate of ICH in those 
patients taking warfarin. In such situations, the newer oral 
anticoagulants with lower risk for ICH than warfarin (0.2% 
compared to 1% per year) may be preferred, but the rate of 
recurrent ICH with these agents are yet to be determined.199  
 
The risk of recurrence of either lobar and deep cerebral 
haemorrhage does not appear to increase with Aspirin and 
reinstitution following ICH may be considered based on the 
risk of ischaemia, underlying cause of ICH and on the added 
risk of haemorrhage from antithrombosis.286, 287 In the 
absence of randomised evidence,286 current management of 
antithrombotic and anticoagulant introduction is largely 
derived from expert opinion and suggest reintroduction of 
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antiplatelets after 2 weeks and approximately 4 weeks for 
anticoagulants.288, 289 
 
Epsilon-aminocaproic acid (EACA) was tested in a small proof-
of concept trial in patients recruited within 12 hours of ICH 
onset.290 A total of 5 gm EACA was administered in 1 hour and 
then 1 gm/hour over 24 hours. EACA failed to prevent 
expansion as growth occurred in three patients of the five 
patients treated with EACA.290 
 
The concept of administering Tranexamic acid (fibrinolytic 
agent) in spontaneous ICH gained optimism from a large 
landmark trial in more than 20,000 trauma patients that 
showed that a significant lowered risk of bleeding (OR 0.85 
95%CI 0.76-0.96) and all cause death (OR 0.91 95%CI 0.85-
0.97) in those patients randomised to receive the drug.291  
A subgroup with traumatic intracranial bleeding allocated to 
Tranexamic acid 1 gm infused over 10 minutes followed by an 
infusion over 8 hours showed non-significant trend to lower 
haematoma growth and improved outcome.292 Following this, 
a small phase study tested the safety and efficacy of 
Tranexamic acid in 24 patients diagnosed with ICH.293 Median 
time from stroke onset to randomisation was 14 hours and 
time from randomisation to treatment was less than half 
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hour.294 Although no significant differences were observed in 
relation to safety and functional outcome, the study showed 
that it is feasible to administer tranexamic acid in the setting 
of acute ICH.294 In another small study involving 156 patients, 
rapid administration of a bolus of tranexamic acid within 24 
hours of stroke was shown to reduce haematoma expansion 
(17.5% versus 4.3%).295 At present, two large trials are 
assessing the efficacy and safety of this drug as potential 
treatment, one in all cases of spontaneous ICH and the other 
only in ‘spot sign positive’ patients.220 296 
 
Other tested approaches include the use of platelet 
transfusions and whether desmopressin improves platelet 
activity in intracerebral haemorrhage patients who take aspirin 
or any other antiplatelet agent.297, 298 Unlike measures of 
anticoagulant activity for example INR for warfarin, or partial 
thromboplastin time for heparin, there are no standardised 
methods for quantifying platelet activity.299 In one recent trial, 
platelet transfusion was associated with harm.300  
 
To-date, there have been five phase II RCTs and one phase III 
trial of any haemostatic drug therapy versus placebo or 
control with outcomes. Meta-analysis show that haemostatic 
therapy and rFVIIa do not lower death or disability in 
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spontaneous ICH but tend to increase the risk of 
thromboembolic events (RR 1.37, 95%CI 0.74 to 2.55).301  
 
In summary, while off-license use of haemostatic agents such 
as PCC’s in ICH is very tempting, more studies are necessary 
to confirm the safety and efficacy. In particular, it will be 
useful to assess treatment effects in patients with longer time 
windows.  
 
1.21.2 Surgical management 
 
Intracranial surgery may involve craniotomy, which involves 
opening the skull or less invasive methods such as endoscopy 
or stereotactic surgery using catheters to evacuate 
haematoma. The opinion that mechanical decompression of a 
growing haematoma and its toxic effects is countered by the 
surgical risks in a patient with ongoing bleeding and 
navigating through pivotal motor and sensory regions. 
Another problem exists in that is unclear when to surgically 
remove intracerebral haematoma clot with clinical studies 
reporting from within 4 hours to 96 hours from the onset of 
symptoms and this limits direct comparison and analysis of 
the impact of timing of surgery.302, 303 To complicating 
matters, when deciding if and when to intervene the opinion 
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varies between neurosurgeons when considering haematoma 
size, location and premorbid dependency.304 
 
1.21.2.1 Craniotomy 
 
Current management of cerebellar ICH is largely derived from 
expert opinion and recommends surgery in those patients with 
>3 cm haematomas or cerebellar haemorrhages with brain 
stem compression or obstruction of the fourth ventricle 
causing hydrocephalus.268, 305, 306  
 
Craniotomy is associated with poor outcome for thalamic and 
pontine haemorrhages and therefore not recommended.307, 308  
 
The STICH  trial (1033 patients) compared the role of 
supratentorial haematoma evacuation within 72 hours and 
initial medical management, although later evacuation was 
allowed because of neurological deterioration.303 The type of 
surgical procedure was left to the discretion of the 
neurosurgeon. The results revealed that patients who 
underwent early surgery did not benefit when compared to 
those who received conservative treatment. Early surgery in 
patients with a GCS score<=8 was associated with poor 
outcome and probable harm.303 The concept of a second 
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randomised trial by the same investigators was derived from a 
subgroup analysis of STICH, which indicated a possible 
advantage with early surgery <8 hours in patients not in a 
coma with lobar haemorrhage and those with haematomas 
extending to within 1 cm of the cortical surface.303, 309 In 
STICH international trial undertaken in 78 centres in 27 
countries, early surgical evacuation of haematoma within 12 
hours of randomisation and initial medical treatment was 
compared with regular medical treatment alone.310 Of 601 
patients recruited, 307 were assigned to early surgery and 
294 participants to conservative treatment. Nearly all patients 
taken to surgery were treated with craniotomy.310 The primary 
outcome was computed from a postal questionnaire based on 
the Extended Glasgow Outcome Scale.303 311 The intention-to-
treat analysis showed a small but non-significant increase in 
favourable outcome in patients treated with early surgery.311 
Additionally, the investigators found trends to benefit from 
early surgery in a subgroup of patients with poorer prognosis 
(GCS between 9-12) and those who suffered rapid decline in 
neurological state.303, 311, 312 Limitations to interpreting the 
results of the two trials are the lack of true randomisation with 
inclusion determined by clinical uncertainty (those with 
haematomas for whom it was uncertain whether surgery 
would be beneficial), variation between institutions in clinical 
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equipoise and the option for cross over between the 
treatments based on clinical condition.195 Equally important, 
intracranial pressure was not measured in both trials and 
therefore its impact on surgical decision-making and outcome 
is unclear. In STICH II, mean time to surgery in those 
allocated to conservative treatment was 64.2 hours, raising a 
debate if these patients should have been taken to surgery 
earlier thereby preventing further neurological injury. Taking 
the two results together along with previous studies, an 
individual patient data meta-analysis indicated that surgery 
may have still have a role in patients with intracerebral 
haemorrhage but uncertainty remains about which patients 
benefits most.311 Inspite of the current evidence, experts still 
favour craniotomy and clot removal in younger patients with 
neurological decline from an initially conscious state with a 
superficial lobar haematoma.309, 313 
 
1.21.2.2 Minimally invasive surgery  
 
The refinement of minimally invasive surgery (MIS) for clot 
evacuation is driven by the lack of effective outcomes by 
craniotomy. Of relevance, both Factor V11a and STITCH trials 
focussed only on a single prognostic factor, ICH size and no 
standard plan was made in the trial protocols to stabilise and 
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remove intraventricular clot that occurred in nearly half of all 
recruited patients. This is important when considering the 
modest treatment effect observed in these trials despite 
consistent evidence that all three factors- ICH size, IVH and 
early clinical deterioration independently affect outcome.303, 314 
In addition, evacuation of haematoma can be compromised by 
clot retraction, advocating the need for clot liquefaction prior 
to complete evacuation.315 MIS offers potential advantages 
over conventional surgery with the possibility of local 
anaesthesia, minimal brain injury, reduced operating time, 
maintain intracranial pressure monitoring during procedure, 
deliver thrombolysis with or without clot aspiration or 
evacuate haematoma under direct vision with an endoscope.  
Using this background, small studies assessed administration 
of recombinant tissue plasminogen activator (r-tPA) as a 
treatment option in ICH.316, 317 The encouraging results led to 
the MISTIE II trial designed to test image-guided removal of 
blood in patients with ICH and performed in two stages: dose 
finding and safety phase.318 In this multicentre trial, eighty-
one patients were allocated to MIS and forty- two participants 
to medical care in accordance with guidelines from the 
American Heart Association. Most patients in the surgical arm 
received surgical aspiration and r-tPA whereas 10 patients had 
  
91 
 
surgical aspiration only. Following surgical aspiration, those 
patients allocated to r-tPA received doses of 0.3 ml or 1.0 ml 
administered through the catheter and the drainage system 
closed for an hour to allow drug -clot interaction. The dosage 
was repeated every 8 hours upto 9 doses until a reduction in 
clot to 20% of the original size or 10 cc was achieved.318 
Follow up CT scans were undertaken to assess drainage. 
Baseline ICH volumes were similar in both treatment arms 
(surgical-43.817.2 cc, medical-42.214.8 cc).318, 319 The 
results revealed a mean reduction in clot size by nearly 50% 
in those treated with surgery and r-tPA whereas those treated 
as per guidelines had a 4% clot size reduction.318 Significant 
adverse events and 30-day mortality were below prespecified 
limits.  
Similar protocols were used when testing the role of r-tPA in 
IVH. With safety aspects of intraventricular r-tPA already 
addressed in a pilot study by Naff and colleagues, results from 
The Clot Lysis Evaluating Accelerated Resolution on 
Intraventricular Haemorrhage (CLEAR-IVH) provided more 
insight into the effectiveness of r-tPA.320-322 In this trial, r-tPA 
in higher doses from 0.3 mg upto 3 mg twice a day increased 
resolution of IVH in all ventricles and quicker in the midline 
than in the posterolateral ventricles.321 Furthermore, IVH 
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reduced faster with increasing r-tPA dose.321 The investigators 
concluded that the differential treatment effect was probably 
due to the midline ventricles closer to the drug delivery 
system promoting greater drug-clot interaction and clot lysis 
and once the ventricular system was opened, r-tPA diverted 
away from regions further from the extraventricular drain.  
A subgroup analysis of a systematic review assessing the 
effectiveness of effectiveness of MIS as compared to 
conservative medical treatment and conventional craniotomy 
in patients with supratentorial intracerebral hemorrhage 
revealed that likely candidates to benefit from MIS are 
conscious patients between 30 to 80 years of age with 
superficial haematoma, those with haematoma volume 
between 25 and 40 ml and treated within 72 hours after the 
onset of symptoms.323 Although the methodological quality of 
included studies were not high, a review involving 1717 
patients concluded that MIS was associated with a significant 
reduction in relative risk of death when compared to both 
craniotomy and medical management.324 Examining the 
current data, no definite conclusions can be made about the 
role of MIS in spontaneous ICH but certainly provides impetus 
to further research in this subject.  
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1.21.2.3 Decompressive surgery 
 
 
The recommendation of decompressive hemicraniectomy 
(DHC) to treat patients with hemispheric ICH is not robust as 
those with traumatic brain injury, high grade subarachnoid 
haemorrhage and malignant middle cerebral artery 
infarction.325 Although mortality has been shown to be 
reduced, survivors are severely disabled.313 DHC is attempted 
in patients with acute elevation in ICP, which can occur within 
few hours after haematoma evacuation.325 In addition, the 
procedure might contribute to improvement in cerebral 
perfusion, oxygen supply and brain compliance.326 In the 
absence of randomised evidence, experts suggest DHC with 
haematoma evacuation in patients with disturbed 
consciousness (GCS<8) and large haematomas volumes 
greater than 60 ml.327 The application of DHC without 
haematoma evacuation is even more unclear.328 For now, DHC 
remains a question of interest and does not form part of 
routine clinical care in ICH.313, 326 
The various therapeutic approaches discussed in the above 
sections are aimed to lessen morbidity and mortality after 
primary brain injury.  The following is a brief outline of work in 
limiting secondary brain injury after ICH, not used in this 
thesis, but included for the purposes of information as well as 
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to inform future work.  The underlying mechanisms underlying 
secondary brain injury are unclear and compared with primary 
brain injury, fewer trials have been undertaken in this area.  
 
1.21.3 Anti-inflammatory therapy 
 
Because many patients continue to deteriorate clinically 
despite no signs of haematoma expansion or rebleeding, there 
is an increased interest in limiting secondary brain injury 
elicited by the physiological response to the haematoma 
(inflammation) in the perihaematoma tissues initiated by 
products of coagulation (thrombin) and clot breakdown 
(haemoglobin and iron).329 Blood brain barrier breakdown in 
ICH as such could be linked to this inflammatory process 
through leucocyte infiltration,330 but also could be a result 
caused by upregulation of leucocyte-derived reactive oxygen 
substances and pro-inflammatory cytokines such as TNF-, 
interleukin -1, chemokines and matrix metalloproteinases- 
MMP9 and MMP 3.331, 332 The inflammatory process has been 
shown to start very soon after ictus, peaks in about a week 
and can persist for a month.333 Activation of the resident 
microglia and astrocytes results in release of chemotactic 
factors and recruitment of haematogenous neutrophils, 
monocytes, macrophages and T cells which then engulf the 
deposited blood and repair damaged and dead tissue. 
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In a small study, the cyclo-oxygenase inhibitor celecoxib given 
for 14 days reduced peri-ICH oedema volume and lowered the 
expansion rate by half of that in the control group.334 Another 
agent with anti-inflammatory properties, pioglitazone has 
been studied in a phase 11 study to determine the rate of 
haematoma resolution and the results are awaited.335 A pilot 
trial of rosuvastatin also testing this hypothesis showed a 
positive effect,336 but another involving simvastatin was 
stopped because of poor enrolment.337  
 
Data from preclinical studies show that the thrombin inhibitor, 
argatroban reduces secondary brain injury after ICH.338, 339 
Antithrombin treatment seems paradoxical given its key role 
in haemostasis after ICH and neuroprotection in small 
concentrations. However, in large doses thrombin has been 
also shown to cause proliferation of mesenchymal cells, 
formation of scar tissue and brain oedema.340 Although the 
majority of haematoma expansion occurs in the first few hours 
after ictus, thrombin release continues for upto 2 weeks.341 
Therefore, there may be a time window after the haematoma 
has stopped expanding when thrombin inhibitors could be 
administered and further research in this area is warranted. 
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1.21.4 Deferoxamine 
 
The chelator, deferoxamine has been tested for its effects 
following growing evidence that excessive iron levels from 
haematoma breakdown mediate neuronal damage.342, 343 In 
preclinical rodent studies, deferoxamine lowered brain 
oedema, neuronal death, cerebral atrophy and improved 
behavioural recovery.342, 344 Based on safety data provided by 
a small study in patients with ICH,345 a larger trial assessing 
the therapeutic efficacy of deferoxamine administration is 
ongoing.346 Other approaches that are being investigated are 
whether inhibiting the enzyme haem oxygenase that releases 
iron from erythrocytes and removing free radicals generated 
by iron can reduce brain injury after ICH.347 
 
1.21.5 Hypothermia 
 
Hypothermia as a treatment approach in ICH is emerging, 
with preclinical studies suggesting the effects are mediated by 
preventing growth of peri-ICH oedema, reducing oxidative 
damage and blood-brain barrier disruption.348, 349 However, 
the benefits depend on the type of cooling system, depth of 
cooling and duration of hypothermia.350 A small study on 12 
patients with large ICH treated with mild endovascular 
hypothermia (35 degrees) for 10 days, reported that 
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treatment was well tolerated and all patients survived upto 
final follow-up at 90 days.351 Furthermore, there was no 
increase in peri-ICH oedema after rewarming. Although, no 
firm conclusion can be made, the results suggest further work 
in this area might be useful.347 
 
Summary 
 
Stroke, is a syndrome of vascular origin with diagnosis made 
at the bedside and confirmed on brain imaging. Management 
in a dedicated stroke unit with specialist staff is important and 
attention should be paid to avoid complications. Intracerebral 
haemorrhage is the most devastating stroke subtype and in 
comparison with ischaemic stroke in which acute treatments 
are proven to be beneficial, is more difficult to treat and 
associated with higher mortality in the acute phase. A 
substantial number of patients decline early from multiple 
factors including haemorrhage size, brain location, early 
haematoma expansion, raised intracranial pressure, 
intraventricular extension and hydrocephalus. The 
pathophysiological mechanisms are now being understood and 
provide a starting point for identification of treatment targets. 
In addition to primary brain injury, secondary brain damage 
occurs from blood and its toxic products released within hours 
and lasts upto several days. Haematoma expansion is 
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maximum in the first few hours and brain scan repetition 
showing surrogate markers of ongoing bleeding appear to be 
useful.  
 
Medical management of intracerebral haemorrhage has shifted 
from one of passive care to specific measures aimed at 
stopping or reducing haematoma expansion, prevention of 
intraventricular extension, treating cerebral oedema and mass 
effect. Accurate, reproducible and validated measurement of 
haemorrhage size (also allowing measurement in change) is 
therefore critical to identify thresholds where treatment may 
benefit or modest at best. Cerebral autoregulation is disrupted 
in the acute phase and accumulating evidence suggests 
lowering elevated blood pressure may not cause ischaemia in 
the penumbra region surrounding the haematoma. A 
complicating factor when deciding if and when to treat post-
stroke hypertension is that the potential risks and benefits 
vary with the type of agent, formulation and route of 
administration. To complicate matters, upto one-half of 
patients admitted with acute stroke are on blood pressure 
lowering medications and it is unclear whether they should be 
continued or stopped. Preclinical studies targeting secondary 
brain injury are promising, but limited clinical data is available 
and many questions remain unanswered. 
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1.22 Aims : The Current Investigation 
 
The work to-date examining intracerebral haemorrhage is 
wide-ranging in its scope, from preclinical models, through 
observational data of clinical studies to clinical trials of 
intervention resulting in consistent and inconsistent evidence 
on several parameters. There appear to be gaps in current 
knowledge on clinical characteristics, radiological parameters 
(haematoma characteristics, markers of haematoma 
expansion) and treatment options (such as non-invasive blood 
pressure treatment, haemostasis and surgery). There is 
variation in both magnitude and rate of recovery with a large 
proportion of patients failing to survive in the first weeks.  
 
The challenges and questions listed above are wide-ranging 
and too complex to be answered by a single study. However, 
if we are to make some progress in this field of acute stroke, 
each or some of these questions must be examined in turn.  
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This thesis will concentrate on few aspects outlined below: 
 
1. To evaluate the methods for quantifying volume of 
intracerebral haemorrhage and to determine sources of 
error that effect variation using data from a large 
multinational trial, The Efficacy of Nitric Oxide in Stroke 
Trial (ENOS) 
2. To assess the effects of blood pressure lowering with 
transdermal glyceryl trinitrate (GTN) in acute 
intracerebral haemorrhage and effects on functional 
outcome 
3. To evaluate the effects of continuing versus stopping 
prior antihypertensive drugs in the hyperacute stages of 
intracerebral haemorrhage using data from ENOS 
4. To compare the baseline characteristics and outcomes of 
patients with spontaneous intracerebral haemorrhage 
from different ethnic backgrounds 
5. To update a systematic review assessing the effects of 
deliberately altering blood pressure in stroke. 
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Chapter 2 - Materials and Methods 
 
Publications contributing to this chapter: 
Bath PM, Woodhouse L, Scutt P, Krishnan K, Wardlaw JM, 
Bereczki D, Sprigg N, Berge E, Beridze M, Caso C, Chen C, 
Christensen H, Collins R, El Etribi A, Laska A, Lees KR, Ozturk 
S, Phillips S, Pocock S, Asita de Silva HA, Szatmari S, Utton S. 
 
Efficacy of nitric oxide, with or without continuing 
antihypertensive treatment, for management of high blood 
pressure in acute stroke (ENOS): a partial-factorial 
randomised controlled trial 
 
Lancet 2015; 385 (9968): 617-28 
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This chapter outlines the background and the methods applied 
to chapter 3,4,5 where the performance characteristics of the 
various methods used to measure ICH parameters (including 
volume, shape, density, bleeding into the ventricles) and the 
relationship between clinical characteristics and functional 
outcomes were assessed. 
 
2.1 Background and purpose 
 
The combination of ICH volume, an early increase in amount 
and initial level of consciousness relate to poor outcome225 and 
therefore the ability to rapidly perform accurate 
measurements can be considered an important component in 
early clinical management. The first study to describe 
calculation of ICH volume was in the 1980’s by Kwak et al and 
involved patients with thalamic haemorrhages.352 Here, the 
maximum width (X), length (Y) and height (Z) of 
haemorrhage on a CT scan was estimated visually and the 
volume derived from multiplying X, Y and Z divided by 2.352 
With advances in scanning techniques, each parameter can be 
measured thereby allowing more accurate value incorporation 
into a formula adjusting for the slice thickness. It was debated 
whether approximating a haemorrhage as a sphere, ellipsoid 
or rectangulopiped figure produced accurate volume 
  
103 
 
measurements, but incorporating shape as an ellipsoid 
correlated well with volume values obtained from software 
aided measurements.251, 353, 354   
 
2.1.1 Intracerebral haemorrhage volume measurement 
 
Three methods are commonly used to measure haematoma 
volume- ABC/2, semi-automatic segmentation (SAS) and fully 
automatic 3-D volume rendering. The ABC/2 method can be 
performed by the bedside whilst SAS and 3-D volume 
rendering need the help of a computer and use of advanced 
software.246, 251, 252, 353-355 
Calculating haematoma volume as an ‘ideal’ ellipsoid equates 
to 4/3 *A/2*B/2*C/2 where ‘A’ constitutes the greatest 
measured length of the haemorrhage, ‘B’ is the largest 
diameter perpendicular to the greatest length and ‘C’ 
corresponds to the number of slices with haemorrhage 
visualised multiplied with the slice thickness.251, 353 
Approximating  3 simplifies the formula to ABC/2. This 
formula was modified in 1993, by Kothari and colleagues.251 
Here, the authors attempted to adjust for the height 
dimension (which assigned a value of 1 for each slice the 
haemorrhage was viewed) by introducing the modified ‘C’ 
rule.251 If the scan slice showing haemorrhage was estimated 
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to be less than 25% of the slice with the largest surface area, 
then that slice was excluded. For a given slice area, a score of 
0.5 was allocated if the measured area was between 25% of 
the largest haemorrhage area and a score of 1 was recorded if 
the measured area was greater than 75% of the largest 
area.251 Next, the sum of each haemorrhage area slice was 
calculated to obtain C. Finally, A, B and C were multiplied 
together and the product divided by 2 to obtain the calculated 
haemorrhage volume in cubic centrimetres (cm3). One 
variation, 2/3 SH where (S) is the largest surface area and the 
height (H) of the haematoma denoted by the scan slice 
thickness multiplied by the number of slices356 has been 
proposed but the methodological reasons are not understood. 
 
SAS method is based on an interactive region growing process 
using computer software to isolate haemorrhage from 
surrounding tissue via the intensity of different tissue types on 
a CT scan.357-359 The user draws a curve through the region of 
interest (ROI) considered to be haemorrhage and the 
algorithm calculates the image features along the user-defined 
path and the computed features are used in the region-
growing process.245 On CT scans, blood appears ‘whitish’ 
(hyperintense between 40-80 Hounsfield units) compared to 
brain tissue and relevant parameters can be set to exclude 
  
105 
 
normal brain tissue and bone. The process can be repeated 
until the user is satisfied with the included segmented region. 
The area of each slice measured within these parameters is 
added together and multiplied with the slice thickness to 
obtain the haemorrhage volume.  
 
3-D volume rendering utilises complex software algorithms 
and provides effective visualisation including rotated views of 
the haemorrhage.359, 360 The user is required to specify the 
position of the ICH on the image and the program extracts the 
surrounding volume and performs the analysis. First, the ICH 
region is highlighted by a light source and the shading 
information is calculated by multiplying the 3-D gradient 
vector of the ICH region with the vector of the light source.245 
Further, distance shading is performed to obtain a realistic 
view of the image and then the scan slices are merged into 
lines.359 Finally, the procedure is repeated for several rotated 
versions of the haematoma region to provide a set of rotated 
3-D views.245 
 
2.1.2 Assessment of Intracerebral haematoma shape 
and density 
 
Variation in visual assessment of intracerebral haematoma 
shape and density attenuation as predictors of haemorrhage 
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growth was first suggested by Fujii et al361 and further 
developed by Barras and colleagues.212, 362 The theory 
underpinning this was a haemorrhage seen on a CT scan 
arising from a ruptured single blood vessel appears 
homogeneous whereas bleeding from multiple foci and 
ongoing bleeding presents with an irregular edge and 
heterogeneous attenuation.212 In a small trial population of 
ICH patients scanned very early, a novel visual and density 
scale was introduced in an ascending order from 1 to 5 and 
each progressive category added an extra lesion edge 
irregularity suggestive of active bleeding on either scale.212 
For example, Category 1 was assigned to a regular shape and 
homogeneous haematoma whilst Category 5 was given to the 
most irregular shape and heterogeneous density.212 Those 
patients with haemorrhages extending into the ventricles were 
excluded. The results revealed a strong relationship between 
shape irregularity and density heterogeneity.212 On a 
continuous scale, the study also revealed that larger 
haematomas were irregular in shape, more heterogeneous at 
baseline and significantly more likely to expand.212  
 
To quantitatively describe haemorrhage shape, it can be 
expressed as a variation from ‘roundness’ or deviation from 
isometry.363 When considering the physical properties, the 
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assessment of a ‘round’ shape may not imply isometry as 
blood leakage and extension occur in any direction when a 
vessel wall ruptures and blood components such as platelets 
and smooth vessel fibres travel at various speeds.363 
Therefore, a concept combining circularity and isometry is 
suggested to describe haemorrhage shape: the formula P2/4A 
where ‘A’ is the surface area of the largest haemorrhage slice 
and ‘P’ is the perimeter.363 The value obtained is a number 
and < 1 implies that the shape is circular and >1 as non-
circular. 
 
Quantitative assessment of haemorrhage density was 
performed in a pilot study of 90 patients with ICH and the 
measured parameters included mean attenuation of 
haemorrhage, standard deviation, coefficient of variation, 
skewness and kurtosis.362 Of these, the coefficient of variation 
was the most significant individual predictor of haematoma 
growth.362 However, patients were from a placebo arm of a 
trial362 and scanned very early.  
 
To conclude, haemorrhage parameters assessed using 
quantitative and qualitative approaches seem to be useful and 
each studied in part. The techniques are reliant on computer 
software, radiological interpretation and so far the information 
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is confined to small datasets. Hence, the objective was set to 
examine the accuracy and reliability of ICH volume calculation 
-formula ABC/2, its modified version, automated 3-D 
rendering in conjunction with estimating haematoma shape 
and density (both qualitative and quantitative) in a large 
population of ICH patients and those receiving treatment. 
Furthermore, examining their association with key clinical 
variables (such as baseline blood pressure, level of 
consciousness and time to scanning) and prognosis might aid 
rapid decision-making in acute clinical situations and selection 
of patients to future clinical trials. The hypothesis was tested 
in the setting of a large, randomised controlled trial, Efficacy 
of Nitric Oxide in Stroke (ENOS)364 involving patients with ICH, 
presenting within 48 hours and treated in various health-care 
systems.  
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2.2 Materials and methods  
 
2.2.1 The Efficacy of Nitric Oxide in Stroke (ENOS) trial 
 
2.2.1.1 Methods 
 
ENOS was an international, multicentre, single-blind, 
prospective randomised controlled trial investigating the 
management of blood pressure in acute stroke.364 The trial ran 
for 13 years and was conducted in accordance with the 
Declaration of Helsinki and ‘International Conference on 
Harmonisation of Good Clinical Practice’. Patient data 
management was according to the UK Data Protection Act 
1998.  
 
2.2.1.2 Subjects 
 
Previously independent patients aged 18 years or older having 
motor weakness in arm/and or leg and systolic blood pressure 
of 140-220 mm Hg presenting within 48 hours of symptom 
onset were assigned to 7 days of transdermal GTN 5 mg patch 
or no GTN. Patients were blinded with placement of a gauze 
dressing over an area of skin out of view with or without the 
patch underneath. A subset of patients who were taking 
antihypertensive drugs prior to their stroke were allocated to 
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continue or stop medications in a partial-factorial design. 
Assent from a proxy carer or relative was allowed if the 
participant was confused, dysphasic or semi-conscious. 
Randomisation was performed centrally over a password 
protected, data encrypted website, with stratification by prior 
antihypertensive treatment and country; minimisation on key 
prognostic variables: sex, age, stroke severity, time to 
treatment and total anterior circulation syndrome. Patients 
were excluded if they had one or more of the following: 
Glasgow coma scale <8; definite need or contraindication to 
nitrates; clinical indication to continue or stop blood pressure 
lowering drugs; confounding neurological disorder or 
psychiatric disease; liver or renal dysfunction.  
 
2.2.1.3 Haemodynamic measures 
 
SBP, DBP and HR were recorded at baseline and daily 1-2 
hours after administration or change in patch with the patient 
lying or sitting in bed.  Day 1 measurement of BP was taken 
1-2 hours after the patch was applied. Both BP and HR values 
were measured using validated automatic digital monitors 
(Omron HEM-705CP or HEM, 757, Illinois, USA).365 
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2.2.1.4 Clinical outcomes 
 
The primary outcome was assessed using the mRS determined 
by a trained assessor masked to treatment allocation in each 
country at day 90 (+10 days). For participants not contacted 
through telephone, information was obtained using a follow up 
questionnaire sent through the post. Key outcomes assessed 
at the end of treatment included blood pressure and heart 
rate, proportion of patients with neurological deterioration 
(defined as reduction in SSS of >5 points or decrease in the 
consciousness domain of SSS of >2 points or both), recurrent 
stroke at day 7, episodes of hypo or hypertension requiring 
medical intervention and death. Other key outcomes included 
disability (Barthel Index), duration of hospital stay, discharge 
destination (patient’s own home or other such as institution) 
and mood (short Zung depression score); these were 
determined centrally at day 90. An independent data 
monitoring committee assessed unblinded safety data in 
respect of safety and efficacy and in the context of other 
ongoing blood pressure trials in stroke. 
 
2.2.1.5 Neuroimaging measures 
 
The diagnosis of ischaemic or haemorrhagic stroke was 
confirmed using CT or MRI scans before or by 7 days after 
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enrolment according to standard imaging protocols in the local 
investigating centre. If possible, a repeat scan was performed 
at end of treatment (day 7+1). Scan interpretation by the 
local investigator was collected; the images were also 
adjudicated centrally over the Internet NeuroGrid366 by an 
independent neuroradiology expert panel blinded to treatment 
allocation. Scans for adjudicated for the location of 
haemorrhage, estimate of its size and for the presence of 
other background findings (mass effect, leukoaraiosis, brain 
atrophy, old infarct or haemorrhage) using validated scoring 
systems.367 The imaging administrator of ENOS transferred 
images to trained observers blinded to clinical data and 
treatment allocation. Haemorrhage parameters including 
volume, shape and density were measured using a software 
suitable Osirix, for viewing CT and MRI images. 
 
2.2.2 Osirix software for Viewing CT/MRI scans 
 
2.2.2.1 Introduction 
 
Osirix (www.osirix-viewer.com) is an image processing 
interactive software available for free to download and view 
CT/MRI images.368, 369 The application displays, reviews, 
interprets and helps in post-processing images optimally 
handed and stored in DICOM (Digital Imaging and 
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Communications in Medicine) format. The software can only 
be installed on a Mac running operating systems (OS).369 For 
the purpose of assessing intracerebral haematoma 
characteristics of patients recruited into ENOS, Osirix version 
3.3.2 was installed on an iMAC 7.1 model, Intel 4GB processor 
with monitor resolution of 1200 pixels.  
 
The 2D viewer window consisting of the Toolbar, The Image 
view and the Preview list is the starting point. The thickness 
between each slice is displayed in the lower left hand viewing 
panel. The Growing Button displays the Region Growing Panel 
with Region of Interest (ROI) tools. In Osirix, ROI is used to 
describe a measurement, area or an annotation. ICH is 
indicated by a high density (white spot or region) in 
parenchymal tissues, according to the principles of a CT scan.  
 
2.2.2.2 General Methods 
 
Once the software is opened, each scan image of a patient 
with intracerebral haemorrhage was obtained using the 
‘Import’ tab. By selecting the study name the image was seen. 
To draw a haemorrhage ROI, the corresponding tool from the 
Mouse Button Function in the 2D viewer bar was selected. The 
length ROI was used to draw simple lines and obtain linear 
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measurements. The starting point was clicked, mouse button 
pressed and dragged to the ending point and released. The 
underlying DICOM image with pixel size information and 
length in cm or μm was shown. If one parameter was incorrect 
or unavailable, the software displayed an error message. This 
was observed when some images were in different format 
other than DICOM, for instance: jpeg, png and gif. In such 
cases, the parameters were defined using the Calibrate 
Resolution tool. 
 
To assign calibration parameters for an image, a centimetre 
scale was used to measure the distance across the scan 
image. With the length and measurement, the number of 
pixels to traverse the distance measured included in the image 
was noted. The value of each pixel length was calculated by 
dividing the measured length using the centimetre scale by 
the number of pixels over that distance. The Calibrate 
Resolution tool was selected, values entered and the OK 
button clicked to derive the ROI’s. 
 
The Brush ROI tool was used to click on the image and the 
desired shape of haemorrhage drawn while holding down the 
mouse button. The mouse button was released to finalise the 
ROI. Following this the ‘compute’ button was clicked and the 
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area (in cm2 or µm2), mean, standard deviation, sum, 
minimum and maximum value were obtained.  The Brush ROI 
is the only ROI that cannot be moved; it is attached to its 
underlying pixels.  
 
The Closed Polygon ROI was used to draw polygons to find 
specific areas of irregular shaped-haemorrhages or in 
presence of other structures. This application is available in 
the ‘Mouse Button’ function in Osirix. Here, clicking on as 
many corners around the haematoma is needed to isolate the 
area of interest and a double-click on the last focus region to 
complete the ROI. The first and the last corners are connected 
upon completion. The area of haemorrhage, perimeter length, 
mean and maximum density heterogeneity are then displayed. 
To measure another area of haemorrhage on the same scan 
slice, all selected ROI’s were deselected by clicking anywhere 
on the first image with a ROI tool or choosing the Deselect All 
ROI’s in the Series item in the ROI menu. 
 
2.2.2.2.1 Calculating Intracerebral haemorrhage volume 
using Osirix 
 
This section describes how haemorrhage volume was 
determined using Osirix.  
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2.2.2.2.1.1 ABC/2 formula 
 
For the ABC/2 method, the scan slice with the largest area of 
haemorrhage was identified. ‘A’ was the measured largest 
diameter of the largest haemorrhage slice, ‘B’ the largest 
diameter perpendicular A on the same slice and C was 
calculated as the number of slices in which the haematoma 
was visualised multiplied by the slice thickness (Figure 2.1).  
For the modified ABC/2, a slice was considered as C 
depending on the size of the haemorrhage area on that 
particular size. The haemorrhage area was considered as ‘1’ 
haemorrhage slice if that area was more than 75% of the 
largest haemorrhage area in that series. If that area was 
between 25-75% of the largest haemorrhage area then it was 
considered as 0.5 haemorrhage slice. If the haemorrhage area 
was less than 25% of the largest haemorrhage area, the slice 
was discarded. 
 
2.2.2.2.1.2 Automatic volume calculator (3-D 
rendering) 
 
The first step was to create a ROI as explained in the earlier 
general methods section. Upper and lower thresholds of 
density values for example, 40-80 Hounsfield units over an 
area of haemorrhage are displayed by clicking on the area 
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with the computer mouse and moving the cursor. In the 
segmentation parameter, upper and lower thresholds of 
density of haemorrhage were then recorded. In the same 
page, the ‘3D growing region (entire series)’ and ‘Neighbour’ 
Algorithm (to exclude an area of similar density elsewhere in 
the brain for example choroid plexus) were selected. Finally, 
the ‘Compute Volume’ tab under ROI Volume in the ROI menu 
was clicked. A 3D image of the haemorrhage shaded in green 
with the computed volume appeared on the screen. (Figure 
2.2) 
 
2.2.2.2.1.3 Semi-automated Segmentation 
 
The first step in segmentation involved isolating areas of 
haemorrhage based on higher densities indicated by moving 
the mouse cursor over the scan image. Once the areas of 
haemorrhage were identified, the segmentation parameters 
were created manually by drawing the ROI using the tools in 
Osirix (as described earlier). The area within each segmented 
region was displayed once the ROI was complete. The final 
step was to sum up each of the slice areas and multiplying the 
value with the slice thickness for each scan. Thus the semi-
automated segmentation volume was obtained. 
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Figure 2.1 Osirix software image of a CT scan of patient 
recruited into the ENOS trial showing an area of 
hyperattenuation in the region of the left internal capsule 
suggesting rupture of the middle cerebral artery. 
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Figure 2.2 Example of using Brush ROI for estimating ICH 
volume. The arrow indicating the region of haemorrhage is 
highlighted in green once the pixel thresholds are determined. 
The panel on the left displays the segmentation parameters. 
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Figure 2.3 Example of closed polygon method using Osirix. 
The panel shows the surface area of haemorrhage, mean, 
standard deviation, min and maximum haematoma density 
attenuation and length (perimeter). 
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Figure 2.4 ABC/2 method using Osirix. The red lines are the 
measured largest haemorrhage diameter ‘A’ and the largest 
perpendicular diameter ‘B’.  
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Figure 2.5 An example of the 3-D image from Osirix showing 
automatic computed haemorrhage volume.  
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Figure 2.6 An example of semi-automated segmentation. The 
highlighted area is the ROI. The scan slice thickness is 
indicated in the bottom left hand corner. 
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Chapter 3 - Performance characteristics of the 
methods used to quantify spontaneous 
intracerebral haemorrhage 
 
Publications contributing to this chapter: 
Krishnan K, Siti F Mukhtar, Lingard J, Houlton A, Walker E, 
Jones T, Sprigg N, Cala LA, Becker JL, Dineen RA, Koumellis P, 
Adami A, Casado AM, Bath PMW, Wardlaw JM 
 
Performance characteristics of methods for quantifying 
spontaneous intracerebral haemorrhage: data from the 
Efficacy of Nitric Oxide in Stroke (ENOS) trial 
(ISRCTN99414122). 
 
Journal of Neurology Neurosurgery and Psychiatry 2015; 0:1-
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ABSTRACT 
 
Background and Purpose 
Poor prognosis after intracerebral haemorrhage (ICH) is 
related to haemorrhage characteristics. With developing 
therapeutic interventions, there is a pressing need to 
understand the performance of haemorrhage descriptors in 
large clinical trials. 
 
Methods 
Clinical and neuroimaging data were obtained for 548 
participants with ICH from the Efficacy of Nitric Oxide in 
Stroke trial. Independent observers performed visual 
categorisation of largest diameter, measured volume using 
ABC/2, modified ABC/2, semi-automated segmentation, fully 
automatic measurement methods; shape, density and 
intraventricular haemorrhage were assessed. Intra-and inter-
observer reliability were determined for these measures. 
 
Results 
 
ICH volume was significantly different between standard 
ABC/2, modified ABC/2 and SAS: (mean) 12.8 (s.d.16.3), 8.9 
(9.2), 12.8 (13.1) cm3 respectively (p<0.0001). There was 
excellent agreement for haemorrhage volume (n=193): ABC/2 
intra-observer intraclass correlation coefficient (ICC) 0.96-
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0.97, inter-observer ICC 0.88; modified ABC/2 intra-observer 
ICC 0.95-0.97, inter-observer ICC 0.91; SAS intra-observer 
ICC 0.95-0.99, inter-observer ICC 0.93; largest diameter: 
(visual) inter-adjudicator ICC 0.82, (visual vs. measured) 
adjudicator vs. observer ICC 0.71; shape intra-observer ICC 
0.88 inter-observer ICC 0.75; density intra-observer ICC 0.86, 
inter-observer ICC 0.73. Graeb score (mean 3.53) and 
modified Graeb (5.22) scores were highly correlated. Larger 
ICH’s were more irregular in shape (64%) (p<0.0001). Using 
modified ABC/2, ICH volume was underestimated in regular 
(by 2.2-2.5 cm3, p<0.0001) and irregular shaped 
haemorrhages (by 4.8-4.9cm3, p<0.0001). Fully automated 
measurement of haemorrhage volume was possible in 5% of 
cases. 
 
Conclusions 
 
Formal measurement of haemorrhage characteristics and 
visual estimates are reproducible. The standard ABC/2 is 
superior to the modified ABC/2 method for quantifying 
intracerebral haemorrhage volume. 
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3.1 Introduction 
 
Spontaneous intracerebral haemorrhage (ICH) is usually a 
severe form of stroke with a high mortality rate (~ 50%) by 
the end of the first year.225 As discussed in the chapter 1, the 
combination of ICH volume and initial Glasgow Coma scale is 
reported to be the strongest independent predictor of 30 day 
outcome.225 Hence, reliable measurement of haemorrhage size 
is an important component of early clinical management and 
for stratification in clinical trials. 
 
Although any effective intervention will ultimately need to 
show an effect on functional outcome (e.g. using the mRS 370) 
in phase III trials, earlier developments will need to study the 
effect of treatment on a surrogate measure. Where the 
intervention aims to limit haemorrhage expansion, accurate, 
reproducible and validated measurement of haemorrhage size 
(thereby allowing measurement of the change in volume) will 
be critical. Hence, phase II trials of blood pressure lowering 
and haemostatic interventions have utilised measurement of 
haemorrhage expansion as a key primary outcome.260, 371  
 
There are multiple methods for measuring haemorrhage 
volume on a CT scan, ranging from qualitative visual 
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estimation to computerised automatic measurement. Visual 
approaches (i.e. visual size categorisation based on the largest 
diameter) are quick and as detailed in chapter 2, ABC/2 
method, modified version of ABC/2, semi-automatic or fully 
automatic computerised methods may also be used. The 
relative advantages and disadvantages of these approaches 
reflect the balance between measurement time, type of data 
required, accuracy and availability of computer workstations, 
and sample size, all studied in part.249, 250, 252, 253 Assessment 
of additional properties of haemorrhage such as shape and 
density212, 362, and extension into the ventricles or 
subarachnoid space as detailed in the introduction, may also 
be useful.240, 241 
 
In this study, we assessed and compared methods for 
measuring haemorrhage size, shape and density, and IVH 
size. The data come from the ‘Efficacy of Nitric Oxide in 
Stroke’ (ENOS) trial,364 which included patients with ICH. 
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3.2 Methods 
 
3.2.1 Patients 
 
The methodology of the ENOS trial is described in chapter 2.  
Participants had a baseline CT or MRI brain scan as part of 
clinical care, usually before randomisation. Where possible, a 
second (research) CT or MRI scan was performed at day 7+1 
(end-of-treatment). DICOM, JPEG, PNG or GIF files are sent, 
to the coordinating centre. Any scans sent on film were 
digitised using a VICOM digitiser (VIDAR Diagnostic PRO 
Advantage, USA). The following study assesses only those 
patients with a CT scan. For each patient, images were 
received with the thinnest slices provided by CT scan 
machines using standardised protocols in the recruiting 
centres. However, during the course of the trial more 
volumetric images were made available because of advances 
in imaging technology.  
 
3.2.2 Scan adjudication 
 
Complete CT scan series were made available for assessment 
by a group of 7 adjudicators comprising accredited 
neuroradiologists or neurologists trained in CT brain imaging 
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assessment in stroke (www.neuroimage.co.uk/sirs, with 
coordination by JMW).367 Images were viewed over the web, 
blind to all clinical and treatment information except for 
patient age, time since onset of stroke and side of brain 
symptoms. Responses were entered directly into the trial 
database via a web-based response form. Collected 
information included whether the patient had an ICH and, its 
location; an estimate of its size (sorted into ordered categories 
based on the longest diameter in any plane): <3, 3-4.9, 5-8, 
>8 cm; and the presence of other qualitative findings (mass 
effect,367 atrophy,367 white matter disease,372 old infarct or 
haemorrhage) using validated scoring methods. 
 
3.2.3 Scan haemorrhage quantification 
 
Scans were visualised and analysed using OsiriX software for 
Mac (version 3, 32 bit, www.osirix-viewer.com)368 and the 
details discussed in chapter 2. Two trained observers (K.K., 
S.M.) measured baseline ICH volumes of 193 patients using 
ABC/2, modified ABC/2, semi-automatic segmentation (SAS) 
and automatic volume calculation (AVC, using 3D rendering of 
a stack of 2D slices). Both observers assessed scans blinded 
to each other’s data, and repeated a proportion of the scans 
(47 and 34 scans for KK and S.M. respectively) at a different 
time blinded to their original measurements. Thus, intra and 
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inter-observer variation could be estimated. For the remaining 
355 patients, one observer (K.K.) calculated ICH volumes 
using all four methods. Appendix I shows a diagram with the 
number of scans used to assess intra and inter observation 
variation. 
 
The methodology of haematoma volume measurement using 
ABC/2 method and the modified version, SAS and AVC is 
detailed in chapter 2. 
 
For SAS and AVC, it was possible to use thresholds so that the 
haemorrhage Region of Interest (ROI) was measured within 
certain segmentation parameters. Upper and lower 
attenuation values (typically 40-80 Hounsfield units) of 
haemorrhage were established manually by sampling from the 
haemorrhage and normal brain. Where the threshold did not 
exclude non-haemorrhage areas (as with the pineal gland, 
calcified choroid plexus, bone) in close proximity with the 
haemorrhage, the haemorrhage boundary was manually 
edited. The area of each slice that was included within these 
parameters was measured, added together and multiplied by 
scan thickness to obtain the semi-automatic segmentation 
volume. AVC used an Osirix ‘3D growing region (entire series)’ 
method after selecting a threshold part of the haemorrhage 
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near to its centre. With all methods, intraventricular 
haemorrhage blood was included in the final ICH volume.  
 
Additionally, four haemorrhage characteristics (area, 
perimeter, mean attenuation, and standard deviation of 
attenuation) were recorded for the haemorrhage from the slice 
with the largest area of haemorrhage. Haemorrhage shape 
and density indices were then calculated as: 
 Shape index 363 = perimeter 2 / 4∏ x area 
 Density index362 = standard deviation / mean (i.e. 
coefficient of variation) 
 
The heterogeneity of haemorrhage shape and density were 
also assessed visually using an ordered categorical scale (1 to 
5) where for an extra lesion edge irregularity an additional 
point was given on the shape and density scale.212 Similarly, 
intraventricular blood volume was assessed visually using the 
Graeb score and modified Graeb ordered categorical scales.240, 
241 
 
Intra- and inter-observer reliability was determined for visual 
categorisation of shape and density. In addition, intraobserver 
reliability was assessed for measured shape, density index, 
Graeb, modified Graeb and intraventricular haemorrhage 
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volume over different reading sessions, separated by a 
minimum of fourteen-days. All adjudication and haemorrhage 
measurements were made blind to baseline and follow-up 
clinical information, other imaging and treatment assignment. 
 
3.3 Statistical Analysis 
 
Data are shown as number (%), median [interquartile range] 
or mean (standard deviation). Measurement of intra-observer 
and inter-observer variability was assessed using the intra-
class correlation coefficient (ICC).373 A probability value of 
<0.05 was considered statistically significant. Analyses were 
performed using SPSS (version 21) and checked with Medistat 
running on an Apple Mac. 
 
3.4 Results 
 
Altogether, 629 patients with ICH were enrolled into ENOS.137, 
374 Of these, 548 patients had CT-confirmed ICH and a 
baseline scan available for measurement; 81 other patients 
either had ICH diagnosed on MRI or had no CT scan available, 
and these were excluded. Patient demographic and clinical 
details are shown in table 3.1. The mean age of the 548 
patients in the present analysis was 67 (standard deviation 
12) years, 66% of patients were male, mean baseline blood 
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pressure was 171 (19)/92 (13) mmHg, and the median time 
from onset of ictus to performing neuroimaging was 4.5 
[interquartile range 5.6] hours. When adjudicated visually by 
experts, 63% of haematomas were located in the middle 
cerebral artery territory (table 3.1); most haemorrhages 
caused mass effect (86%) and many patients had 
leukoaraiosis (66%) and/or previous stroke lesion (49%) 
present on their scans. The most frequent visually assessed 
haemorrhage length category was 3-5cm (224, 41.3%), 
closely followed by <3 cm (220, 40.6%) with much fewer 
larger haemorrhages. The mean measured haemorrhage 
length was 3.4 cm (longest diameter) (Table 3.1). 
 
3.4.1 Intracerebral Haemorrhage (ICH) volume 
 
ICH volume was significantly different between ABC/2, 
modified ABC/2 and SAS: 12.8 (mean) (s.d.16.3), 8.9 (9.2), 
12.8 (13.1) cm3 respectively (p<0.0001) (Table 3.2). The ICC 
was ‘excellent’ at 0.84-0.96 when comparing the observers’ 
measurements for each of ABC/2, modified ABC/2 and semi-
automatic segmentation (Table 3.2). The observers found 
haemorrhage volume to be larger, by an average of 2.7-4.0 
cm3 with standard ABC/2 as compared to modified ABC/2, and 
1.4-4.0 cm3 smaller with SAS as compared to modified ABC/2. 
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As the mean ICH value increased, the difference between ICH 
volume measured by modified ABC/2 versus the other two 
methods increased (Figures 3.1, 3.2) but no significant 
difference was observed between standard ABC/2 and SAS 
(Table 3.2, Figure 3.3). The slope of the best-fit regression 
line for the increasing difference between modified ABC/2 
versus ABC/2 was -0.44, and -0.36 for modified ABC/2 versus 
SAS (both p<0.0001)(Figure 3.1, Figure 3.2).  
 
We used the intraclass correlation coefficient (ICC) to assess 
intra and inter observer agreement and values between 0.75 
and 1.00 were defined as excellent, 0.60 and 0.74 as good 
and 0.40 to 0.59 as fair. There was good intra-observer 
agreement for measurements assessed on 34-47 scans (5-
10% of the total of 548). For ABC/2, modified ABC/2 and 
semi-automatic segmentation, the intra-observer ICC was 
‘excellent’ ranging between 0.97-0.98, and 0.95-0.99 
respectively (Table 3.3).   
 
There was excellent inter-observer agreement (ICC) based on 
193 scans at 0.88 for ABC/2, 0.91 for modified ABC/2, and 
0.93 for SAS (Table 3.4). Both ABC/2 and modified ABC/2 
showed excellent correlation with SAS (p<0.0001, Figures 
3.4-3.6). Only 23 of 548 scans were amenable to analysis 
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using the fully automatic volume calculation method as the 
software was unable to handle scan image with varying slice 
thickness; this approach was therefore ignored in further 
analyses.  
 
Across the ICH visual size categories, ICH volumes calculated 
by modified ABC/2 were significantly smaller compared to SAS 
(Figure 3.7). As the ICH size category increased, the 
difference between modified ABC/2 and SAS also increased. 
By comparison, there was no significant difference between 
ICH volumes measured by standard ABC/2 and SAS when 
compared by ICH visual size categorisation (Figure 3.7).  
  
There was good agreement between the adjudicators across 
ICH visual size categories (n=47, ICC 0.82, p<0.001) (Table 
3.5) using the ordered categorical scale (<3, 3-4.9, 5-8, >8 
cm 367) and strong agreement between visual size category 
and the observer’s measured largest diameter in the axial 
plane ‘A’ (ICC 0.71, p<0.001) (Table 3.6). 
 
3.4.2 Intracerebral haemorrhage (ICH) volume and 
shape 
 
The most common shape was irregular (64%) followed by 
regular ICH. Small ICH’s (5.5-8.06 cm3) were more regularly 
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shaped than larger haemorrhages (p<0.0001) (Table 3.7). 
Using modified ABC/2, haemorrhage volume was significantly 
lower for regular shaped haemorrhages when compared with 
ABC/2 (by 2.5 cm3) and SAS (by 2.2 cm3) (Table 3.7) (Figure 
3.8); the difference was greater with larger irregular shaped 
haemorrhages (between standard ABC/2 and modified ABC/2 
by 4.8 cm3 and SAS and modified ABC/2 by 4.9 cm3). When 
compared by shape, ICH volume calculated by standard ABC/2 
did not differ from those measured by SAS (Figure 3.8).  
 
3.4.3 Intracerebral haemorrhage (ICH) shape and 
density in patients with no IVH 
 
Intra- and inter-agreements were both ‘good’ for visual 
assessments of haemorrhage shape: intra-observer ICC 0.88 
(Table 3.8), inter-observer ICC 0.75 (n=47) (Table 3.9); and 
density: intra-observer ICC 0.86, inter-observer ICC 0.73. 
Intra-observer ICC for calculated shape index was 0.53 and 
0.86 for density index (Table 3.8). 
 
3.4.4 Intraventricular haemorrhage (IVH) volume and 
severity 
 
Intra-observer agreement for assessment of IVH volume on 
baseline scans from 49 patients was excellent (ICC 0.98-0.99) 
whether using the Graeb score, modified Graeb score or semi-
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automatic segmentation (Table 3.8). The Graeb and modified 
Graeb scores were highly correlated with each other (rs=0.88, 
p<0.01). Both were also highly correlated with measured IVH 
volume using the SAS method: Graeb, (rs=0.73, p<0.01); 
modified Graeb (rs=0.72, p<0.01).  
 
3.4.5 Comparison of ICH volume by ABC/2, modified 
ABC/2 to SAS 
 
We performed a non-systematic review to compare our study 
with previously published work comparing ABC/2, modified 
ABC/2 and SAS volume measures in ICH.249-254, 356, 375, 376 
(Figures 3.9-3.12).  
 
Some studies used the standard ABC/2 formula, others used 
variations of it;249, 251 Gebel and colleagues used the central 
haemorrhage slice to measure largest diameter ‘A’ and found 
higher volumes computed by ABC/2 when compared to 
SAS.249 With regards to shape, three studies studied errors in 
warfarin-related haemorrhage due to higher frequencies of 
irregular shape.250, 252, 253 Huttner et al, showed that volume of 
regular shaped haematomas using ABC/2 were significantly 
increased in both regular and irregular shaped 
haemorrhages.250 However, the large slice thickness used 
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during CT image acquisition in this study may have produced 
significant errors during calculation.250  
 
This review comparing all three methods showed that ABC/2 
formula tended to marginally overestimate ICH volume, but 
there was no absolute significant difference compared to SAS 
(Figure 3.9); when assessed by variability in haemorrhage 
shape, the results follow the same sequence (Figure 3.10). By 
comparison, ICH volumes computed using modified ABC/2 are 
significantly smaller when compared with SAS; the difference 
is greater as the haemorrhage sizes became larger and more 
irregular (Figure 3.11). 
 
3.5 Discussion 
 
This is the first study, to our knowledge, that compares 
several methods for assessing volume of spontaneous ICH and 
intraventricular haemorrhage volume on CT scanning and 
tests the effect of haematoma shape and regularity on these 
measures. The major findings are: (1) Agreement within and 
between observers was excellent for measures of 
haemorrhage volume (ABC/2, modified ABC/2, SAS) and other 
haemorrhage parameters (visual categorisation by maximum 
length, description of shape, density and intraventricular 
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haemorrhage); (2) Haemorrhage volumes measured by 
modified ABC/2 were significantly lower from those measured 
by ABC/2 and SAS planimetry; the discrepancy increased as 
haematoma size became larger; (3) Larger haemorrhages 
were significantly more irregular in shape; (4) Agreement was 
good between visual size categorisation and measured 
computerised measurement of maximum haemorrhage 
diameter; (5) Attempts to perform a fully automated volume 
measurement method failed in more than 95% of patients, as 
the software was unable to work with scans in which slice 
thicknesses varied.  
 
The sources of error that effect variation between ABC/2 and 
SAS merit consideration. First, the largest diameter of 
haemorrhage was measured in the axial plane but this may 
not be the largest ICH diameter, which may also have 
contributed to differences between ‘A’ and the visual size 
categorisation. Sucu et al suggested using the maximum 
length and width not necessarily on the same slice and found 
better correlation between ABC/2 and SAS.377 However, this 
adaptation applies only to chronic subdural haematomas which 
differ from spontaneous haemorrhages by extending to the 
cranial vault and being crescentic.377 Second, when using the 
ABC/2, the scan plane is measured through AB/2, the formula 
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for the area of a triangle. However, a triangle is not 
necessarily the most appropriate description of a haematoma. 
Last, standard ABC/2 approximates haematoma volume as an 
ellipsoid with all three axes extending in three perpendicular 
directions;352 to compensate for varying slice thickness, ‘C’ is 
derived by multiplying the number of slices of which the 
haematoma is seen by the slice thickness in centimetres. For 
the modified ABC/2, ’C’ does not include slices if the area of 
the haemorrhage is less than 25% of the largest area,251 an 
approach that has no theoretical justification. Hence, this 
method does not estimate all three Cartesian co-ordinates of 
the ellipsoid. Since the modified ABC/2 method 
underestimated ICH volume (by 2 to 4 cm3), and small 
differences in volume equate to variation in outcome,211 the 
modified ABC/2 method cannot be recommended. Further, 
modern CT scanners provide thin slices and the ability to 
directly measure ‘C’ thereby eliminating the need for 
approximating slice areas.88, 248  
 
Although computer-assisted methods are considered the gold 
standard for volume measure,225, 249, 250, 358 the SAS method 
was time consuming and at times technically challenging. For 
instance, it was difficult to set segmentation parameters to 
identify a haemorrhage that was adjacent to bone; and the 
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threshold may miss an area of haemorrhage. Additionally, the 
threshold method will not account for oedema associated with 
the ICH, which increases mass effect; thus the space 
occupying effect of the ICH may be much larger than its 
measured hyperattenuated area. As segmentation is semi-
automatic, it is feasible to adjust manually for errors if they 
are apparent, although any adjustment may be subjective. All 
images require visual checking and manual correction; failure 
to do this would result in erroneous measurements. The 
problem is compounded by more irregular spontaneous 
haemorrhages e.g. due to amyloid, in anticoagulant-
associated bleeds and in traumatic haematomas, where 
typically lesions are irregular, of varied attenuation and often 
next to bone.  
 
In this series of patients with spontaneous intracerebral 
haemorrhage, a high proportion (64%) of irregular shaped 
haemorrhages were found. The effectiveness of the ABC/2 
method has been validated in regular, oval shaped 
haemorrhages but researchers have doubted its accuracy in 
complex irregular haemorrhages (e.g. as seen with warfarin or 
in large or amyloid-related haemorrhage) and those with 
intra-ventricular extension.250, 358 It has been suggested that 
adjusting the denominator from 2 to 3 in ABC/2 in irregularly 
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shaped haematomas may produce more accurate measures, 
but this concept is yet to be supported.250, 253 Combining the 
present and published findings,356 it may be postulated that as 
the haemorrhage became more irregular, the surface area and 
volume changes more than the largest diameter. Hence the 
area of the largest haemorrhage slice may be more 
representative of total haemorrhage size than its diameter. As 
a result, the true volume of an irregular haemorrhage may be 
better estimated using SAS. This finding is important since 
irregular shape haemorrhages are more likely to expand and 
affect morbidity and mortality.378 
 
Our study is novel in design as it compares two commonly 
used methods ABC/2 and the modified formula (25%/75% 
distinction) with computer-assisted SAS and pragmatic visual 
scoring. Moreover, haemorrhage shape was incorporated in 
the analysis so that the source of error within each individual 
measurement method was assessed further. Our results show 
good compatibility between ABC/2 and computer-assisted SAS 
irrespective of haematoma shape and poor approximation 
using modified ABC/2. 
 
There are several potential explanations for variation in inter-
observer performance. Thinner slices may produce more 
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accurate volume measurement 88, 248 although the scans were 
identical for each observer. Alternatively, each additional slice 
to measure increases the potential for errors. Furthermore, 
observers may have chosen slightly different window settings; 
Additionally, although the observers were all trained in using 
OsiriX, accuracy in measurement does depend on operator 
experience.88, 247  
 
When comparing haemorrhage size on the basis of its longest 
measured diameter (‘A’ in ABC/2) with an adjudicated visual 
categorisation, there was ‘strong’ agreement within the 
adjudicators and between the observers and adjudicators, 
with ICC 0.72. Hence it is unsurprising that the visual category 
versus largest measured axial diameter has slightly lower 
agreement than some of the other measured values. Note that 
the visual categorization assigns an ordinal value based on the 
largest size in any plane, not just the axial plane, and thus is 
not the same as a linear measure of largest axial diameter. 
 
Our study also shows that qualitative descriptors of 
haemorrhage characteristics of haemorrhage shape, density, 
presence of intraventricular haemorrhage using the Graeb and 
modified Graeb scores can be reliably measured and are 
reproducible. 
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Of note, when measuring density heterogeneity, we used only 
the coefficient of variation (cv) whereas Barras used four 
additional measures (although these were apparently inferior 
to cv).362 Calculation of shape index using parameters 
obtained from the windowed haemorrhage had a low ICC of 
0.53. When this result is held in context with similar computed 
volumes, it could be interpreted that the observer chose 
different threshold settings which explains the source of 
variability. 
 
This study has several strengths including the use of multiple 
assessors, multiple methods for assessing haemorrhage 
characteristics, and a large dataset. To minimise 
measurement error, observers were trained to use the OsiriX 
software for measuring brain CT scan parameters and in 
recognition of haemorrhages. Similarly, CT adjudicators were 
experienced neuroradiologists. Multiple observers were used 
to allow measurement of both intra-observer and inter-
observer variation. The dataset involved patients from five 
continents and so the findings have excellent external validity. 
Nevertheless, the study has three significant limitations. First, 
the data come from a randomised controlled trial in acute 
stroke. Trial exclusion criteria can limit the type of patients 
  
147 
 
(and therefore variation in haemorrhage) so that the dataset 
studied here did not include patients with normal/low blood 
pressure, GCS<8, or without motor signs. As a result, patients 
with very large haematoma were underrepresented. Second, 
the time from stroke onset to neuroimaging was relatively 
long (median 4.2 hours), reflecting that the ENOS protocol 
allowed enrolment up to 48 hours after stroke. Hence ICH on 
later scans may already have developed some peri-ICH 
oedema. Finally, just over 25% of the patients had 
measureable intraventricular haemorrhage and therefore the 
results do not represent a population where intraventricular 
haemorrhage is more frequent. The failure to get a fully 
automated volume measure in 95% of scans may be less of a 
problem with other software that can handle scans of variable 
slice thickness. 
 
In conclusion, the modified ABC/2 formula significantly 
underestimates haemorrhage volume when compared to 
standard ABC/2 and computer assisted semiautomated 
segmentation; the difference increased as haematoma volume 
became larger and more irregular in shape. Most relevant for 
clinicians, our results show that the standard ABC/2 method 
offers more accurate quantification of intracerebral 
haemorrhage volume by the bedside. Although semi-
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automated segmentation is consistent and reliable, the 
method is slow, reliant on manual correction, advanced 
software and likely to cause delay in clinical decision-making 
often in emergency situations. Further research is required to 
create a faster computerised volumetric model for accurate 
and reliable measurement of haematomas in the clinical 
setting. The visual categorisation has the strength of providing 
an ‘instant’ marker of haemorrhage size in the acute situation 
and can be applied in the absence of measurement tools and 
historical cut film data, and where very large study sizes or 
very moved images preclude computer based ABC/2 or SAS 
measurements. This study importantly shows that 
haemorrhage characteristics can be reliably measured as 
accuracy is pivotal to clinical trials in which ICH volume 
change may be a surrogate end-point.  
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Table 3.1 Baseline demographic, clinical and 
neuroradiological factors in 548 patients with primary 
intracerebral haemorrhage in the ENOS trial. Data are number 
(%), median [interquartile range], or mean (standard 
deviation). 
 
Variable Data 
Demographics  
Age (years) 67.9 (12.1) 
Sex, male (%) 360 (65.7) 
Country, UK (%)  
  Asia 117 (21.4) 
  Europe 67 (21.4) 
  Other (Africa, Australasia, North America) 42 (7.7) 
  UK 322 (58.8) 
Clinical findings  
Pre-morbid modified Rankin Scale =0 (%) 418 (76.3) 
Previous stroke (%) 69 (12.6) 
Prior antihypertensive medication use (%) 227 (41.4) 
Prior history of high BP (%) 341 (62.2) 
Diabetes mellitus (%) 67 (12.2) 
Ischaemic heart disease (%) 56 (10.2) 
Atrial fibrillation (%) 30 (6.5) 
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Total anterior circulation syndrome (%) 195 (35.6) 
Scandinavian Stroke Scale (/58) 30.1 (12.3) 
National Institutes of Health Stroke Scale 
(/42) 
12.8 (5.3) 
Systolic blood pressure (mmHg) 171.6 (19.3) 
Diastolic blood pressure (mmHg) 92.2 (13.3) 
Heart rate (bpm) 77.7 (14.5) 
Time, stroke to neuroimaging (hr) 4.5 [11.6] 
Adjudicated CT scan findings  
Location of haemorrhage (%)  
  Middle cerebral artery territory (MCA) 346 (63.1) 
  Anterior cerebral artery territory (ACA) 22 (4.0) 
  Posterior cerebral artery territory (PCA) 5 (0.9) 
  MCA + ACA 2 (0.4) 
  Borderzone 14 (2.6) 
  Lacunar (ie small subcortical) stroke 142 (25.9) 
  Brainstem and/or cerebellum 16 (2.9) 
Leukoariosis 362 (66.1) 
Lesion mass effect (minimal to extreme 
swelling) 
470 (85.9) 
Previous stroke lesion 270 (49.3) 
Intraventricular haemorrhage 
Intracerebral haematoma size category (%) 
141 (25.7) 
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  <3 cm 
  3 to <5cm 
  5 to 8 cm 
  >8 cm 
220(40.6) 
224 (41.3) 
87 (16.1) 
11 (2.0) 
Measured CT scan findings  
Volume, ABC/2 (cm3)  12.77 
(16.32) 
Longest diameter (cm) 3.38 (1.4) 
With IVH, n=141  
  Graeb score (/12) 240 3.52 (2.4) 
  Modified Graeb score (/32) 241 5.19 (4.7) 
Without IVH, n=407  
  Shape (/5)378  3.00 (1.4) 
  Shape index363  1.22 (1.1) 
  Density (/5)378  2.54 (1.3) 
  Density index362 0.19 (0.1) 
bpm: beats per minute; IVH: intraventricular haemorrhage; 
SAS: semi-automatic segmentation. NIHSS calculated from 
SSS379 
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Table 3.2 Comparison by two observers of different methods for measuring haemorrhage volume (cm3) on CT 
scans: ABC/2 versus modified ABC/2 versus semi-automated segmentation (SAS). Data are mean (standard 
deviation), difference (∆) in haemorrhage volume and intra-class correlation (lowest value is listed).  
 
 Haematoma volume Difference p value ICC 
Observer1 
n=548 
ABC/2 
12.77(16.32) 
Modified ABC/2 
8.90(9.21) 
3.96 <0.0001 0.84 
 ABC/2 
12.77(16.32) 
SAS 
12.76(13.06) 
-0.01 1.00  
 SAS 
12.76(13.06) 
Modified ABC/2 
8.90(9.21) 
3.97 <0.0001 
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Observer 2 
n=193 
ABC/2 
12.05(12.40) 
Modified ABC/2 
9.70(10.05) 
2.67 <0.0001  
 
 
0.96 
 ABC/2 
12.05(12.40) 
SAS 
11.08(11.38) 
0.05 0.89 
 SAS 
11.08 (11.38) 
Modified ABC/2 
9.70(10.05) 
1.38 <0.0001 
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Table 3.3 Intra-observer comparison for two observers (KK and SM) of haemorrhage size (n=47, 34 scans 
respectively) on baseline CT scans from patients with ICH. Data are mean (standard deviation), difference in 
means, and intra-class correlation (ICC). Both observers assessed scans blinded to each other’s data, and 
repeated a proportion of the scans at a different time blinded to their original measurements. 
SAS: semi-automatic segmentation volume 
 
   Diff (p) ICC   Diff (p) ICC 
Observer  1    2    
Measurement 1 2   1 2   
Modified ABC/2 (cm3) 8.67 (8.34) 9.10 (8.34) 0.43 (0.80) 0.97 16.88 (14.60) 16.90 (14.63) 0.016 (0.97) 0.95 
ABC/2 (cm3) 
SAS (cm3) 
10.42 (10.28) 
11.11 (10.38) 
10.98 (10.79) 
11.69 (10.99) 
-0.55 
0.58 (0.80) 
0.97 
0.98 
20.97 (19.32) 
19.41 (15.32) 
20.15 (17.98) 
19.42 (15.51) 
0.82 (0.39) 
-0.11 (0.87) 
0.96 
0.99 
Diameter (A) (cm) 3.41 (1.28) 3.37 (1.31) 0.04 (0.89) 0.98 3.89 (1.48) 4.01 (1.45) -0.12 (0.43) 0.96 
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Table 3.4 Inter-observer comparison for two observers  (n=193) of haemorrhage volume (cm3) on CT scans from 
patients with ICH. 
 
 
 
 
 
Data are mean (standard deviation), difference (∆) in haemorrhage volumes and intra-class correlation coefficient 
 
 
 
 
 Observer Difference 
(∆) 
ICC 
1 2 
ABC/2 
 
10.58 (10.20) 
 
12.05 (12.40) -1.40 0.88 
Modified ABC/2 
 
8.42 (8.53) 9.70 (10.05) -1.3 0.91 
SAS 
 
12.02 (12.05) 
 
11.08 (11.38) 0.95 0.93 
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Table 3.5 Inter-adjudicator comparison of visually estimated 
longest haemorrhage diameter across four size categories (<3 
cm, 3-5 cm, 5-8 cm, >8 cm) in 47 patients; intra-class 
correlation (ICC)=0.82, p<0.001.  
 
 Observer 2  
Observer 
1 
<3 3-5 5-8 >8 Total 
<3 36 3 0 0 39 
3-5 1 3 1 0 5 
5-8 0 0 3 0 3 
>8 0 0 0 0 0 
Total 37 6 4 0 47 
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Table 3.6 Comparison of visually estimated maximum 
haemorrhage category versus computerised measurement 
(n=548). Data are number (%), mean (standard deviation) or 
median [interquartile range]; intra-class correlation (ICC) = 
0.71 (p<0.001). Modal diameter 0.59 cm 
 
 
  
Size 
category 
(cm) 
 Axial diameter 
‘A’, minimum 
(cm) 
Axial diameter 
‘A’, mean 
(SD) (cm) 
Axial diameter 
‘A’, maximum 
(cm) 
<3  0.66 2.22 (0.74) 5.10 
3 to <5   0.59 3.76 (0.92) 7.29 
5 to 8  2.12 5.07 (1.09) 7.53 
>8  3.46 5.44 (1.27) 7.52 
3 to <5 
[<3] 
 0.59 3.38 (1.39) 7.53 
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Table 3.7 Comparison of volumes (cm3) using ABC/2, 
modified ABC/2 and semi-automated segmentation (SAS) 
(n=548) by haematoma shape. Data are mean (standard 
deviation), difference (∆) in volume and p value. 
 
  Haematoma volume Difference 
(∆) 
 
p value 
 
 
Regular 
(1,2) 
n=198 
 
ABC/2 
8.06(10.43) 
 
Modified ABC/2 
5.56(6.31) 
2.51 <0.0001 
ABC/2 
8.06(10.43) 
 
SAS 
7.77(8.75) 
0.29 0.20 
SAS 
7.77(8.75) 
 
Modified ABC/2 
5.56(6.31) 
2.21 <0.0001 
 
 
Irregular 
(3,5) 
n=350 
 
ABC/2 
15.48(18.37) 
Modified ABC/2 
10.66(10.07) 
 
4.81 <0.0001 
ABC/2 
15.48(18.37) 
SAS 
15.62(14.22) 
 
-0.14 0.82 
SAS 
15.62(14.22) 
Modified ABC/2 
10.66(10.07) 
 
4.96 <0.0001 
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Table 3.8 Intra-observer comparison of haemorrhage shape, 
Graeb and modified-Graeb scores, and intraventricular 
haemorrhage. Data are mean (standard deviation) and intra-
class correlation coefficient (ICC). 
 
 
 
 
 Measure 1 Measure 2 ICC 
Without IVH, n=82    
   Shape (/5) 3.68 (1.18) 3.74 (1.14) 0.88 
   Shape index 1.26 (0.37) 1.24 (0.34) 0.53 
   Density (/5) 2.94 (1.07) 2.87 (0.99) 0.86 
   Density index 0.22 (0.09) 0.21 (0.08) 0.86 
With IVH, n=49    
   Graeb score (/12)  4.10 (2.47) 4.04 (2.43) 0.99 
   Modified Graeb score (/32) 6.94 (4.94) 7.04 (4.96) 0.99 
   Volume (by SAS, cc3) 5.36 (8.33) 5.69 (9.32) 0.98 
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Table 3.9 Inter-observer comparison of visually estimated 
haemorrhage shape and density. Data are mean (standard 
deviation) and intra-class correlation coefficient (ICC). 
 
 Observer 1 Observer 2 ICC 
N=48    
Shape (/5)  2.70 (1.23) 2.96 (1.28) 0.75, p<0.001 
Density (/5) 1.62 (0.60) 1.92 (0.70) 0.73, p<0.001 
 
An ascending scale of 1 to 5 was used and higher scores mean 
adding an extra lesion edge or irregularity on either scale. 
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Figure 3.1 Bland-Altman Plot for assessment of variation in 
estimating haematoma volume between modified ABC/2 and 
standard ABC/2 (n=548), r2 = 0.64, p<0.0001. The 
continuous and dotted lines represent the regression lines. 
The slope of the best-fit regression line gradient was -0.44 
(p<0.0001). 
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Figure 3.2 Bland Altman plot for assessment of variation in 
estimating haematoma volume between modified ABC/2 and 
semi-automatic segmentation (n=548), r2 =0.45, p<0.0001. 
The continuous and the dotted lines represent the regression 
lines. The slope of the best-fit regression line was -0.36 
(p<0.0001) 
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Figure 3.3 Bland Altman plot for assessment of variation in 
estimating haematoma volume (n=548) using ABC/2 and 
semi-automatic segmentation (n=548), r2 =0.03, p<0.0001.  
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Figure 3.4 Graph for assessment of variation between two 
observers in estimating haematoma volume using ABC/2 and 
semi-automatic segmentation (n=193), r2 =0.93, p<0.0001. 
The continuous and the dotted lines represent the regression 
lines. The slope of the best-fit regression line was 1.05 
(p<0.0001). 
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Figure 3.5 Graph for assessment of variation in estimating 
haematoma volume using ABC/2 and modified ABC/2 
(n=193), r2 =0.94, p<0.0001. The continuous and the dotted 
lines represent the regression lines. The slope of the best-fit 
regression line was 0.78 (p<0.0001) 
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Figure 3.6 Graph for assessment of variation in estimating 
haematoma volume using modified ABC/2 and semi-automatic 
segmentation, r2 =0.86, p<0.0001. The continuous and the 
dotted lines represent the regression lines. The slope of the 
best-fit regression line was 1.31 (p<0.0001) 
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Figure 3.7 Box plots of ICH volumes (n=548) by visually 
estimated size and corresponding volume measured by ABC/2, 
modified ABC/2 and SAS. The difference between modified 
ABC/2 versus standard ABC/2 and modified ABC/2 versus SAS 
increases as the size category increases and is present in all 
four size categories [<3 (paired t-test p<0.0001), 3-
5(p<0.001), 5-8(p<0.0001) and >8 (p<0.0001)]. There was 
no significant difference between standard ABC/2 and SAS in 
all four size categories. 
 
 
 168 
 
Figure 3.8 Box plots of ICH volumes (n=548) by visually 
assessed shape and corresponding volume assessed by 
ABC/2, modified ABC/2 and SAS show:(i) larger ICH’s are 
irregular in shape (p<0.0001); (ii) the mean difference 
between modified ABC/2 versus standard ABC/2 and modified 
ABC/2 versus SAS increased as haematoma shape became 
more irregular (paired t-test p<0.0001). No significant 
difference was observed between standard ABC/2 and SAS. 
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Figure 3.9 Forest plot of studies comparing ICH volume 
measurement by ABC/2 and computer- assisted planimetry in 
spontaneous and anticoagulant related ICH. The squares 
indicate the point estimates and the width of the horizontal 
lines is the 95% confidence interval of the estimate. The 
diamond at the bottom represents the point estimate as well 
as the 95% confidence intervals of the overall effect within the 
categories. 
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Figure 3.10 Forest plot of studies comparing variation 
between ABC/2 and computer- assisted planimetry 
measurements by haematoma shape. The squares indicate the 
point estimates and the width of the horizontal lines is the 
95% confidence interval of the estimate. The diamond at the 
bottom represents the point estimate as well as the 95% 
confidence intervals of the overall effect within the categories. 
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Figure 3.11 Forest plot of studies comparing ICH volume by 
modified ABC/2 and computer-assisted planimetry in 
spontaneous and anticoagulation related ICH. The squares 
indicate the point estimates and the width of the horizontal 
lines is the 95% confidence interval of the estimate. The 
diamond at the bottom represents the point estimate as well 
as the 95% confidence intervals of the overall effect within the 
categories. 
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Abstract 
 
Background and purpose 
The Efficacy of Nitric oxide in Stroke (ENOS) trial found that 
transdermal glyceryl trinitrate (GTN, a nitric oxide donor) 
lowered blood pressure but did not improve functional 
outcome in patients with acute stroke. However, GTN was 
associated with improved outcome if patients were 
randomised within 6 hours of stroke onset. 
 
Methods 
In this pre-specified subgroup analysis, the effect of GTN (5 
mg/day for 7 days) versus no GTN was studied in 629 patients 
with intracerebral haemorrhage presenting within 48 hours 
and with systolic blood pressure >140 mm Hg. The primary 
outcome was the modified Rankin Scale at 90 days. 
 
Results 
Mean blood pressure at baseline was 172/93 mm Hg and 
significantly lower (difference -7.5/-4.2 mm Hg; both p< 0.05) 
on day 1 in 310 patients allocated to GTN as compared with 
319 randomised to no GTN. No difference in the mRS was 
observed between those receiving GTN versus no GTN 
(adjusted odds ratio, OR for worse outcome with GTN 1.04, 
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95% confidence interval (CI) 0.78-1.37; p=0.84). In the 
subgroup of 61 patients randomised within 6 hours, GTN 
improved functional outcome with a shift in the modified 
Rankin Scale (OR 0.22, 95% CI 0.07-0.69, p=0.001). There 
was no significant difference in the rates of serious adverse 
events between GTN and no GTN. 
 
Conclusions 
In patients with intracerebral haemorrhage within 48 hours of 
onset, GTN lowered blood pressure, was safe but did not 
improve functional outcome. Very early treatment might be 
beneficial but needs assessment in further studies. 
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4.1 Introduction 
 
As detailed in the chapter 1, spontaneous intracerebral 
haemorrhage (ICH) is a severe form of stroke with more than 
two-third of survivors disabled at three months and less than 
one-half surviving the first year.380 High blood pressure (BP) is 
common in acute ICH and is associated independently with a 
worse outcome,118 in part mediated through expansion of the 
haematoma.381, 382 In the large INTERACT-2 trial, intensive BP 
lowering during the first 6 hours was associated with a trend 
to improved functional outcome in comparison with guideline 
BP lowering.261 In contrast, in a subgroup analysis of patients 
with acute ICH enrolled into the Scandinavian Candesartan 
Acute Stroke Trial (SCAST), treatment with oral candesartan 
was associated with a worse functional outcome.383 Hence, the 
management of high BP in acute ICH remains uncertain. 
 
Transdermal glyceryl trinitrate (GTN), a nitric oxide donor is a 
candidate treatment for acute ICH because it can lower blood 
pressure without changing cerebral blood flow, has no 
negative effects on platelet function 384-386 and can be given to 
patients with dysphagia, a common clinical complication of 
stroke.264 The Efficacy of Nitric Oxide in Stroke trial (ENOS) 
assessed the safety and efficacy of blood pressure lowering 
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with transdermal glyceryl trinitrate (GTN), a nitric oxide 
donor, in 4,011 patients with acute stroke;137 nearly one-fifth 
of these presented with spontaneous ICH.137 Although the 
main analysis showed that GTN did not improve death or 
dependency at 90 days after acute ischaemic stroke or ICH, 
apparent benefit was observed in patients randomised within 
6 hours of stroke onset.137 This result mirrored a result seen in 
the pre-hospital pilot Rapid Intervention with Glyceryl 
trinitrate in Hypertensive stroke Trial (RIGHT) where GTN was 
administered by paramedics within 4 hours of onset.264 In this 
pre-specified analysis,387 we have further assessed the effect 
of GTN in the subgroup of patients randomised into the ENOS 
trial following ICH, both overall (here called ENOS-ICH) and 
within 6 hours; the time window of 6 hours matches that for 
recruitment into the INTERACT-2 trial,261 and encompasses 
the time window studied in RIGHT.264 
 
4.2 Methods 
 
The ENOS trial protocol is detailed in chapter 2. The statistical 
analysis plan, baseline data and main results have been 
published.137, 374, 387 During treatment, BP was measured daily 
using a validated automatic BP monitor (Omron 705CP) 
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supplied to each site.388 In the present analysis, we included 
all patients enrolled into ENOS with ICH (ENOS-ICH). 
4.3 Brain imaging 
 
Participants had a baseline CT or MRI scan as part of clinical 
care, usually before randomisation. Where possible, a second 
research CT or MRI was performed at day 7+1 (end of 
treatment). All imaging assessments were performed by a 
single investigator (KK), masked to clinical data and treatment 
assignment. 
 
4.4 Outcomes 
 
As detailed in chapter 2, the primary outcome was functional 
outcome assessed using the modified Rankin Scale at 90 days 
after randomisation. Secondary outcomes studied at day 90 
included activities of daily living (Barthel Index, BI 389); 
cognition (modified telephone Mini-Mental State Examination, 
t-MMSE 390); and Telephone Interview for Cognition Scale, 
(TICS-M 391); health-related quality of life (European Quality 
of Life-5 dimensions-3 level, EQ-5D,392 from which health 
utility status, HUS, was calculated 393) and mood (short Zung 
Depression Score, ZDS 394). Safety outcomes comprised all-
cause mortality and case-specific fatality, early neurological 
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deterioration (defined as a decrease of at least 5 points or 
decrease in consciousness of more than 2 points from baseline 
to day 7 on the Scandinavian Stroke Scale, SSS), recurrent 
stroke by day 7, symptomatic hypotension, hypertension,137 
and serious adverse events. Outcomes at day 90 were 
assessed via telephone by trained investigators at national 
coordinating centres who were masked to treatment 
allocation. 
 
4.5 Analyses 
 
Statistical analysis was performed by intention-to-treat and 
followed the trial’s statistical analysis plan and analysis 
approaches used in the primary publication.137, 387 Analyses 
were performed for all patients with ICH in ENOS, and 
separately for those with ICH who were randomised within 6 
hours of onset. Data are shown as number (%), median 
[interquartile range], or mean (standard deviation). Patients 
who died were allocated an extreme score: -5: Barthel Index; 
EQ-VAS -1: EQ-VAS, SSS 0, t-MMSE, TICS-M, verbal fluency; 
0: health utility status (derived from EQ-5D); 6: mRS and 
102.5: Zung Depression Scale.137, 395 Comparisons between 
the treatment groups were performed with binary logistic 
regression, ordinal logistic regression, Cox proportional 
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regression, or multiple linear regression. Statistical models 
were adjusted for prognostic baseline covariates: age, systolic 
BP, SSS score, time from symptom onset to randomisation, 
haematoma volume and treatment assignment (GTN vs no 
GTN). Odds ratio, hazard ratio or mean difference, with 95% 
confidence intervals, are given and statistical significance was 
set at p<0.05. Heterogeneity of treatment effect was assessed 
by including an interaction term in adjusted models. Analyses 
were performed using SPSS (version 21) on an Apple Mac. 
 
4.6 Results 
 
4.6.1 Baseline characteristics 
 
Between July 2001 and October 2013, a total of 629 
participants with ICH were enrolled in the trial; 310 
participants were randomly assigned to receive GTN and 319 
participants to no GTN (Table 4.1). Baseline characteristics 
were well matched between the two groups. The average age 
was 67 years; 66% of patients were male; 54% were enrolled 
from the UK; mean time from onset to recruitment 25 hours; 
and mean stroke severity 30.5 (s.d.12.4) on the SSS, 
equivalent to NIHSS 12.6 (5.3). 
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A majority (71%) of patients had their baseline scans 
performed within 12 hours of onset (Table 4.1). 87% of 
haemorrhages were deep-seated in the lacunar and striato-
capsular brain regions, most haematomas caused mass effect 
(moderate or extreme swelling, 63%), and many patients had 
leukoaraiosis (67%). Evidence of a previous stroke was 
present in 50% of patients and brain atrophy was seen in 62% 
of the available scans. The mean haematoma volume was 
13.3 cm3, and 153 (26%) of patients had an intraventricular 
haemorrhage. More information on baseline neuroimaging is 
given in Table 4.2. 
 
4.6.1.1 Blood pressure 
 
Mean BP at baseline was 172.1/93.4 mmHg and fell in both 
treatment groups over the first week. Following the first dose 
of GTN versus no GTN, BP was significantly lower by 7.5/4.2 
mmHg (p=0.02/0.05 respectively); BP did not differ thereafter 
(Figure 4.1). 
 
 
4.6.1.2 Clinical outcomes 
 
At day 90, the median mRS was 3 [IQR 2] in both the GTN 
and no GTN groups and did not differ in an adjusted analysis, 
common OR 1.04 (0.78-1.38) (Table 4.3, Figure 4.2) or 
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unadjusted analysis (data not shown). A test of ‘goodness-of-
fit’ showed that the assumption of proportional odds was not 
violated (p=0.09). When assessed in subgroups defined by 
baseline clinical or neuroimaging factors, there were 
significant interactions between treatment and mRS for time 
to randomisation and stroke subtype (Figures 4.3 and 4.4). 
 
The cumulative risk of all causes of death during follow up did 
not differ between GTN and no GTN (adjusted hazard ratio 
1.02, 95% CI 0.67-1.56, p=0.92; Figure 4.5). There were no 
significant differences between the two groups in any of the 
secondary outcomes studied at days 7 or 90, including 
measures of disability, cognition, mood and quality of life 
(Table 4.3). The number of patients with a serious adverse 
event during follow-up did not differ between the treatment 
groups (24.2% vs. 21.9%, p=0.50) (Table 4.4). 
 
4.6.2 Relationship between baseline neuroimaging and 
mRS at day 90 
 
Table 4.5 shows the association between baseline 
neuroimaging characteristics and the primary outcome of 
mRS. Imaging measures that were significantly associated 
with outcome on both univariate and co-variate adjusted 
analyses comprised the presence of intraventricular 
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haemorrhage or atrophy, irregular haematoma shape and 
heterogeneous density. 
 
4.6.3 Patients randomised within 6 hours 
 
Of the 629 patients with ICH, 61 (9.7%) participants were 
randomised within 6 hours; the average time to treatment 
was 4.4 (1.2) hours (Table 4.1). Patients were less likely to be 
enrolled in Asia or other non-UK countries, had a larger initial 
haemorrhage volume (mean 16.9 cm3) and were more likely 
to have IVH. 
 
Patients randomised to GTN (versus no GTN) had less 
impairment (higher SSS) at day 7, and were less likely to die 
in hospital (Table 4.3). At day 90, GTN was associated with an 
improved functional outcome assessed using the mRS, 
manifest as a shift to less dependency (Table 4.3, Figure 4.6). 
Similarly, participants randomised to GTN were less disabled 
and had significantly better quality of life, mood and cognition 
scores (Table 4.3). A trend to a reduction in death was seen in 
those patients randomised to GTN versus no GTN (adjusted 
hazard ratio 0.19, 95% CI 0.03-1.01, p=0.051). 
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4.6.4 Effect of GTN on haemorrhage measures at day 7 
 
One hundred and eighty-one patients had repeat brain 
imaging at one week for an assessment of the effect on 
haemorrhage characteristics (Table 4.6). Of these, 93 patients 
received GTN and 88 to no GTN. When adjusted for baseline 
value, treatment with GTN was associated with a non-
significant reduction in haematoma volume (mean difference -
4.3 cm3; p=0.06). 
 
4.7 Discussion 
 
In this subgroup of patients enrolled into the ENOS trial with 
ICH, functional outcome (assessed using the mRS) did not 
improve with GTN as compared to no GTN. This result mirrors 
that across the main study and is in spite of GTN reducing BP 
by 7.5/4.2 mm Hg. Further, no benefit was seen in key 
secondary outcomes, including activities of daily living, 
cognition, mood and quality of life. The absence of significant 
differences in the rates of deaths or serious adverse events 
between the two treatment groups suggests that treatment 
with GTN is safe. In a pre-specified analysis of the effect of 
treatment in patients randomised within 6 hours of ICH onset, 
GTN reduced early impairment; late dependency, disability, 
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and death; and improved late cognition, mood and quality of 
life. 
 
These findings may have a number of explanations. First, 
patients could be randomised up to 48 hours after stroke 
onset. The large INTERACT-2 trial suggested that intensive BP 
lowering might be effective in patients enrolled within 6 hours 
261 so the time window for recruitment into ENOS (mean 25.1 
hours, maximum 48 hours) may have been too long. 
Supporting this is the observation that patients randomised 
within 6 hours of the onset of ICH into ENOS appeared to 
benefit with less dependency, disability, impairment and mood 
disturbance, and better cognition and quality of life. Very early 
BP lowering might help limit haematoma expansion.260, 396 
Second, the degree by which BP was lowered may have been 
too small; INTERACT-2 achieved a reduction of 14 mmHg by 6 
hours and showed a near-significant effect on functional 
outcome.261 Last, the length of BP control in ENOS-ICH was 
limited to 3 days as tachyphylaxis developed, a known feature 
of organic nitrate therapy. Nevertheless, these explanations 
are confounded by results from the subgroup of patients with 
ICH randomised into the large SCAST trial,383 where oral 
candesartan was associated with a worse functional 
outcome.383 Here, treatment could be started up to 30 hours 
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after stroke onset and the difference in BP between active and 
placebo groups was smaller than in ENOS-ICH at 6.3/3.3 
mmHg.  
 
The reduction in ICH volume in the GTN group (4 cm3) was 
similar to the effect observed in trials of rFVIIa although the 
agent was tested in earlier time windows.277, 278 Mechanisms 
by which nitric oxide donors might reduce haematoma 
volume, and improve functional outcome if given early, 
include lowering BP, neuroprotection, and improving collateral 
blood flow. The latter two effects have been seen in 
experimental models of brain ischaemia397, 398 and may be of 
relevance after ICH. 
 
This subgroup analysis of ENOS has a number of strengths 
including recruitment of patients with ICH from multiple ethnic 
groups across five continents over a wide time window 
representative of routine clinical practice. Baseline 
neuroimaging and clinical outcomes were assessed masked to 
treatment assignment,399 follow-up was near complete,137 and 
the analysis was pre-specified.387 However, exclusion of 
patients with low or normal BP (systolic BP <140 mmHg) or 
very high (>220 mmHg), those with reduced consciousness 
(GCS<8), and those without motor signs, will have limited the 
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external validity of the findings and especially the number of 
patients with large haematoma. 
 
In conclusion, this subgroup analysis of ENOS was neutral and 
did not identify any beneficial effect or harm in lowering BP 
with GTN in patients with acute ICH. Trasndermal GTN 
appears to be safe and modestly effective in lowering BP in 
acute ICH, which can be useful in patients who are unable to 
swallow. The results in those patients randomised within 6 
hours of ICH onset support ongoing or planned trials of 
lowering BP in the ultra-acute and hyper-acute periods after 
stroke, including the ATACH-2 trial of intravenous 
nicardipine,400 and RIGHT-2 trial of GTN administered in the 
pre-hospital phase of stroke (ISRCTN26986053). 
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Table 4.1 Baseline clinical and neuroimaging characteristics of all patients with intracerebral haemorrhage and 
those randomised within 6 hours. Data are number (%), median [interquartile range], or mean (standard 
deviation). Comparison of patients randomised within 6 hours versus those randomised later by Fisher’s exact 
test, Mann-Whitney U test or t test. 
 
 All GTN No GTN All <6 hours GTN No GTN 2p  
Clinical characteristics         
Number of patients (N) 629 310 319 61 29 32 -  
Age (years) 67.0 (12.4) 66.6 (12.0) 67.5 (12.7) 69.6 (12.5) 68.3 (11.4) 70.8 (13.5) 0.12  
Sex, male (%) 415 (66.0) 217 (70.0) 198 (62.1) 38 (62.3) 16 (55.2) 22 (68.8) 0.56  
Premorbid mRS>0 (%) 143 (22.7) 66 (21.3) 77 (24.1) 12 (19.7) 5 (17.2) 7 (21.9) 0.58  
Country (%)         
   UK 337 (53.6) 170 (54.8) 167 (52.4) 35 (57.4) 18 (62.1) 17 (53.1) 0.57  
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   Asia 179 (28.5) 87 (28.1) 92 (28.8) 8 (13.1) 2 (6.9) 6 (18.8) 0.010 
   Other 113 (18.0) 53 (17.1) 60 (18.8) 18 (29.5) 9 (31.0) 9 (28.1) 0.028 
Time to randomisation 
(hours) 
25.1 (13.0) 25.2 (13.1) 25.1 (12.9) 4.4 (1.2) 4.5 (1.1) 4.4 (1.3) -  
   <6 hours (%) 61 (9.7) 29 (9.4) 32 (10.0) - - - -  
Smoking, current (%) 124 (20.4) 58 (19.3) 66 (21.4) 11 (18.0) 8 (27.6) 3 (9.4) 0.84  
Treated hypertension (%) 253 (40.2) 121 (39.0) 132 (41.4) 17 (27.9) 8 (27.6) 9 (28.1) 0.06  
Previous stroke (%) 79 (12.6) 41 (13.2) 38 (11.9) 10 (16.4) 6 (20.7) 4 (12.5) 0.39  
Ischaemic heart disease 
(%) 
58 (9.2) 29 (9.4) 29 (9.1) 5 (8.2) 3 (10.3) 2 (6.3) 0.86  
Atrial fibrillation (%) 42 (6.7) 18 (5.8) 24 (7.5) 2 (3.3) 1 (3.4) 1 (3.1) 0.30  
Diabetes mellitus (%) 81 (12.9) 44 (14.2) 37 (11.6) 9 (14.8) 3 (10.3) 6 (18.8) 0.68  
TACS (%) 217 (34.5) 105 (33.9) 112 (35.1) 22 (36.1) 10 (34.5) 12 (37.5) 0.81  
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SSS (/58) 30.5 (12.4) 30.1 (12.7) 30.9 (12.1) 30.1 (11.1) 30.3 (11.4) 30.0 (10.9) 0.81  
   NIHSS (/42), calculated  12.6 (5.3) 12.7 (5.5) 12.4 (5.2) 12.7 (4.8) 12.7 (4.9) 12.8 (4.7) 0.81  
Glasgow Coma Scale [/15] 15.0 [1.0] 15.0 [1.0] 15.0 [1.0] 15.0 [1.0] 15.0 [1.0] 15.0 [1.0] 0.43  
Blood pressure (mmHg)         
   Systolic 172.1 (19.4) 172.3 (18.9) 171.8 (19.9) 172.4 (16.8) 174.4 (19.2) 170.6 (14.4) 0.90  
   Diastolic 93.4 (13.9) 94.0 (13.1) 92.7 (14.6) 95.7 (12.2) 96.9 (13.4) 94.7 (11.1) 0.19  
Heart rate (bpm) 77.9 (14.5) 78.0 (14.6) 77.8 (14.4) 76.7 (13.6) 75.6 (15.5) 77.8 (11.8) 0.54  
Neuroimaging characteristics         
Available scan 587 (93.3) 296 (95.5) 291 (91.2) 57 (93.4) 28 (96.6) 29 (90.6) 0.89  
Time, onset-neuroimaging 
(%) 
        
   <12 hours 414 (70.5) 220 (74.3) 194 (66.7) 53 (93.0) 27 (96.4) 26 (89.7) 0.78  
   >12 hours 173 (29.5) 76 (25.7) 97 (33.3) 4 (7.0) 1 (3.6) 3 (10.3) 0.50  
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Adjudicated findings         
Haematoma location (%)         
   Lobar or cerebellar  † 79 (13.5) 42 (14.2) 37 (12.7) 12 (21.1) 7 (25.0) 5 (17.2) 0.76  
   Deep ‡ 508 (86.5) 254 (85.8) 254 (87.3) 45 (78.9) 21 (75.0) 24 (82.8) 0.75  
Mass effect (%)         
   No swelling or mild 
swelling 
218 (37.2) 107 (36.3) 111 (38.1) 22 (38.6) 11 (39.3) 11 (37.9) 1.00  
   Moderate to severe 
swelling 
299 (50.9) 155 (52.4) 144 (49.5) 28 (49.1) 14 (50.0) 14 (48.3) 0.90  
   Extreme swelling 70 (11.9) 34 (11.5) 36 (12.4) 7 (12.3) 3 (10.7) 4 (13.8) 1.00  
Leukoaraiosis (%) 391 (66.6) 199 (67.2) 192 (66.0) 38 (66.7) 19 (67.9) 19 (65.5) 1.00  
Previous stroke lesion (%) 291 (49.6) 149 (50.3) 142 (48.8) 33 (57.9) 18 (64.3) 15 (51.7) 0.21  
Atrophy (%) 366 (62.3) 186 (62.8) 180 (61.9) 40 (70.2) 19 (67.9) 21(72.4) 0.79  
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Measured CT scan findings         
Volume, ABC/2 (cm3) 13.3 (16.5) 13.2 (15.3) 13.3 (17.7) 16.9 (30.5) 13.0 (14.4) 20.8 (40.7) 0.09  
With IVH (n=151, 25.7%)         
   Volume, ABC/2 (cm3) 18.5 (23.6) 17.7 (18.3) 19.2 (27.8) 31.8 (52.2) 21.1 (20.6) 40.1 (67.9) 0.018 
   IVH Volume (ml) 4.8 (7.3) 4.2 (5.0) 5.4 (9.0) 7.2 (6.2) 7.1 (5.7) 7.3 (6.8) 0.18  
   Shape index363 2.4 (3.7) 2.2 (1.9) 2.6 (4.8) 3.2 (2.1) 3.3 (2.9) 3.2 (1.5) 0.35  
   Density index 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.3 (0.1) 0.006 
   Graeb score (/12) 240 3.0 [2.0, 
4.0] 
3.0 [2.0, 
4.0] 
3.0 [2.0, 
5.0] 
4.0 [2.5, 6.0] 4.0 [2.0, 6.0] 4.0 [3.0, 6.0] 0.047 
Without IVH (n=436, 
74.3%) 
        
   Volume, ABC/2 (cm3) 11.4 (12.6) 11.7 (13.9) 11.1 (11.2) 11.0 (11.8) 10.3 (11.1) 11.7 (12.9) 0.87  
   Shape index 363 1.2 (1.1) 1.2 (1.2) 1.2 (1.0) 1.4 (1.1) 1.3 (0.9) 1.5 (1.3) 0.73  
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   Density index362 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.0) 0.2 (0.1) 0.52  
 
bpm: beats per minute; ICH: intracranial haemorrhage; IVH: intraventricular haemorrhage; MCA: middle cerebral 
artery; mRS: modified Rankin scale; NIHSS: National Institute of Health Stroke scale; SSS: Scandinavian Stroke 
Scale; TACS: total anterior circulation syndrome. 
† Lobar: borderzone regions, cerebellar and or brainstem, ACA, PCA territory and MCA territory excluding 
striatocapsular regions 
‡ Deep: lacunar, MCA territory including striatocapsular regions 
Shape index was calculated as perimeter of haematoma/4∏ x surface area.363 Density index was determined as 
standard deviation/mean Hounsfield attenuation unit.362  
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Table 4.2 Additional information on baseline neuroimaging data for all patients with intracerebral haemorrhage 
and those randomised within 6 hours. Data are number (%), median [interquartile range], or mean (standard 
deviation). 
 
Neuroimaging All GTN No GTN <6 hours GTN No GTN 
Number of patients (N) 629 310 319 61 29 32 
Participants with a scan 
available 
587 (93.3) 296 (95.5) 291 (91.2) 57 (93.4) 28 (96.6) 29 (90.6) 
Adjudicated findings       
Haematoma location 
(%) 
      
   Lacune 155 (26.4) 83 (28.0) 72 (24.7) 13 (22.8) 6 (21.4) 7 (24.1) 
   Borderzone 16 (2.7) 6 (2.0) 10 (3.4) 1 (1.8) 1 (3.6) 0 (0) 
   Cerebellum and/or 
brainstem 
17 (2.9) 9 (3.0) 8 (2.7) 2 (3.5) 1 (3.6) 1 (3.4) 
   MCA territory 372 (63.4) 183 (61.8) 189 (64.9) 38 (66.7) 19 (67.9) 19 (65.5) 
   ACA or PCA territory 27 (4.6) 15 (5.1) 12 (4.1) 3 (5.3) 1 (3.6) 2 (6.9) 
Longest diameter (cm)       
   <3 235 (40.4) 119 (40.8) 116 (40.1) 24 (42.1) 12 (42.9) 12 (41.4) 
   3-5 242 (41.7) 120 (41.1) 122 (42.2) 19 (33.3) 10 (35.7) 9 (31.0) 
   5-8 93 (16.0) 45 (15.4) 48 (16.6) 12 (21.1) 4 (14.3) 8 (27.6) 
   >8 11 (1.9) 8 (2.7) 3 (1.0) 2 (3.5) 2 (7.1) 0 (0) 
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Sub-arachnoid 
haemorrhage (%) 
94 (16.0) 47 (15.9) 47 (16.2) 10 (17.5) 4 (14.3) 6 (20.7) 
Subdural haematoma 
(%) 
4 (0.7) 2 (0.7) 2 (0.7) 1 (1.8) 1 (3.6) 0 (0) 
Remote ICH (%) 4 (0.7) 3 (1.0) 1 (0.3) 0 (0) 0 (0) 0 (0) 
Measured CT scan 
findings 
      
Diameter, max (cm) 3.4 (1.4) 3.4 (1.4) 3.5 (1.4) 3.6 (1.4) 3.5 (1.4) 3.6 (1.5) 
With IVH (n=151, 
25.7%) 
      
   Shape (/5) 378 5.0 [2.0] 5.0 [2.0] 5.0 [1.0] 5.0 [0.5] 5.0 [1.0] 5.0 [0.0] 
   Density (/5) 378 3.0 [2.0] 3.0 [2.0] 3.0 [2.0] 3.0 [3.0] 2.0 [2.0] 4.0 [2.0] 
   Modified Graeb score 
(/32) 241  
3.0 [4.5] 3.0 [4.0] 3.0 [5.0] 6.5 [7.5] 4.0 [5.0] 7.0 [6.0] 
Without IVH (n=436, 
74.3%) 
      
   Shape (/5) 378 3.0 [2.0] 3.0 [2.0] 3.0 [2.0] 2.0 [2.5] 2.0 [2.0] 3.0 [3.0] 
   Density (/5) 378 2.0 [1.0] 2.0 [1.0] 2.0 [1.0] 2.0 [1.0] 2.0 [1.0] 2.0 [2.0] 
 
ACA: anterior cerebral artery; ICH: intracerebral haemorrhage; MCA: middle cerebral artery; PCA: posterior 
cerebral artery. Intracerebral haemorrhage shape and density were determined using a 5-point ordered categorical 
scale. 
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Table 4.3 Secondary outcomes at day 7 and day 90 for all patients with intracerebral haemorrhage and those 
randomised within 6 hours. Data are number (%), mean (standard deviation) with 95% confidence intervals. Data 
are number of patients (%), mean (standard deviation) or median [interquartile range]. Comparison by logistic 
regression, ordinal regression or multiple regression with adjustment for age, sex, pre-morbid mRS, history of 
previous stroke, history of diabetes, severity, total anterior circulation syndrome, volume of intracerebral 
haemorrhage, systolic blood pressure, feeding status and time to randomisation. 
 
 
Outcome N 
 
GTN No GTN 
OR/MD 
(95% CI) 2p 
<6 
hours GTN No GTN 
OR/MD 
(95% CI) 
2p 
 
Patients 629 310 319   61 29 32   
Day 7 (or discharge) 627 310 317        
Death (%) 627 10 (3.2) 10 (3.2) 1.03 (0.38, 2.88) 0.95 60 2 (6.9) 4 (12.5) - 1.00 
SSS (/58) 625 34.5 (15.4) 34.8 (16.0) 0.18 (-1.30, 1.69) 0.80 60 33.4 (16.4) 27.1 (19.6) 7.0 (1.0, 13.1) 0.033 
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Outcome N 
 
GTN No GTN 
OR/MD 
(95% CI) 2p 
<6 
hours GTN No GTN 
OR/MD 
(95% CI) 
2p 
 
Recurrence (%) 626 8 (2.6) 4 (1.3) 2.43 (0.63, 9.29) 0.19 60 0 1 (3.1) - 1.00 
           
Hospital events 623 308 315   59 29 30   
Died in hospital (%) 623 28 (9.0) 32 (10.2) 0.92 (0.48, 1.76) 0.79 59 2 (6.9) 9 (30.0) - - 
Death or discharge to 
institution (%) 
623 121 (39.3) 131 (41.6) 0.84 (0.59, 1.22) 0.37 59 14 (48.3) 14 (46.7) 1.20 (0.32, 4.43) 0.79 
Day 90 623 309 316   61 29 32   
Death (%) 625 42 (13.6) 47 (14.9) 0.91 (0.55, 1.55) 0.76 61 2 (6.9) 12 (37.5) † 0.006 
Modified Rankin Scale 
(/6) 
625 3 [2] 3 [2] 1.04 (0.78, 1.38) 0.81 61 3 [2] 4 [4] 0.19 (0.06, 0.59) 0.004 
Barthel Index 622 62.3 (38.1) 61.4 (39.7) 1.26 (-3.65, 6.17) 0.62 61 66.9 (36.4) 46.9 (45.7) 20.71 
(6.34, 35.07) 
0.005 
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Outcome N 
 
GTN No GTN 
OR/MD 
(95% CI) 2p 
<6 
hours GTN No GTN 
OR/MD 
(95% CI) 
2p 
 
t-MMSE 369 10 (7.2) 10.1 (7.4) 0.04 (-1.20, 1.28) 0.95 38 11.9 (6.4) 6.5 (8.3) 3.38 (-0.29, 7.10) 0.008 
TICS-M 370 11.9 (9.3) 12.7 (9.3) -0.64 (-2.20, 0.93) 0.43 39 16.6 (9.1) 7.1 (9.3) 7.17 (2.20, 12.12) 0.005 
Animal naming (/∞) 376 8.2 (7.8) 7.9 (7.4) 0.28 (-1.09, 1.65) 0.69 39 12.8 (8.0) 4.8 (7.3) 7.92 (2.93, 12.92) <0.001 
ZDS (/100) 516 60.1 (24.2) 59.6 (24.3) 0.62 (-3.12, 4.43) 0.73 50 54.2 (20.6) 71.8 (28.6) -17.58 (-32.25, -3.01) <0.001 
HUS (/1) 621 0.45 (0.31) 0.46 (0.32) -0.01 (-0.05, 0.03) 0.60 61 0.53 (0.3) 0.53 (0.32) 0.19 (0.06, 0.32) 0.003 
EQ-VAS (/100) 543 54.6 (31.3) 55.1 (31.5) -0.44 (-5.16, 4.27) 0.85 57 60.9 (26.7) 40.4 (38.1) 21.28 (6.31, 36.25) 0.005 
Dead or institution (%) 616 97 (31.4) 92 (29.1) 1.09 (0.72, 1.67) 0.68 61 13 (44.8) 14 (43.8) 0.51 (0.12, 2.18) 0.36 
 
BI: Barthel Index; EQ-VAS: EQ-Visual Analogue Scale; HUS: health utility status; ICH: intracranial haemorrhage; 
mRS: modified Rankin Scale; t-MMSE: Modified telephone Mini-Mental State Examination; SAE: serious adverse 
event; SBP: systolic blood pressure; SSS: Scandinavian Stroke Scale; TICS-M: Modified Telephone Interview for 
Cognitive Status; ZDS: Zung Depression Scale. † Fisher’s exact test 
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Table 4.4 Serious adverse events at day 90 for all patients with intracerebral haemorrhage at day 90 and those 
randomised within 6 hours. Data are number of patients (%) and mean (standard deviation). NA denotes not 
applicable. 
 
 All <6 hours 
 GTN No GTN 2p GTN No GTN 2p 
Complication of initial stroke 13 (4.2) 9 (2.8) 0.35 0  2 (6.3) 0.50 
Extension of initial stroke 13 (4.2) 4 (1.3) 0.027 1 (3.4) 3 (9.4) 0.61 
Recurrent  stroke 7 (2.3) 7 (2.2) 0.96 0 0 NA 
Myocardial infarction 1 (0.3) 2 (0.6) 1.00 0 2 (6.3) 0.49 
Other cardiovascular cause 10 (3.2) 20 (6.3) 0.07 1 (3.4) 3 (9.4) 0.61 
Pulmonary embolism 4 (1.3) 4 (1.3) 1.00 0 0 NA 
Pneumonia 13 (4.2) 25 (7.8) 0.06 1 (3.4) 2 (6.3) 1.00 
Sudden cardiac death 1 (0.3) 1 (0.3) 1.00 0 1 (3.1) 1.00 
Other cause 4 (1.3) 4 (1.3) 1.00 2 (6.9) 1 (3.1) 1.00 
Total SAEs 75 (24.2) 70 (21.9) 0.50 5 (17.2) 14 (43.8) 0.026 
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Table 4.5 Relationships between baseline imaging characteristics and functional outcome (modified Rankin Scale) 
at day 90. Results are odds ratio or mean difference with 95% confidence interval with comparison by logistic 
regression, ordinal regression or multiple regression; results are unadjusted, and adjusted for age, sex, severity 
(Scandinavian Stroke Scale) and time from stroke onset to imaging. 
  
Haematoma characteristics 
Univariate analyses 
OR/MD (95% CI) 
2p 
Co-variate adjusted 
OR/MD (95% CI) 
2p 
Haematoma location          
   Lobar 1.32 (0.87, 2.00) 0.19 1.31 (0.85, 2.03) 0.22 
   Deep 1.08 (0.76, 1.53) 0.68 0.84 (0.58, 1.21) 0.35 
Side of the brain                         
   Left  0.89 (0.67, 1.37) 0.40 0.76 (0.57, 1.01) 0.18 
   Right 1.10 (0.83, 1.45) 0.50 1.29 (0.97, 1.71) 0.09 
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   Bilateral 2.41 (0.51, 11.50) 0.50  2.50 (0.41, 15.35) 0.32 
Mass effect  2.30 (1.61, 3.29) <0.0001 1.35 (0.93, 1.96) 0.18 
Leukoaraiosis 2.14 (1.58, 2.90) <0.0001 1.34 (0.96, 1.86) 0.09 
Previous stroke lesion 1.19 (0.90, 1.59) 0.23 1.18 (0.88, 1.59) 0.28 
Remote haemorrhage 5.21 (1.11, 24.57) 0.04 1.39 (0.20, 9.03) 0.75 
Subarachnoid haemorrhage 2.22 (1.50, 3.28) <0.0001 1.47 (0.97, 2.21) 0.07 
Intraventricular haemorrhage 2.61 (1.86, 3.67) <0.0001 1.92 (1.35, 2.74) <0.0001 
Cerebral atrophy 2.70 (1.99, 3.66)     <0.0001 1.46 (1.14, 1.86) 0.002 
Volume ABC/2 (cm3) 1.02 (1.01, 1.03) <0.0001 1.01 (0.99, 1.02) 0.56 
Largest measured diameter (cm) 1.12 (1.07, 1.32) <0.001 0.88 (0.74, 1.04) 0.14 
Largest visual diameter  2.52 (1.69, 3.76) <0.0001 1.24 (0.81, 1.89) 0.32 
Haemorrhage shape (/5) 1.36 (1.23, 1.51) <0.0001 1.28 (1.15, 1.42) <0.0001 
Haemorrhage density (/5) 1.42 (1.27, 1.60) <0.0001 1.27 (1.13, 1.42) <0.0001 
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Haematoma characteristics 
Univariate 
analyses 
OR/MD (95% CI) 
2p 
Co-variate adjusted 
OR/MD (95% CI) 
2p 
Shape index  1.04 (0.98, 1.12) 0.22 1.03 (0.96, 1.11) 0.38 
Density index  1.00 (1.00, 1.01) 0.24 1.00 (0.99, 1.01) 0.45 
Haemorrhages with IVH         
   Volume (ABC/2 cm3) 1.01 (0.99, 1.02) 0.19 1.00 (0.97, 1.03) 0.94 
   IVH volume (cm3) 1.02 (0.98, 1.06) 0.40 1.01 (0.97, 1.06) 0.56 
   Haemorrhage shape (/5) 1.31 (1.03, 1.67) 0.026 1.42 (1.11, 1.82) <0.0001 
   Haemorrhage density (/5) 1.69 (1.37, 2.11) <0.0001 1.49 (1.19, 1.86) <0.0001 
   Graeb score (12) 1.07 (0.94, 1.22) 0.31 1.03 (0.90, 1.18) 0.67 
   Modified Graeb score (32) 1.03 (0.96, 1.10) 0.45 1.00 (0.94, 1.08) 0.80 
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   Shape index 0.98 (0.91, 1.06) 0.63 0.99 (0.92, 1.08) 0.89 
   Density index 1.00 (1.00, 1.00) 0.13 1.00 (0.99, 1.00) 0.63 
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Table 4.6 Effect of treatment on neuroimaging measures at day 7 in 181 patients with a baseline scan prior to 
randomisation, for all patients with intracerebral haemorrhage and those randomised within 6 hours. Data are 
number (%), median [interquartile range], or mean (standard deviation), and odds ratio or mean difference with 
95% confidence intervals. Comparison by logistic regression, ordinal regression or multiple regression with 
adjustment for baseline value.  
 
Scan variables 
 
All Adjusted 
 
  GTN No GTN 
OR/MD 
2p 
(95% CI) 
Haematoma location  93 88 
  
Lobar (%) 10 (10.8) 11 (12.5) 1.24 (0.49, 3.15) 0.66 
Deep (%) 83 (89.2) 77 (42.5) 0.63 (0.10, 3.85) 0.61 
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Scan variables 
 
All Adjusted 
 
  GTN No GTN 
OR/MD 
2p 
(95% CI) 
Intraventricular haemorrhage (%)  25  (26.9) 19 (21.6) 0.85 (0.43, 1.70) 0.65 
Subarachnoid haemorrhage (%) 7 (7.5) 11 (12.5) 0.50 (0.17, 1.49) 0.21 
Mass effect (%)  79 (84.9) 81 (92.0)   1.04 (0.72, 1.50) 0.84 
Brain tissue reduction (%) 53 (57.0) 59 (67.0) 0.51 (0.24, 1. 10) 0.09 
Cortical atrophy (%) 44 (47.3) 42 (47.7) 1.26 (0.47, 3.36) 0.64 
Central atrophy (%) 48 (51.6) 58 (65.9) 0.92 (0.60, 2.10) 0.73 
Leukoaraiosis (%) 64 (68.8) 63 (71.6) 0.83 (0.37, 1.87) 0.66 
Previous stroke lesion (%) 41 (44.1) 51 (60.0) 0.57 (0.28, 1.16) 0.12 
Visual longest diameter (cm) 
  
0.66 (0.34, 1.27) 0.21 
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Scan variables 
 
All Adjusted 
 
  GTN No GTN 
OR/MD 
2p 
(95% CI) 
    <3 38 (40.1) 36 (40.9) 
  
    3-5 46 (49.5) 28 (31.8) 
  
    5-8 6 (6.5) 20 (22.7) 
  
    >8 3 (3.2) 4 (4.5) 
  
Volume ABC/2 (cm3) 15.4 (16.0) 19.2 (21.4) -4.30 (-8.78, 0.23) 0.06 
Largest measured diameter 3.6 (1.3) 3.8 (1.6) -0.04 (-0.33, 0.25) 0.81 
Shape index 1.7 (0.8) 1.7 (1.0) -0.04 (-0.31, 0.24) 0.80 
Shape [/5] 2 [2,3] 2 [1,3] 0.14 (-0.19, 0.47) 0.41 
Density index 0.4 (0.7) 0.3 (0.5) 0.10 (-0.07, 0.28) 0.27 
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Scan variables 
 
All Adjusted 
 
  GTN No GTN 
OR/MD 
2p 
(95% CI) 
Density [/5] 2 [1,3] 2 [1,3] 0.12 (-0.18, 0.43) 0.43 
 
No IVH (n=137) 
    
 
  
Volume ABC/2(cm3) 14.7 (15.3) 18.4 (18.4) -4.52 (-9.05, 0.01) 0.05 
Shape index 1.5 (0.6) 1.7 (1.0) -0.12 (0.42, 0.17) 0.42 
Shape [/5] 2 [1,3] 2 [2,3] 0.04 (-0.31, 0.39) 0.82 
Density index 0.4 (0.9) 0.3 (0.7) 0.15 (-0.11, 0.41) 0.26 
Density [/5] 2 [1,3] 2 [1,3] 0.34 (-0.03, 0.71) 0.07 
With IVH (n=44)         
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Scan variables 
 
All Adjusted 
 
  GTN No GTN 
OR/MD 
2p 
(95% CI) 
Volume ABC/2(cm3) 17.1(17.9) 18.4 (17.4) -0.64 (-8.53, 7.24) 0.87 
IVH volume (cm3) 3.0 (6.0) 3.7 (5.9) 0.52 (-4.96, 6.01) 0.85 
Shape index 2.0 (1.0) 2.1 (1.2) -0.12 (-0.79, 0.55) 0.73 
Shape [/5] 4 [3,5] 4 [3,5] 1.00 (0.50, 1.99) 0.99 
Density index 0.3 (0.1) 0.3 (0.1) -0.01 (-0.06, 0.04) 0.66 
Density [/5] 2 [1,3] 2 [1,3] 0.00 (-0.64, 0.63) 1.00 
Graeb score 2.9 (1.8) 2.1 (1.3) 0.94 (-0.25, 2.12) 0.12 
Modified Graeb score 3.4 (2.7) 2.5 (2.2) 1.23 (-0.59, 3.05) 0.18 
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Figure 4.1 Blood pressure levels for patients with 
intracerebral haemorrhage during 7 days treatment for GTN 
versus no GTN group. Blood pressure was 172/93 mm Hg at 
baseline and after the first dose was significantly lower in 310 
patients allocated to GTN as compared to 319 patients 
randomised to no GTN: difference -7.5/-4.2 mm Hg. There 
was no significant difference thereafter. MD signifies mean 
difference in systolic and diastolic blood pressure between the 
two treatment groups. 
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Figure 4.2 Distribution of modified Rankin scores for all 625 
patients with intracerebral haemorrhage at day 90: glyceryl 
trinitrate versus no glyceryl trinitrate. Comparison by ordinal 
logistic regression adjusted for age, sex, premorbid mRS, 
history of previous stroke, history of diabetes, total anterior 
circulation syndrome, systolic blood pressure, feeding status, 
time to randomisation, and allocation to continue or stop pre-
stroke antihypertensive drugs. Adjusted common odds ratio 
1.04 (95% CI 0.78, 1.38), p=0.81. 
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Figure 4.3 Effect of glyceryl trinitrate versus no glyceryl 
trinitrate on distribution of modified Rankin Scale in pre-
specified clinical subgroups of patients with intracerebral 
haemorrhage at day 90. Analysis adjusted for age, sex, pre-
morbid mRS, history of previous stroke, history of diabetes, 
severity, total anterior circulation syndrome, volume of 
intracerebral haemorrhage, systolic blood pressure, feeding 
status and time to randomisation. Black squares indicate point 
estimates (with the area of the square proportional to the 
number of events) and the width of the horizontal lines is the 
95% confidence interval of the estimate. The rectangle at the 
bottom represents the point estimate as well as the 95% 
confidence intervals of the overall effect within categories. 
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Figure 4.4 Effect of glyceryl trinitrate versus no glyceryl 
trinitrate on the primary outcome of modified Rankin Scale in 
pre-specified neuroimaging subgroups at day 90. Analysis 
adjusted for age, sex, pre-morbid mRS, history of previous 
stroke, history of diabetes, severity, total anterior circulation 
syndrome, volume of intracerebral haemorrhage, systolic 
blood pressure, feeding status and time to randomisation. 
Black squares indicate point estimates (with the area of the 
square proportional to the number of events) and the width of 
the horizontal lines is the 95% confidence interval of the 
estimate. The rectangle at the bottom represents the point 
estimate as well as the 95% confidence intervals of the overall 
effect within categories. 
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Figure 4.5 Effect of glyceryl trinitrate versus no glyceryl 
trinitrate on survival to day 90 in patients with intracerebral 
haemorrhage. Comparison by Cox proportional hazards 
regression adjusted for age, sex, premorbid mRS, history of 
previous stroke, history of diabetes, total anterior circulation 
syndrome, systolic blood pressure, feeding status, time to 
randomisation, and allocation to continue versus stop pre-
stroke antihypertensive drugs. Adjusted hazard ratio 1.02 
(95% CI 0.67-1.56), p=0.92. 
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Figure 4.6 Distribution of modified Rankin scores for patients 
randomised within 6 hours at day 90: glyceryl trinitrate 
(n=29) versus no glyceryl trinitrate (n=32). Comparison by 
ordinal logistic regression adjusted for age, sex, premorbid 
mRS, history of previous stroke, history of diabetes, total 
anterior circulation syndrome, systolic blood pressure, feeding 
status, time to randomisation, and allocation to continue 
versus stop pre-stroke antihypertensive drugs. Adjusted 
common odds ratio 0.19 (95% CI 0.06, 0.59), p=0.004. 
 
 
 
 
 
 
  
020406080100
No GTN
GTN
6
5
4
  
216 
 
 
Chapter 5 - The effects of continue versus 
stopping pre-stroke antihypertensive drugs in 
acute intracerebral haemorrhage  
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ABSTRACT 
 
Background and purpose 
More than 50% of patients with acute intracerebral 
haemorrhage (ICH) are taking antihypertensive drugs before 
ictus. Although antihypertensive therapy should be given long 
term for secondary prevention, whether to continue or stop 
such treatment during the acute phase of ICH remains 
unclear, a question that was addressed in the Efficacy of Nitric 
oxide in Stroke (ENOS) trial. 
 
Methods 
ENOS was an international multicentre, prospective, 
randomised, blinded end-point trial. Among 629 patients with 
ICH and systolic blood pressure between 140-220 mm Hg, 
246 patients who were taking antihypertensive drugs were 
assigned to continue (n=119) or stop temporarily (n=127) 
drugs for 7 days. The primary outcome was the modified 
Rankin Score at 90 days. Secondary outcomes included death, 
length of stay in hospital, discharge destination, activities of 
daily living, mood, cognition and quality of life. 
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Results 
Blood pressure (baseline 171/92 mm Hg) fell in both groups 
but was significantly lower at 7 days in those patients 
assigned to continue antihypertensive drugs (difference 
9.4/3.5mm Hg; p<0.01). At 90 days, the primary outcome did 
not differ between the groups, adjusted common odds ratio 
for worse outcome with continue versus stop drugs; OR 0.92 
(95 % CI, 0.45-1.89; p=0.83). There was no difference 
between the treatment groups for any secondary outcome 
measure, or rates of death or serious adverse events. 
 
Conclusion 
Among patients with acute ICH, immediate continuation of 
antihypertensive drugs during the first week did not reduce 
death or major disability in comparison with stopping 
treatment temporarily. 
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5.1 Introduction 
 
High blood pressure (BP) is present in 75% of patients with 
acute intracerebral haemorrhage (ICH) and is substantially 
higher than premorbid levels._401-403 More than 50% of 
patients with acute ICH are taking antihypertensive drugs 
prior to their stroke and hospital admission.  
 
Although lowering BP long term after stroke is key for 
secondary prevention,404 it remains unclear whether pre-
stroke antihypertensive drugs should be continued or stopped 
temporarily during the acute phase.405 Arguments both for and 
against each strategy can be postulated and guidelines lack 
firm recommendations related to this subject.135, 406 
Continuing prior antihypertensive drugs after ICH might limit 
haematoma expansion, reduce the development of cerebral 
oedema and early recurrence, and improve long-term 
outcome.404, 407 And yet, continuing treatment may lead to the 
development of hypotension thereby compromising regional 
cerebral perfusion because of dysfunctional cerebral 
autoregulation.408 Further, continuing treatment involves 
administering tablets at a time when many patients have 
dysphagia and limited enteral access, a risk for aspiration 
pneumonia. Stopping treatment may result in secondary 
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prevention being forgotten thereby raising the risk of 
recurrent events and worsening outcomes long term. 
 
Two trials have examined the question of whether pre-stroke 
BP drugs should be continued or stopped temporarily during 
the acute phase of stroke. COSSACS found no difference in 
functional outcome, death, or serious adverse events, 
although it had low statistical power with only 763 participants 
recruited of a planned 2900 patients.409 No differential effect 
in patients with ICH versus ischaemic stroke were reported. 
The Efficacy of Nitric Oxide trial (ENOS) trial assessed the 
effects of glyceryl trinitrate (GTN) versus no GTN in 4011 
participants with acute stroke; patients who were taking pre-
stroke antihypertensive medications were also randomised to 
continue or stop these for seven days in a partial factorial 
design.364 Although ENOS was neutral for both 
interventions,137 a subgroup of patients randomised to 
continue treatment within 12 hours had a worse functional 
outcome (unpublished data), an effect also seen in a meta-
analysis of individual patient data from COSSACS and ENOS 
combined (Woodhouse et al, unpublished). Here, we report 
the results of a pre-planned subgroup analysis of patients 
enrolled into ENOS with ICH and who were randomised to 
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continue versus stop pre-stroke antihypertensive therapy,387 
including those randomised within 12 hours of stroke onset. 
 
5.2 Methods 
 
5.2.1 ENOS trial 
 
Details of the ENOS study protocol, statistical analysis plan, 
patient characteristics at baseline, and main results, have 
been published (ISRCTN99414122).137, 374, 387 
 
In participants assigned to continue antihypertensive drugs, 
medication was administered orally and those with dysphagia 
received treatment through a nasogastric feeding tube. If oral 
or tube feeding was not possible, treatment was withheld until 
feasible. Open label antihypertensive drugs could be 
administered during the treatment period according to clinical 
need. During treatment, BP was measured once daily using a 
validated automatic clinical monitor (Omron HEM-705 CP or 
HEM-757, Illinois, USA)388 with a cuff of suitable size. After 
day 7, antihypertensive therapy that had been stopped was 
re-started according to clinical need. In this subgroup 
analysis, we included all patients with ICH recruited into the 
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continue versus stop pre-stroke antihypertensive drugs part of 
ENOS. 
 
5.3 Outcomes 
 
As detailed in chapter 2, the primary outcome was the 
modified Rankin Scale (mRS, scores: 0=no residual disability; 
5= bedbound and requiring 24 hour care; 6=death410) 
assessed at day 90. Key secondary outcomes were activities 
of daily living (Barthel Index, BI, scores: 0=severe disability 
to 100=no disability411), cognition (modified telephone Mini-
Mental State Examination, t-MMSE, scores: 0=severe 
dementia to 18=normal;390 Telephone Interview for Cognition 
Scale, TICS-M, scores: 0=severe dementia to 37=normal;391 
verbal fluency as animal naming, scores: 0=none to infinity); 
health-related quality of life (European Quality of Life-5 
dimensions, EQ-5D,392 from which health utility status (HUS) 
was calculated, scores: -0.594=very poor, 0=death to 
1.0=perfect;392 European Quality of Life-Visual analogue scale, 
EQ-VAS, scores: 0=very poor to 100=excellent) and mood 
(short Zung depression Score, ZDS, scores: 0=normal to 
100=severe depression 394). Safety outcomes included death, 
early neurologic deterioration (defined as a decrease of at 
least 5 points on the SSS from baseline to day 7 and/or 
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decrease in consciousness of more than 2 points on the SSS 
consciousness domain), recurrent stroke by day 7, 
hypotension (requiring intervention such as leg elevation or 
administration of fluids), hypertension (requiring treatment to 
lower BP) and serious adverse events. Serious adverse events 
whether related to treatment (definite, uncertain, no causality, 
unknown) and the systems affected by the adverse event 
were recorded by the local investigators. 
 
5.4 Imaging 
 
Brain imaging adjudication and haemorrhage quantification in 
ENOS are detailed in chapter 2 and 3. All imaging 
assessments were performed by a single investigator (KK), 
masked to clinical data and treatment assignment. 
 
5.5 Analyses 
 
As for the mRS and HUS, which have a separate category for 
death, we assigned an extreme score for death when 
analysing each of the other outcome scale. Values used were: 
-5: Barthel Index; -1: EQ-VAS, SSS, t-MMSE, TICS-M, verbal 
fluency; 0: EQ-5D/HUS; 102.5: ZDS.137, 387 Comparisons were 
performed with binary logistic regression (dichotomous data), 
Cox regression (death), ordinal logistic regression (ordered 
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categorical data),412 or multiple linear regression (continuous 
data). Analyses were adjusted for prognostic covariates: age, 
sex, pre-morbid mRS, history of previous stroke, history of 
diabetes, severity (Scandinavian Stroke Scale, SSS), stroke 
syndrome (total anterior circulation vs other), systolic BP, 
feeding status, time to randomisation, and treatment 
assignment (GTN vs no GTN). Heterogeneity of treatment 
effect was assessed by including an interaction term in the 
adjusted statistical model for each of the following pre-defined 
subgroups: age, time to randomisation, presence of ipsilateral 
carotid stenosis, number of pre-stroke antihypertensive drugs, 
feeding status, stroke severity, blood pressure level at time of 
randomisation, feeding status, and treatment with GTN or no 
GTN. Analysis was performed using SPSS software (SPSS 
Statistics, Chicago, IL) version 22 on an Apple iMac computer. 
P values <0.05 were considered as statistically significant. 
 
5.6 Results 
 
Recruitment into ENOS ran between July 2001 and October 
2014. During this period 629 patients with ICH were recruited 
into the trial, with 246 patients randomised to continue 
(n=119) or stop (n=127) antihypertensive drugs (Table 5.1). 
39 patients were randomised within 12 hours (continue 18, 
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stop 21). The treatment groups were well matched at 
baseline, with mean age 69 years; male 59%, mean BP 
171/92 mmHg and severity SSS 29.6 (NIHSS ~13.0 with 
mean ICH volume 12.0 cm3). Most haematomas (89%) were 
located primarily in the deeper brain regions and many 
patients had leukoaraiosis (70%) and/or evidence of a 
previous stroke (51%) (Table 5.2); 72% of neuroimaging was 
performed within 12 hours of stroke onset. 
 
5.6.1 Blood pressure 
 
Mean blood pressure was 171/92 mmHg at baseline and 
declined in both groups over the seven days of randomised 
treatment; by day 7, BP was lower by 9/4 mmHg in the group 
randomised to continue treatment (Figure 5.1). Baseline BP 
was 176/97 mmHg in patients randomised with 12 hours, and 
was lower by 28/16 mmHg at day 7 in those continuing 
treatment (Figure 5.2). 
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5.6.2 Clinical outcomes 
 
There was no difference in mRS between the treatment groups 
at day 90, common odds ratio (OR) for worse outcome in the 
continue group 0.92 (95%CI 0.45-1.89; p=0.83) (Figure 5.3). 
A test of ‘goodness-of-fit’ showed no evidence that the 
assumption of proportional odds had been violated (p=0.07). 
There were no significant interactions between the effect of 
randomised treatment on mRS in pre-selected subgroups 
(Figure 5.4). Additionally, there was no difference in mRS in 
patients randomised within 12 hours to continue versus stop 
prestroke BP drugs (Figure 5.5). The rates of clinical 
hypotension and hypertension were similar between the two 
groups (Table 5.3). There were no significant differences 
between the two groups at day 90 in any of the secondary 
clinical outcomes (Table 5.3) or death (Figure 5.6), or serious 
adverse rates (Table 5.4). 
 
 
5.7 Discussion 
 
In this pre-planned subgroup analysis of patients in ENOS with 
acute ICH, there was no difference in the primary outcome of 
function between patients randomised to 7 days of continuing 
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versus stopping pre-stroke antihypertensive therapy;387 this 
finding was consistent across all pre-specified subgroups of 
patients. Similarly, there were no differences in safety 
outcomes, or secondary outcome measures at day 90.  
 
The overall neutral results seen for the continue versus stop 
comparison in ENOS (including both ischaemic stroke and 
ICH)137 are similar to those seen in the smaller COSSACS 
trial.409 COSSACS recruited only 38 patients with ICH and has 
not reported these results separately; hence this subgroup 
cannot be compared with the present substudy. Nevertheless, 
the two trials differed in several key aspects including time 
window for recruitment, exclusion or inclusion of dysphagia 
(and so differences in baseline severity), baseline BP, length 
of treatment, and timing of measurement of the primary 
endpoint. In an individual patient data meta-analysis of 
COSSACS and ENOS combined, no difference in mRS was seen 
in 284 patients with ICH who were randomised to continue 
versus stop pre-stroke antihypertensive therapy (Woodhouse 
et al, unpublished). In that meta-analysis, mRS was worse in 
patients randomised to continue treatment, irrespective of 
stroke type, if enrolled within 12 hours of onset. This finding 
was present in ENOS (unpublished data) but is not replicated 
in the present sub-study, presumably due to the small number 
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of patients and wide confidence intervals. Blood pressure 
lowering might reduce death or major disability if treatment is 
started within 6 hours of stroke.260, 261, 264 However, the 
present analysis assessed the issue of continuing or stopping 
pre-existing antihypertensive treatment (where differences in 
BP between the treatment groups take days to develop), 
whereas the other trials initiated antihypertensive treatment 
in the hyperacute phase of stroke. Since it took several days 
for BP to differ between the randomised groups, it appears 
that short term high BP, as occurred in the group that were 
randomised to stop treatment temporarily, is not detrimental 
providing the difference occurs after the hyperacute period. 
Importantly, this observation appears to apply to those 
recruited within 12 hours where BP was higher by 28/16 
mmHg at one week in those stopping treatment temporarily, a 
BP difference that was not associated with a worse outcome. 
 
The strengths of the present study are two-fold. First, it 
assessed a broad population of patients with ICH, with 
international enrolment from multiple race-ethnicity groups, 
and inclusion of patients with a wide range of severity, 
including those with dysphagia. And second, the data come 
from a high fidelity trial with blinded assessment of outcomes, 
independent and masked adjudication of events, and near 
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complete follow-up.137 However, two limitations should be 
noted. First, ENOS excluded patients with very high blood 
pressure, reduced consciousness (GCS<8), or without motor 
signs. As a result, patients with large haemorrhages may have 
been underrepresented. Second, fewer than 5% of patients 
had bleeding into the posterior fossa and therefore the results 
cannot be extrapolated to a population with posterior fossa 
haemorrhages. Recent observational data have shown that the 
blood pressure rise is steeper, and final levels higher, in such 
patients as compared with lobar haemorrhages.403 
 
In conclusion, this subgroup analysis of ENOS was neutral and 
did not identify any beneficial effects in continuing pre-stroke 
antihypertensive drugs in patients during the first week after 
acute ICH. Although BP lowering reduces chronic stroke 
recurrence, the present results suggest it is reasonable to 
withhold antihypertensive drugs taken before the onset of ICH 
until patients are neurologically stable and appropriate enteral 
or oral access has been established. 
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Table 5.1 Baseline clinical characteristics of 246 patients with intracerebral haemorrhage and those randomised 
within 12 hours. Data are number (%), mean (standard deviation) or median [interquartile range]. Comparison of 
patients randomised within 12 hours versus those later by Fischer’s exact test, Mann-Whitney U test or t test. 
 
Characteristics All Continue Stop <12 hours Continue Stop 2p 
Number of patients (N) 246 119 127 39 18 21   
Country, UK (%) 138 (56.1) 68 (57.1) 70 (55.1) 20 (51.3) 10 (55.6) 10 (47.6) 0.52 
Age (years) 69.2 (11.5) 68.8 (11.3) 69.6 (11.6) 68.3 (13.0) 67.1 (13.7) 69.3 (12.6) 0.58 
Sex, male (%) 144 (58.5) 70 (58.8) 74 (58.3) 25 (64.1) 13 (72.2) 12 (57.1) 0.44 
Smoking, current (%) 37 (15.5) 20 (17.4) 17 (13.8) 4 (10.8) 2 (11.8) 2 (10.0) 0.19 
Pre-morbid mRS>0 (%) 81 (32.9) 43 (36.1) 38 (29.9) 9 (23.1) 5 (27.8) 4 (19.0) 0.23 
Previous stroke (%) 45 (18.3) 20 (16.8) 25 (19.7) 3 (7.7) 0 3 (14.3) 0.06 
Prior antihypertensive (%) 241 (98.0) 116 (97.5) 125 (98.4) 39 (100.0) 18 (100.0) 21 (100.0) 0.33 
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Number of BP drugs (%)               
   0      3 (1.2) 1 (0.8)      2 (1.6) - - - - 
   1 107 (43.5) 55 (46.2) 52 (40.9) 20 (51.3) 13 (72.2) 7 (33.3) 0.22 
   2 58 (23.6) 28 (23.5) 30 (23.6) 9 (23.1) 3 (16.7) 6 (28.6) 0.47 
   3 25 (10.2) 8 (6.7) 17 (13.4) 5 (12.8) 1 (5.6) 4 (19.0) 1.00 
   4 11 (4.5) 4 (3.4) 7 (5.5) 2 (5.1) 1 (5.6) 1 (4.5) 1.00 
   5 1 (0.4) 1 (0.8) 0 - - - - 
Treated BP agent (%)               
   ACE-inhibitor 106 (43.1) 51 (42.9) 55 (43.3) 17 (43.6) 6 (33.3) 11 (52.4) 0.29 
   ARA 49 (19.9) 24 (20.2) 25 (19.7) 5 (12.8) 1 (5.6) 4 (19.0) 0.35 
   ß-receptor antagonist 70 (28.5) 26 (21.8) 44 (34.6) 10 (25.6) 3 (16.7) 7 (33.3) 0.73 
   Calcium channel blocker 95 (38.6) 43 (36.1) 52 (40.9) 18 (46.2) 5 (27.8) 13 (61.9) 0.12 
   Centrally acting agent 8 (3.3) 4 (3.4) 4 (3.1) 2 (5.1) 1 (5.6) 1 (4.8) 1.00 
   Diuretic 63 (25.6) 34 (28.6) 29 (22.8) 11 (28.2) 7 (38.9) 4 (19.0) 0.53 
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   Alpha-receptor antagonist 13 (5.3) 8 (6.7) 5 (3.9) 3 (7.7) 2 (11.1) 1 (4.8) 1.00 
   Other 3 (1.2) 1 (0.8) 2 (1.6) 0 - - - 
Previous high BP (%) 238 (96.7) 115 (96.6) 123 (96.9) 39 (100.0) 18 (100.0) 21 (100.0) 0.21 
Diabetes mellitus (%) 49 (19.9) 22 (18.5) 27 (21.3) 10 (25.6) 4 (22.2) 6 (28.6) 0.33 
Ischaemic heart disease (%) 39 (15.9) 18 (15.1) 21 (16.5) 4 (10.3) 1 (5.6) 3 (14.3) 0.58 
Atrial fibrillation (%) 28 (11.4) 13 (10.9) 15 (11.8) 5 (12.8) 1 (5.6) 4 (19.0) 0.75 
TACS (%) 89 (36.2) 44 (37.0) 45 (35.4) 10 (25.6) 8 (44.4) 2 (9.5) 0.15 
SSS (/58) 29.6 (12.6) 28.5 (12.3) 30.6 (12.9) 31.3 (11.4) 27.4 (12.4) 34.6 (9.4) 0.37 
   NIHSS (/42), calculated 
379 
13.0 (5.4) 13.4 (5.3) 12.5 (5.5) 12.2 (4.9) 13.9 (5.4) 10.8 (5.4) 0.37 
Glasgow Coma Scale [/15] 15 [1] 15 [1] 15 [1] 15 [1] 15 [1] 15 [0] 0.13 
Systolic BP (mmHg) 170.8 (18.4) 
169.5 
(16.9) 
172.1 
(19.7) 
175.8 (17.9) 175.0 (16.6) 
176.4 
(19.3) 
0.07 
Diastolic BP (mmHg) 92.3 (13.4) 93.3 (14.0) 91.4 (12.8) 96.5 (11.7) 95.6 (14.1) 97.3 (9.5) 0.031 
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Heart rate (bpm) 77.4 (15.8) 77.9 (15.9) 77.0 (15.9) 79.2 (17.9) 80.3 (15.1) 78.2 (20.3) 0.22 
Feeding status               
Normal diet 77 (31.3) 43 (36.1) 34 (26.8) 15 (38.5) 6 (33.3) 9 (42.9) 0.28 
Soft diet 58 (23.6) 22 (18.5) 36 (28.3) 10 (25.6) 7 (38.9) 3 (14.3) 0.09 
Nasogastric tube feeding 15 (6.1) 7 (5.9) 8 (6.3) 2 (5.1) 1 (5.6) 1 (4.8) 1.00 
Percutaneous feeding tube 0 - - - - - - 
IV/SC fluids 45 (18.3) 20 (16.8) 25 (19.7) 4 (10.3) 2 (11.1) 2 (9.5) 1.00 
 
ARA: angiotensin receptor antagonist; BP: blood pressure; bpm: beats per minute; IV: intravenous; mRS: 
modified Rankin scale; NIHSS: National Institutes of Health Stroke scale; NIHSS: National Institute of Health 
Stroke scale; SC: subcutaneous; SSS: Scandinavian Stroke Scale; TACS: total anterior circulation syndrome. 
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Table 5.2 Baseline neuroimaging characteristics of 246 patients with intracerebral haemorrhage and those 
randomised within 12 hours. Data are number (%) or mean (standard deviation). Comparison of patients 
randomised within 12 hours with those randomised later by Fisher’s exact test, Mann-Whitney U test or t test. 
 
Neuroimaging parameters All Continue Stop <12 hours Continue Stop 2p 
Participants with a scan 
available 
234 (95.1) 115 (96.6) 119 (93.7) 35 (89.7) 17 (94.4) 18 (85.7)  
Time, onset to 
neuroimaging (%) 
       
   <12 hours 169 (72.2) 84 (73.0) 85 (71.4) 33 (94.3) 17 (100.0) 16 (88.9) 0.89 
   12-24 hours 38 (16.2) 19 (16.5) 19 (16.0) 1 (2.9) - 1 (5.6) - 
   >24 hours 27 (11.5) 12 (10.4) 15 (12.6) 1 (2.9) - 1 (5.6) - 
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Location of haematoma 
(%) 
       
   Lobar † 18 (7.7) 6 (5.2) 12 (10.1) 3 (8.6) 2 (11.8) 1 (5.6) 0.41 
   Deep ‡ 207 (88.5) 107 (93.0) 100 (84.0) 32 (91.4) 15 (88.2) 17 (94.4) 0.10 
   Posterior ¶ 9 (3.8) 2 (1.7) 7 (5.9) - - - 0.28 
ICH Volume ABC/2 
(cm3)413  
12.1 (14.0) 11.5 (13.6) 12.8 (14.5) 13.1 (17.0) 21.1 (20.5) 5.2 (6.3) 0.67 
IVH volume (cm3) 3.1 (4.6) 3.1 (4.5) 3.0 (4.8) 3.9 (3.4) 5.1 (3.5) 1.8 (2.3) 0.61 
Longest diameter (cm) 3.2 (1.4) 3.2 (1.3) 3.3 (1.5) 3.3 (1.5) 3.8 (1.6) 2.8 (1.2) 0.76 
Visual ICH size category 
(cm)367 
       
   <3 113 (49.1) 53 (46.9) 60 (51.3) 17 (48.6) 5 (29.4) 12 (66.7) 0.25 
   3-5 80 (34.8) 42 (37.2) 38 (32.5) 10 (28.6) 6 (35.3) 4 (22.2)  
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   5-8 35 (1.2) 17 (15.0) 18 (15.4) 8 (22.9) 6 (35.3) 2 (11.1)  
   >8 2 (0.9) 1 (0.9) 1 (0.9) - - -  
Shape (/5)212  3.3 (1.3) 3.4 (1.5) 3.2 (1.4) 3.4 (1.5) 4.0 (1.4) 2.8 (1.3) 0.69 
   Index 363 1.7 (3.1) 1.8 (4.0) 1.6 (1.7) 1.7 (1.3) 2.2 (1.4) 1.3 (1.1) 0.34 
Density (/5) 378 2.7 (1.4) 2.6 (1.3) 2.8 (1.4) 2.7 (1.4) 2.8 (1.4) 2.5 (1.4) 0.84 
   Index 362 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.34 
Graeb score 240 3.4 (2.2) 3.3 (2.1) 3.4 (2.3) 4.9 (2.1) 6.2 (0.8) 2.7 (1.5) 0.033 
   Modified241  5.0 (4.4) 4.9 (3.5) 5.2 (4.8) 8.0 (4.4) 10.4 (3.5) 4.0 (2.0) 0.034 
Leukoaraiosis (%) 171 (73.1) 82 (71.3) 89 (78.8) 21 (60.0) 10 (58.8) 11 (61.1) 1.00 
Mass effect (%)        
   No swelling to mild 
swelling (%) 
98 (41.9) 47 (40.9) 51(42.9) 17 (48.6) 5 (29.4) 12 (66.7) 0.55 
 237 
 
   Moderate to severe 
swelling (%) 
33 (14.1) 18 (15.7) 15 (12.6) 18 (51.4) 12 (70.6) 6 (33.3) 0.14 
Previous stroke lesion (%) 126 (53.8) 60 (52.2) 66 (55.5) 20 (57.1) 10 (58.8) 10 (55.6) 0.06 
Brain tissue reduction (%) 153 (65.4) 77 (67.0) 76 (63.9) 22 (62.9) 12 (70.6) 10 (55.6) 0.42 
Cortical atrophy (%) 119 (50.9) 58 (50.4) 61 (51.3) 15 (42.9) 6 (35.3) 9 (50.0) 0.70 
Central atrophy (%) 146 (62.4) 72 (62.6) 74 (62.2) 22 (62.9) 12 (70.6) 10 (61.1) 0.65 
† Lobar: ICH centred on borderzone regions, ACA, PCA territory and MCA territory excluding striatocapsular 
regions 
‡ Deep: ICH centred on lacunar, MCA territory including striatocapsular regions 
¶ Posterior: ICH centred on cerebellum and or brainstem 
Shape index363 = haematoma perimeter / 4∏ x surface area 
Density index362 = standard deviation/mean of Hounsfield units  
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Table 5.3 Primary and secondary outcomes at day 7 and day 90: continue versus stop pre-stroke 
antihypertensive drugs. Data are number of patients (%), median [interquartile range], or mean (standard 
deviation). Comparison by logistic regression, ordinal regression or multiple regression, shown as odds ratio (OR) 
or mean difference (MD), with adjustment for age, sex, pre-morbid mRS, history of previous stroke, history of 
diabetes, stroke severity, stroke syndrome (total anterior circulation), systolic blood pressure, feeding status, time 
to randomisation, and treatment assignment (glyceryl trinitrate versus none). 
Outcome N All Continue Stop 
Unadjusted 
OR/MD (95%CI) 
2p 
Adjusted 
OR/MD (95% CI) 
2p 
Day 7 (or discharge)   246 119 127         
Death (%) 246 6 (2.4) 2 (1.7) 4 (3.2) 0.53 (0.09, 2.92) 0.46 0.47 (0.07, 3.01)  0.58 
SSS (/58) 244 33.2 (16.1) 33.1 (16.3) 33.3 (15.9) -0.3 (-4.3, 3.8) 0.90 -0.8 (-4.0, 2.5) 0.64 
Recurrent stroke 
(%) 
245 6 (2.5) 3 (2.5) 3 (2.4)  1.06 (0.21, 5.36)  0.37 1.01 (0.18, 5.92) 0.99 
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SBP (mmHg) 210  155.4 (26.0)  150.6 (26.4) 160 (24.9) -6.2 (-12.2, -0.2) 0.043 -7.5 (-14.7, -0.3) 0.037 
Hypotension (%) 246 3 (1.2) 2 (1.7) 1 (0.8) 2.15 (0.19, 24.07) 0.53 0.09 (0.00, 6.06) 0.26 
Hypertension (%) 246 36 (14.6) 15 (12.6) 21 (16.5) 0.73 (0.36, 1.49) 0.39 0.77 (0.57, 2.92) 0.54 
Hospital events   244 118 126         
Died in hospital (%) 244 28 (11.5) 14 (11.9) 14 (11.1) 1.08 (0.49, 2.37) 0.86 1.03 (0.35, 2.38) 0.85 
Hospital Stay (days) 244 11 [7,33] 12 [7,33] 11 [7,27] -1.67 (-8.38, 5.03) 0.62 -0.68 (-7.09, 5.72)  0.83 
Death or institution 
(%) 
244 105 (43.0) 51 (43.2) 54 (42.9) 0.76 (0.45, 1.27) 0.29 0.69 (0.38, 1.24) 0.22 
Day 90     119 126         
Death (%) 245 42 (17.1) 19 (16.0) 23 (18.3) 0.85 (0.44, 1.66) 0.64 0.82 (0.37, 1.82) 0.72 
mRS (/6) 245 3.5 (1.7) 3.5 (1.7) 3.5 (1.6) 1.0 (0.7, 1.6) 0.94 1.0 (0.7, 1.6) 0.86 
Barthel Index 245 57.4 (39.8) 57.1 (39.8) 57.6 (40.0) -0.6 (-10.6, 9.5) 0.91 -3.2 (-11.7, 5.3) 0.45 
tMMSE 141 9.1 (7.43) 9.0 (7.4) 9.2 (7.5) -0.2 (-2.7, 2.3) 0.89 -1.1 (-3.2, 0.9) 0.28 
TICS-M 130 18.9 (15.9) 19.2 (15.9) 18.6 (15.9) 0.7 (-4.9, 6.2) 0.82 -1.4 (-6.1, 3.3) 0.55 
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Animal naming (/∞) 136 7.2 (7.5) 7.2 (7.3) 7.2 (7.7) -0.6 (-3.1, 1.9) 0.64 -0.6 (-3.3, 2.1) 0.66 
ZDS (/100) 197 64.3 (24.0) 64.1 (23.4) 64.4 (24.7) -0.3 (-7.1, 6.4) 0.92 1.7 (-4.2, 7.7) 0.57 
EQ-5D/HUS (/1) 244 0.42 (0.31) 0.40 (0.30) 0.43 (0.33) -0.03 (-0.11, 0.05) 0.52 -0.04 (-0.11, 0.03) 0.24 
EQ-VAS (/100) 213 50.1 (31.5) 50.9 (31.0) 49.4 (32.1) 1.6 (-7.0, 10.1) 0.72 -1.9 (-9.6, 5.9) 0.64 
 
BI: Barthel Index; EQ-5D: EuroQol-5 dimensions; EQ-VAS: EuroQol-Visual Analogue Scale; HUS: Health utility 
status; ICH: intracranial haemorrhage; mRS: modified Rankin Scale; t-MMSE: Modified telephone Mini-Mental 
State Examination; SAE: serious adverse event; SBP: systolic blood pressure; SSS: Scandinavian Stroke Scale; 
TICS-M: Modified Telephone Interview for Cognitive Status; VAS: Visual Analogue Scale; ZDS: Zung Depression 
Scale.  
Range of scores: 
Scandinavian Stroke Scale (SSS): -1 (death) to 0 (coma with quadriplegia) to 58 (normal neurological status). 
Barthel Index: -5 (death) to 0 (severe disability) to 100 (no disability). 
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Modified telephone Mini-Mental State Examination (t-MMSE): -1 (death), 0 (severe dementia) to 18 (normal). 
Modified Telephone Interview for Cognitive Status (TICS-M): -1 (death, 0 (severe dementia) to 37 (normal). 
Verbal fluency (number of animals named in one minute): -1 (death), 0 (none named) to infinity.  
Health utility status (HUS, derived from European Quality of Life-5 dimensions, EQ-5D): -0.5 (very poor quality of 
life, 0 (death) to 1.0 (perfect quality of life). European Quality of Life-Visual Analogue Scale (EQ-VAS): -1 (death), 
0 (very poor) to 100 (excellent). Zung Depression Scale (ZDS): 0 (normal), 100 (severe depression) to 102.5 
(death) 
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Table 5.4 Serious adverse events at day 90 for continue versus stop pre-stroke antihypertensive drugs in 246 
patients with intracerebral haemorrhage. Data are number of patients (%) and mean (standard deviation). 
Adverse event Continue Stop 2p Continue Stop 2p 
  All   Fatal  
Neurological † 10 (8.4) 14 (11.0) 0.50 6 (5.0) 8 (6.3) 0.67 
Cardiac ‡ 4 (3.4) 10 (7.9) 0.17 2 (1.7) 2 (1.6) 1.00 
Pulmonary embolism 1 (0.8) 2 (1.6) 1.00 1 (0.8) 0 (0.0) 0.48 
Pneumonia 8 (6.7) 8 (6.3) 0.89 6 (5.0) 4 (3.1) 0.53 
Other causes 0 (0.0) 1 (0.8) 1.00 - - - 
Total 27 (22.7) 35 (27.6) 0.38 6 (33.3) 4 (19.0) 0.46 
† Includes complication of initial stroke, extension of initial stroke, symptomatic intracranial haemorrhage and 
recurrent stroke 
‡ Includes myocardial infarction, sudden cardiac death and other cardiovascular causes 
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Figure 5.1 Blood pressure levels in patients with intracerebral 
haemorrhage who were randomised to continue or stop pre-
stroke antihypertensive drugs. Day 0 is at randomisation; day 
1 is 2 hours post-randomisation. MD is the mean difference in 
systolic and diastolic blood pressure for the continue versus 
stop groups. Comparisons by independent t test at each time 
point (with Bonferroni correction), and repeated analysis of 
variance: p<0.01/0.01. Both systolic and diastolic blood 
pressure had significantly diverged by day 4 
(2p=0.010/2p<0.026). 
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Figure 5.2 Blood pressure levels in patients with intracerebral 
haemorrhage who were randomised within 12 hours to 
continue or stop pre-stroke antihypertensive drugs. Day 0 is 
at randomisation; day 1 is 2 hours post-randomisation. MD is 
the mean difference in systolic and diastolic blood pressure for 
the continue versus stop groups. Comparisons by independent 
t test at each time point (with Bonferroni correction), and 
repeated analysis of variance: p<0.01/<0.01. Both systolic 
and diastolic blood pressure had significantly diverged by day 
5 (p<0.001). 
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Figure 5.3 Distribution of modified Rankin scores at day 90 in 
patients randomised to continue versus stop pre-stroke 
antihypertensive drugs. Comparison by ordinal logistic 
regression with adjustment: common odds ratio 0.96 (95% CI 
0.60 -1.51; p=0.84). 
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Figure 5.4 Subgroup analysis on the effects of functional 
outcome at day 90: continue versus stop. 2p is test for 
interaction. 
 
 
ACE-I: angiotensin converting enzyme-inhibitor; GTN: glyceryl 
trinitrate; LACS: lacunar syndrome; PACS: partial anterior 
circulation syndrome; POCS: posterior circulation syndrome; 
RAAS: renin-angiotensin-aldosterone system; TACS: total 
anterior circulation syndrome 
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Figure 5.5 Distribution of modified Rankin scores at day 90 in 
39 patients randomised within 12 hours to continue versus 
stop pre-stroke antihypertensive drugs. Comparison with 
Mann-Whitney U-test (p=0.43). 
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Figure 5.6 Comparison of survival between continue versus 
stop groups at day 90. Comparison using Cox proportional 
hazards model: hazard Ratio 1.01 (95% CI 0.81-1.27; 
p=0.88). 
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Chapter 6 - Relationship between baseline 
characteristics and outcome in Asian, Black and 
Caucasian patients with spontaneous 
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Abstract 
 
Background and purpose 
Although poor prognosis after intracerebral haemorrhage 
relates to risk factors and haematoma characteristics, there is 
limited evidence for the effect of race-ethnicity. 
 
Methods 
Data from 1011 patients with intracerebral haemorrhage 
enrolled into hyperacute trials and randomised to control were 
obtained from the Virtual International Stroke Trials Archive 
(VISTA) and Efficacy of Nitric Oxide in Stroke (ENOS) Trial. 
Clinical characteristics and functional outcome were compared 
among three racial groups – Asians, Blacks and Caucasians. 
 
Results 
The majority of patients were Caucasian (78.1%) followed by 
Asians (14.5%) and Blacks (5.5%). At baseline, Caucasians 
were older and had larger haematoma volumes; Blacks had 
lower Glasgow Coma Scale and higher systolic blood pressure 
(all p<0.05). Although the primary outcome of modified 
Rankin scale (mRS) did not differ at 90 days (p=0.14), there 
were significant differences in mortality (p<0.0001) and 
quality of life (EQ-5D p<0.0001; EQ-VAS p 0.015). In test of 
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multiple comparisons, Caucasians were more likely to die 
(p=0.0003) and had worse quality of life  (EQ-5D p=0.003; 
EQ-VAS p<0.0001) as compared to Asians.  
 
Conclusion 
Race-ethnicity appears to explain some of the variation in 
clinical characteristics and outcomes after acute intracerebral 
haemorrhage. Factors that explain this variation need to be 
identified. 
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6.1 Introduction 
 
Spontaneous intracerebral haemorrhage (ICH) is a severe 
cause of stroke associated with significant morbidity and 
mortality.414 In contrast to ischaemic stroke where incidence 
has declined in recent decades, the number of admissions for 
ICH continues to increase.14, 18 Variations in ICH incidence and 
outcome occur between different race-ethnicity groups. A 
higher incidence of ICH is observed among black and Hispanic 
populations when compared with Caucasians.15, 17, 415 The 
SINO-MONICA-Beijing study reported greater mortality due to 
ICH in China compared to other countries.416 Death caused by 
stroke was reported to be higher in Asians compared to 
Caucasian patients in the UK and Canada.417, 418 The causes 
for these observations are unclear and might be explained by 
increased prevalence of risk factors such as diabetes and 
hypertension among Asians.419-422 Additional explanatory 
factors also appear to include blood pressure at 
presentation.17, 423-425 However, studies assessing ICH in 
different race-ethnicity groups have mostly involved small 
centres with limited numbers of patients, and have restricted 
comparisons to differences between two racial populations.16, 
17, 415, 426 
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In this study, we compared baseline clinical characteristics and 
functional outcome in three racial groups in patients with ICH. 
The data came from the Virtual International Stroke Trials 
Archive (VISTA) collaboration,427 and the Efficacy of Nitric 
Oxide in Stroke (ENOS) trial.137 
 
6.2 Methods 
  
6.2.1 Data sources 
 
Included patients came from the VISTA-ICH archive, which 
includes data from a number of completed randomised 
controlled trials,427 and the acute ENOS blood pressure 
trial.137, 374 Patients were those with spontaneous ICH, as 
diagnosed locally using routine neuroimaging, and who were 
treated within 6 hours of onset. We included patients allocated 
to the control group in ENOS, as patients assigned to 
intervention are not included in VISTA. Patients were excluded 
if: age<18, ICH attributed to trauma, planned surgical 
evacuation, previously dependent (mRS >2), concurrent 
illness with life expectancy <6 months, pregnant or breast 
feeding women, and those already participating in a study 
involving another drug or device. 
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6.2.2 Baseline data 
 
Data at baseline were obtained for age, sex, time from ictus to 
treatment, medical history (previous stroke, hypertension, 
ischaemic heart disease, diabetes mellitus, 
hypercholesterolemia, atrial fibrillation, and prior 
antithrombotic use), level of consciousness (Glasgow Coma 
Scale, GCS), stroke severity (National Institutes of Health 
Stroke Scale, NIHSS), systolic blood pressure (SBP), and 
heart rate. In VISTA, race (and ethnicity) was defined as Asian 
(Filipino, Oriental, Asian, Indian, Palestinian and Arabic), Black 
(black, African/American, Caribbean), Caucasian (white or 
Caucasian) and Others (American Indian, mixed-coloured, 
mixed, Hispanic, coloured, Hawaiian and Pacific Islanders). 
 
6.2.3 Outcome data 
 
Outcome at day 90 was assessed using the modified Rankin 
scale (mRS) and all cause mortality; where available, data on 
disability (Barthel Index, BI) and quality of life (Euro-QoL, EQ-
5D) were also assessed.  
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6.2.4 Neuroimaging 
 
Depending on trial protocol, CT scans were performed 
following treatment and then again at 72 hours. As in ENOS, 
information from CT scans in VISTA was sought for 
haemorrhage location, lesion volume, oedema volume, 
presence of mass effect, subarachnoid bleeding, 
intraventricular haemorrhage, brain atrophy and leukoaraiosis.  
 
6.3 Statistical analysis 
 
The primary outcome was the mRS at day 90. Baseline 
characteristics and outcomes were compared by Pearson χ2 
test for categorical variables, and analysis of variance for 
continuous variables. The relationship between baseline 
haematoma volume and mRS between ethnic groups was 
analysed using multiple regression. Individual comparisons 
between ethnic groups were made using Bonferroni correction. 
Mortality was assessed using Kaplan-Meier curves and Cox 
Regression. Analyses were adjusted for age, NIHSS, ICH 
volume and time to treatment. Confidentiality agreements 
precluded identification of the individual trials in VISTA-ICH 
and so analyses were not adjusted for trial. Since death is 
present in outcome scores such as mRS (6), HUS (0) and BI (-
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5), death was scored for EQ-VAS as -1. Statistical significance 
was set at p<0.05. All analyses were performed using SPSS 
(version 21) running on an Apple Mac computer. 
 
6.4 Results 
 
6.4.1 Baseline clinical and neuroimaging characteristics 
 
A total of 1011 patients were identified: 979 recruited from 
VISTA-ICH,427 and 32 from ENOS.137 The mean age was 66.2 
years, 63.2% were male, the average time to treatment was 
3.7 hours, and the mean GCS was 13.8 (Table 6.1). The 
majority of patients were Caucasian (78.1%), followed by 
Asians (14.5%) and Blacks. Less than 2% were in the ‘other 
group’ and these were removed from further analyses. When 
analysed by baseline characteristics, Black patients were 
younger and more likely to have a previous history of 
hypertension and higher SBP at baseline. Caucasian patients 
trended to have more atrial fibrillation, and Asian patients 
were less likely to have a prior history of antithrombotic use. 
The mean ICH volume was 22.7 cm3 and most haematomas 
were located in the deep subcortical white matter of the brain 
(Table 6.1). 
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6.4.2 Clinical outcomes 
 
Table 6.2 shows clinical and radiological outcome measures by 
ethnicity. The primary outcome, mRS, did not differ between 
race groups at either day 7 or 90 (Figure 6.1). Similarly, there 
was no difference in NIHSS during the first 7 days. Whilst the 
Barthel Index differed at 7 days, it was not significant at day 
90 using a test of multiple comparisons. Quality of life, 
assessed using two measures (health utility status derived 
from EQ-5D, and EQ-VAS), differed between the three groups 
(Table 6.2, Figure 6.2); following adjustment for multiple 
comparisons, Caucasians had worse quality of life scores for 
both EQ-5D and EQ-VAS as compared to Asians (Table 6.2). 
Adjusted survival rates differed between race-ethnicity groups 
(Table 6.2, Figure 6.3), explained by a significant difference 
between Asians and Caucasians (p=0.005). There were no 
other significant differences for other outcomes. 
 
6.4.3 Neuroimaging outcomes 
 
ICH volume differed across the race groups on both the first 
follow-up scan (Table 6.2, Figure 6.4) and at 72 hours. (Table 
6.2); in both cases, Caucasians tended to have larger 
haematoma (Table 6.2). Similarly, oedema volumes differed 
across the race groups on both the first follow-up scan and at 
 259 
 
day 7 with Caucasian patients have large oedema volumes 
than Black patients. The presence of hydrocephalus also 
differed and was highest in Caucasians. The presence of 
intraventricular haemorrhage, subarachnoid haemorrhage and 
midline shift did not differ between the race groups (Table 
6.2). 
 
When assessing the relationship between baseline haematoma 
volume and mRS, there was a significant difference in the 
slope of the regression lines between the race-ethnicity 
groups; Blacks and Asians appeared to have a worse mRS for 
a given haematoma volume (p=0.047; Figure 6.5). There 
were no other significant differences between any of the other 
comparison groups.  
 
6.5 Discussion 
 
To our knowledge, this is the first study to examine clinical 
and neuroimaging features and outcomes in ICH patients 
across three race groups. Significant differences in age, the 
frequency of previous stroke and hypertension, Glasgow coma 
scale, blood pressure and ICH volume were present between 
Caucasian, Asian and Black patients. Similarly, differences in 
neuroimaging features were present for haematoma location 
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and volume, oedema volume, and the presence of 
subarachnoid haemorrhage, hydrocephalus, leukoaraiosis and 
cerebral atrophy. Although there was no difference in the 
primary outcome of mRS at day 90, significant differences in 
case fatality and quality of life were seen. Similarly, 
differences in ICH and oedema volume, and the presence of 
hydrocephalus, were present between the race groups.  
 
Black patients were younger and a larger proportion had a 
history of hypertension which could be associated with 
increased smoking, alcohol and drug abuse.16, 426 It is 
noteworthy that BP in Blacks was higher on admission and 
probably reflects inadequate control, poor compliance with 
treatment or treatment resistance.426, 428 Higher BP in the 
acute phase of ICH is common 210 and associated with 
neurological deterioration through haematoma expansion and 
re-bleeding.210, 429, 430 The treatment implications of racial 
difference in BP lowering needs investigation as evidence 
suggests that early treatment is both safe and feasible,261 and 
is now recommended in guidelines.431, 432 In contrast to a 
previous report of greater mortality in Blacks for every stroke 
subtype,433 VISTA-ENOS found reduced survival in Caucasians 
with ICH. This finding is difficult to explain and may relate to 
haemorrhage location, inherent susceptibility to ICH or quality 
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of care or simply that race-ethnic differences persist even 
after controlling for such characteristics. 
 
As would be expected, ICH survivors had a quality of life 
worse than that reported in the general population.434, 435 The 
difference between Caucasians and Asians has been reported 
previously,423, 436 and may relate to family values, cultural 
attitudes and care preferences.436, 437 In one study, Asians 
were more likely to be living at home whilst Caucasians were 
less likely to be discharged home despite better functional 
improvement.438 Apart from cultural and family factors, age, 
female sex, stroke severity, persistent neglect and 
socioeconomic status have also been shown to affect quality of 
life after stroke.439, 440 
 
The strengths of the study include a relatively large sample 
size for a study population with detailed clinical, radiological 
information and multiple functional endpoints. The included 
patients were from neutral RCT’s or control group and 
therefore assessment of the race-ethnic differences avoided 
the confounding effects of active treatment. However, there 
are some limitations. First, the analysis of observational data 
from RCT’s has the disadvantage that patients were included 
on the basis of pre-specified selection criteria. Therefore, the 
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results may not be applicable to a population of unselected 
ICH patients. Second, the VISTA collaboration does not reveal 
the identities of the individual trials and so it is uncertain as to 
what inclusion criteria were used to select patients. 
Additionally, analyses could not be adjusted for the source 
trials, which is important since trials themselves are a 
determinant of outcome. Third, ethnicity relates to culture, 
geography, language and it is not clear from the data if this 
was self-reported or defined by the investigator. Fourth, to 
compensate for limited numbers, distinct subpopulations were 
grouped into one ethnic group (for example Asians included 
people from China, Philippines, the Indian subcontinent, and 
Arabian peninsula) whilst small groups, present in the ‘others’ 
category were excluded. This may have not been appropriate 
as stroke risk and functional outcome vary within 
subpopulations living in the same country and between 
countries.441, 442 Last, the analysis is limited to trials sharing 
information within the collaboration and therefore those 
studies that are not represented in VISTA would not have 
been included. 
 
In conclusion, this analysis from hyperacute trials in acute 
haemorrhagic stroke found significant race differences in 
baseline clinical characteristics and haematoma measures. 
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There were no difference in the primary outcome of death or 
dependency but differences in death rates and quality of life 
were apparent. Further studies are needed to which factors 
explain race-ethnic differences and whether these differences 
become larger over time. This could include developing 
countries or those without access to specialist stroke care 
teams. 
 
 
 
 
 264 
 
Table 6.1 Baseline characteristics of 1011 patients with intracerebral haemorrhage by ethnicity.  Data are 
number (%) or mean (standard deviation). Comparisons by chi-square test or one-way analysis of variance. 
 
Demographics N All Caucasian Asian Black Other 2p 
C v A 
2p 
C v B 
2p 
A v B 
2p 
Number of patients (%)  1011 790 (78.1) 147 (14.5) 56 (5.5) 18 (1.8) 
    
Clinical findings  
 
 
     
   
Age (years) 1011 66.2 (12.5) 67.7 (12.1) 61.3 (12.5) 58.4 (11.3) 61.9 (11.0) <0.001 <0.0001 <0.0001 0.13 
Sex, male (%) 982 621 (63.2) 489 (63.3) 40 (65.6) 32 (57.1) 10 (71.4) 0.56 0.64 0.39 0.33 
OTT (hrs) 1007 3.7 (1.2) 3.7 (1.2) 3.6 (1.4) 3.4 (1.2) 3.7 (1.2) 0.08 0.26 0.035 <0.0001 
Medical history           
   Previous stroke (%) 1011 106 (10.5) 71 (9.0) 24 (16.3) 8 (14.3) 3 (16.7) 0.017 0.011 0.23 0.83 
   Hypertension (%) 1011 813 (80.4) 613 (77.6) 133 (90.5) 52 (92.9) 15 (83.3) <0.0001 <0.0001 0.006 0.78 
   IHD (%) 1011 105 (10.4) 92 (11.6) 10 (6.8) 3 (5.4) 0 (0) 0.07 0.11 0.19 1.00 
   Diabetes mellitus (%) 1011 177 (17.5) 135 (17.1) 25 (17.0) 11 (19.6) 6 (33.3) 0.89 1.00 0.59 0.68 
   HC (%) 997 49 (4.8) 43 (5.4) 5 (3.4) 1 (1.8) 0 (0) 0.49 0.40 0.42 1.00 
   Atrial fibrillation (%) 1011 68 (6.7) 62 (7.8) 4 (2.7) 2 (3.6) 0 (0) 0.047 0.022 0.43 0.67 
   Antithrombotic(s) (%) 162 162 (16.0) 143 (18.1) 8 (5.4) 7 (12.5) 4 (22.2) 0.005 1.00 0.77 0.87 
 265 
 
NIHSS (/42) † 1008 13.7 (1.9) 13.7 (5.6) 13.3 (6.0) 15.1 (7.4) 13.7 (1.9) 0.12 0.37 0.08 0.07 
GCS (/15) 1010 13.8 (1.8) 13.8 (1.8) 13.4 (1.9) 13.2 (2.2) 14.1 (1.7) 0.010 0.037 0.015 0.37 
Systolic BP (mmHg) 1008 174.4 (29.2) 173.1 (29.3) 176.7 (26.5) 185.7 (40.0) 174.4 (29.2) 0.005 0.18 0.002 0.041 
Diastolic BP (mmHg) 1007 93.2 (19.0) 91.6 (18.5) 97.1 (18.5) 106.0 (21.1) 93.8 (20.8) <0.001 0.001 <0.0001 0.003 
Heart rate (bpm) 1005 80.0 (15.1) 78.1 (15.4) 76.6 (13.8) 79.9 (14.6) 78.2 (14.1)     0.34     0.27 0.40 0.14 
Neuroimaging           
Haematoma location (%)           
   Lobar 863 134 (13.3) 122 (15.4) 5 (3.4) 7 (12.5) 0 0.001 <0.0001 0.57 0.045 
   Subcortical white matter 893 685 (67.8) 541 (68.5) 93 (63.3) 42 (75.0) 9 (50.0) 0.006 0.30 0.73 0.34 
   Thalamus 600 217 (21.5) 181 (22.9) 22 (15.0) 10 (17.9) 4 (22.2) 1.00 1.00 1.00 1.00 
   Brain stem/cerebellum 893 21 (2.1) 17 (2.2) 2 (1.4) 1 (1.8) 1 (5.6) 0.82 0.75 1.00 1.00 
Haematoma volume (cm3) 996 22.7 (23.1) 24.2 (24.9) 17.8 (13.1) 15.8 (14.1) 18.5 (17.3) 0.005 0.03 0.014 0.34 
Oedema volume (cm3) 874 13.9 (15.7) 14.9 (16.9) 11.1 (9.2) 9.9 (10.4) 8.1 (7.8) 0.007 0.015 0.041 0.48 
Midline shift (%) 885 623 (61.6) 488 (61.8) 90 (61.2) 38 (67.9) 7 (38.9) 0.62 0.67 0.43 0.71 
SAH (%) 1007 80 (7.9) 73 (9.2) 3 (2.0) 1 (1.8) 3 (16.7) 0.003 0.02 0.05 1.00 
IVH (%) 876 286 (28.3) 234 (29.6) 33 (22.4) 17 (30.4) 2 (11.1) 0.22 0.14 0.75 0.26 
Hydrocephalus (%) 860 619 (61.2) 517 (65.4) 64 (43.5) 29 (51.8) 9 (50.0) <0.001 <0.0001 0.004 0.74 
Leukoaraiosis (%) 619 287 (28.4) 251 (31.8) 21 (14.3) 12 (21.4) 3 (21.4) 0.28 0.29 0.18 0.66 
Cerebral atrophy (%) 1007 552 (54.6) 469 (59.4) 50 (34.0) 21 (37.5) 12 (66.7) <0.001 <0.0001 0.002 0.74 
 266 
 
 
† Calculated 379 from Scandinavian Stroke Scale in ENOS 
BP: blood pressure; GCS: Glasgow Coma Scale; HC: hypercholesterolemia; IHD: ischaemic heart disease; IVH: 
intraventricular haemorrhage; OTT: onset to treatment; SAH: subarachnoid haemorrhage 
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Table 6.2 Clinical and radiological outcomes by race groups. Data are number (%) and mean (standard 
deviation). Comparisons between group differences made by chi-square test or analysis of variance; multiple 
comparisons include Bonferroni correction. 
 
 n All Caucasian Asian       Black Other 2p C v A C v B A v B 
Patients  1011 790 147 56 18  2p 2p 2p 
Clinical           
mRS (/6)           
   Day 7 538 4.1 (1.1) 4.2 (1.1) 4.2 (0.8) 3.9 (1.3) 4.6 (0.5) 0.36 1.00 0.07 0.12 
   Day 90 873 3.2 (1.6) 3.2 (1.6) 3.0 (1.6) 3.4 (1.7) 3.1 (1.8) 0.14 0.18 1.00 0.37 
NIHSS (/42) †           
   Day 1 936 13.1 (7.0) 13.1 (7.0) 12.8 (6.7) 13.2 (8.1) 12.4 (6.5) 0.89 1.00 1.00 1.00 
   Day 3 564 12.5 (8.0) 12.7 (8.2) 11.0 (6.3) 11.6 (8.3) 14.8 (7.0) 0.29 0.42 1.00 1.00 
   Day 7 534 10.8 (7.1)  10.9 (7.9) 10.2 (6.1) 10.7 (7.5) 13.1 (6.7) 0.80 1.00 1.00 1.00 
   Day 90 958 8.1 (9.8) 8.1 (10.1) 6.0 (5.7) 9.6 (10.4) 9.7 (10.6) 0.31 0.88 0.96 0.41 
Barthel Index 
(/100) 
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   Day 7 539 28.9 (31.1) 28.6 (31.2) 30.6 (29.1) 33.9 (36.5) 14.4 (16.1) 0.010 1.00 1.00 1.00 
   Day 90 872 63.0 (37.4) 62.9 (37.6) 66.0 (35.7) 56.4 (39.0) 66.5 (39.1) 0.28 1.00 0.68 0.34 
Day 90           
   Death (%) 1011 211 (20.9) 189 (23.3) 11 (7.5) 9 (16.1) 2 (11.1) <0.001 <0.001 0.59 0.33 
   EQ-5D (/1) 487 0.29 (0.37) 0.25 (0.36) 0.46 (0.40) 0.31 (0.40) 0.40 (0.39) <0.001 <0.001 1.00 0.18 
   EQ-VAS (/100) 321 46.0 (33.5) 43.3 (33.6) 57.0 (30.2) 44.2 (35.2) 42.5 (60.1) 0.015 0.012 1.00 0.34 
Neuroimaging           
ICH vol. (cm3)           
   Follow up scan 523 32.3 (32.2) 34.7 (34.4) 26.2 (23.8) 23.7 (23.6) 18.9 (24.1) 0.017 0.07 0.14 1.00 
   72 hours 930 27.3 (28.6) 28.7 (30.4) 23.3 (19.7) 20.1 (20.3) 21.6 (20.4) 0.019 0.13 0.09 1.00 
Oedema vol. (cm3)           
   Follow up scan 428 31.8 (31.8) 34.1 (33.9) 29.1 (25.7) 19.7 (20.8) 19.7 (18.4) 0.030 0.65 0.038 0.46 
   72 hours 924 33.6 (30.9) 33.6 (30.9) 29.9 (22.1) 22.0 (19.6) 24.8 (23.4) 0.009 0.53 0.012 0.26 
IVH (%)           
   Follow up scan 399 195 (19.3) 145 (18.4) 35 (23.8) 14 (25.0) 1 (5.6) 0.98 0.90 1.00 1.00 
   72 hours 811 344 (34.0) 277 (35.1) 46 (31.3) 19 (33.9) 2 (11.1) 0.41 0.54 0.55 1.00 
72 hours           
   SAH (%) 566 97 (9.6) 87 (11.0) 7 (4.8) 2 (3.6) 1 (5.6) 0.23 0.21 0.20 0.71 
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   Hydrocephalus (%) 791 605 (59.8) 498 (63.0) 67 (45.6) 31 (55.4) 9 (50.0)  <0.001 <0.001 0.016 0.60 
   Midline shift (%) 790 628 (62.1) 490 (62.0) 94 (63.9) 37 (66.1) 7 (38.9) 0.54 0.25 0.72 0.37 
 
A: Asians; B: Blacks; C: Caucasians; EQ-5D: European Quality of Life-5 dimensions; EQ-VAS: European Quality of 
Life-Visual Analogue Scale; ICH: intracerebral haemorrhage; IVH: intraventricular haemorrhage; mRS: modified 
Rankin scale; NIHSS: National Institutes of Health Stroke Scale; SAH: subarachnoid haemorrhage 
†Calculated from Scandinavian Stroke Scale in the ENOS trial 379 
Range of scores for patients in ENOS: 
Barthel Index: -5 (death) to 0 (severe disability) to 100 (no disability). 
Health utility status (HUS, derived from European Quality of Life-5 dimensions, EQ-5D): -0.5 (very poor quality of 
life, 0 (death) to 1.0 (perfect quality of life). European Quality of Life-Visual Analogue Scale (EQ-VAS): -1 (death), 
0 (very poor) to 100 (excellent). 
Zung Depression Scale (ZDS): 0 (normal), 100 (severe depression) to 102.5 (death) 
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Figure 6.1 Distribution of modified Rankin scores between the 
three race groups at day 90.  
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Figure 6.2 Box plots of Euro Quality of Life-5Dimension-3 
level scores (n=487) at day 90. Comparison by ANOVA 
2p<0.001; Caucasian vs Asian 2p<0.001, Caucasian vs Black 
1.00, Asian vs Black 2p=0.18. 
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Figure 6.3 Cox regression with adjustment for age, baseline 
systolic blood pressure, stroke severity (NIHSS), haematoma 
volume and time to treatment: overall p=0.021; Asians vs 
Caucasians, hazard ratio 0.42 (95% CI 0.22, 0.77); p=0.005. 
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Figure 6.4  Intracerebral haematoma volume (n=523) on 
first follow-up imaging by race. Comparison by ANOVA 
2p=0.017; Caucasian vs Asian 2p=0.07, Caucasian vs black 
0.14, Asian vs black 2p=1.0. 
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Figure 6.5 Relationship between haematoma volume at 
baseline and functional outcome, assessed as the modified 
Rankin Scale (mRS), at day 90 for Caucasians, Asians and 
Blacks. The continuous and dotted lines indicate the 
regression lines. 
 
 
Overall comparison between the three ethnicities (using 
ANCOVA) showed a difference in the slopes of the regression 
lines between the three groups (p<0.0001). Individual 
comparisons found significant difference in the slopes of the 
regression lines between Blacks vs Asians (p=0.047; using 
Bonferroni correction). There were no significant differences 
between any of the other ethnic group comparisons. Analysis 
was adjusted for age, baseline NIHSS, ICH volume and time to 
treatment. 
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Chapter 7 - The effects of deliberately altering 
blood pressure in acute stroke: a systematic 
review and meta-analysis 
 
Publications contributing to this chapter:  
1. PMW Bath, K Krishnan. Interventions for deliberately 
altering blood pressure in acute stroke. Cochrane Database 
of Systematic Reviews 2014, Issue 10. Art. No.: 
CD000039.  
2. Kailash Krishnan, Philip MW Bath. Interventions for 
deliberately altering blood pressure in acute stroke. Stroke. 
2015; 46:00-00. 
3. Kailash Krishnan, Philip MW Bath. Interventions for 
deliberately altering blood pressure in acute stroke. Oral 
presentation at the UK Stroke Forum 2014. 
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Introduction 
This chapter is an abbreviated version of a systematic review 
and meta-analysis of published and unpublished randomised 
controlled trials aimed at altering BP within 1 week of acute 
ischaemic or haemorrhagic stroke and a review of the 
methodology is described in this section. 
 
Background 
Traditional medical review articles broadly narrate the 
literature and attempt to synthesise results and conclusions of 
a particular subject. However, this approach is subject to 
personal bias of the author/s, a bias in the selection of the 
included studies and inferences may not be easily verified.443, 
444 By comparison, a systematic review poses a specific 
research question taking into account all relevant literature 
including studies with and without conflicting results, 
appraises their quality and provides an answer that is 
reproducible and free of bias.445 In addition to identifying 
whether certain groups of studies (e.g. small studies, studies 
with negative results) are excluded in the analysis, a 
systematic review offers the following advantages:  
 summarises large amounts of information 
 reports the generalisibility and consistency in studies 
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 discusses when the study data is sparse or of poor 
quality 
 identifies common definitions for outcomes 
 extracts estimates of outcomes 
 describes the robustness of the results 
 allows hypothesis generation in subgroups 
 discusses why an intervention may work thereby 
reducing delay between research findings and 
implementation in clinical practice. The conclusions in a 
systematic review are reliable because of the thorough 
and standardised methods used. 
 
After defining a precise question, a comprehensive literature 
search is undertaken appropriate to the topic of interest. 
Between 30-80% of all randomised controlled trials can be 
found on MEDLINE and other standard database search 
engines and therefore other sources are used, including hand 
searching references listed in the primary source, reviewing 
conference abstracts, internet trial registers, ‘grey literature’ 
(e.g. non peer reviewed journals, product information from 
pharmaceutical companies), contacting investigators for 
unpublished information and ‘raw data’ via personal 
communication.445, 446 Involvement of more than one reviewer 
at this stage is important to determine the level of detail in 
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each search strategy, reasons for study inclusion or exclusion 
and to avoid losing relevant data.445, 447 Once selected, the 
studies should be evaluated for quality. Various scoring 
systems are available,446, 448 but in essence all included 
studies are assessed for the following: whether the selected 
participants are similar to those in clinical practice, adequate 
concealment of random allocation, use of appropriate 
statistical tests, withdrawal reporting and blinding in outcome 
assessment. 
 
The statistical techniques used to analyse data from all 
included studies is known as meta-analysis.443 This is 
performed in two steps. First, the treatment effect is 
computed for each study. For continuous data, the mean 
difference or standardised mean difference is used. The 
former is used when the outcome is measured on the same 
scale (e.g. blood pressure measurement) and the latter is 
calculated when different scales are used to measure the 
same outcome (e.g. scoring of pain). With categorical data, 
risk ratio (RR), odds ratio (OR), absolute risk reduction (AR) 
and number needed to treat (NNT) are used as measures of 
effect.  
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The second stage of a meta-analysis is combining the 
extracted data to derive an overall pooled effect with greater 
weightage given to studies with more information. The 
approach chosen to combine data depends whether 
heterogeneity between the individual studies is present. 
Heterogeneity suggests that the results of each individual 
study are not compatible with the results of the others. 
Common sources of this variation include clinical (e.g. 
differences in patient selection, drug dosage, frequency, route 
of administration, measuring outcomes) or methodological 
(trial design, comparators, time to assess outcome and 
methods to ascertain outcome) differences. Advanced 
software such as the Review Manager (RevMan) endorsed by 
the Cochrane collaboration will investigate for statistical 
heterogeneity using the 2 and the I2 tests. 2 assesses 
whether the differences in study results are attributed to 
chance alone and a value of 0.10 is considered significant.443, 
445 The I2 computes heterogeneity as a percentage and a value 
>40% suggests this. If statistical heterogeneity is 
demonstrated, explanations such as clinical heterogeneity or 
differences between participants or trial design should be 
sought. If the latter is thought to be present, the analysis will 
use a random effects model;449 this means that the meta-
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analysis result is an un-weighted average effect size across all 
the included studies. 
 
Another important factor to be taken into account is 
publication bias, where studies are more likely to be published 
if their results are ‘significant’ than if their results are negative 
or inconclusive. This can be assessed using a funnel plot,450 
which visually depicts the effect estimates (e.g. OR) from each 
study on the horizontal axis against a measure of study 
precision (standard error) on the vertical axis. In the absence 
of any bias, the plot will display as an inverted funnel with the 
apex centred on the summary estimate and 95% of all studies 
included within 1.96 standard errors on each side.451  
 
The results of the meta-analysis are displayed in a standard 
graphical way using a forest plot.452 The figure can be 
sectioned into five columns.449, 453 All included studies are 
displayed as rows. The first column usually shows the study 
ID’s, usually the first author followed by the year. The second 
and third columns indicate the intervention and control 
groups. The fourth column gives the visual display of the 
study results. The line in the middle represents’ the line of no 
effect’ and assigned a value of 1 for a binary outcome variable 
(OR, RR) or 0 for a continuous outcome variable. The square 
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is the mean effect estimate for that study and the area is 
proportional to the weighting given to that study. The 
horizontal line through each square is the length of the 95% 
confidence interval. The longer the line, the greater is the 
width of the confidence interval. The fifth column gives the 
numerical value for each study identical to the visual display 
of the graph in the fourth column. The diamond at the bottom 
row of the graph is the summary result; the middle of the 
diamond lies on the value for the overall effect estimate and 
the horizontal tips represent the confidence interval. 
If the diamond does not cross the ‘line of no effect’, then the 
result represents an overall positive or negative effect. 
Conversely if the diamond crosses the vertical line, there is no 
statistical difference between the groups.  
 
As with all papers, the last step is writing which includes a 
summary of the results, recommendations for clinical work 
(for example, in whom the intervention is likely to benefit, 
under what conditions) and what areas or topics require more 
research. 
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ABSTRACT 
 
Background  
  
It is unclear whether blood pressure should be altered actively 
during the acute phase of stroke. This is an update of a 
Cochrane review first published in 1997, and previously 
updated in 2001 and 2008. 
 
Methods   
 
Randomised controlled trials of interventions that would be 
expected on pharmacological grounds to alter BP within one 
week of acute ischaemic or haemorrhagic stroke were 
identified through electronic searches of databases and patient 
data collated. The effect of altering BP on functional outcome 
(modified Rankin scale, mRS; Barthel Index, BI) and blood 
pressure were assessed both overall and in pre-specified 
subgroups, including by time to treatment. Results were 
reported as odds ratio (OR) with 95% confidence interval (CI) 
for dichotomous data and as mean difference (MD) for 
continuous data. 
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Results 
 
Twenty-six trials involving 17,011 participants were included 
(8497 participants were assigned active therapy and 8514 
participants received placebo/control). Not all trials 
contributed to each outcome. Most data came from trials that 
had a wide time window for recruitment; four trials gave 
treatment within six hours and one trial within eight hours. 
The trials tested alpha-2 adrenergic agonists (A2AA), 
angiotensin converting enzyme inhibitors (ACEI), angiotensin 
receptor antagonists (ARA), calcium channel blockers (CCBs), 
nitric oxide donors, thiazide-like diuretics, and target-driven 
BP lowering. One trial tested phenylephrine. 
 
Blood pressure lowering did not reduce death or dependency 
by stroke type (OR 0.98, 95% CI 0.92 to 1.05) or time to 
treatment (OR 0.98, 95% CI 0.92 to 1.05). Treatment within 
six hours of stroke appeared effective in reducing death or 
dependency (OR 0.86, 95% CI 0.76 to 0.99) but not death 
(OR 0.70, 95% CI 0.38 to 1.26) at end of trial. Although death 
or dependency did not differ between patients who continued 
pre-stroke antihypertensive treatment versus those who 
stopped it temporarily (worse outcome with continuing 
treatment, OR 1.06, 95% CI 0.91 to 1.24), disability scores at 
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end of trial were worse in patients randomised to continue 
treatment (Barthel Index, MD -3.2, 95% CI -5.8, -0.6) 
 
Conclusions 
 
There is insufficient evidence that lowering blood pressure 
during the acute phase of stroke improves functional outcome. 
Continuing pre stroke antihypertensive drugs immediately 
may be harmful. It is reasonable to withhold BP-lowering 
drugs until patients are medically and neurologically stable, 
and have suitable oral or enteral access, after which drugs can 
than be reintroduced. Further trials are needed to identify 
which patients are most likely to benefit from early treatment, 
in particular whether treatment started very early is beneficial. 
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7.1 Introduction 
 
Acute stroke, whether due to infarction or haemorrhage is 
associated with high blood pressure in 75% of patients of 
whom 50% have a previous history of high blood pressure.454, 
455 The mechanisms underlying high blood pressure in stroke 
are complex and the adverse effects on outcome in both 
ischaemic stroke and haemorrhagic stroke was discussed in 
chapter 1. Haematoma expansion is related to high blood 
pressure in patients with intracerebral haemorrhage although 
this relationship may be confounded by stroke severity and 
time to presentation.115, 210, 361, 456  
 
A Cochrane review of BP intervention in stroke published in 
2001 and updated in 2008 included more information from 
thirteen randomised controlled trials analysing 1153 
patients.457 With a relatively small amount of data, there was 
insufficient evidence to evaluate the effect of altering blood 
pressure during the acute phase of stroke. The presented 
review and meta-analysis includes all new trials completed 
and published since 2008. Although many of the data are from 
trials testing BP alteration in the acute phase (<=48 hours), 
some recent trials have examined specific questions such as 
BP lowering in intracerebral haemorrhage,260, 261 the use of an 
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ARA to lower BP,458 the use of glyceryl nitrate in stroke137 or 
lowering BP in the pre-hospital setting phase of stroke.264, 459 
Furthermore, two trials136, 137 have now investigated whether 
to continue or stop temporarily pre-stroke antihypertensive 
therapy. This systematic review includes these this data and 
provides new information of deliberate blood pressure 
intervention in acute stroke. 
 
7.2 Methods 
 
7.2.1 Types of studies   
 
Published and unpublished randomised controlled trials of 
vasoactive drugs in acute ischaemic stroke or acute 
intracerebral haemorrhage (ICH) where the aim of the trial 
was to alter blood pressure, and drug therapy was initiated 
within one week of stroke onset. We excluded uncontrolled 
studies, confounded controlled studies where two or more 
active interventions were compared, and studies of patients 
with subarachnoid haemorrhage. 
 
7.2.2 Types of participants   
 
Adults (age 18 or older) of either sex with acute ischaemic 
stroke or ICH who were eligible for randomisation to either 
active treatment, or placebo or open control. 
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7.2.3 Types of interventions   
 
We sought randomised controlled trials evaluating single or 
multiple agents of deliberate blood pressure lowering or 
elevation in acute stroke, regardless of dosage or route of 
treatment, as compared against placebo or open control. We 
also included trials with two groups receiving different doses 
of the same BP lowering agent, and studies assessing effects 
of continuing or stopping pre-existing antihypertensive 
treatment. 
 
7.2.4 Types of outcome measures   
 
Primary outcomes   
 
 Combined death or disability/dependency at end of trial 
(>= one month after stroke).  
 Death or dependency was defined as modified Rankin 
Scale (mRS) >2 (or >3 as available). Death or disability 
was defined as Barthel Index <60. 
 
Secondary outcomes  
 
 Blood pressure when first measured after randomisation 
 Early case fatality (< one month). 
 Late case fatality (>= one month). 
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 Early neurological deterioration (< one month).  
As there is no consensus on how early neurological 
deterioration should be standardised, we used the trial-
specific definition as a decrease in SSS of >5points or a 
decrease in consciousness part of the SSS by > 2 points,137 
increase in NIHSS of 2460 or more136, 261, 262 or decline of 2 
or more points in GCS.261  
 Late disability or dependency (Barthel Index >=one 
month) 
 Baseline and on-treatment blood pressure and heart 
rate 
 
7.2.5 Search methods 
 
These comprised electronic searches and assessment of 
studies referenced in published systematic and non-systematic 
reviews. No language restrictions were applied. 
 
7.2.5.1 Electronic searches   
 
We searched the Cochrane Stroke Group Trials Register, (last 
searched by the Managing Editor in February 2014), the 
Cochrane Database of Systematic reviews (CDSR) and the 
Cochrane Central Register of Controlled Trials (CENTRAL) (The 
Cochrane Library Issue 2, 2014), MEDLINE (Ovid) (1966 to 
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May 2014), EMBASE (Ovid) (1974 to May 2014), Science 
Citation Index (ISI, Web of Science, 1981 to May 2014) and 
the Stroke Trials Registry 
(www.strokecenter.org/trials/)(searched May 2014). The 
search terms included those used in a previous review and 
listed in the Appendix I. 
 
7.2.5.2 Searching other resources   
 
We searched reviews of in acute stroke relating to drugs which 
may alter blood pressure, including: calcium channel blockers 
(CCBs) (Horn 2001), nitric oxide (Bath 2002), pentoxifylline 
(Bath 2004a) and prostacyclin (Bath 2004b). In addition, we 
searched reference lists of included trials and relevant papers. 
We contacted principal investigators and researchers when we 
required additional information. For a previous version of this 
review (BASC 2001), one author (PB) contacted the following 
pharmaceutical companies: Bayer (nimodipine), Napp 
(pentoxifylline), Novartis (isradipine), Lipha Sante 
(naftidrofuryl), Hoffmann la Roche (N-methyl-D-aspartate), 
Hoechst (flunarizine) and UCB Pharma (piracetam). 
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7.3 Data collection 
 
Review authors extracted data using a standard proforma; KK 
entered data into Review Manager (RevMan 2012) and PB 
checked the data. 
 
7.3.1 Selection of studies   
 
For this update, one review author (KK) screened the records 
obtained from the electronic searches and excluded obviously 
irrelevant studies. We obtained the full paper copy of the 
remaining studies and both review authors (KK and PB) 
selected trials for inclusion criteria detailed previously. We 
resolved any disagreements by discussion.  
 
7.3.2 Data extraction and management   
 
We extracted data from published and unpublished material 
where available. We recorded information on the method of 
randomisation, concealment of allocation, blinding of 
treatment administration, stroke type (ischaemia, 
haemorrhage, or mixed), drug dose, route of administration 
(oral, sublingual, intravenous, transdermal) and timing, blood 
pressure and heart rate before and during treatment, numbers 
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of deaths, functional disability, quality of life, and length of 
stay. 
 
7.3.3 Assessment of risk of bias in included studies   
 
We assessed the methodological quality of the trials using the 
following criteria: 
 Method of randomisation. 
 Balance of prognostic factors. 
 Allocation concealment. 
 Blinding of treatment administration. 
 Intention to treat analysis. 
 Blinding of outcome assessment. 
 Follow up. 
The quality criteria were used to derive an overall assessment 
bias score as 'low risk' (all criteria met), moderate risk (one or 
more criteria unclear) and high risk (one or more criteria 
absent).461  
 
7.3.4 Measures of treatment effect   
 
We calculated the weighted estimate of the typical treatment 
effect across trials using the Cochrane Review Manager 
software, RevMan 5 (RevMan 2012): odds ratio (OR) using the 
Mantel-Haenszel with random-effects model for binary data, 
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and mean difference (MD) using the inverse variance method 
for continuous data, each with 95% confidence intervals (CI).  
 
7.3.5 Unit of Figure issues   
 
The primary outcome was based on the modified Rankin Scale 
(mRS 0 to 6, where death =6) assess using the binary 
outcome of combined death or dependency (mRS >1 or >2 
depending on trial definition). The Barthel Index (disability 
measure of activities of daily living) was also assessed (BI 100 
to -5, where death =-5). Where functional outcome was not 
assessed, we excluded the trial from the analysis of functional 
outcome. 
 
 
7.3.6 Dealing with missing data   
 
We attempted to collect missing data from trial investigators. 
In instances where on-treatment blood pressure data were not 
provided or could not be obtained from study authors, we 
obtained data (mean, SD) from graphs in the trial publication; 
where the SD was not presented graphically, baseline data 
were used, a conservative strategy. We excluded trials from 
individual analyses when summary data were omitted in the 
trial publication. 
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7.3.7 Assessment of heterogeneity   
 
Heterogeneity between RCTs' results was assessed using the 
I2 statistic based on the DerSimonian-Laird formula. 
 
7.4 Data synthesis   
 
We performed statistical analysis using RevMan version 5.2 
(RevMan 2012). We reported outcomes as odds ratio (OR) 
with 95% confidence intervals (CI) for dichotomous data, and 
mean difference (MD) with 95% CI for continuous data. We 
used a random-effects model to analyse individual results 
regardless of whether there was heterogeneity or not; this is a 
conservative strategy and takes into account that the trials 
had heterogenous designs and participant populations. 
 
7.5 Subgroup analysis and investigation of 
heterogeneity   
 
We assessed the primary outcomes in pre-specified 
subgroups: 
 Class or type of intervention. 
 Type of stroke: ischaemic; intracerebral haemorrhage.  
We planned a priori subgroup analysis on the number of 
patients in the treated and control groups who were dead or 
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dependent at the end of follow up according to stroke 
location: cortical versus subcortical ischaemic stroke, deep 
intracerebral haemorrhage versus others.  
The definition of deep haemorrhage was not defined in all the 
trials and we therefore used the data as provided.  
 Timing of intervention: ultra-acute (<=4 hours) and 
pre-hospital; hyper-acute (<=6 hours) and in hospital; 
acute (<=48 hours); sub-acute (<=168 hours). 
 
We considered I2 greater than 50% to have significant 
heterogeneity. If significant heterogeneity was present, we 
looked for potential causes, e.g. differences in trial design and 
study participants. 
 
7.6 Sensitivity Analysis  
 
The analyses were based on all trials. No sensitivity analyses 
were performed. 
 
7.7 Results 
 
The results of the search process of the present review are 
shown in Figure 7.1. 
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7.7.1 Description of studies   
 
Twenty-six trials involving 17,011 patients (8497 active, 8514 
placebo/control) were included in this analysis.  
 
7.7.2 Results of the search   
 
The quantity of outcome data varied between studies: 
 Outcomes not universally collected. 
 Some data still to be published. 
 ‘Raw data' available by personal communication. 
If a trial used more than one dose of a particular drug then 
the trial identifier is written as author followed by year and 
dose of the drug. Referencing the whole trial was given by 
author and year. For example the Fagan 1988 trial comprises: 
(Fagan 1988 120 mg; Fagan 1988 240 mg).462 
 
7.7.3 Included studies   
 
Twenty six trials were identified and fulfilled the inclusion 
criteria. 
Three trials compared more than one drug against the control 
group262, 463, 464 and two studies compared different doses.385, 
462 
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Trial protocols and group data were obtained from published 
material for nineteen studies,136, 137, 262, 264, 266, 458, 460, 462, 463, 
465-474 whilst individual patient data were provided by seven 
sets of authors.385, 463, 475-477 We obtained unpublished SBP, 
DBP and heart rate data for active and control groups by 
contacting the authors for three trials.136, 465, 468  
 
A variety of strategies and drug classes were used to lower 
blood pressure: 
 Alpha-2-adrenoceptor agonist, oral centrally-acting 
(clonidine: two participants): One trial463 
 ACE-I (captopril, perindopril or lisinopril: 152 
participants): Five trials262, 266, 463, 468, 476  
 Angiotensin receptor antagonist (ARA), oral 
(candesartan or telmisartan: 4190 participants): Six 
trials 458 466, 474, 478-480  
 Beta-receptor antagonist (labetalol: 56 participants): 
One trial 262  
 CCBs (nimodipine or nicardipine: 75 participants): Three 
trials 462, 463, 475 
 Diuretic, oral thiazide-like (bendrofluazide: 18 
participants): One trial 467  
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 Nitric oxide donor (NO) donor, transdermal nitrate 
(glyceryl trinitrate, GTN: 4197 participants): Five trials 
137, 385, 477, 481, 482  
 Intensive versus guideline blood pressure targets (7421 
participants): Five trials 261, 460, 469, 472, 483  
 Continue versus Stop pre-stroke antihypertensive drugs 
(2860 participants): Two trials 136, 137  
 
One strategy was used to raise blood pressure: 
Sympathomimetic, intravenous (phenylephrine: 9 
participants): One trial 465  
 
The trials recruited patients with only ischaemic stroke, mixed 
stroke (IS and ICH), or only ICH: 
 Ischaemic stroke: 12 trials 462, 463, 465-468, 471, 474, 476, 478, 
480, 483  
In the Fagan study (Fagan 1988 120 mg; Fagan 1988 
240 mg) patients were recruited with presumed 
'ischaemic' stroke based on history and neurological 
examination.462 
 Mixed stroke: 10 trials 136, 137, 262, 266, 385, 458, 475, 477, 481, 482  
 Intracerebral haemorrhage (ICH): 4 trials 261, 460, 464, 469  
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Trials recruited participants at different time frames after 
stroke: 
Ultra-acute (<4 hours of onset)/pre-hospital: 2 trials 266, 482  
Hyper-acute (<6 hours)/hospital: 2 trials 261, 469  
Acute (<48 hours): 11 trials 136, 262, 458, 460, 464, 466, 468, 475, 480, 483  
Sub-acute (<168 hours): 10 trials385, 463, 465, 467, 474, 476-479, 481  
Timing unclear: 1 trial 462  
 
Trials variously defined enrolment blood pressure levels: 
 Hypertension (systolic BP >120-170 and <=220 mm 
Hg): 19 trials137, 262, 266, 385, 458, 463, 466-469, 471-474, 476, 477, 
480, 484 
 Normotension (systolic BP <140 mmHg): 2 trials 465, 478  
 No BP criteria: 3 trials 136, 462, 475  
 
Trials treated participants for varying lengths of time: 
 For 1 day: 1 trial464 
 For up to two days: 3 trials460, 465, 475  
 For up to three days: 1 trial463 
 For 7-12 days: 13 trials137, 385, 458, 466, 467, 469, 472, 473, 477, 
480, 481 
 For 14 days: 5 trials136, 262, 468, 476, 483 
 For 21 days: 1 trial462 
 For 28 days: 1 trial478 
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 For 3 months: 1 trial474  
 For up to 2.5 years: 1 trial;471 outcomes at 1-3 months 
are used and longer-term follow-up data are ignored. 
 
The trials recruited from one or more centres: 
 Single centre: 14 trials264, 266, 385, 460, 463, 465, 467, 468, 474-478, 
481 
 Multicentre: 12 trials136, 137, 262, 458, 462, 466, 469, 472, 473, 479, 
480, 483  
 
17,011 participants received placebo or control treatment 
across the studies. Three trials compared two or more active 
treatment groups (8497 participants) with one control group 
(8512 participants).385, 462, 463 One study reported on 19 
participants from a larger randomised controlled trial462; 
further information on the main study is not available. One 
trial was performed in two stages: this review includes the 
first phase, a double-blind comparison of candesartan versus 
placebo478 and excludes the second open-label comparison of 
candesartan and an ACE-I. One study expressly included 
patients with either ICH, who were given intravenous 
nimodipine (treatment: eight participants; placebo: three 
participants), or ischaemic stroke, who were given oral 
nimodipine (treatment: 38 participants; placebo: 39 
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participants);475 10 participants (treatment: two participants; 
placebo: eight participants) were treated with 
antihypertensive agents for malignant hypertension, and two 
participants treated with intravenous nimodipine for 
subarachnoid haemorrhage were excluded.475 Data from two 
trials were only available from published abstract.478, 480  
 
7.7.4 Blood pressure measurements 
 
Sixteen studies reported the method by which blood pressure 
was measured, including equipment model type and patient 
posture.136, 137, 262, 264, 385, 458, 463, 467, 468, 474, 476, 477, 483 The 
Fagan trial only reported the average blood pressure 
measurements at, and for one hour after, morning dosing over 
seven days of treatment (Fagan 1988 120 mg/Fagan 1988 
240 mg); in the absence of individual patient data, it is not 
possible to determine the blood pressure at selected time 
points during treatment.462 Furthermore, this trial co-
administered beta blockers to some patients, although these 
were always given at least two hours before or after 
nimodipine. In the ACCESS study during the first three days 
blood pressure measurements were performed by nurses as 
part of routine clinical care; on day seven, an automatic 24-
hour blood pressure recording was performed.466 The other 
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nine trials266, 462, 465, 466, 469, 472, 473, 475, 480 made no mention of 
patient posture or how blood pressure was measured. 
 
Three trials recorded systolic but not diastolic BP after the first 
intervention.261, 460, 464 
 
7.7.5 Outcomes 
 
The trials reported a variety of outcomes: 
 Modified Rankin Scale (mRS) and/or Barthel Index (BI) 
at >=1 months: 15 trials.136, 137, 262, 264, 385, 458, 466-469, 473, 
477, 479, 481, 483 Historically, trials dichotomised outcome as 
death or dependency, defined as mRS>2, or mRS>3, or 
BI<60. Ordinal analysis of ordered categorical data is 
more efficient statistically and provides information on 
severity of outcome412 and recent trials have used 
ordinal analysis of mRS data.137, 262, 458, 469, 473, 474, 479, 483  
 Case fatality at >=1 months: 15 trials136, 137, 262, 264, 385, 
458, 466-469, 473, 477, 479, 481, 483  
 Early neurological impairment (e.g. National Institutes of 
Health Stroke Scale, Scandinavian Stroke Scale) at <1 
month: 11 trials136, 262, 463, 465, 467-469, 472, 473, 476, 483  
 Hospital length of stay: four trials137, 262, 264, 483  
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7.7.6 Excluded studies 
 
66 studies were excluded because they: lacked randomisation, 
were irrelevant to the questions addressed in the current 
review, and/or failed to provide BP or outcome assessments. 
 
7.7.7 Other studies 
 
8 studies are either awaiting assessment485-488 or are 
ongoing.400, 489-491 
 
7.8 Statistical Analyses 
 
Four trials compared more than one treatment against a 
common control group.262, 385, 462, 463 The most appropriate 
analysis according to a previous update of this review involved 
dividing the control group participants equally between 
treatment groups to prevent control participants being 
counted more than once and thereby artificially narrowing the 
confidence intervals.  
 
7.9 Risk of bias in included studies 
 
Ten trials used CT prior to entry to identify460, 469, 472, 473, 475 or 
exclude463, 465-467, 476 patients with ICH. The Fagan study 
attempted to exclude ICH through information from the 
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history and neurological examination; it may therefore have 
inadvertently included some patients with ICH.462  
 
7.9.1 Allocation bias 
 
We classified allocation concealment as 'low risk', 'high risk' or 
'unclear risk' according to the Cochrane Handbook for 
Systematic Reviews.461  
 
7.9.2 Blinding (performance and detection bias) 
 
The method of randomisation was given for 23 trials.136, 137, 
262, 264, 266, 385, 458, 460, 465-469, 472-474, 476-481, 483 Two authors were 
unable to describe the method of randomisation463, 475 and one 
did not respond to our communication.462  
Patients and investigators were blinded to treatment as 
follows: 
 
 Double-blind (patient and investigator blinded): 13 
trials262, 266, 458, 462, 463, 466-468, 474, 476, 478, 479, 481  
 Single-blind (patient-blinded): 4 trials137, 264, 385, 477  
 Open-label: six trials136, 385, 460, 472, 473, 480  
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7.9.3 Incomplete outcome data (attrition bias) 
 
Sixteen trials were analysed by intention to treat (ITT).136, 137, 
262, 264, 385, 458, 460, 462, 463, 469, 473, 477, 479, 481, 483, 492 In one study 
we excluded 10 patients from the analysis because they had 
been treated with antihypertensive agents for concurrent 
accelerated (malignant) hypertension.475 Cardiovascular data 
were analysed on a per-protocol basis and outcome data by 
intention to treat in a trial of lisinopril.468 
 
7.9.4 Selective reporting (reporting bias) 
 
We assessed selective reporting as low risk, high risk or 
unclear risk according to the Cochrane Handbook for 
Systematic Reviews.461 We did not see evidence of selective 
reporting in any of the trials. 
 
7.9.5 Other potential sources of bias 
 
One trial randomised patients before neuroimaging and those 
having a non-ischaemic stroke were subsequently withdrawn 
from the study.468 Two trials did not state the method of 
randomisation.465, 467 We did not find any other potential risks 
to the validity of the included studies. 
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7.10 Effects of interventions 
 
The result section is split into three parts: 
 Comparisons of BP lowering with control 
 Comparisons of continuing versus stopping temporarily 
pre-stroke antihypertensive drugs 
 Comparisons of BP elevation with control 
 
7.10.1 Blood pressure lowering 
 
7.10.1.1 Clinical outcomes 
 
Twenty- one trials provided data on one or more outcomes 
relating to treatment with: 
 ACE-I (lisinopril): three trials262, 266, 468  
 
 ARA (candesartan, telmisartan): five trials458, 466, 474, 479, 
480 
 
 Beta-receptor antagonist (labetalol): one trial262 
 
 Calcium channel blockers (nimodipine): one trial475  
 
 NO donors (glyceryl trinitrate):five trials137, 264, 385, 477, 481  
 
 Intensive BP-lowering: six trials262, 460, 469, 472, 473, 483  
 
 BP elevation (phenylephrine): one trial465 
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7.10.1.1.1 Death or dependency, end of trial 
 
7.10.1.1.1.1 Stroke type 
 
The effect of lowering BP did not vary by stroke subtype 
(ischaemic stroke, mixed stroke, ICH) across 14 trials (Figure 
7.2). 
 
7.10.1.1.1.2 Stroke location 
 
The effect of lowering BP did not vary by stroke location (ICH 
deep or not, ischaemic stroke cortical or subcortical) across six 
trials with 11951 patients (Figure 7.3). Although there was 
insufficient evidence for heterogeneity, BP lowering in deep 
ICH almost reached significance (OR 0.86, 95% CI 0.73-1.00, 
p=0.06) (Figure 7.3). 
 
7.10.1.1.1.3 Time to treatment 
 
Data from 15 trials involving 15,520 patients are available. 
There was significant reduction in death or dependency if 
treatment was administered during the hyperacute period and 
in hospital (OR 0.87, 95% CI 0.76-0.99, p=0.03). Recruitment 
of participants later than this was associated with no benefit 
(Figure 7.4). 
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7.10.1.1.2 Death, early and end of trial 
 
There was no overall effect of treatment on early death or 
death at end of trial when analysed by stroke type (Figure 7.5, 
Figure 7.7) or time to treatment (Figure 7.6, Figure 7.8). 
 
7.10.1.1.3 Barthel Index (disability), end of trial 
 
Barthel Index was assessed at the end of follow-up in 2 trials 
with 4350 patients (Figure 7.9). Although no significant 
difference was observed with stroke type (Figure 7.9), BI 
scores were lower if treatment was started within six 6 hours 
of stroke onset (Figure 7.10). 
 
7.10.1.1.4 Early neurological deterioration 
 
Subgroup differences were not present when analysed by 
stroke type (Figure 7.11). However, subgroup differences 
were apparent when assessed by time to treatment (Figure 
7.12); specifically, an increase in neurological deterioration 
was seen in participants with acute stroke (<=48 hours post 
stroke) (OR 1.39, 95% CI 1.07-1.81, p=0.01) but not when 
trials specifically treated earlier during the ultra-acute and 
hyper-acute periods. 
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7.10.1.1.5 Quality of life 
 
Quality of life, assessed using the EQ-5D and transformed into 
a Health Utility Status, was assessed in three trials (Figure 
7.13). Health Utility HUS scores were higher/better with BP 
lowering (MD 0.03, 95% CI 0.01-0.04 MD 0.02, p=0.19). 
However, subgroup differences were heterogeneity was 
apparent between studies (I2=76.0%) with a significant result 
in INTERACT-2 but not ENOS-GTN.137, 473 When broken down 
into stroke types, patients with intracerebral haemorrhage in 
INTERACT-2 treated with BP lowering tended to report better 
quality of life.261 When assessed by time to treatment, HUS 
scores were higher in participants treated <=6 hours (MD 
0.06, 95% CI 0.03-0.08), but not when treated later (Figure 
7.14). 
 
7.10.1.1.6 Length of stay 
 
Length of stay was not influenced by lowering blood pressure 
and there were no subgroup differences by stroke type or time 
to treatment (Figure 7.15 and Figure 7.16). 
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7.10.1.2 Haemodynamic measures 
 
7.10.1.2.1 Blood pressure 
 
The effect of different BP-lowering strategies on BP after the 
first dose are summarised in Figures 7.17, 7.18 and 7.19. 
Altogether, 24 trials studied 15,432 participants; most 
participants received an ARA, a NO donor or intensive BP-
lowering. The focus for the following comments are on systolic 
rather than diastolic BP. The magnitude of BP reduction varied 
between -4.6/-2.5 mmHg for oral ARA (primarily candesartan 
and telmisartan) and -13.7/-7.9 mmHg for ACE-Is. When 
assessed by stroke type, heterogeneity was present; slightly 
larger reductions in BP were seen in patients with ICH (-11.8/-
5.1 mmHg) with mixed stroke intermediate (-7.9/-3.0 mmHg) 
and ischaemic stroke least (-7.0/-3.1 mmHg) (Figure 6.18). 
Similarly, the magnitude of reduction varied by time to 
randomisation or treatment (I2=89%); a graded decrease was 
seen by time with the largest reduction occurring in 
participants treated during the ultra-acute/pre-hospital (-
16.0/-15.0 mmHg), hyper-acute/hospital (-13.4/-7.5 mmHg), 
acute (-8.2/-2.8 mmHg) and sub-acute (-7.3/-4.9 mmHg) 
periods. 
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7.10.2 Continue versus stop pre-stroke 
antihypertensive drugs 
 
Two trials, COSSACS and ENOS tested whether pre-stroke 
antihypertensives should be continued in the immediate post-
stroke period, or stopped temporarily.136, 137 The total number 
of participants numbered 2860. 
 
7.10.2.1 Clinical outcomes 
 
7.10.2.1.1Death or dependency, end of trial 
 
There was no significant difference in mRS at day 90 between 
those patients assigned to continue or stop antihypertensives 
by stroke type or time to treatment across both trials (Figure 
7.20 and Figure 7.21). 
 
7.10.2.1.2 Death, early and end of trial 
 
The rates of death at the end of treatment, and end of trial, 
did not differ by stroke type or time to treatment (Figure 7.22, 
Figure 7.24, Figure 7.23 and Figure 7.25). 
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7.10.2.1.3 Barthel Index 
 
Barthel Index scores were lower in patients assigned to 
continue treatment (MD -3.2, 95% CI -0.6, -5.8, p=0.02) 
(Figure 7.26). 
 
7.10.2.1.4 Neurological deterioration, early 
 
The rate of early neurological deterioration at the end of 
treatment did not differ between the treatment groups (Figure 
7.27). 
 
7.10.2.1.5 Quality of life 
 
Quality of life, assessed using the EQ-5D and transformed into 
a Health Utility Status, was lower (i.e. worse) in patients 
randomised to continue pre-stroke antihypertensive drugs 
(MD -0.03, 95% CI -0.05, +0.01, p=0.008) (Figure 7.28). 
 
7.10.2.2 Haemodynamic measures 
 
7.10.2.2.1 Blood pressure 
 
Blood pressure was lower by -7.9/-1.2 mmHg at the first 
measurement after randomisation in participants randomised 
to continue treatment with the reduction in systolic BP much 
greater in COSSACS than in ENOS (Figure 7.29 and Figure 
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7.30). By the end of treatment, BP was lower by -11.3/-6.4 
mmHg in the continue group (Figure 7.30 and Figure 7.31). 
 
7.10.3 Blood pressure elevation therapy in acute stroke 
 
7.10.3.1 Phenylephrine 
 
Phenylephrine non-significantly increased systolic BP at 24 
hours (MD 21 mmHg, 95% CI -13, +55 mmHg), but had no 
significant effect on diastolic BP (Figure 7.33 and Figure 
7.34).465 However the results came from only one study and 
so definite conclusions can be made. 
7.11 Discussion   
 
Twenty-six trials, involving 17,011 participants with stroke, 
assessed the effects of deliberate BP alteration. 
 
7.11.1 BP lowering 
 
The results come from 25 trials that studied 15,432 
participants. 
 
7.11.1.1 Clinical outcomes 
 
Overall, lowering BP did not improve outcome, whether 
assessed as death, combined death or dependency, 
 313 
 
neurological deterioration or quality of life. The findings were 
consistent irrespective of type of stroke. However, when 
assessed by time to treatment, very early BP-lowering (before 
hospital presentation or within six hours of stroke onset) was 
associated with reduced death or dependency, and improved 
quality of life.264, 473 
 
7.11.1.2 Haemodynamic effects 
 
All the studied antihypertensive drug classes lowered BP 
during the period of treatment. Reductions in BP after the first 
treatment varied between -4.6/-2.5 mmHg for oral ARA and -
21.0/-7.9 mmHg for ACE-I. Slightly larger reductions in BP 
were seen in patients with ICH (-11.8/-5.1 mmHg) than in 
those with ischaemic stroke (-7.0/-3.1 mmHg). The largest 
reductions were seen if treatment was started very early 
before hospital presentation (-16.0/-15.0 mmHg); smaller 
reductions occurred if treatment was started beyond 48 hours 
after stroke onset (-7.3/-4.9 mmHg). 
 
7.11.1.3 Comments 
 
A variety of hypotheses can be postulated for why functional 
outcome was better if BP lowering was started very early after 
stroke. First, the magnitude of BP-lowering may be important 
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since the greatest improvement in outcome occurred when 
treatment was started early. Second, the type of intervention 
may be important since improved outcome was seen with 
early intensive BP lowering,261 and early nitrate 
administration.137, 264 Conversely, apparent hazard was seen 
with ARA drugs.383, 458 Perhaps surprisingly, stroke type may 
not be particularly relevant since differential effects on 
outcome were not seen for IS versus ICH. 
 
In summary, very early treatment with an appropriate agent 
or target BP may be the most important strategy to test in the 
future, irrespective of stroke type.  
 
7.11.2 Continue versus Stop pre-stroke 
antihypertensive drugs 
 
The results come from two trials that studied 2860 
participants.136, 137  
 
7.11.2.1 Clinical outcomes 
 
The findings were mixed with some comparisons, in particular 
dependency (mRS), death, and neurological deterioration, 
neutral for the comparison of continue versus stop pre-stroke 
antihypertensive drugs. In contrast, measures of disability 
(BI) and quality of life (EQ-5D, transformed into a Health 
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Utility Status) were worse in patients randomised to continue 
treatment immediately. 
 
7.11.2.2 Haemodynamic effects 
 
Immediately continuing antihypertensive drugs taken before 
stroke was associated with a lower BP by -7.9/-1.2 mmHg at 
the first measurement after randomisation, and -11.3/-6.4 
mmHg by end-of-treatment. 
 
7.11.2.3 Comments 
 
The discrepancy in findings for two measures of functional 
outcome, mRS and BI, is challenging to explain. First, it may 
represent chance such that no difference exists between the 
interventions. Second, it could reflect outcome bias since it is 
not possible to test this question in a double-blind placebo-
controlled design. Nevertheless, both trials used blinded 
outcome assessment for both mRS and BI. Further, since a 
majority of stroke physicians tend to continue treatment in 
routine practice,493 the result seen across the two results is 
counter-intuitive. Last, the difference may be real in which 
case mRS, usually considered to be the optimal functional 
outcome in stroke trials,370 failed to detect a difference in 
contrast to a comparison of BI scores. 
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If continuing drugs immediately is, indeed, hazardous, then 
the two trials do not identify the cause. Drugs that attenuate 
stress hormones, in particular that down-regulate the renin-
angiotensin-aldosterone-system (RAAS) were commonly taken 
before stroke, e.g. ACE-I, ARA and ß-receptor antagonists. 
Initiating these drugs in the acute phase of stroke has been 
associated with harm.458, 494 So it can be postulated that 
continuing these during the acute phase of stroke is 
potentially harmful. Alternatively, continuing drugs in patients 
who are dysphagic and who do not have safe enteral access 
for feeding may be hazardous through aspiration of these 
drugs and then the development of pneumonia. The ENOS 
trial gives some support for this hypothesis.137  
 
The main implication for clinicians is that it is reasonable to 
withhold BP-lowering drugs until patients are medically and 
neurologically stable, and have suitable oral or enteral access, 
after which drugs can then be reintroduced. 
 
7.11.3 General 
 
An important problem with some of the trials was the absence 
of detailed information on how blood pressure was measured. 
Hence, the quality of blood pressure readings is unknown. It is 
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essential that future trials describe in detail how blood 
pressure is measured by including the following information. 
 Equipment: manufacturer, model, measurement method 
(mercury, anaeroid or oscillometry, and manual or 
automatic), and whether the equipment has been 
independently validated, and if so by whom. 
 Measurer: who measured blood pressure, and how they 
were trained, assessed, re-trained and re-assessed. 
 Measurements: the number of readings at each time 
point, site of measurement (brachial, finger, etc) and 
what position the patient was in (supine, sitting, 
standing). 
 
Little is known on the effect of BP altering in older patients 
with acute stroke, who comprise the largest group of patients, 
including those with IS who need thrombolysis. Of the trials, 
only two had mean age over 75 years contributing to a total of 
98 patients.262, 264 The number and proportion of older 
patients is likely to increase with population ageing. As the 
variation in response by individuals to BP modulating agents 
increases with age, e.g. related to concurrent isolated systolic 
hypertension or cardiac dysfunction, it may be inappropriate 
to assume that the effects of changing BP seen in younger 
populations will necessarily be the same in older ones. 
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This review is Part 1 of the Blood pressure in Acute Stroke 
Collaboration and reports only those trials which specifically 
set out to alter blood pressure in patients with acute stroke. 
Part 2 of the project assesses all randomised controlled trials 
in acute stroke where vasoactive drugs were administered and 
includes all those studies covered in Part 1. Although progress 
has been made in the number and quality of stroke trials in 
the last few years, substantial number of questions remain. 
The number of patients included in this review is very small in 
comparison to the global burden of stroke (about 15,000,000 
per year worldwide). At present, any benefit of treatment is 
small, and additional data are required to recommend changes 
to routine clinical practice. The centres which took part in the 
trials were interested and familiar with the management of 
acute stroke. To extrapolate these results in routine clinical 
practice to less specialist centres could result in greater 
hazard or completely negate any potential benefit. Therefore, 
there is a need for new centres to participate in trials.  
Further evidence is needed on: 
 How to select patients 
 The influence of age, time of onset, stroke subtype, 
severity, choice of drug, dose, route of administration 
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and blood pressure variability, on response to active 
changes in BP. 
Recent guidelines based on largely observational data 
recommend that hypertension should not be treated for up to 
two weeks after an IS unless severe hypertension, 
hypertensive encephalopathy, heart failure, cardiac ischaemia, 
aortic dissection, or continued intracerebral bleeding are 
present.495-497 Persistent hypertension after two weeks should 
be treated since the risk of stroke in patients with 
cerebrovascular disease is dependent on systolic and diastolic 
blood pressure.498 In the PROGRESS trial, perindopril (with or 
without indapamide) reduced the risk of stroke among both 
hypertensive and non-hypertensive patients with a history of 
stroke or transient ischaemic attack.499 Further, evidence from 
the Heart Outcomes Prevention Evaluation (HOPE) trial 
suggests that an ACE-I may reduce stroke and other vascular 
events in patients with prior cerebrovascular disease.500 
Overall lowering blood pressure in patients with chronic stroke 
reduces the subsequent risk of recurrence.404  
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7.12 Conclusions 
 
7.12.1 Implications for practice 
 
 The lack of definitive results for BP lowering, and very 
limited data for raising BP, mean that no firm 
recommendations can be made. 
 
 There is no evidence to support the routine policy of 
immediately continuing prestroke antihypertensive 
drugs; treatment may be re-started once patients have 
stabilised medically and neurologically, and once safe 
feeding or enteral access is available. 
 
 The very limited data related to BP elevation mean that 
no recommendations can be made. 
 
7.12.2 Implications for research 
 
Large randomised controlled trials of blood pressure lowering 
are needed to: 
 Test the effect of ultra-acute/pre-hospital lowering of BP 
in RCTs. 
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 Test the effect of hyper-acute/hospital lowering of BP in 
RCTs. Two trials are important examples of ongoing 
studies400, 489  
 Determine the effects on long -term survival (>=one 
year). 
 Determine the effects on quality of life and cost-
effectiveness. 
An individual patient data (IPD) meta-analysis is required to: 
 Identify subgroups of patients who are likely to benefit 
or be harmed, e.g. by age, sex, race-ethnicity group, 
baseline BP, history of hypertension, stroke type (IS, 
ICH). 
 Identify what type of treatment is required, e.g. drug 
class, route, dose of administration. 
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Table 7.1 Characteristics of included studies 
 
Trial Size A/C Male 
(%) 
Stroke 
type 
Enrolment 
time (hrs) 
Intervention Rx duration 
(days) 
Primary outcomes 
        
ACCESS466 173/166 51 IS 24-48 candesartan 4 mg/ placebo (po) 7 BP, BI at 3 months 
ACCOST478 19/19 - IS 120 candesartan 4 mg/ placebo 
(po) 
28 BP, all death and death due to 
vascular causes, NIHSS, mRS, BI at 3 
months 
Bath 16/21 49 IS, 
PICH 
120 GTN/placebo (td) 12 24 hour ABPM at day 0,1 and 8, mRS, 
BI at 3 months 
CATIS470 2033/2033 62 IS 48 Intensive (iv/po)/  stop 
prestroke BPdrugs 
14 BP at day 1,7,14, death/dependency 
at day 14 and 90 
CHHIPS- 57/30 53 IS, ICH 24 Lisinopril/placebo (po/sl/iv) 14 mRS at 2 weeks 
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lis262 
CHIPPS-
lab262 
56/29 61 IS, 
PICH 
24  Labetalol/placebo (po/sl/iv) 14 mRS at 2 weeks 
COSSACS136 379/384 74 IS, 
PICH 
48  Continue/stop prestroke BP 
drugs 
14 mRS at 2 weeks 
Dyker476 14/14 61 IS 168  Perindopril 4mg/ placebo (po) 15 BP, NIHSS at baseline and day 15 
ENOS137 2000/2011 57 IS, 
PICH 
48 GTN 5 mg/placebo (td); 
continue/stop prestroke BP 
drugs 
7 mRS at day 90 
Eveson468 18/22 63 IS 24 Lisinopril/placebo (po) 14 NIHSS at day 14, mRS and BI at day 
14 and 90 
Fagan462        
120 mg 
10/9 45+ IS - Nimodipine 20 mg/ placebo 
(po) 
21 BP for 7 days 
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Fagan462   
240 mg 
10/9 45+ IS - Nimodipine 20 mg/ placebo 
(po) 
21 BP for 7 days 
Hillis465 9/6 27 IS 168 Phenylephrine 
(iv)/conventional management 
3 NIHSS at day 3, cognition 
ICH-
ADAPT472 
39/36 67 PICH 24 Intensive/guideline (iv) 1 Perihaematoma CBF 
INTERACT 
pilot469 
203/201 65 PICH 6 Intensive/guideline (po/iv) 7 Proportional change in haematoma 
volume 
INTERACT 
2013473 
1382/1412 64 PICH 6 Intensive/guideline (po/iv) 7 mRS at day 90 
Koch460 21/21 61 PICH 8 Intensive/guideline 2 NIHSS, GCS at 24 and 48 hours 
Lisk463 10/6 25 IS 72 Nicardipine 20 mg, captopril 
12.5 mg, clonidine 0.1 
3 NIHSS, BP 
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mg/placebo (po) 
PILFAST459 6/8 100 IS, 
PICH 
3 Lisinopril 5 mg/placebo 
(po/sl/ng) 
7 BP 
PRoFESS479 647/713 64 IS 72 Telmisartan/placebo (po) 2.5 years BP, HR at day 7, 30 and 90   
Rashid 1385 20/30 46 IS, 
PICH 
72 GTN 5mg/control (td) 10 mRS, BI, quality of life at 3 months 
Rashid 2385 20/30 46 IS, 
PICH 
72 GTN 5mg/control (td) 10 mRS, BI, quality of life at 3 months 
Rashid 3385 20/30 46 IS, 
PICH 
72 GTN 5mg/control (td) 10 mRS, BI, quality of life at 3 months 
RIGHT264 25/16 60 IS, 
PICH 
4 GTN 5mg/control (td) 7 SBP at 2 hours, mRS day 90 
SCAST458 1017/1012 60 IS, 30 Candesartan/placebo (po) 7 mRS at 6 months, composite of 
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PICH vascular death, nonfatal MI or non-
fatal stroke in first 6 months 
TAST474 12/7 83 IS 120 Telmisartan/placebo (po/ng) 90 Ipsilateral hemispheric CBF 
Uzuner iv475 8/3 63 IS, 
PICH 
24 Nimodipine/placebo (iv) 2 BP, HR 
Uzuner po475 38/39 63 IS, 
PICH 
24 Nimodipine/placebo (po) 2 BP, HR 
VENTURE480 203/202 - IS 24 Valsartan/no valsartan 7 mRS at day 90 
Willmot477 12/6 70 Clinical 
stroke 
120 GTN 5mg/no patch (td) 7 Central, peripheral BP 
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A: active; BI: Barthel index; BP: blood pressure; C: control/placebo; HR: heart rate; IS: Ischaemic stroke; mRS: 
modified Rankin scale; PICH: primary intracerebral haemorrhage; po:per oral; sl: sublingual; td: transdermal; iv: 
intravenous; Rx: treatment  
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Figure 7.1 Search process of relevant studies 
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Figure 7.2 Death or dependency, end of trial by stroke type 
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Figure 7.3 Death or dependency, end of trial by stroke 
location 
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Figure 7.4 Death or dependency, end of trial by time to 
treatment 
 
 
 
 
  
 332 
 
Figure 7.5 Death early, by stroke type 
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Figure 7.6 Death, early by time to treatment 
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Figure 7.7 Death, end of trial by treatment 
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Figure 7.8 Death, end of trial by time to treatment 
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Figure 7.9 Barthel Index, end of trial, by stroke type 
 
 
 
 
Figure 7.10 Barthel Index, end of trial by time to treatment 
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Figure 7.11 Early neurological deterioration, by stroke type 
 
 
Figure 7.12 Early neurological deterioration, by time to 
treatment 
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Figure 7.13 Quality of life (EuroQoL) at end of trial, by stroke 
type 
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Figure 7.14 Quality of life (EuroQoL) at end of trial, by time 
to treatment 
 
 
 
Figure 7.15 Length of stay, by stroke type 
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Figure 7.16 Length of stay, by time to treatment 
 
 
 
Figure 7.17 SBP, first after randomisation by intervention 
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Figure 7.18 SBP, first after randomisation by stroke type 
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Figure 7.19 SBP, first after randomisation by time to 
treatment 
 
 
Figure 7.20 Death or dependency, end of trial by stroke type, 
continue vs stop 
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Figure 7.21 Death or dependency, end of trial by time to 
treatment, continue vs stop 
 
 
 
Figure 7.22 Death early, by stroke type, continue vs stop 
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Figure 7.23 Death early, by time to treatment, continue vs 
stop 
 
 
 
Figure 7.24 Death, end of trial, by stroke type, continue vs 
stop 
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Figure 7.25  Death, end of trial, by time to treatment, 
continue vs stop 
 
 
 
Figure 7.26 Barthel index, end of trial, by continue vs stop 
 
 
 
 
Figure 7.27 Early neurological deterioration, by continue vs 
stop 
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Figure 7.28 Quality of life (EuroQoL) at end of trial, by 
continue vs stop 
 
 
 
Figure 7.29 SBP, first after randomisation, by continue vs 
stop 
 
 
 
Figure 7.30 DBP, first after randomisation, by continue 
vs stop 
 
 
Figure 7.31 SBP, at end of treatment by continue vs stop 
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Figure 7.32 DBP, at end of treatment by continue vs 
stop 
 
 
Figure 7.33 SBP at day 1  
 
 
 
Figure 7.34 DBP at day 1 
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Chapter - 8 Discussion 
 
8.1 Introduction 
 
The management of acute intracerebral haemorrhage has 
been a topic of debate and focus of research especially in the 
last few decades. Systematic work has revealed the following: 
haematoma volume and early expansion is frequent with 
potential consequences of neurological deterioration and 
death;211, 225 strong association exists between high blood 
pressure and poor outcome after stroke124, 501 and treating 
high blood pressure which is low cost and widely available 
appears attractive.  Whilst new research relating to these 
topics adds insight into a small area in this vast subject, 
attempts to answer one question often reveals new areas of 
uncertainty.  
 
I return to some of the objectives outlined in the introduction 
and discuss under various headings. 
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8.2 Assess the performance characteristics of the 
methods used to measure intracerebral haemorrhage 
volume 
 
Haematoma volume is the most potent predictor of poor 
prognosis after ICH.225 Limiting haemorrhage expansion is 
used as a surrogate marker of functional outcome in recent 
trials of blood pressure lowering, haemostatic therapy or 
surgery260, 261, 277, 310, 502, 503 and therefore the ability to 
accurately calculate volume becomes critical. The ABC/2 
formula and its modified version (where slices of haemorrhage 
are excluded if less than 25% of the largest surface area)251, 
352 are commonly used but researchers have doubted the 
accuracy and reliability as the implicit assumption is 
haematoma volume is approximated to an ellipsoid.250, 252-254, 
355, 356 Computer assisted SAS or 3-D automatic volume 
rendering are also used but rely on good quality electronic 
scan images and advanced software.246, 252, 355  Previous work 
examining these methods highlighted issues relating to 
measurement time, type of data, accuracy, availability of 
computer and sample size, all studied in part.246, 252-254 
 
With this background, a study was undertaken to investigate 
the reliability and causes for variation and error between three 
methods commonly used to measure haemorrhage volume: 
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ABC/2, modified ABC/2 and SAS. In addition, the reliability of 
a novel way of estimating longest haemorrhage diameter in an 
ordered category (less than 3 cm, 3-5 cm, 5-8 cm and >8 cm) 
was also assessed.  This is the largest study in the field of 
spontaneous ICH and CT scans from the large multinational 
trial ENOS was used for this purpose (details listed in chapter 
2). The results revealed that volume calculation by each of the 
methods: ABC/2, modified ABC/2 and SAS had minimal intra 
and inter-observer variation demonstrating excellent internal 
validity. Standard ABC/2 was easy to use, quick to perform 
and produced similar volumes compared to SAS. By 
comparison, haemorrhage volumes calculated using modified 
ABC/2 were significantly lower compared with ABC/2 and SAS 
and the difference enlarged as haematomas became bigger. 
When assessing qualitative estimates of haemorrhage size in a 
ordered escalation, our results found that visual categorisation 
was quick, consistent and reliable making it potentially useful 
in emergency situations when moved images preclude 
accurate volumetric measurements or measuring tools are not 
accessible.  
 
To compare our study results with those previously published, 
a review of studies analysing ABC/2, modified ABC/2 and SAS 
was undertaken and 11 studies identified. Although the overall 
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patient numbers were small, sufficient methodological 
information was available to conclude that consistent ICH 
volumetric calculation can be achieved using standard ABC/2. 
This is relevant from a practical perspective, as in the absence 
of a readily available computerised software program, 
clinicians will be able to obtain a reliable calculation of ICH 
volume using ABC/2. Such crucial information might influence 
treatment decisions such as surgical intervention or prevent 
incorrect initiation of ‘do not resuscitate’ orders.  
 
We extended the hypothesis by examining the reliability 
between volume computed by ABC/2, modified ABC/2 and 
SAS according to haematoma shape. It is known that irregular 
shaped haematomas are more likely to expand and affect 
survival after stroke.361 The results showed that ICH volumes 
produced by standard ABC/2 were reliable and consistent 
compared with SAS, irrespective of haemorrhage shape. By 
comparison, ICH volume was significantly lesser using the 
modified ABC/2 method for small, regular shaped 
haemorrhages and the difference larger as haemorrhages 
became bigger and more irregular. It is possible that the 
haemorrhage volumes in ENOS were too small to detect any 
difference between standard ABC/2 and SAS as previous work 
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has questioned the accuracy in more larger and complex 
shaped irregular haemorrhages.250  
 
One report suggested that haematoma shape may depend on 
brain location and degree of cerebral atrophy.253 As such 
criteria were not used to select our dataset, these questions 
were not tested and need further exploration. In our study, it 
was also not possible to examine whether an individual 
haematoma shape at one given time point on a CT changed to 
another shape as in ENOS patients had scans at the time of 
entry into the trial and a second scan if possible at 7 days. 
Ongoing trials should take this into account and hopefully will 
provide answers in this area.220, 280, 504 
 
Our report that the settings for computer assisted SAS is 
being cumbersome and extremely time consuming is 
consistent with previous studies.246, 252, 253 We were also not 
able to assess the reliability of fully automated 3-D rendering 
using Osirix; this is reflected in the small number of volumes 
calculated making it difficult even for hypothesis generation. 
This is because Osirix was unable to handle scans with 
variable slice thickness. Other software packages are able to 
manage this issue but experience significant delays in image 
acquisition.246, 252 In a small study of patients with 
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intracerebral haemorrhage, acquisition time ranged between 
20-30 minutes for each CT raising questions of the use of fully 
automated 3-D rendering in clinical situations and therefore 
more work to develop faster algorithms is needed.252 Even 
with faster software, it is important not to forget that the SAS 
and 3-D rendering still require user discretion and manual 
intervention for final ICH volume estimation. Future work 
should test whether various computer-assisted methods 
supported by different software produce similar results.246 
 
The present study did not assess the accuracy and reliability 
of these methods in larger and more complex warfarin related 
haemorrhages as ENOS examined the effect of blood pressure 
lowering in a population of spontaneous ICH. Warfarin related 
ICH is associated with more morbidity and mortality 205, 505 as 
the propensity for haematoma expansion is greater.205 Hence, 
work analysing the reliability of volumetry in this area is 
crucially needed. Similarly, work should be encouraged in the 
field of novel anticoagulants because of lack of data and 
increasing use in an ageing population with atrial fibrillation.506 
Assessing the reliability of these methods in perihaematoma 
oedema is also needed as it has been shown to affect clinical 
outcome.232, 233 
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8.3 Blood pressure lowering with transdermal glyceryl 
trinitrate (GTN) in acute intracerebral haemorrhage 
 
As detailed in chapter 4, a subgroup analysis of ENOS was 
performed to investigate whether blood pressure lowering with 
transdermal GTN was associated with improved functional 
outcome after acute haemorrhagic stroke. Functional outcome 
was measured using the modified Rankin scale at 90 days (0 
to 6, 0 indicating no symptons, five meaning severe 
dependency and 6 denoting death). Patients were recruited 
worldwide and received care in different healthcare systems 
and therefore represent a wide perspective of stroke care. The 
results revealed that in 629 patients, GTN reduced SBP by 8 
mm Hg but did not improve functional outcome. Given 
concerns about worsening functional outcome with an ARA 
agent like candesartan,507 the absence of worsening on 
neuroimaging measures at day 7 (end of treatment) and 
adverse events including hypotension, early and late fatality 
with GTN is reassuring and supports trials further testing of 
this agent in acute stroke.133, 134 
 
When examined by prespecified time windows as in 
INTERACT-2 (within 6 hours),261 participants treated with GTN 
were less likely to die and reported better quality of life and 
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scored higher on cognitive assessment. Although careful 
interpretation should be made given the small numbers of 
patients, GTN when given very early is postulated to have 
other effects in addition to BP lowering such as 
neuroprotection and improving reperfusion by opening 
collateral circulation as supporting evidence was shown in a  
pilot trial of the drug in hyperacute stroke, RIGHT.264  RIGHT 
demonstrated that paramedics could successfully screen 
patients with stroke symptons, consent, randomise and start 
BP lowering in a pre-hospital setting.264 The mean time from 
stroke onset to randomisation was 55 minutes and after 2 
hours of treatment with GTN, SBP was lowered by 18 mm 
Hg.264 Taking together the results from ENOS and RIGHT and 
a previous large trial in acute intracerebral haemorrhage,137, 
261, 264 the results support further testing whether very early 
BP lowering might benefit in improving functional outcome as 
is being undertaken in ongoing randomised controlled 
trials.133, 134, 268 In addition, parameters such as blood 
pressure variability, central and cerebral haemodynamics 
could also be assessed as evidence suggests that these factors 
could impact short term and long term functional outcome.508, 
509 Future trials could also examine changes to haemorrhage 
characteristics at various time points during treatment as this 
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may provide information on potential mechanisms of drug 
action. 
 
It is important to highlight that the data came from a 
randomised controlled trial with prespecified inclusion and 
exclusion criteria. Patients with very high blood pressure 
(>220 mm Hg) were excluded from ENOS and so no results 
are available for those with severe hypertension. As a result, 
strength of the relationship between BP lowering and 
functional outcome as a result might have been 
underestimated. Patients with comorbidities such as MI and 
cardiac failure with SBP pressure levels less than 140 mm Hg 
will have been excluded and therefore information on such 
patients is not available. Low BP may result in poor perfusion 
of the penumbra surrounding the haematoma and result in 
poor outcome.510, 511 Another issue is that a low proportion of 
patients with IVH were recruited into ENOS and therefore such 
patients with will have been underrepresented. This may have 
affected the strength of the relationship between BP lowering 
and functional outcome. One other factor to highlight is time. 
ENOS allowed recruitment upto 48 hours and so it is possible 
that some haemorrhages may have already expanded and this 
will have affected the ability of BP lowering to have any effect. 
Furthermore, some patients with higher blood pressure will 
 358 
 
have been missed as it is known blood pressure falls within 
the first few hours after stroke onset.512  
 
That functional outcome may be predicted using simple visual 
assessments of characteristics such as haematoma shape and 
density is highly relevant for treating clinicians. Rapid 
assessment of shape and density might identify those at high 
risk of haematoma growth and allow recruitment into clinical 
trials aimed at detecting any treatment effect. Alternatively, 
including a large irregular ICH with extension into the 
ventricles may not translate into favourable effect.  
 
The present work is novel adding more information to this 
area of ICH but more work to identify clinical and radiological 
factors at stroke onset. To-date, most predictors of poor 
outcome in ICH are irreversible including age, haemorrhage 
location and baseline level of consciousness leaving only one 
factor haemorrhage volume as potentially modifiable.225, 513 
Finding the ‘spot sign’ on CT angiography might be useful but 
questions surround the time dependent variability and 
interpretation in the presence of potential confounders such as 
blood pressure lowering and haemostatic agents.44, 514 
However, it is known of the association between ‘spot positive’ 
status of haematoma and adverse clinical outcome515 and 
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therefore clinical trials in this group of patients are needed.280, 
281, 296 Future work should also examine pathophysiological 
factors or possible mechanisms. With this knowledge, agents 
targeting patients who might benefit most may be identified.   
 
8.4 Effects of continue versus stopping prestroke 
antihypertensive drugs in acute intracerebral 
haemorrhage 
 
Upto 50% of patients admitted with acute stroke are on blood 
pressure lowering tablets and it was unclear whether they 
should be continued or stopped temporarily during the acute 
phase of stroke. Treating hypertension by continuing prior 
antihypertensive drugs in the immediate period after ICH 
seems advantageous by reducing stroke recurrence, 
haematoma expansion and improving functional outcome.404 
The issue may become complicated by the fact that many 
patients develop swallowing problems after stroke and may 
not be able to take the tablets even if prescribed. On the other 
hand, lowering blood pressure by continuing treatment might 
cause profound hypotension and dehydration, a common 
problem in acute stroke patients who may not be taking fluids 
appropriately. Stopping treatment might limit hazard as seen 
in trials of angiotensin receptor antagonists, β-receptor 
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antagonists and calcium channel blockers.494, 507, 516 The 
clinical equipoise that resulted from these opposing arguments 
led onto research in this area. The COSSACS trial attempted 
to answer this question and did not show any potential harm 
from treatment continuation, but was statistically 
underpowered.136 Keeping this in mind, Chapter 5 of this 
thesis explored this question in a subgroup analysis using data 
from ENOS.  
 
Among 629 patients with haemorrhagic stroke, 246 patients 
were assigned to continue or stop pre-existing 
antihypertensive drugs temporarily for 7 days. For those 
assigned to continue, medication was administered orally and 
those with dysphagia received treatment through a 
nasogastric feeding tube. The results revealed no significant 
difference in the functional outcome assessed using mRS at 
day 90 among those who continued prior antihypertensive 
drugs compared to those stopped treatment. When analysing 
rates of survival, more deaths seemed to occur in those 
assigned to stop antihypertensive drugs implying they did 
worse. This was even after confirming that the timing of 
ascertainment of death between the groups was similar and 
the data and figures checked for any numerical or labelling 
errors. The observed result is difficult to explain but overall 
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there was no significant difference. The analysis is novel as it 
examined the association between clinical and neuroimaging 
parameters in haemorrhagic stroke during the acute phase.  
 
A combined analysis including the results of ENOS and 
COSSACS revealed that measures of disability and quality of 
life were worse in patients randomised to continue treatment. 
Although the primary outcome of mRS was not significantly 
affected by treatment continuation, the signs of possible harm 
in key secondary variables suggest that it seems sensible to 
withhold blood pressure lowering drugs until patients are 
stable and ensure suitable oral and enteral access is 
established. Given practical issues in implementing this 
complex question in the setting of a large trial,136 it is unlikely 
there will be any future studies looking into continue versus 
stopping pre-existing antihypertensives in acute stroke. 
Guidelines do not advise on this issue,517 but will need to 
update the recommendations based on the results of 
COSSACS and ENOS. 
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8.5 Compare the baseline characteristics and outcomes 
of patients with intracerebral haemorrhage from 
different ethnic backgrounds 
 
Whilst previous work indicates ethnic variation in risk factors 
for ICH, little is known whether these manifest as differences 
in clinical characteristics, haematoma parameters or functional 
outcome. With this background, an analysis was conducted in 
Chapter 6 using data from ENOS and the VISTA collaboration 
(Virtual International Stroke Trials Archive). Only those 
patients randomised to control were included to avoid any 
potential confounding treatment factors. This is the first study 
addressing this aspect of haemorrhagic stroke and the results 
found significant differences in age, GCS, BP and ICH volume 
at baseline among 3 ethnic groups- Caucasians, Asians and 
Blacks. Although no difference was observed in mRS at day 
90, there were significant differences in mortality rates and 
quality of life. After adjusting for baseline characteristics, 
Asians were less likely to die and scored higher in the 5 
domains of the European-Quality of life questionnaire 
compared to Caucasians. The causes for these disparities are 
open to question and may be partly explained by lifestyle 
factors. Whether genetic or cultural differences impacted upon 
the findings was beyond the scope of this study and needs 
further exploration. 
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More than three-quarter of patients in this cohort were 
Caucasians suggesting that future trials need to achieve better 
balance of treatment and control allocation within populations. 
This would be of relevance when drawing conclusions about 
outcomes between hospitals within regions or between 
countries. It is equally important to mention that in this 
analysis distinct subpopulations were combined into one ethnic 
group (for example including Filipinos, Indian and Arabics as 
Asians) and this might have not been appropriate. Although 
this was undertaken to compensate for small patient numbers, 
it would be important for future studies to examine for 
differences among subpopulations. This is because stroke 
incidence and outcomes are known to differ between 
population groups living in the same country and between 
countries.420, 518, 519  
 
Most patients with ICH in this cohort were males reflecting a 
higher incidence but whether clinical and outcome differences 
exist within or between sexes are limited520 and need further 
assessment. This would be important as interactions between 
sex and ethnicity will affect the incidence of ICH. For example, 
a higher incidence of ICH is observed in Japanese men 
compared to women.521, 522 In a population-based study of 
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Chinese men, a higher incidence was observed in those living 
in Changsha but not in Beijing or Shanghai.523 When exploring 
the question of sex-difference in future research, examining 
variation in haematoma according to location, volume and 
expansion might also help. 
 
It is important to highlight that patients in this study came 
from randomised controlled trials with specific inclusion and 
exclusion criteria and this may have led to selection bias. 
Therefore, the results may not be applicable to a population of 
unselected patients. The information was limited to trials 
sharing information with the VISTA collaboration and therefore 
those that are not represented need to be examined. Future 
analysis could also include developing countries and those 
which do not have access to specialist stroke teams. 
 
8.6 Deliberate BP intervention in acute stroke 
 
Whilst previous work indicates high BP is associated with poor 
early and late outcome after acute stroke, it is still debated as 
to whether it should or should not be treated during the acute 
phase. Pathophysiological evidence argues against in the 
context of impaired cerebral autoregulation during the acute 
phase whilst observational data favours lowering. Current 
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guidelines recommend blood pressure lowering only if the 
blood pressure is greater than 220/120 mm Hg, greater than 
200/100 with end-organ damage (concomitant hypertensive 
encephalopathy, aortic dissection, cardiac ischaemia, renal 
failure) or more than 200/120 mm Hg in primary ICH.268, 495, 
517  
 
As detailed in Chapter 7, a meta-analysis of blood pressure 
altering trials aimed at improving clinical outcome in acute 
stroke was performed. This was an update since the first 
review in 2001, updated again in 2008 and included 17,011 
patients. The new trials included tested BP alteration using 
single agents, blood pressure lowering to no target to pre-
specified targets and functional outcomes ranged from near-
negative to neutral to near-positive. The overall result was 
that blood pressure lowering did not improve functional 
outcome irrespective of type of stroke. However, there were 
signs that treatment initiated very early might reduce death or 
dependency and therefore justifies further research as is being 
undertaken in ongoing randomised controlled trials.133, 134 
 
Few aspects relating to blood pressure lowering in this review 
warrant discussion. Despite the evidence, it remains unclear 
as to which antihypertensive agent should be used to lower 
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blood pressure in acute stroke. Trials involving angiotensin 
receptor antagonists reduced blood pressure but appeared to 
cause harm whereas trials of outcome with nitrates ranged 
from neutral to signs of benefit when administered early.137, 
264, 507 No significant benefit on outcome was seen with 
thiazide diuretics although the information came from one 
trial.467 Agents such as alpha-receptor antagonists, 
hydralazine, diuretics and centrally acting drugs were used in 
combination in trials of target driven BP lowering making it 
difficult to analyse the effects of any single agent. More 
homogeneous data is therefore needed and crucial information 
will become available when ongoing trials of single agents are 
completed.133, 134 Another important clinical issue during BP 
lowering is dysphagia which occurs in a significant proportion 
of patients after stroke and therefore starting tablets might 
not be an option. Alternative approaches include applying a 
transdermal GTN patch or to use short acting intravenous 
agents such as nicardipine and clevidipine but more work in 
this area is needed. 
 
Another important issue is the lack of knowledge as to when 
to start BP lowering after acute stroke. Whilst the present 
meta-analysis does not give the answer in a precise manner, 
it attempts in a way by showing that functional outcome was 
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better if BP lowering was started within 6 hours of onset and 
delay beyond 6 hours was not associated with clinical benefit. 
The observed results were probably relate to the magnitude of 
BP lowering as seen in INTERACT-2 and the postulated 
neuroprotective effect of GTN very early after stroke but no 
firm conclusions can be made as the summary result was 
neutral. Of recent, the ATACH-2 investigators attempted to 
extend this knowledge using intravenous nicardipine in ICH 
patients presenting within 4.5 hours of ictus with GCS over 5 
and randomly assigned patients to 140 to 179 mmHg or 110 
to 139 mmHg.524 The trial planned to enrol more patients, but 
was stopped prematurely after 1000. Although nicardipine 
appeared to an effect on haematoma expansion, there was no 
significant difference in the primary outcome of death or 
disability which occurred in 38.7% of the intensive group 
compared to 37.7% of the standard group (adjusted relative 
risk, 1.04; 95% confidence interval, 0.85 - 1.27; p= 0.72).524  
 
One other issue related to this analysis was the lack of clarity 
as to what magnitude of reduction might benefit. Whilst 
previous work showed that a 8-14 mm Hg reduction may 
reduce the risk of poor outcome, the number of included 
studies were few and patient numbers small.132 The trials in 
this review differed in the blood pressure level for enrolment 
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and treatment targets varied from intensive control to 
guideline based to no pre-specified level. Repeating the meta-
regression with the current data and results from ongoing 
trials might provide more clear answers.  
 
If blood pressure lowering is thought to benefit, it is not clear 
from the data as to how long patients should be treated for. 
Trials in this review varied from 1 day upto 2.5 years making 
the shift from primary to secondary prevention after stroke 
appear indistinct. The work from a previous meta-analysis 
suggests that treatment for a short period may be effective132 
and supporting further testing in this area of stroke 
research.134, 525 
 
There was limited information on long-term follow-up, as most 
trials (including the most recent ones) performed follow up at 
three months. This might be early as patients with severe 
stroke (included in the trials) can experience recovery upto six 
months. Moreover, a longer time-point on functional outcome 
might highlight continued benefit or potential harm as shown 
recently by the SCAST study group with candesartan.526 
Future trials may therefore consider long-term follow up but it 
should be remembered that outcome assessment may be 
 369 
 
confounded by concurrent interventions such as 
physiotherapy. 
 
One of the key limitations of this analysis was the lack of 
information on how blood pressure was measured including 
equipment, who took the measurement and how they were 
trained, the number of readings at each time point and what 
position the patient was in (supine, sitting or standing). Of the 
included 26 studies, only 16 reported on BP equipment, the 
measurer and how the measurements were taken. Some 
studies had no recording of blood pressure and therefore 
excluded from the analysis. Although attempts were made to 
contact the individual trialists, only few provided data and the 
rest did not respond. It is essential that future studies should 
report such information as significant imbalances in values will 
affect treatment effect. The outcomes in this review were not 
adjusted for key variables such as age, baseline stroke 
severity, blood pressure, stroke type and this is important as 
they might have had a significant impact upon the results. 384, 
466, 527 Some of these factors might have been addressed by 
providing individual patient data and therefore future trialists 
should be encouraged to do so. One approach would be to 
share and publish results under the auspices of a 
collaboration. 
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The data in these trials was derived from patients with little 
comorbidity and as yet little is known about altering BP in 
older patients with multiple medical problems who comprise 
the largest population in both ischaemic and haemorrhagic 
stroke. It should also be remembered that the responses of 
older patients with reduced cerebrovascular reactivity and 
those with severe hypertension might not show similar 
responses to younger population during blood pressure 
modulation.  
 
Conclusions 
 
In conclusion, this thesis has investigated several questions in 
acute haemorrhagic stroke. It provides new information on 
assessment of acute intracerebral haemorrhage descriptors 
and assessed their relationship with clinical outcomes. The 
data from a multinational international randomised clinical trial 
from which the body of this thesis is derived provides more 
information of the management of blood pressure in acute 
haemorrhagic stroke. It showed that transdermal GTN 5 mg 
lowered blood pressure, tended to reduce haematoma volume 
but did not reduce death or dependency. A meta-analysis 
including recently published trials in acute stroke 
demonstrated that beta-receptor antagonists, oral calcium 
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channel blockers, angiotensin converting enzyme inhibitors, 
angiotensin-receptor antagonists blockers deliberately altered 
blood pressure in acute stroke. This updated work also 
established that immediately re-starting prior antihypertensive 
drugs taken before stroke may increase disability and worsen 
quality of life. The current work demonstrates that lowering 
blood pressure early in acute haemorrhagic stroke may 
benefit, and therefore justifies ongoing randomised clinical 
trials in this area. Work in this thesis has also shown that 
clinical features and outcomes in acute intracerebral 
haemorrhage vary among ethnic groups. However, more 
research is needed to examine whether genetic susceptibility, 
socio-economic factors or cultural differences play a role. 
  
 
 
 
  
 372 
 
References 
 
1. Tunstall-Pedoe H. The who monica project monitoring trends and 
determinants in cardiovascular disease a major international 
collaboration. Journal of Clinical Epidemiology. 1988;41:105-114 
2. Pessin MS, Duncan GW, Mohr JP, Poskanzer DC. Clinical and 
angiographic features of carotid transient ischemic attacks. New 
England Journal of Medicine. 1977;296:358-362 
3. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL, et al. 
Transient ischemic attack--proposal for a new definition. N Engl J 
Med. 2002;347:1713-1716 
4. Sudlow CLM, Warlow CP. Comparable studies of the incidence of 
stroke and its pathological types - results from am international 
collaboration. Stroke. 1997;28:491-499 
5. Reducing brain damage: Faster access to stroke care. . In: Health 
Do. ed.: National Audit Office. 2005 
6. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of 
stroke in the united kingdom. Pharmacoeconomics. 2003;21:43-50 
7. Fernandez RL, Nicola Paul LM, Alastair M. Gray, Sarah T. 
Pendlebury, Linda M. Bull, Sarah J.V. Welch, et al. Population-based 
study of disability and institutionalization after transient ischemic 
attack and stroke. Stroke. 2013 
8. Feigin V, Lawes C, Bennett D, Barker-Collo S, Parag V. Changing 
worldwide stroke epidemiology in the 21st century: Stroke 
incidence rates in developing countries for the first time exceed 
those in developed countries and parallel changes in official stroke 
mortality rates. Circulation. 2010;122:E82-E82 
9. Feigin V, Lawes C, Bennett D, Barker-Collo S, Parag V. Worldwide 
stroke incidence and early case fatality reported in 56 population-
based studies: A systematic review. Lancet Neurology. 2009;8:355-
369 
10. Asplund K, Karvanen J, Giampaoli S, Jousilahti P, Niemela M, Broda 
G, et al. Relative risks for stroke by age, sex, and population based 
on follow-up of 18 european populations in the morgam project. 
Stroke. 2009;40:2319-2326 
11. Bonita R. Epidemiology of stroke. Lancet. 1992:342-344 
12. Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and 
occurrence of total (first-ever and recurrent) stroke. Stroke. 
1999;30:2523-2528 
13. Rolfe C. British Medical Bulletin 2000: 275-286 
14. Islam M, Anderson C, Hankey GJ, Hardie K, Carter K, Broadhurst R, 
et al. Trends in incidence and outcome of stroke in perth, western 
australia during 1989 to 2001: The perth community stroke study. 
Stroke. 2008;39:776-782 
15. Labovitz DL, Halim A, Boden-Albala B, Hauser WA, Sacco RL. The 
incidence of deep and lobar intracerebral hemorrhage in whites, 
blacks and hispanics. Neurology. 2005;65:518-522 
 373 
 
16. Qureshi AI, Safdar K, Patel M, Janssen RS, Frankel MR. Stroke in 
young black patients. Risk factors, subtypes, and prognosis. Stroke. 
1995;26:1995-1998 
17. Kissela B, Schneider A, Kleindorfer D, Khoury J, Miller R, Alwell K, 
et al. Stroke in a biracial population: The excess burden of stroke 
among blacks. Stroke. 2004;35:426-431 
18. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, et 
al. Change in stroke incidence, mortality, case-fatality, severity, and 
risk factors in oxfordshire, uk from 1981 to 2004 (oxford vascular 
study). Lancet. 2004;363:1925-1933 
19. Warlow CP. Epidemiology of stroke. Lancet. 1998;352:SIII1-SIII4 
20. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, 
Anderson CS, et al. Long-term risk of first recurrent stroke in the 
perth community stroke study. Stroke. 1998;29:2491-2500 
21. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification 
and natural-history of clinically identifiable subtypes of cerebral 
infarction. Lancet. 1991;337 
22. Warlow CP DM, van Gijn J, Hankey GJ, Sandercock PAG, Bamford 
JM, Wardlaw J. Stroke. A practical guide to management.: Oxford: 
Blackwell Science; 1996. 
23. Lindley RI, Warlow CP, Wardlaw JM, Dennis MS, Slattery J, 
Sandercock PAG. Interobserver reliability of a clinical classification 
of acute cerebral infarction. Stroke. 1993;24:1801-1804 
24. Wardlaw J. What causes lacunar stroke? Journal of Neurology 
Neurosurgery and Psychiatry. 2005;76:617-619 
25. Michael Brainin, Heiss. W-D. Textbook of stroke medicine. New York, 
United States of America: Cambridge University Press; 2010. 
26. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon Dl, 
et al. Classification of subtype of acute ischemic stroke - definitions 
for use in a multicenter clinical trial. Stroke. 1993;24:35-41 
27. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford 
MJ. Validation of clinical classification schemes for predicting 
stroke: Results from the national registry of atrial fibrillation. 
JAMA. 2001;285:2864-2870 
28. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical 
risk stratification for predicting stroke and thromboembolism in 
atrial fibrillation using a novel risk factor-based approach: The 
euro heart survey on atrial fibrillation. Chest. 2010;137:263-272 
29. Jackson C, Sudlow C. Are lacunar strokes really different? A 
systematic review of differences in risk factor profiles between 
lacunar and nonlacunar infarcts. Stroke. 2005;36:891-901 
30. Hart RG, Diener H-C, Coutts SB, Easton JD, Granger CB, O'Donnell 
MJ, et al. Embolic strokes of undetermined source: The case for a 
new clinical construct. Lancet Neurology. 2014;13:429-438 
31. Wardlaw J, Seymour J, Cairns J, Keir S, Lewis S, Sandercock P. 
Immediate computed tomography scanning of acute stroke is cost-
effective and improves quality of life. Stroke. 2004;35:2477-2483 
 374 
 
32. Writing committee. Diagnosis and initial management of acute 
stroke and transient ischaemic attack. NICE Clinical guideline 68. 
2008 
33. The Intercollegiate Stroke working party. National clinical 
guideline for stroke. Royal College of Physicians. 2016;5th edition 
34. Rother J. Ct and mri in the diagnosis of acute stroke and their role 
in thrombolysis. Thrombosis Research. 2001;103:S125-S133 
35. Wardlaw J, Keir S, Seymour J, Lewis S, Sandercock P, Dennis M, et 
al. What is the best imaging strategy for acute stroke? Health 
Technology Assessment. 2004;8:1-+ 
36. José G. Merino, Warach. S. Imaging of acute stroke. Nature Reviews 
Neurology.6:560-571 
37. Wardlaw JM, Muir KW, Macleod MJ, Weir C, McVerry F, Carpenter 
T, et al. Clinical relevance and practical implications of trials of 
perfusion and angiographic imaging in patients with acute 
ischaemic stroke: A multicentre cohort imaging study. Journal of 
Neurolgy Neurosurgery and Psychiatry. 2013 
38. Kidwell CS, Chalela JA, Saver JL, Starkman S, Hill MD, Demchuk AM, 
et al. Comparison of mri and ct for detection of acute intracerebral 
hemorrhage. Jama-Journal of the American Medical Association. 
2004;292:1823-1830 
39. Brazzelli M, Sandercock PA, Chappell FM, Celani MG, Righetti E, 
Arestis N, et al. Magnetic resonance imaging versus computed 
tomography for detection of acute vascular lesions in patients 
presenting with stroke symptoms. 2009 
40. Wardlaw JM, Statham PF. How often is haemosiderin not visible on 
routine mri following traumatic intracerebral haemorrhage? 
Neuroradiology. 2000;42:81-84 
41. Barber PA, Demchuk AN, Hudon ME, Pexman JHW, Hill MD, Buchan 
AM. Hyperdense sylvian fissure mca "dot" sign - a ct marker of 
acute ischemia. Stroke. 2001;32:84-88 
42. Ozdemir O, Leung A, Bussiere M, Hachinski V, Pelz D. Hyperdense 
internal carotid artery sign - a ct sign of acute ischemia. Stroke. 
2008;39:2011-2016 
43. Al-Nakshabandi NA. The swirl sign. Radiology. 2001;218:433 
44. Wada R, Aviv RI, Fox AJ, Sahlas DJ, Gladstone DJ, Tomlinson G, et al. 
Ct angiography "spot sign" predicts hematoma expansion in acute 
intracerebral hemorrhage. Stroke. 2007;38:1257-1262 
45. Almekhlafi MA, Kosior JC, Dowlatshahi D, Demchuk AM. Spot sign 
and live-imaged dramatic intracerebral hematoma expansion. 
Neurology. 2011;76:1275-1276; author reply 1276 
46. Kim J, Smith A, Hemphill JC, Smith WS, Lu Y, Dillon WP, et al. 
Contrast extravasation on ct predicts mortality in primary 
intracerebral hemorrhage. AJNR Am J Neuroradiol. 2008;29:520-
525 
47. Sun SJ, Gao PY, Sui BB, Hou XY, Lin Y, Xue J, et al. "Dynamic spot 
sign" on ct perfusion source images predicts haematoma expansion 
in acute intracerebral haemorrhage. European Radiology. 2013 
 375 
 
48. Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, et 
al. Guidelines for the management of spontaneous intracerebral 
hemorrhage in adults. Stroke. 2007;38:e391-e413 
49. WHO-Stroke. Recommendations on stroke prevention, diagnosis 
and therapy. Report of the who task force on stroke and other 
cerebrovascular disorders. Stroke. 1989 
50. Abbott RD, Yin Y, Reed DM, Yano K. Risk of stroke in male cigarette 
smokers. New England Journal of Medicine. 1986;315:717-720 
51. Romero JR, Morris J, Pikula A. Stroke prevention: Modifying risk 
factors. Therapeutic advances in cardiovascular disease. 
2008;2:287-303 
52. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et 
al. Varenicline, an alpha 4 beta 2 nicotinic acetylcholine receptor 
partial agonist, vs sustained-release bupropion and placebo for 
smoking cessation - a randomized controlled trial. Jama-Journal of 
the American Medical Association. 2006;296:47-55 
53. Lancaster T, Stead L, Silagi C, Sowden A, Cochrane Tobacco 
Addiction R. Effectiveness of interventions to help people stop 
smoking: Findings from the cochrane library. British Medical 
Journal. 2000;321:355-358 
54. Lancaster T, Stead LF. Self-help interventions for smoking 
cessation. The Cochrane database of systematic reviews. 
2000:CD001118-CD001118 
55. Reynolds K, Lewis LB, Nolen JDL, Kinney GL, Sathya B, He J. Alcohol 
consumption and risk of stroke - a meta-analysis. Jama-Journal of 
the American Medical Association. 2003;289:579-588 
56. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, 
et al. Primary prevention of ischemic stroke - a guideline from the 
american heart association/american stroke association stroke 
council: Cosponsored by the atherosclerotic peripheral vascular 
disease interdisciplinary working group; cardiovascular nursing 
council; clinical cardiology council; nutrition, physical activity, and 
metabolism council; and the quality of care and outcomes research 
interdisciplinary working group - the american academy of 
neurology affirms the value of this guideline. Stroke. 2006;37:1583-
1633 
57. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. 
Guidelines for prevention of stroke in patients with ischemic stroke 
or transient ischemic attack - a statement for healthcare 
professionals from the american heart association/american stroke 
association council on stroke - co-sponsored by the council on 
cardiovascular radiology and intervention - the american academy 
of neurology affirms the value of this guideline. Stroke. 
2006;37:577-617 
58. Zhang H, Thijs L, Staessen JA. Blood pressure lowering for primary 
and secondary prevention of stroke. Hypertension. 2006;48:187-
195 
 376 
 
59. Anonymous. Post-stroke antihypertensive treatment study. A 
preliminary result. Pats collaborating group. Chinese Medical 
Journal. 1995;108:710-717 
60. Arima H, Anderson C, Omae T, Woodward M, Hata J, Murakami Y, et 
al. Effects of blood pressure lowering on major vascular events 
among patients with isolated diastolic hypertension the 
perindopril protection against recurrent stroke study (progress) 
trial. Stroke. 2011;42:2339-2341 
61. Sleight P. The hope study (heart outcomes prevention evaluation). 
Journal of the renin-angiotensin-aldosterone system : JRAAS. 
2000;1:18-20 
62. Drayer JIM, Weber MA, Sealey JE, Laragh JH. Low and high renin 
essential- hypertension: A comparison of clinical and biochemical 
characteristics. American Journal of the Medical Sciences. 
1981;281:135-142 
63. Williams B. Treatment of hypertension in the uk: Simple as abcd? 
Journal of the Royal Society of Medicine. 2003;96:521-522 
64. Collins R, Peto R, Hennekens C, Doll R, Bubes V, Buring J, et al. 
Aspirin in the primary and secondary prevention of vascular 
disease: Collaborative meta-analysis of individual participant data 
from randomised trials. Lancet. 2009;373:1849-1860 
65. Sandercock PAG, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet 
therapy for acute ischaemic stroke. Cochrane Database of 
Systematic Reviews. 2008 
66. Halkes PHA, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A, Esprit 
Study Group. Aspirin plus dipyridamole versus aspirin alone after 
cerebral ischaemia of arterial origin (esprit): Randomised 
controlled trial. Lancet. 2006;367 
67. Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. 
European stroke prevention - study 2 - dipyridamole and 
acetylsalicylic acid in the secondary prevention of stroke. 
Nervenheilkunde. 1999;18:380-390 
68. Bath P, Cotton D, Martin R, Palesch Y, Yusuf S, Sacco R, et al. Effect 
of combined aspirin and extended-release dipyridamole versus 
clopidogrel on functional outcome and recurrence in acute, mild 
ischemic stroke profess subgroup analysis. Stroke. 2010;41:732-
738 
69. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al. 
Clopidogrel and aspirin versus aspirin alone for the prevention of 
atherothrombotic events. New England Journal of Medicine. 
2006;354:1706-1717 
70. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste 
M, et al. Aspirin and clopidogrel compared with clopidogrel alone 
after recent ischaemic stroke or transient ischaemic attack in high-
risk patients (match): Randomised, double-blind, placebo-
controlled trial. Lancet. 2004;364:331-337 
71. Benavente O, Hart R, McClure L, Szychowski J, Coffey C, Pearce L, et 
al. Effects of clopidogrel added to aspirin in patients with recent 
 377 
 
lacunar stroke. New England Journal of Medicine. 2012;367:817-
825 
72. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel 
with aspirin in acute minor stroke or transient ischemic attack. The 
New England journal of medicine. 2013;369:11-19 
73. Bath PMW, TARDIS Trial Investigators. Results of the triple 
antiplatelets for reducing dependency after ischaemic stroke. 
International Stroke Conference, Texas, USA. 2017 
74. Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, et al. 
Atrial-fibrillation and stroke - prevalence in different types of 
stroke and influence on early and long-term prognosis (oxfordshire 
community stroke project). British Medical Journal. 
1992;305:1460-1465 
75. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic 
therapy to prevent stroke in patients who have onvalvular atrial 
fibrillation. Annals of Internal Medicine. 2007;146:857-867 
76. Sandercock P. Immediate anticoagulation for acute stroke in atrial 
fibrillation:No. Stroke. 2006;37:3054-3055 
77. Hylek E, Skates S, Sheehan M, Singer D. An analysis of the lowest 
effective intensity of prophylactic anticoagulation for patients with 
nonrheumatic atrial fibrillation. New England Journal of Medicine. 
1996;335:540-546 
78. Sandercock PA GL, Liu LM. Anticoagulants for preventing 
recurrence following presumed non-cardioembolic ischaemic 
stroke or transient ischaemic attack. 2009 
79. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJM, 
Carotid Endarterectomy Trialists C. Endarterectomy for 
symptomatic carotid stenosis in relation to clinical subgroups and 
timing of surgery. Lancet. 2004;363:915-924 
80. Rerkasem K, Rothwell PM. Carotid endarterectomy for 
symptomatic carotid stenosis. 2011 
81. Carotid stenting trialists' collaboration. Short-term outcome after 
stenting versus endarterectomy  for symptomatic carotid stenosis: 
A preplanned meta-analysis of individual patient data. Lancet. 
2010;376:1062-1073 
82. Abbott AL, Adelman MA, Alexandrov AV, Barber PA, Barnett HJM, 
Beard J, et al. Why calls for more routine carotid stenting are 
currently inappropriate. Stroke. 2013;44:1186-1190 
83. Huisa BN SA, Zivin JA. Atorvastatin in stroke: A review of sparcl and 
subgroup analysis. Vascular Health and Risk Management. 
2010;6:229-236 
84. Collins R, Armitage J, Parish S, Sleight P, Peto R, Collaborat HPS, et 
al. Effects of cholesterol-lowering with simvastatin on stroke and 
other major vascular events in 20 536 people with cerebrovascular 
disease or other high-risk conditions. Lancet. 2004;363:757-767 
85. Shahar E, Chambless L, Rosamond W, Boland L, Ballantyne C, 
McGovern P, et al. Plasma lipid profile and incident ischemic stroke 
- the atherosclerosis risk in communities (aric) study. Stroke. 
2003;34:623-631 
 378 
 
86. Amarenco P, Bogousslavsky J, Callahan A, III, Goldstein LB, 
Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke 
or transient ischemic attack. New England Journal of Medicine. 
2006;355:549-559 
87. Lee SH, Bae HJ, Yoon BW, Kim H, Kim DE, Roh JK. Low 
concentration of serum total cholesterol is associated with 
multifocal signal loss lesions on gradient-echo magnetic resonance 
imaging - analysis of risk factors for multifocal signal loss lesions. 
Stroke. 2002;33:2845-2849 
88. Divani AA, Majidi S, Luo X, Souslian FG, Zhang J, Abosch A, et al. The 
abcs of accurate volumetric measurement of cerebral hematoma. 
Stroke. 2011;42:1569-1574 
89. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective 
Studies C. Age-specific relevance of usual blood pressure to 
vascular mortality: A meta-analysis of individual data for one 
million adults in 61 prospective studies. Lancet. 2002;360:1903-
1913 
90. Roberta Ravenni, Joe F. Jabre, Alberto Mazza. Primary stroke 
prevention and hypertension treatment: Which is the first-line 
strategy? Neurology International. 2011;5 
91. Domanski MJ, Davis BR, Pfeffer MA, Kastantin M, Mitchell GF. 
Isolated systolic hypertension - prognostic information provided 
by pulse pressure. Hypertension. 1999;34:375-380 
92. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, 
et al. Prognostic significance of visit-to-visit variability, maximum 
systolic blood pressure, and episodic hypertension. Lancet. 
2010;375:895-905 
93. Webb AJS, Fischer U, Mehta Z, Rothwell PM. Effects of 
antihypertensive-drug class on interindividual variation in blood 
pressure and risk of stroke: A systematic review and meta-analysis. 
Lancet. 2010;375:906-915 
94. Johansson BB. Hypertension mechanisms causing stroke. Clinical 
and Experimental Pharmacology and Physiology. 1999;26:563-565 
95. Wardlaw J, Smith C, Dichgans M. Mechanisms of sporadic cerebral 
small vessel disease: Insights from neuroimaging. Lancet 
Neurology. 2013;12:483-497 
96. Wardlaw J, Doubal F, Valdes-Hernandez M, Wang X, Chappell F, 
Shuler K, et al. Blood-brain barrier permeability and long-term 
clinical and imaging outcomes in cerebral small vessel disease. 
Stroke. 2013;44:525-527 
97. Poels MM ZK, Verwoert GC, Vernooij MW, Hofman A, van der Lugt 
A, Witteman JC, Breteler MM, Mattace-Raso FU, Ikram MA. Arterial 
stiffness and cerebral small vessel disease: The rotterdam scan 
study. Stroke. 2012:2637-2642 
98. Leenders Kl, Perani D, Lammertsma AA, Heather JD, Buckingham P, 
Healy MJR, et al. Cerebral blood flow, blood volume and oxygen 
utilization - normal values and effect of age. Brain. 1990;113:27-47 
 379 
 
99. Strandgaard S, Mackenzie ET, Jones JV, Harper AM. Studies on 
cerebral-circulation of baboon in acutely induced hypertension. 
Stroke. 1976;7:287-290 
100. Auer LM, Ishiyama N, Pucher R. Cerebrovascular response to 
intracranial hypertension. Acta Neurochirurgica. 1987;84:124-128 
101. Qureshi AI, Harris-Lane P, Kirmani JF, Ahmed S, Jacob M, Zada Y, et 
al. Treatment of acute hypertension in patients with intracerebral 
hemorrhage using american heart association guidelines. Crit Care 
Med. 2006;34:1975-1980 
102. Shah QA, Ezzeddine MA, Qureshi AI. Acute hypertension in 
intracerebral hemorrhage: Pathophysiology and treatment. Journal 
of the Neurological Sciences. 2007;261:74-79 
103. Sacco S, Carolei A. Autoregulation might explain why blood 
pressure is not associated with haematoma enlargement in acute 
intracerebral haemorrhage. European Journal of Neurology. 
2008;15 
104. Grabowski M, Mattsson B, Nordborg C, Johansson B. Brain capillary 
density and cerebral blood flow after occlusion of the middle 
cerebral artery in normotensive wistar-kyoto rats and 
spontaneously hypertensive rats. Journal of Hypertension. 1993;11 
105. Markus HS. Cerebral perfusion and stroke. Journal of Neurology 
Neurosurgery and Psychiatry. 2004;75:353-361 
106. Strangaard S, Poulson OB. Regulation of cerebal blood flow in 
health and disease. Journal of Cardiovascular Pharmacology.19:89-
83 
107. Strandgaard S, Paulson OB. Cerebral blood flow and its 
pathophysiology in hypertension. American Journal of 
Hypertension. 1989;2:486-492 
108. Baron J-C. Perfusion thresholds in human cerebral ischemia: 
Historical perspective and therapuetic implications. 
Cerebrovascular Diseases. 2001;11:2-8 
109. Strandgaard S. Autoregulation of cerebral blood flow in 
hypertensive patients - modifying influence of prolonged 
antihypertensive treatment on tolerance to acute, drug-induced 
hypotension. Circulation. 1976;53:720-727 
110. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, et al. A 
systematic review of the effectiveness, cost-effectiveness and 
barriers to implementation of thrombolytic and neuroprotective 
therapy for acute ischaemic stroke in the nhs. Health Technology 
Assessment 2002.6 
111. Wardlaw J, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley 
R, et al. Recombinant tissue plasminogen activator for acute 
ischaemic stroke: An updated systematic review and meta-analysis. 
Lancet. 2012;379:2364-2372 
112. Broderick JP, Diringer MN, Hill MD, Brun NC, Mayer SA, Steiner T, et 
al. Determinants of intracerebral hemorrhage growth - an 
exploratory analysis. Stroke. 2007;38:1072-1075 
113. Adnan I. Qureshi RAH, Jawad F. Kirmani, Abutaher M. Yahia, 
L.Nelson Hopkins. Cerebral blood flow changes associated with 
 380 
 
intracerebral hemorrhage. Neurosurgery Clinics of North 
America.13:355-370 
114. Alqadri SL, Qureshi AI. Management of acute hypertensive 
response in patients with intracerebral hemorrhage. Curr 
Atheroscler Rep. 2012;14:322-327 
115. Bath P, Chalmers J, Powers W, Beilin L, Davis S, Lenfant C, et al. 
International society of hypertension (ish): Statement on the 
management of blood pressure in acute stroke. Journal of 
Hypertension. 2003;21:665-672 
116. Arboix A, Roig H, Rossich R, Martinez EM, Garcia-Eroles L. 
Differences between hypertensive and non-hypertensive ischemic 
stroke. European Journal of Neurology. 2004;11:687-692 
117. Christensen H, Meden P, Overgaard K, Boysen G. The course of 
blood pressure in acute stroke is related to the severity of the 
neurological deficits. Acta Neurologica Scandinavica. 
2002;106:142-147 
118. Willmot M, Leonardi-Bee J, Bath PMW. High blood pressure in 
acute stroke and subsequent outcome - a systematic review. 
Hypertension. 2004;43:18-24 
119. Hachinski VC, Oppenheimer SM, Wilson JX, Guiraudon C, Cechetto 
DF. Asymmetry of sympathetic consequences of experimental 
stroke. Arch Neurol. 1992;49:697-702 
120. Sevoz-Couche C, Comet MA, Bernard JF, Hamon M, Laguzzi R. 
Cardiac baroreflex facilitation evoked by hypothalamus and 
prefrontal cortex stimulation: Role of the nucleus tractus solitarius 
5-ht2a receptors. American Journal of Physiology-Regulatory 
Integrative and Comparative Physiology. 2006;291:R1007-R1015 
121. Szilagyi JE, Taylor AA, Skinner JE. Cryoblockade of the 
ventromedial frontal-cortex reverses hypertension in the rat. 
Hypertension. 1987;9:576-581 
122. Resstel LBM, Correa FMA. Medial prefrontal cortex nmda receptors 
and nitric oxide modulate the parasympathetic component of the 
baroreflex. European Journal of Neuroscience. 2006;23:481-488 
123. Vidale S. “Relation between change in blood pressure in acute 
stroke and risk of early adverse events and poor outcome”. Stroke. 
2012;43 
124. Qureshi AI. Acute hypertensive response in patients with stroke - 
pathophysiology and management. Circulation. 2008;118:176-187 
125. Willmot M, Leonardi-Bee J, Bath PMW. High blood pressure in 
acute stroke and subsequent outcome - a systematic review. 
Hypertension. 2004;43 
126. Weaver CS, Leonardi-Bee J, Bath-Hextall FJ, Bath PMW. Sample size 
calculations in acute stroke trials: A systematic review of their 
reporting, characteristics, and relationship with outcome. Stroke. 
2004;35 
127. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford G, Kaste M, et al. 
Relationship of blood pressure, antihypertensive therapy, and 
outcome in ischemic stroke treated with intravenous thrombolysis 
retrospective analysis from safe implementation of thrombolysis in 
 381 
 
stroke-international stroke thrombolysis register (sits-istr). Stroke. 
2009;40:2442-2449 
128. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure 
and clinical outcomes in the international stroke trial. Stroke. 
2002;33:1315-1320 
129. Arakawa S, Saku Y, Ibayashi S, Nagao T, Fujishima M. Blood 
pressure control and recurrence of hypertensive brain 
hemorrhage. Stroke. 1998;29:1806-1809 
130. Sare GM, Bath PMW, Gray LJ, Moulin T, Woimant F, England T, et al. 
The relationship between baseline blood pressure and computed 
tomography findings in acute stroke data from the tinzaparin in 
acute ischaemic stroke trial (taist). Stroke. 2009;40:41-46 
131. Geeganage CM, Bath PM. Interventions for deliberately altering 
blood pressure in acute stroke. Stroke. 2009 
132. Geeganage CM, Bath PMW. Relationship between therapeutic 
changes in blood pressure and outcomes in acute stroke a 
metaregression. Hypertension. 2009;54:775-U180 
133. Bath PMW. Rapid intervention with glyceryl trinitrate in 
hypertensive stroke trial-2. Trials Registry. 2015;ISRCTN26986053 
134. Sanossian N. Field administration of stroke therapy-blood pressure 
lowering (fast-bp). ClinicalTrials.gov(NCT01811693).  
135. Hemphill 3rd JC, Greenberg SM, Anderson CS, Becker K, Bendok BR, 
Cushman M, et al. Guidelines for the management of spontaneous 
intracerebral hemorrhage. Stroke. 2015;46:2032-2060 
136. Robinson TG, Potter JF, Ford GA, et al. Effects of antihypertensive 
treatment after acute stroke in the continue or stop post-stroke 
antihypertensives collaborative study (cossacs): A prospective, 
randomised, open, blinded-endpoint trial. Lancet Neurology. 
2010;9:767-775 
137. Bath PMW, Woodhouse L, Scutt P, Krishnan K, Wardlaw JM, 
Bereczki D, et al. Efficacy of nitric oxide, with or without continuing 
antihypertensive treatment, for management of high blood 
pressure  in acute stroke (enos):  A partial-factorial randomised 
controlled trial. Lancet. 2015;385:617-628 
138. Anonymous. 'Know stroke. Know the signs. Act in time.'. 2008 
139. Nor A, McAllister C, Louw S, Dyker A, Davis M, Jenkinson D, et al. 
Agreement between ambulance paramedic- and physician-
recorded neurological signs with face arm speech test (fast) in 
acute stroke patients. Stroke. 2004;35:1355-1359 
140. Govan L, Weir CJ, Langhorne P, Stroke Unit Trialists Collaboration. 
Organized inpatient (stroke unit) care for stroke. Stroke. 
2008;39:2402-2403 
141. Langhorne P, Tong B, Stott D. Association between physiological 
homeostasis and early recovery after stroke. Stroke. 2000;31:2526-
2527 
142. Laird E, Coates V. Systematic review of randomized controlled 
trials to regulate glycaemia after stroke. Journal of Advanced 
Nursing. 2013;69:263-277 
 382 
 
143. Sandercock PA CC, Tseng MC. Low-molecular-weight heparins or 
heparinoids versus standard unfractionated heparin for acute 
ischaemic stroke. 2008 
144. Dennis M, Cranswick G, Deary A, Fraser A, Graham C, Grant S, et al. 
Effectiveness of thigh-length graduated compression stockings to 
reduce the risk of deep vein thrombosis after stroke (clots trial 1): 
A multicentre, randomised controlled trial. Lancet. 2009;373:1958-
1965 
145. Dennis M, Sandercock P, Reid J, Graham C, Forbes J, Murray G. 
Effectiveness of intermittent pneumatic compression in reduction 
of risk of deep vein thrombosis in patients who have had a stroke 
(clots 3): A multicentre randomised controlled trial. Lancet 
2013;382:516-524 
146. Chen Z, Hui J, Liu L, Liu Z, Peto R, Sandercock P, et al. Cast: 
Randomised placebo-controlled trial of early aspirin use in 20,000 
patients with acute ischaemic stroke. Lancet. 1997;349:1641-1649 
147. Sandercock P, Collins R, Counsell C, Farrell B, Peto R, Slattery J, et 
al. The international stroke trial (ist): A randomised trial of aspirin, 
subcutaneous heparin, both, or neither among 19 435 patients with 
acute ischaemic stroke. Lancet. 1997;349:1569-1581 
148. The National Institute of Neurological Disorders and Stroke rt-PA 
Stroke Study Group. Tissue plasminogen activator for acute stroke. 
New England Journal of Medicine. 1995;333:1581-1587 
149. Sandercock P, Lindley R, Wardlaw JM. Antiplatelet, anticoagulant 
and fibrinolytic agents in acute ischemic stroke and tia. British 
Journal of Hospital Medicine. 1992;47:731-& 
150. Menon BK, Saver JL, Prabhakaran S, Reeves M, Liang L, Olson DM, 
et al. Risk score for intracranial hemorrhage in patients with acute 
ischemic stroke treated with intravenous tissue-type plasminogen 
activator. Stroke. 2012;43:2293-2299 
151. Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee T-
H, et al. Low-dose versus standard-dose intravenous alteplase in 
acute ischemic stroke. New England Journal of Medicine. 
2016;374:2313-2323 
152. Eric Sussman CK, Michael McDowell, Peter Yang, Eric Nelson, 
Sophie Greenberg, Daniel Sahlein, Sean Lavine, Philip Meyers and 
E. Sander Connolly Endovascular thrombectomy following acute 
ischemic stroke: A single-center case series and critical review of 
the literature. Brain Sciences. 2013;3:521-539 
153. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, 
et al. Endovascular therapy after intravenous t-pa versus t-pa alone 
for stroke. N Engl J Med. 2013;368:893-903 
154. Ciccone A VL, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, Boccardi E; 
SYNTHESIS Expansion Investigators. Endovascular treatment for 
acute ischemic stroke. N Engl J Med. 2013;368(10):904-913. 
155. Kidwell CS JR, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer 
JR, Olson S, Schwamm LH, Yoo AJ, Marshall RS, Meyers PM, Yavagal 
DR, Wintermark M, Guzy J, Starkman S, Saver JL, MR RESCUE 
Investigators. A trial of imaging selection and endovascular 
 383 
 
treatment for ischaemic stroke. The New England journal of 
medicine. 2013:914 - 923 
156. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, 
et al. Site of arterial occlusion identified by transcranial doppler 
predicts the response to intravenous thrombolysis for stroke. 
Stroke. 2007;38:948-954 
157. Riedel CH, Zimmermann P, Jensen-Kondering U, Stingele R, Deuschl 
G, Jansen O. The importance of size: Successful recanalisation by 
intravenous thrombolysis in acute anterior stroke depends on 
thrombus length. Stroke. 2011;42:1775-1777 
158. Zaidat OO, Suarez JI, Santillan C, Sunshine JL, Tarr JW, Paras VH, et 
al. Response to intra-arterial and combined intravenous and intra-
arterial thrombolytic therapy in patients with distal internal 
carotid artery occlusion. Stroke. 2002;33:1821-1826 
159. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma 
HF, Yoo AJ, et al. A randomized trial of intra-arterial treatment for 
acute ischemic stroke. New England Journal of Medicine. 
2015;372:11-20 
160. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, 
et al. Randomized assessmen of rapid endovascular treatment for 
acute ischemic stroke. New England Journal of Medicine. 
2015;372:1019-1030 
161. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, 
et al. Endovascular therapy for ischemic stroke with perfusion-
imaging selection. New England Journal of Medicine. 
2015;372:1009-1018 
162. Saver JL, Goyal M, Bonafe A, Diener H, Levy E, Pereira VM, et al. 
Stent-retriever thrombectomy after intravenous t-pa vs t-pa alone 
in stroke. New England Journal of Medicine. 2015;372:2285-2295 
163. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours 
after symptom onset in ischemic stroke. New England Journal of 
Medicine. 2015;Epub ahead of print 
164. Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, 
Demchuk AM, et al. Endovascular thrombectomy after large-vessel 
ischaemic stroke: A meta-analysis of individual patient data from 
five randomised trials. Lancet. 2016;387:1723-1731 
165. Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, 
et al. Time to treatment with endovascular thrombectomy and 
outcomes from ischemic stroke: A meta-analysis. JAMA. 
2016;316:1279-1288 
166. Treadwell SD, Thanvi B. Malignant middle cerebral artery (mca) 
infarction: Pathophysiology, diagnosis and management. 
Postgraduate Medical Journal. 2010;86:235-242 
167. Symon L, Pasztor E, Branston NM. Distribution and density of 
reduced cerebral blood flow following acute middle cerebral artery 
occlusion - experimental study by technique of hydrogen clearance 
in baboons. Stroke. 1974;5:355-364 
168. Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, 
Wikner J, et al. Hematoma growth and outcome in treated 
 384 
 
neurocritical care patients with intracerebral hemorrhage related 
to oral anticoagulant therapy: Comparison of acute treatment 
strategies using vitamin k, fresh frozen plasma, and prothrombin 
complex concentrates. Stroke. 2006;37:1465-1470 
169. Staykov D, Gupta R. Hemicraniectomy in malignant middle cerebral 
artery infarction. Stroke. 2011;42:513-516 
170. Vahedi K, Vicaut E, Mateo J, Kurtz A, Orabi M, Guichard J-P, et al. 
Sequential-design, multicenter, randomized controlled trial of early 
decompressive craniectomy in malignant middle cerebral artery 
infarction (decimal trial). Stroke. 2007;38:2506-2517 
171. Juttler E, Schwab S, Schmiedek P, Unterberg A, Hennerici M, 
Woitzik J, et al. Decompressive surgery for the treatment of 
malignant infarction of the middle cerebral artery (destiny). Stroke. 
2007;38:2518-2525 
172. Hofmeijer J, Kappelle LJ, Algra A, Amelink GJ, van Gijn J, Worp VD, et 
al. Surgical decompression for space-occupying cerebral infarction 
(the hemicraniectomy after middle cerebral artery infarction with 
life-threatening edema trial (hamlet): A multi-centre, open, 
randomised trial. Lancet. 2009;8:326-333 
173. Rahme R, Zuccarello M, Kleindorfer D, Adeoye OM, Ringer AJ. 
Decompressive hemicraniectomy for malignant middle cerebral 
artery territory infarction: Is life worth living? Journal of 
Neurosurgery. 2012;117:749-754 
174. Touzani O, Young AR, Mackenzie ET. The window of therapeutic 
opportunity following focal cerebral ischaemia. Pharmacology of 
Cerebral Ischemia 1994. 1994:575-588 
175. The European Ad Hoc Consensus Group. Neuroprotection as initial 
therapy in acute stroke. Cerebrovascular  Diseases. 1998;8:59-72 
176. White A, Murphy A. Administration of thiazolidinediones for 
neuroprotection in ischemic stroke: A pre-clinical systematic 
review. Journal of Neurochemistry. 2010;115:845-853 
177. Shejun Feng QY, Ming Liu, Weizheng Li, Wenming Yuan, Shihong 
Zhang, Bo Wu, Juntao Li. Edaravone for acute ischaemic stroke. 
2011 
178. van der Worp HB, Macleod MR, Kollmar R, European Stroke Res 
Network H. Therapeutic hypothermia for acute ischemic stroke: 
Ready to start large randomized trials? Journal of Cerebral Blood 
Flow and Metabolism. 2010;30:1079-1093 
179. Kollmar R, Gebhardt B, Schwab S. Eurohyp-1 trial. Eu-funded 
therapy study on the effectiveness of mild therapeutic hypothermia 
for acute ischemic stroke. Nervenarzt. 2012;83:1252-+ 
180. Belenichev IF SI, Dunaev VV, Orlovskiĭ MA, Bukhtiiarova NV, 
Kovalenko SI. Pharmacological neuroprotection against 
experimental acute cerebral ischemia of neurons of sensomotor 
area of frontal cortex and hippocampus in rats. Eksp Klin Farmakol. 
2006;69(5) 
181. The Tirilazad International Steering Committee. Tirilazad for acute 
ischaemic stroke. Cochrane Database of Systematic Reviews. 2001 
 385 
 
182. Sherman D, Atkinson R, Chippendale T, Levin K, Ng K, Futrell N, et 
al. Intravenous ancrod for treatment of acute ischemic stroke - the 
stat study: A randomized controlled trial. Jama-Journal of the 
American Medical Association. 2000;283:2395-2403 
183. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. 
Intra-arterial prourokinase for acute ischemic stroke - the proact ii 
study: A randomized controlled trial. Jama-Journal of the American 
Medical Association. 1999;282:2003-2011 
184. Davalos A, Castillo J, Alvarez-Sabin J, Secades J, Mercadal J, Lopez S, 
et al. Oral citicoline in acute ischemic stroke - an individual patient 
data pooling analysis of clinical trials. Stroke. 2002;33:2850-2857 
185. Gaist D, Wallander M, Gonzalez-Perez A, Garcia-Rodriguez L. 
Incidence of hemorrhagic stroke in the general population: 
Validation of data from the health improvement network. 
Pharmacoepidemiology and Drug Safety. 2013;22:176-182 
186. Dubas F. Small vessel pathology and cerebral hemorrhage. Journal 
of Neuroradiology. 2003;30:298-302 
187. Pleşea IE CA, Georgescu CC, Enache SD, Zaharia B, Georgescu CV, 
Tenovici M. Study of cerebral vascular structures in hypertensive 
intracerebral haemorrhage. Rom J Morphol Embryol. 
2005;2005;46(3):249-256 
188. Fonseca A, Ferro J. Drug abuse and stroke. Curr Neurol Neurosci 
Rep. 2013 
189. Aguilar MI, Brott TG. Update in intracerebral hemorrhage. The 
Neurohospitalist. 2011;1:148-159 
190. Brouwers HB, Greenberg SM. Hematoma expansion following acute 
intracerebral hemorrhage. Cerebrovascular Diseases. 2013;35:195-
201 
191. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. 
Spontaneous intracerebral hemorrhage. N Engl J Med. 
2001;344:1450-1460 
192. Broderick J, Diringer M, Hill M, Brun N, Mayer S, Steiner T, et al. 
Determinants of intracerebral hemorrhage growth: An exploratory 
analysis. Stroke. 2007;38:1072-1075 
193. Hemphill J, Bonovich D, Besmertis L, Manley G, Johnston S. The ich 
score - a simple, reliable grading scale for intracerebral 
hemorrhage. Stroke. 2001;32:891-896 
194. Moussouttas M, Malhotra R, Fernandez L, Maltenfort M, Holowecki 
M, Delgado J, et al. Role of antiplatelet agents in hematoma 
expansion during the acute period of intracerebral hemorrhage. 
Neurocritical Care. 2010;12:24-29 
195. Moussouttas M. Challenges and controversies in the medical 
management of primary and antithrombotic-related intracerebral 
hemorrhage. Therapeutical Advances in Neurological Disorders. 
2012 
196. Naidech A, Bassin S, Bernstein R, Batjer H, Alberts M, Lindholm P, 
et al. Reduced platelet activity is more common than reported anti-
platelet medication use in patients with intracerebral hemorrhage. 
Neurocritical Care. 2009;11:307-310 
 386 
 
197. Naidech A, Bendok B, Garg R, Bernstein R, Alberts M, Bleck T, et al. 
Reduced platelet activity is associated with more intraventricular 
hemorrhage. Neurosurgery. 2009;65:684-688 
198. Siddiqui FM, Qureshi AI. Effect of pre-morbid aspirin use on 
hematoma expansion, disability and death among 4734 patients 
with spontaneous intracerebral hemorrhage. Neurology. 
2011;76:A630-A630 
199. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and 
intracranial hemorrhage - facts and hypotheses. Stroke. 
1995;26:1471-1477 
200. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-
associated hemorrhage and cerebral amyloid angiopathy - a 
genetic and pathologic study. Neurology. 2000;55:947-951 
201. Goodnough LT, Shander A. How i treat warfarin-associated 
coagulopathy in patients with intracerebral hemorrhage. Blood. 
2011;117:6091-6099 
202. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system 
bleeding during antithrombotic therapy recent - data and ideas. 
Stroke. 2005;36:1588-1593 
203. Flibotte JJ HN, O’Donnell J, Greenberg SM, Rosand J. . Warfarin, 
hematoma expansion, and outcome of intracerebral hemorrhage. . 
Neurology. 2004:1059–1064. 
204. Ichikawa K, Yanagihara C. Sedimentation level in acute 
intracerebral hematoma in a patient receiving anticoagulation 
therapy: An autopsy study. Neuroradiology. 1998;40:380-382 
205. Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P, Investigators C, 
et al. Hematoma growth in oral anticoagulant related intracerebral 
hemorrhage. Stroke. 2008;39:2993-2996 
206. Fisher CM. Pathological observations in hypertensive cerebral 
hemorrhage. Journal of Neuropathology and Experimental 
Neurology. 1971;30:536-550 
207. Greenberg SM, Nandigam RNK, Delgado P, Betensky RA, Rosand J, 
Viswanathan A, et al. Microbleeds versus macrobleeds evidence for 
distinct entities. Stroke. 2009;40:2382-2386 
208. Brouwers HB, Biffi A, Ayres AM, Schwab K, Cortellini L, Romero JM, 
et al. Apolipoprotein e genotype predicts hematoma expansion in 
lobar intracerebral hemorrhage. Stroke. 2012;43:1490-+ 
209. Almandoz JED, Yoo AJ, Stone MJ, Schaefer PW, Goldstein JN, Rosand 
J, et al. Systematic characterization of the computed tomography 
angiography spot sign in primary intracerebral hemorrhage 
identifies patients at highest risk for hematoma expansion the spot 
sign score. Stroke. 2009;40:2994-3000 
210. Kazui S, Minematsu K, Yamamoto H, Sawada T, Yamaguchi T. 
Predisposing factors to enlargement of spontaneous intracerebral 
hematoma. Stroke. 1997;28:2370-2375 
211. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, 
et al. Early hemorrhage growth in patients with intracerebral 
hemorrhage. Stroke. 1997;28:1-5 
 387 
 
212. Barras CD, Tress BM, Christensen S, MacGregor L, Collins M, 
Desmond PM, et al. Density and shape as ct predictors of 
intracerebral hemorrhage growth. Stroke. 2009;40:1325-1331 
213. Silva Y, Leira R, Tejada J, Lainez JM, Castillo J, Davalos A, et al. 
Molecular signatures of vascular injury are associated with early 
growth of intracerebral hemorrhage. Stroke. 2005;36:86-91 
214. Steiner T, Boesel J. Options to restrict hematoma expansion after 
spontaneous intracerebral hemorrhage. Stroke. 2010;41:402-409 
215. Qureshi AI, Tariq N, Divani AA, Novitzke J, Hussein HH, Palesch YY, 
et al. Antihypertensive treatment of acute cerebral hemorrhage. 
Critical Care Medicine. 2010;38:637-648 
216. Qureshi A, Wilson D, Hanley D, Traystman R. No evidence for an 
ischemic penumbra in massive experimental intracerebral 
hemorrhage. Neurology. 1999;52:266-272 
217. Qureshi AI, Palesch YY, Investigators A. Antihypertensive treatment 
of acute cerebral hemorrhage (atach) trial: Final results. Stroke. 
2009;40 
218. Arima H, Huang Y, Wang JG, Heeley E, Delcourt C, Parsons M, et al. 
Earlier blood pressure-lowering and greater attenuation of 
hematoma growth in acute intracerebral hemorrhage interact pilot 
phase. Stroke. 2012;43:2236-U2429 
219. Moussouttas M, Malhotra R, Fernandez L, Maltenfort M, Holowecki 
M, Delgado J, et al. Impact of intraventricular hemorrhage upon 
intracerebral hematoma expansion. Neurocritical Care. 
2011;14:50-54 
220. Sprigg N, Renton CJ, Dineen RA, Kwong Y, Bath PMW. Tranexamic 
acid for spontaneous intracerebral hemorrhage: A randomized 
controlled pilot trial. Journal of Stroke and Cerebrovascular 
Diseases. 2014;23:1312-1318 
221. Hanley D. Minimally invasive surgery plus rt-pa for ich evacuation 
phase iii (mistie iii). ClinicalTrials.gov (NCT01827046).  
222. Dowlatshahi D, Kosior JC, Idris S, Eesa M, Dickhoff P, Joshi M, et al. 
Planimetric hematoma measurement in patients with 
intraventricular hemorrhage is total volume a preferred target for 
reliable analysis? Stroke. 2012;43:1961-1963 
223. Dowlatshahi D, Demchuk AM, Flaherty ML, Ali M, Lyden PL, Smith 
EE, et al. Defining hematoma expansion in intracerebral 
hemorrhage relationship with patient outcomes. Neurology. 
2011;76:1238-1244 
224. Dowlatshahi D, Kosior JC, Idris S, Eesa M, Dickhoff P, Joshi M, et al. 
Planimetric hematoma measurement in patients with 
intraventricular hemorrhage: Is total volume a preferred target for 
reliable analysis? Stroke. 2012;43:1961-1963 
225. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of 
intracerebral hemorrhage. A powerful and easy-to-use predictor of 
30-day mortality. Stroke. 1993;24:987-993 
226. Yang GY, Betz AL, Chenevert TL, Brunberg JA, Hoff JT. Experimental 
intracerebral hemorrhage: Relationship between brain edema, 
 388 
 
blood flow, and blood–brain barrier permeability in rats. J 
Neurosurg. 1994:pp. 93–102 
227. Gebel JM, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S, et 
al. Natural history of perihematomal edema in patients with 
hyperacute spontaneous intracerebral hemorrhage. Stroke. 
2002;33:2631-2635 
228. Bullock R, Mendelow AD, Teasdale GM, Graham DI. Intracranial 
haemorrhage induced at arterial pressure in the rat. Part 1: 
Description of technique, icp changes and neuropathological 
findings. Neurological research. 1984;6:184-188 
229. Zazulia AR, Diringer MN, Videen TO, Adams RE, Yundt K, Aiyagari V, 
et al. Hypoperfusion without ischemia surrounding acute 
intracerebral hemorrhage. J Cereb Blood Flow Metab. 2001;21:804-
810 
230. Carhuapoma J, Wang P, Beauchamp N, Keyl P, Hanley D, Barker P. 
Diffusion-weighted mri and proton mr spectroscopic imaging in the 
study of secondary neuronal injury after intracerebral hemorrhage. 
Stroke. 2000;31:726-732 
231. Kim-Han J, Kopp S, Dugan L, Diringer M. Perihematomal 
mitochondrial dysfunction after intracerebral hemorrhage. Stroke; 
a journal of cerebral circulation. 2006;37:2457-2462 
232. Gebel J, Jauch E, Brott T, Khoury J, Sauerbeck L, Salisbury S, et al. 
Relative edema volume is a predictor of outcome in patients with 
hyperacute spontaneous intracerebral hemorrhage. Stroke. 
2002;33:2636-2641 
233. Arima H, Wang J, Huang Y, Heeley E, Skulina C, Parsons M, et al. 
Significance of perihematomal edema in acute intracerebral 
hemorrhage- the interact trial. Neurology. 2009;73:1963-1968 
234. Hinson HE, Hanley DF, Ziai WC. Management of intraventricular 
hemorrhage. Current Neurology and Neuroscience Reports. 
2010;10:73-82 
235. Steiner T, Diringer MN, Schneider D, Mayer SA, Begtrup K, 
Broderick J, et al. Dynamics of intraventricular hemorrhage in 
patients with spontaneous intracerebral hemorrhage: Risk factors, 
clinical impact, and effect of hemostatic therapy with recombinant 
activated factor vii. Neurosurgery. 2006;59:767-773 
236. Hallevi H, Albright KC, Aronowski J, Barreto AD, Martin-Schild S, 
Khaja AM, et al. Intraventricular hemorrhage - anatomic 
relationships and clinical implications. Neurology. 2008;70:848-
852 
237. Steinke W, Sacco RL, Mohr JP, Foulkes MA, Tatemichi TK, Wolf PA, 
et al. Thalamic stroke - presentation and prognosis of infarcts and 
hemorrhages. Archives of Neurology. 1992;49:703-710 
238. Maas MB, Nemeth AJ, Rosenberg NF, Kosteva AR, Prabhakaran S, 
Naidech AM. Delayed intraventricular hemorrhage is common and 
worsens outcomes in intracerebral hemorrhage. Neurology. 
2013;80:1295-1299 
 389 
 
239. Young WB, Lee KP, Pessin MS, Kwan ES, Rand WM, Caplan LR. 
Prognostic-significance of ventricular blood in supratentorial 
hemorrhage - a volumetric study. Neurology. 1990;40:616-619 
240. Graeb DA, Robertson WD, Lapointe JS, Nugent RA, Harrison PB. 
Computed tomographic diagnosis of intraventricular hemorrhage- 
etiology and prognosis Radiology. 1982;143:91-96 
241. Morgan T, Dawson J, Spengler D, Lees K, Aldrich C, Mishra N, et al. 
The modified graeb score an enhanced tool for intraventricular 
hemorrhage measurement and prediction of functional outcome. 
Stroke. 2013;44:635-641 
242. Hallevi H, Dar NS, Barreto AD, Morales MM, Savitz SI, Martin-Schild 
S, et al. Rapid estimation of ivh volume using the ivh score: 
Research and clinical utility. Neurology. 2008;70:A245-A245 
243. Hallevi H, Dar NS, Barreto AD, Morales MM, Martin-Schild S, 
Abraham AT, et al. The ivh score: A novel tool for estimating 
intraventricular hemorrhage volume: Clinical and research 
implications. Critical Care Medicine. 2009;37:969-974 
244. Ruscalleda J, Peiro A. Prognostic factors in intraparenchymatous 
hematoma with ventricular hemorrhage. Neuroradiology. 
1986;28:34-37 
245. Sven Loncaric APD, Dubravko Cosic, Domagoj Kovacevic, Joseph 
Broderick, Thomas Brott. 3-d image analysis of intra-cerebral brain 
hemorrhage from digitized ct films. Computer Methods and 
Programs in Biomedicine. 1995;46(3):207-216 
246. Kosior J, Idris S, Dowlatshahi D, Alzawahmah M, Eesa M, Sharma P, 
et al. Quantomo: Validation of a computer-assisted methodology 
for the volumetric analysis of intracerebral haemorrhage. 
International Journal of Stroke. 2011;6:302-305 
247. Hussein HM, Tariq NA, Palesch YY, Qureshi AI, et al. Reliability of 
hematoma volume measurement at local sites in a multicenter 
acute intracerebral hemorrhage clinical trial. Stroke. 2013;44:237-
239 
248. Prionas ND, Ray S, Boone JM. Volume assessment accuracy in 
computed tomography: A phantom study. J Appl Clin Med Phys. 
2010;11:3037 
249. Gebel JM, Sila CA, Sloan MA, Granger CB, Weisenberger JP, Green 
CL, et al. Comparison of the abc/2 estimation technique to 
computer-assisted volumetric analysis of intraparenchymal and 
subdural hematomas complicating the gusto-1 trial. Stroke. 
1998;29:1799-1801 
250. Huttner HB, Steiner T, Hartmann M, Köhrmann M, Juettler E, 
Mueller S, et al. Comparison of abc/2 estimation technique to 
computer-assisted planimetric analysis in warfarin-related 
intracerebral parenchymal hemorrhage. Stroke. 2006;37:404-408 
251. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, 
Zuccarello M, et al. The abcs of measuring intracerebral 
hemorrhage volumes. Stroke. 1996;27:1304-1305 
252. Freeman WD, Barrett KM, Bestic JM, Meschia JF, Broderick DF, 
Brott TG. Computer-assisted volumetric analysis compared with 
 390 
 
abc/2 method for assessing warfarin-related intracranial 
hemorrhage volumes. Neurocrit Care. 2008;9:307-312 
253. Sheth KN, Cushing TA, Wendell L, Lev MH, Romero JM, Schwab K, et 
al. Comparison of hematoma shape and volume estimates in 
warfarin versus non-warfarin-related intracerebral hemorrhage. 
Neurocrit Care. 2010;12:30-34 
254. Maeda AK, Aguiar LZ, Martins C, Bichinho GL, Gariba MA. 
Hematoma volumes of spontaneous intracerebral hemorrhage: The 
ellipse (abc/2) method yielded volumes smaller than those 
measured using the planimetric method. Arquivod de Neuro-
Psiquiatria. 2013;71:540-544 
255. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer 
SA, et al. Hematoma growth is a determinant of mortality and poor 
outcome after intracerebral hemorrhage. Neurology. 
2006;66:1175-1181 
256. Moon J-S, Janjua N, Ahmed S, Kirmani J, Harris-Lane P, Jacob M, et 
al. Prehospital neurologic deterioration in patients with 
intracerebral hemorrhage. Critical Care Medicine. 2008;36:172-175 
257. Naval NS, Nquist PA, Carhuapoma R. Management of spontaneous 
intracerebral hemorrhage. Neuro Clin. 2008;26(2):373-384 
258. Elliott J, Smith M. The acute management of intracerebral 
hemorrhage: A clinical review. Anesthesia and Analgesia. 
2010;110:1419-1427 
259. Butcher KS, Baird T, MacGregor L, Desmond P, Tress B, Davis S. 
Perihematomal edema in primary intracerebral hemorrhage is 
plasma derived. Stroke. 2004;35:1879-1885 
260. Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, et al. 
Intensive blood pressure reduction in acute cerebral haemorrhage 
trial (interact): A randomised pilot trial. Lancet Neurology. 
2008;7:391-399 
261. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. 
Rapid blood-pressure lowering in patients with acute intracerebral 
hemorrhage. New England Journal of Medicine. 2013:2355-2365 
262. Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, et 
al. Controlling hypertension and hypotension immediately post-
stroke (chhips): A randomised, placebo-controlled, double-blind 
pilot trial. Lancet Neurology. 2009;8:48-56 
263. Sandset EC, Bath PMW, Boysen G, Jatuzis D, Korv J, Luders S. The 
angiotensin-receptor blocker candesartan for treatment of acute 
stroke (scast): A randomised, placebo controlled, double-blind 
trial. Lancet. 2011;377:741-750 
264. Ankolekar S, Fuller M, Cross I, Renton C, Cox P, Sprigg N, et al. 
Feasibility of an ambulance-based stroke trial, and safety of 
glyceryl trinitrate in ultra-acute stroke: The rapid intervention 
with glyceryl trinitrate in hypertensive stroke trial (right, 
isrctn66434824). Stroke. 2013;44:3120-3128 
265. Jusufovic M, Sandset EC, Bath PMW, Berge E, SCAST study group. 
Blood pressure lowering treatment with candesartan in patients 
with acute hemorrhagic stroke. Stroke. 2014;45:3440-3442 
 391 
 
266. Shaw L PL, McLure S, Howel D, McColl E, Younger P, Ford GA 
Paramedic initiated lisinopril for acute stroke treatment (pil-fast): 
Results from the pilot randomised controlled trial. Emergency 
Medicine Journals. 2013 
267. Broderick JP, Brott TG, Duldner J, Tomsick T, Leach A. Initial and 
recurrent bleeding are the major causes of death following 
subarachnoid haemorrhage. Stroke. 1994;25:1342-1347 
268. Hemphill III JC, Greenberg SM, Anderson CS, Becker K, Bendok BR, 
Cushman M, et al. Guidelines for the management of spontaneous 
intracerebral hemorrhage. Stroke. 2015;46:[epub ahead of print] 
269. Watson H, Baglin T, Laidlaw S, Makris M, Preston F. A comparison 
of the efficacy and rate of response to oral and intravenous vitamin 
k in reversal of over-anticoagulation with warfarin. British Journal 
of Haematology. 2001;115:145-149 
270. Makris M GM, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. 
Emergency oral anticoagulant reversal: The relative efficacy of 
infusions of fresh frozen plasma and clotting factor concentrate on 
correction of the coagulopathy. Thromb Haemost. 1997:470-480 
271. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of 
prothrombin complex concentrates in reversing warfarin 
anticoagulation: A review of the literature. American Journal of 
Hematology. 2008;83:137-143 
272. Steiner T, Poli S, Griebe M, Husing M, Hajda J, Freiberg A. Fresh 
frozen plasma versus prothrombin complex concentrate in patients 
with intracranial haemorrhage related to vitamin k antagonists 
(inch): A randomised trial. Lancet. 2016;15:566-573 
273. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. 
Exploratory study on the reversal of warfarin with rfviia in healthy 
subjects (vol 116, pg 693, 2010). Blood. 2010;116:5079-5079 
274. Tanaka KA, Szlam F, Dickneite G, Levy JH. Effects of prothrombin 
complex concentrate and recombinant activated factor vii on 
vitamin k antagonist induced anticoagulation. Thrombosis Research. 
2008;122:117-123 
275. Mayer SA, Brun NC, Broderick J, Davis S, Diringer MN, Skolnick BE, 
et al. Safety and feasibility of recombinant factor viia for acute 
intracerebral hemorrhage. Stroke. 2005;36:74-79 
276. Hedner U. Mechanism of action of factor viia in the treatment of 
coagulopathies. Seminars in Thrombosis and Hemostasis. 
2006;32:77-85 
277. Mayer S, Brun N, Begtrup K, Broderick J, Davis S, Diringer M, et al. 
Recombinant activated factor vii for acute intracerebral 
hemorrhage. New England Journal of Medicine. 2005;352:777-785 
278. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et 
al. Efficacy and safety of recombinant activated factor vii for acute 
intracerebral hemorrhage. New England Journal of Medicine. 
2008;358:2127-2137 
279. Mayer SA, Davis SM, Skolnick BE, Brun NC, Begtrup K, Broderick JP, 
et al. Can a subset of intracerebral hemorrhage patients benefit 
 392 
 
from hemostatic therapy with recombinant activated factor vii? 
Stroke. 2009;40:833-840 
280. Flaherty M. The spot sign for predicting and treating ich growth 
study "stop-it". Clinical Trials Registry(NCT00810888). 2012 
281. Gladstone D. ""Spot sign" selection of intracerebral hemorrhage to 
guide hemostatic therapy (spotlight)". 2011 
282. Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, et 
al. Apixaban in patients with atrial fibrillation. New England Journal 
of Medicine. 2011;364:806-817 
283. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh 
A, et al. Dabigatran versus warfarin in patients with atrial 
fibrillation. New England Journal of Medicine. 2009;361:1139-1151 
284. Connolly SJ, Milling Jr TJ, Eikelboom JW, Gibson M, Curnutte JT, 
Gold A, et al. Andexanet alfa for acute major bleeding associated 
with factor xa inhibitors. The New England journal of medicine. 
2016;375:1131-1141 
285. Levy JH, Key NS, Azran MS. Novel oral anticoagulants implications 
in the perioperative setting. Anesthesiology. 2010;113:726-745 
286. Gathier CS, Algra A, Rinkel GJ, van der Worp HB. Long-term 
outcome after anticoagulation-associated intracerebral 
haemorrhage with or without restarting antithrombotic therapy. 
Cerebrovascular  Diseases. 2013;36:33-37 
287. Viswanathan A, Rakich SM, Engel C, Snider R, Rosand J, Greenberg 
SM, et al. Antiplatelet use after intracerebral hemorrhage. 
Neurology. 2006;66:206-209 
288. Goldstein JN. Should anticoagulation be resumed after 
intracerebral hemorrhage? Cleveland Clinic Journal of Medicine. 
2010;77:791-799 
289. Panduranga P, Al-Mukhaini M, Shehab A. Management dilemmas in 
patients with mechanical heart valves and warfarin-induced major 
bleeding. World Journal of Cardiology. 2012;4:54-59 
290. Piriyawat P, Morgenstern LB, Yawn DH, Hall CE, Grotta JC. 
Treatment of acute intracerebral hemorrhage with epsilon-
aminocaproic acid - a pilot study. Neurocritical Care. 2004;1:47-51 
291. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, et al. 
Effects of tranexamic acid on death, vascular occlusive events, and 
blood transfusion in trauma patients with significant haemorrhage 
(crash-2): A randomised, placebo-controlled trial. Lancet. 
2010;376:23-32 
292. Perel P, AlShahi Salman R, Kawahara T, Morris Z, Prieto-Merino D, 
Roberts I, et al. Crash-2 (clinical randomisation of an 
antifibrinolytic in significant haemorrhage) intracranial bleeding 
study: The effect of tranexamic acid in traumatic brain injury - a 
nested, randomised, placebo-controlled trial. Health Technology 
Assessment. 2012;16:1-+ 
293. Sprigg N, Dineen R, Bath PM. Tranexamic acid for acute 
intracerebral haemorrhage (tich). 2010 
 393 
 
294. Sprigg N, Renton CJ, Kwong Y, Dineen R, Bath PM. Tranexamic acid 
for acute intracerebral haemorrhage (tich): Results of the first 
randomised controlled trial. UK Stroke Forum. 2012 
295. Sorimachi T, Fujii Y, Morita K, Tanaka R. Rapid administration of 
antifibrinolytics and strict blood pressure control for intracerebral 
hemorrhage. Neurosurgery. 2005;57:837-843 
296. Davis SM. Stop-aust: The spot sign and tranexamic acid on 
preventing ich growth - australasia trial. ClinicalTrials.gov 
(NCT01702636).  
297. de Gans K, Haan RJ, Majoie CB, Koopman MM, Brand A, Dijkgraaf 
MG, et al. Patch: Platelet transfusion in cerebral 
haemorrhage:Study protocol for a multicentre, randomised, 
controlled trial. BMC Neurology. 2010;10 
298. Naidech AM, Mass MB, Levasseur-Franklin KE, Liotta EM, J.C. G, 
Berman M, et al. Desmopressin improves platelet activity in acute 
intracerebral haemorrhage. Stroke. 2014;45:2451-2453 
299. Naidech A, Jovanovic B, Liebling S, Garg R, Bassin S, Bendok B, et al. 
Reduced platelet activity is associated with early clot growth and 
worse 3-month outcomed after intracerebral hemorrhage. Stroke. 
2009;40:2398-2401 
300. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, Gans K, Koopman 
M, Brand A, et al. Platelet transfusion versus standard care after 
acute stroke due to spontaneous intracerebral haemorrhage 
associated with antiplatelet therapy (patch): A randomised open-
label, phase 3 trial. Lancet. 2016;387:2605-2613 
301. Al-Shahi Salman R. Haemostatic drug therapies for acute 
spontaneous intracerebral haemorrhage. The Cochrane database of 
systematic reviews. 2009:CD005951-CD005951 
302. Pantazis G, Tsitsopoulos P, Mihas C, Katsiva V, Stavrianos V, 
Zymaris S. Early surgical treatment vs conservative management 
for spontaneous supratentorial intracerebral hematomas: A 
prospective randomized study. Surgical Neurology. 2006;66:492-
502 
303. Mendelow AD GB, Fernandes HM, Murray GD, Teasdale GM, Hope 
DT, Karimi A, Shaw MD, Barer DH; STICH investigators. Early 
surgery versus initial conservative treatment in patients with 
spontaneous supratentorial intracerebral haematomas in the 
international surgical trial in intracerebral haemorrhage (stich): A 
randomised trial. Lancet. 2005;365(9457):387-397 
304. Fernandes HM, Mendelow AD. Spontaneous intracerebral 
haemorrhage: A surgical dilemma. British Journal of Neurosurgery. 
1999;13:389-394 
305. Kirollos R, Tyagi A, Ross S, van Hille P, Marks P. Management of 
spontaneous cerebellar hematomas: A prospective treatment 
protocol. Neurosurgery. 2001;49:1378-1386 
306. Da Pian R, Bazzan A, Pasqualin A. Surgical versus medical 
treatment of spontaneous posterior fossa haematomas: A 
cooperative study on 205 cases. Neurol Res. 1984;6(3):145-151 
 394 
 
307. Kanaya H, Saiki I, Ohuchi T, Mizukami M, Kanaya K, Yamori Y, et al. 
Hypertensive ich in japan: Update on surgical treatment. 
In:Hypertensive intracerebral hemorrhage. 1983;147 
308. Jun Morioka MF, Shoichi Kato, Hirosuke Fujisawa, Tatsuo Akimura, 
Michiyasu Suzuki, Shotai Kobayashi, Japan Standard Stroke 
Registry Group Surgery for spontaneous intracerebral hemorrhage 
has greater remedial value than conservative therapy. Surgical 
Neurology. 2005;65:67-72 
309. Barbara A. Gregson, Broderick JP, Ludwig M. Auer, Hunt Batjer, 
Xian-Cheng Chen, Seppo Juvela, et al. Individual patient data 
subgroup meta-analysis of surgery for spontaneous supratentorial 
intracerebral hemorrhage. Stroke. 2012;43:1496-1504 
310. Mendelow AD GB, Rowan EN, Murray GD, Gholkar A, Mitchell PM; 
for the STICH II Investigators. Early surgery versus initial 
conservative treatment in patients with spontaneous 
supratentorial lobar intracerebral haematomas (stich ii): A 
randomised trial. Lancet. 2013;382:397-403 
311. Mendelow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, 
Mitchell PM, et al. Early surgery versus initial conservative 
treatment in patients with spontaneous supratentorial lobar 
intracerebral haematomas (stich ii): A randomised trial. Lancet. 
2013 
312. Gautschi OP, Schaller K. Surgery or conservative therapy for 
cerebral haemorrhage? The Lancet. 2013 
313. Mitchell P, Gregson BA, Vindlacheruvu RR, Mendelow AD. Surgical 
options in ich including decompressive craniectomy. Journal of the 
Neurological Sciences. 2007;261:89-98 
314. Mayer S, Brun N, Begtrup K, Broderick J, Davis S, Diringer M, et al. 
Efficacy and safety of recombinant activated factor vii for acute 
intracerebral hemorrhage. New England Journal of Medicine. 
2008;358:2127-2137 
315. Thiex R. Future perspectives on the fibrinolytic therapy of 
intracerebral hemorrhages. Central Nervous System Agents in 
Medicinal Chemistry. 2011;11:150-156 
316. Johnson WD, Bouz PA. Use of intralesional tpa in spontaneous 
intracerebral hemorrhage: Retrospective analysis. Acta Neurochir 
Suppl. 2011;111:425-428 
317. Huttner HB, Tognoni E, Bardutzky J, Hartmann M, Kohrmann M, 
Kanter IC, et al. Influence of intraventricular fibrinolytic therapy 
with rt-pa on the long-term outcome of treated patients with 
spontaneous basal ganglia hemorrhage: A case-control study. 
European Journal of Neurology. 2008;15:342-349 
318. Morgan T, Zuccarello M, Narayan R, Keyl P, Lane K, Hanley D. 
Preliminary findings of the minimally-invasive surgery plus rtpa 
for intracerebral hemorrhage evacuation (mistie) clinical trial. Acta 
Neurochir Suppl. 2008:147-151 
319. Mould WA, Carhuapoma JR, Muschelli J, Lane K, Morgan TC, McBee 
NA, et al. Minimally invasive surgery plus recombinant tissue-type 
 395 
 
plasminogen activator for intracerebral hemorrhage evacuation 
decreases perihematomal edema. Stroke. 2013;44:627-634 
320. Naff NJ, Carhuapoma JR, Williams MA, Bhardwaj A, Ulatowski JA, 
Bederson J, et al. Treatment of intraventricular hemorrhage with 
urokinase - effects on 30-day survival. Stroke. 2000;31:841-847 
321. Webb AJS, Ullman NL, Mann S, Muschelli J, Awad IA, Hanley DF. 
Resolution of intraventricular hemorrhage varies by ventricular 
region and dose of intraventricular thrombolytic the clot lysis: 
Evaluating accelerated resolution of ivh (clear ivh) program. 
Stroke. 2012;43:1666-1668 
322. Naff N, Williams MA, Keyl PM, Tuhrim S, Bullock MR, Mayer SA, et 
al. Low-dose recombinant tissue-type plasminogen activator 
enhances clot resolution in brain hemorrhage the intraventricular 
hemorrhage thrombolysis trial. Stroke. 2011;42:3009-3016 
323. Zhou X, Chen J, Li Q, Ren G, Yao G, Liu M, et al. Minimally invasive 
surgery for spontaneous supratentorial intracerebral hemorrhage 
a meta-analysis of randomized controlled trials. Stroke. 
2012;43:2923-2930 
324. Ramanan M, Shankar A. Minimally invasive surgery for primary 
supratentorial intracerebral haemorrhage. Journal of clinical 
neuroscience : official journal of the Neurosurgical Society of 
Australasia. 2013;20:1650-1658 
325. Takeuchi S, Wada K, Nagatani K, Otani N, Mori K. Decompressive 
hemicraniectomy for spontaneous intracerebral hemorrhage. 
Neurosurgical Focus. 2013;34 
326. Fung C, Murek M, Z'Graggen WJ, Kraehenbuehl AK, Gautschi OP, 
Schucht P, et al. Decompressive hemicraniectomy in patients with 
supratentorial intracerebral hemorrhage. Stroke. 2012;43:3207-
3211 
327. Hayes SB, Benveniste RJ, Morcos JJ, Aziz-Sultan MA, Elhammady 
MS. Retrospective comparison of craniotomy and decompressive 
craniectomy for surgical evacuation of nontraumatic, 
supratentorial intracerebral hemorrhage. Neurosurgical Focus. 
2013;34 
328. Murthy JMK, Chowdary GVS, Murthy T, Bhasha PSA, Naryanan TJ. 
Decompressive craniectomy with clot evacuation in large 
hemispheric hypertensive intracerebral hemorrhage. Neurocritical 
Care. 2005;2:258-262 
329. Xi G, Keep R, Hoff J. Mechanisms of brain injury after intracerebral 
haemorrhage. The Lancet. 2006;5:53-63 
330. Wang J. Preclinical and clinical research on inflammation after 
intracerebral hemorrhage: An update. Progress in Neurobiology. 
2010;92:463-477 
331. Hua Y, Wu J, Keep RF, Nakamura T, Hoff JT, Xi G. Tumor necrosis 
factor-alpha increases in the brain after intracerebral hemorrhage 
and thrombin stimulation. Neurosurgery. 2006;58:542-550 
332. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. 
Glia. 2002;39:279-291 
 396 
 
333. Venkatasubramanian C, Mlynash M, Finley-Caulfield A, et al. 
Natural history of perihematomal edema after intracerebral 
hemorrhage measured by serial magnetic resonance imaging. 
Stroke. 2011;42:73-80 
334. Lee SH, Park HK, Ryu WS, Lee JS, Bae HJ, Han MK. Effects of 
celecoxib on hematoma and edema volumes in primary 
intracerebral hemorrhage: A multicenter randomized controlled 
trial. European Journal of Neurology. 2013;20:1161-1169 
335. Gonzales NR, Sangha N, Kauffman T, Cai C, Sline MR, Pandurengan 
R, et al. The safety of pioglitazone for hematoma resolution in 
intracerebral hemorrhage (shrinc): Safety results. International 
Stroke Conference. 2014;45 
336. Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo JG, Rodriguez-
Leyva I, Gonzalez-Aguirre D, Gordillo-Moscoso A, et al. Use of 
statins for the treatment of spontaneous intracerebral 
haemorrhage: Results of a pilot study. Central European 
Neurosurgery. 2009;70:15-20 
337. Naval N. Simvastatin for intracerebral hemorrhage study. Clinical 
Trials. gov. 2008 
338. Nagatsuna T, Nomura S, Suehiro E, Fujisawa H, Koizumi H, Suzuki 
M. Systemic administration of argatroban reduces secondary brain 
damage in a rat model of intracerebral hemorrhage: 
Histopathological assessment. Cerebrovascular Diseases. 
2005;2005:192-200 
339. Kitaoka T, Hua Y, Xi G, Hoff JT, Keep RF. Delayed argatroban 
treatment reduces edema in rat model of intracerebral 
haemorrhage. Stroke. 2002;33:3012-3018 
340. Xi G, Reiser G, Keep RF. The role of thrombin and thrombin 
receptos in ischemic, hemorrhagic and traumatic brain injury. 
Journal of Neurochemistry. 2003;84:3-9 
341. Matsuoka H, Hamada R. Role of thrombin in cns damage associated 
with intracerebral haemorrhage: Opportunity for pharmacological 
intervention? CNS Drugs. 2002;16:509-516 
342. Okauchi M, Hua Y, Keep R, Morgenstern LB, Xi G. Effects of 
deferoxamine on intracerebral hemorrhage-induced brain injury in 
aged rats. Stroke. 2009;40:1858-1863 
343. Nakamura T, Keep RF, Hua Y, Nagao S, Hoff JT, Xi G. Iron-induced 
oxidative brain injury after experimental intracerebral 
hemorrhage. Acta Neurochir Suppl. 2006;96:194-198 
344. Nakamura T, Keep RF, Hua Y, Schallert T, Hoff JT, Xi G. 
Deferoxamine-induced attenuation of brain edema and 
neurological deficits in a rat model of intracerebral hemorrhage. 
Neurosurgery. 2004;100:672-678 
345. Selim M. Deferoxamine mesylate: A new hope for intracerebral 
hemorrhage: From bench to clinical trials. Stroke. 2009;40:S90-91 
346. Selim M, Yeatts S, Goldstein JN, et al. Safety and tolerability of 
deferoxamine mesylat in patients with acute intracerebral 
hemorrhage. Stroke. 2011;42:3067-3074 
 397 
 
347. Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: Mechanisms of 
injury and therapeutic targets. Lancet Neurology. 2012;11:720-731 
348. Kawanishi M, Kawai N, Nakamura T, Luo C, Tamiya T, Nagao S. 
Effect of delayed mild brain hypothermia on edema formation after 
intracerebral hemorrhage in rats. Journal of Stroke and 
Cerebrovascular Diseases. 2008;17:187-195 
349. Fingas M, Penner M, Silasi G, Colbourne F. Treatment of 
intracerebral hemorrhage in rats with 12 h, 3 days and 6 days of 
selective brain hypothermia. Experimental Neurology. 
2009;219:156-162 
350. Staykov D, Huttner HB, Kohrmann M, Bardutzky J, Schellinger PD. 
Novel approaches to the treatment of intracerebral haemorrhage. 
International Journal of Stroke. 2010;5:457-465 
351. Kollmar R, Staykov D, Dorfler A, Schellinger PD, Schwab S, 
Bardutzky J. Hypothermia reduces perihemorrhagic edema after 
intracerebral hemorrhage. Stroke. 2010;41:1684-1689 
352. Kwak R, Kadoya S, Suzuki T. Factors affecting the prognosis in 
thalamic hemorrhage. Stroke. 1983;14:493-500 
353. Newman GC. Clarification of abc2 rule for ich volume. Stroke. 2007 
354. Broderick JP, Brott TG, Grotta JC. Intracerebral hemorrhage volume 
measurement. Stroke. 1994;25:1081 
355. Sheth KN, Cushing TA, Wendell L, Lev MH, Romero JM, Schwab K, et 
al. Comparison of hematoma shape and volume estimates in 
warfarin versus non-warfarin-related intracerebral hemorrhage. 
Neurocrit Care. 2010;12:30-34 
356. Yang W, Feng Y, Zhang Y, Yan J, Fu Y, Chen S. Volume quantification 
of acute infratentorial hemorrhage with computed tomography: 
Validation of the formula 1/2abc and 2/3sh. Plos One. 2013;8 
357. Zimmerman RD, Maldjian JA, Brun NC, Horvath B, Skolnick BE. 
Radiologic estimation of hematoma volume in intracerebral 
hemorrhage trial by ct scan. AJNR Am J Neuroradiol. 2006;27:666-
670 
358. Kosior J, Idris S, Dowlatshahi D, Alzawahmah M, Eesa M, Sharma P, 
et al. Quantomo: Validation of a computer-assisted methodology 
for the volumetric analysis of intracerebral haemorrhage. 
International Journal of Stroke. 2011;6:302-305 
359. Bhanu Prakash KN, Zhou S, Morgan TC, Hanley DF, Nowinski WL. 
Segmentation and quantification of intra-ventricular/cerebral 
hemorrhage in ct scans by modified distance regularized level set 
evolution technique. International Journal of Computer Assisted 
Radiology and Surgery. 2012;7:785-798 
360. Liu J, Huang S, Ihar V, Ambrosius W, Lee LC, Nowinski WL. 
Automatic model-guided segmentation of the human brain 
ventricular system from ct images (vol 6, pg 718, 2010). Academic 
Radiology. 2010;17:1226-1226 
361. Fujii Y, Tanaka R, Takeuchi S, Koike T, Minakawa T, Sasaki O. 
Hematoma enlargement in spontaneous intracerebral hemorrhage. 
J Neurosurg. 1994;80:51-57 
 398 
 
362. Barras CD, Tress BM, Christensen S, Collins M, Desmond PM, 
Skolnick BE, et al. Quantitative ct densitometry for predicting 
intracerebral hemorrhage growth. American Journal of 
Neuroradiology. 2013;34:1139-1144 
363. Pabst W, Gregerova E. Characterisation of particle and particle 
systems. ICT. 2007:1-123 
364. The ENOS Trial Investigators. Glyceryl trinitrate vs. Control, and 
continuing vs. Stopping temporarily prior antihypertensive 
therapy, in acute stroke: Rationale and design of the efficacy of 
nitric oxide in stroke (enos) trial (isrctn99414122). International 
Journal of Stroke. 2006;1:245-249 
365. O' Brien E, Mee F, Atkins F, Thomas M. Evaulation of three devices 
for self-measurement of blood pressure monitoring according to 
the revised british hypertension society protocol: The omron hem-
705 cp, philips hp 5332 and nissei ds-175. Blood Pressure 
Monitoring. 1996;1:55-67 
366. Wardlaw J, Bath P, Sandercock P, Perry D, Palmer J, Watson G, et al. 
The neurogrid stroke examplar clinical trial protocol. International 
Journal of Stroke. 2007;2:63-69 
367. Wardlaw JM, Sellar RJ. A simple practical classification of cerebral 
infarcts on ct and its interobserver reliability. American Journal of 
Neuroradiology. 1994;15:1933-1939 
368. Rosset A, Spadola L, Ratib O. Osirix: An open-source software for 
navigating in multidimensional dicom images. Journal of Digital 
Imaging. 2004;17:205-216 
369. Heuberger J, Rosset A. Osirix user manual the complete reference. 
266 rue de Bernex CH-1233 Bernex Switzerland Pixmeo 2012  
370. Lees KR, Bath PMW, Schellinger PD, et al. Contemporary outcome 
measures in acute stroke research: Choice of primary outcome 
measure. Stroke. 2012;43:1163-1170 
371. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et 
al. Efficacy and safety of recombinant activated factor vii for acute 
intracerebral hemorrhage. New England Journal of Medicine. 
2008;358:2127-2137 
372. Sandercock P, Lindley R, Wardlaw J, Dennis M, Lewis S, Venables G, 
et al. The third international stroke trial (ist-3) of thrombolysis for 
acute ischaemic stroke. Trials. 2008;9:37 
373. Shrout P, Fleiss J. Intraclass correlations: Uses in assessing rater 
reliability. Psychological Bulletin. 1979:420-428 
374. ENOS Investigators. Baseline characteristics of the 4011 patients 
recruited into the "efficacy of nitric oxide in stroke (enos) trial. 
International Journal of Stroke. 2014;9:711-720 
375. Wang CW, Juan CJ, Liu YJ, Hsu HH, Liu HS, Chen CY, et al. Volume-
dependent overestimation of spontaneous intracerebral hematoma 
volume by the abc/2 formula. Acta Radiol. 2009;50:306-311 
376. Zhao KJ, Liu Y, Zhang RY, Wang XQ, Gao C, Shen JK. A precise, 
simple, convenient and new method for estimation of intracranial 
hematoma volume-the formula 2/3sh. Neurological Research. 
2009;31:1031-1036 
 399 
 
377. Sucu HK, Gokmen M, Gelal F. The value of xyz/2 technique 
compared with computer-assisted volumetric analysis to estimate 
the volume of chronic subdural hematoma. Stroke. 2005;36:998-
1000 
378. Barras CD, Tress BM, Christensen S, et al. Density and shape as ct 
predictors of intracerebral hemorrhage growth. Stroke. 
2009;40:1325-1331 
379. Gray LJ, Ali M, Lyden PD, Bath PM. Interconversion of the national 
institutes of health stroke scale and scandinavian stroke scale in 
acute stroke. Journal of Stroke and Cerebrovascular Diseases. 
2009;18:466-468 
380. Poon MTC, Fonville AF, Al-Shahi Salman R. Long-term prognosis 
after intracerebral haemorrhage: Systematic review and meta-
analysis. Journal of Neurology, Neurosurgery and Psychiatry. 
2014;85:660-667 
381. Terayama Y, Tanahashi N, Fukuuchi Y, Gotoh F. Prognostic value of 
admission blood pressure in patients with intracerebral 
hemorrhage. Keio cooperative stroke study. Stroke. 1997;28:1185-
1188 
382. Qureshi AI, Mohammad YM, Yahia AM, Suarez JI, Siddiqui AM, 
Kirmani JF, et al. A prospective multicenter study to evaluate the 
feasibility and safety of aggressive antihypertensive treatment in 
patients with acute intracerebral hemorrhage. Journal of Intensive 
Care Medicine. 2005;20:34-42 
383. Jusufovic M, Sandset E, Bath P, Berge E. Blood pressure lowering 
treatment with candesartan in patients with acute hemorrhagic 
stroke. Stroke. 2014;45:3440-3442 
384. Bath PMW, Pathansali R, Iddenden R, Bath FJ. The effect of 
transdermal glyceryl trinitrate, a nitric oxide donor, on blood 
pressure and platelet function in acute stroke. Cerebrovasc Dis. 
2001;11:265-272 
385. Rashid P, Weaver C, Leonardi-Bee J, Bath F, Fletcher S, Bath P. The 
effects of transdermal glyceryl trinitrate, a nitric oxide donor, on 
blood pressure, cerebral and cardiac hemodynamics, and plasma 
nitric oxide levels in acute stroke. Journal of stroke and 
cerebrovascular diseases : the official journal of National Stroke 
Association. 2003;12:143-151 
386. Willmot M, Ghadami A, Whysall B, Clarke W, Wardlaw J, Bath PM. 
Transdermal glyceryl trinitrate lowers blood pressure and 
maintains cerebral blood flow in recent stroke. Hypertension. 
2006;47:1209-1215 
387. Bath P, Houlton A, Woodhouse L, Sprigg N, Wardlaw J, Pocock S. 
Statistical analysis plan for the ‘efficacy of nitric oxide in stroke’ 
(enos) trial. International Journal of Stroke. 2014;9:372-374 
388. O'Brien E, Mee F, Atkins N, Thomas M. Evaluation of three devices 
for self-measurement of blood pressure according to the revised 
british hypertension society protocol: The omron hem-705cp, 
philips hp5332, and nissei ds-175. Blood Pressure Monitoring. 
1996;1:55-61 
 400 
 
389. Sulter G, Steen C, de Kayser J. Use of the barthel index and modified 
rankin scale in acute stroke trials. Stroke. 1999;1999:1538-1541 
390. Metitieri T, Geroldi C, Pezzini A, et al. The itle-mmse: An italian 
telephone version of the mini-mental state examination. 
International Journal of Geriatric Psychiatry. 2001;16:166-167 
391. Desmond DW, Tatemichi TK, Hanzawa L. The telephone interview 
for cognitive status (tics): Reliability and validity in a stroke 
sample. International Journal of Geriatric Psychiatry. 1994;9:803-
807 
392. Whynes DK, Sprigg N, Selby J, Berge E, Bath PMW. Testing for 
differential item functioning within the eq-5d. Medical Decision 
Making. 2013;33:252-260 
393. Sprigg N, Selby J, Fox L, Berge E, Whynes D, Bath P. Very low quality 
of life after acute stroke: Data from the efficacy of nitric oxide in 
stroke trial. Stroke. 2013;44:3458-3462 
394. Zung WWK. A self-rating depression scale. Archives of General 
Psychiatry. 1965;12:63-70 
395. Ankolekar S, Renton C, Sare G, Ellender S, Sprigg N, Wardlaw JM, et 
al. Relationship between poststroke cognition, baseline factors, and 
functional outcome: Data from "efficacy of nitric oxide in stroke" 
trial. Journal of Stroke and Cerebrovascular Diseases. 2014;23:1821-
1829 
396. Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores S, 
Ehtisham A, et al. Effect of systolic blood pressure reduction on 
hematoma expansion, perihematomal edema, and 3-month 
outcome among patients with intracerebral hemorrhage: Results 
from the antihypertensive treatment of acute cerebral hemorrhage 
study. Arch Neurol. 2010;67:570-576 
397. Willmot M, Gray L, Gibson C, Murphy S, Bath PMW. A systematic 
review of nitric oxide donors and l-arginine in experimental stroke; 
effects on infarct size and cerebral blood flow. Nitric Oxide-Biology 
and Chemistry. 2005;12:141-149 
398. Morikawa E, Rosenblatt S, Moskowitz MA. L-arginine dilates rat 
pial arterioles by nitric oxide-dependent mechanisms and 
increases blood flow during focal cerebral ischaemia. British 
Journal of Pharmacology. 1992;107:905-907 
399. The ENOS Trial Investigators. Glyceryltrinitrate vs. Control, and 
continuing vs.Stopping temporarily prior antihypertensive therapy 
in acute stroke:Rationale and design of the efficacy of nitric oxide 
(enos) trial (isrctn99414122). Int J Stroke. 2006;1:245-249 
 
400. Qureshi AI, Palesch YY. Antihypertensive treatment of acute 
cerebral hemorrhage (atach) ii: Design, methods, and rationale. 
Neurocrit Care. 2011;15:559-576 
401. Chen S, Chen S, Hsu C, Hogan E. Progression of hypertensive 
intracerebral hemorrhage. Neurology. 1989;39:1509-1514 
402. Leira R, Davalos A, Silva Y, Gil-Peralta A, Tejada J, Garcia M, et al. 
Early neurologic deterioration in intracerebral hemorrhage - 
predictors and associated factors. Neurology. 2004;63:461-467 
 401 
 
403. Fischer U, Cooney MT, Bull LM, Silver LE, Chalmers J, Anderson CS, 
et al. Acute post-stroke blood pressure relative to premorbid levels 
in intracerebral haemorrhage versus major ischaemic stroke: A 
population-based study. Lancet Neurology. 2014;13:374-384 
404. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and the 
secondary prevention of stroke and other vascular events: A 
systematic review. Stroke. 2003;34:2741-2749 
405. Lees KR, Dyker AG. Blood pressure control after acute stroke. J 
Hypertens Suppl. 1996;14:S35-38 
406. Steiner T, Al-Shahi Salman R, Beer R, Christensen H, Cordonnier C, 
Csiba L, et al. European stroke organisation (eso) guidelines for the 
management of spontaneous intracerebral hemorrhage. 
International Journal of Stroke. 2014;9:840-855 
407. Neal B, MacMahon S, Chapman N. Effects of ace inhibitors, calcium 
antagonists, and other blood-pressure-lowering drugs: Results of 
prospectively designed overviews of randomised trials. Blood 
pressure lowering treatment trialists' collaboration. Lancet. 
2000;2000:1955-1964 
408. Strandgaard S, Olesen J, Skinhoj E, Lassen NA. Autoregulation of 
brain circulation in severe arterial hypertension. British Medical 
Journal. 1973;3:507-510 
409. Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, et 
al. Effects of antihypertensive treatment after acute stroke in the 
continue or stop post-stroke antihypertensives collaborative study 
(cossacs): A prospective, randomised, open, blinded-endpoint trial. 
Lancet Neurol. 2010;9:767-775 
410. Lees KR, Bath PMW, Schellinger PD, Kerr DM, Fulton R, Hacke W, et 
al. Contemporary outcome measures in acute stroke research: 
Choice of primary outcome measure Stroke 2012;43:1163-1170 
411. Sulter G, Steen C, de Keyser J. Use of the barthel index and modified 
rankin scale in acute stroke trials. Stroke. 1999;30:1538-1541 
412. Bath PM, Lees KR, Schellinger PD, et al. Statistical analysis of the 
primary outcome in acute stroke trials Stroke 2012;43:1171-1178 
413. Krishnan K, Mukhtar SF, Lingard J, Houlton A, Walker E, Jones T, et 
al. Performance characteristics of methods for quantifying 
spontaneous intracerebral haemorrhage: Data from the efficacy of 
nitric oxide in stroke (enos) trial. Journal of Neurology 
Neurosurgery and Psychiatry. 2015;86:1258-1266 
414. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. 
Lancet. 2009;373:1632-1644 
415. Bruno A, Carter S, Qualls C, Nolte KB. Incidence of spontaneous 
intracerebral hemorrhage among hispanics and non-hispanic 
whites in new mexico. Neurology. 1996;47:405-408 
416. Chen DY, Roman GC, Wu GX, Wu ZS, Yao CH, Zhang M, et al. Stroke 
in china (sin0-monica-beijing study) 1984-1986. 
Neuroepidemiology. 1992;11:15-23 
417. Wild S, Mckeigue P. Cross sectional analysis of mortality by country 
of birth in england and wales, 1970–92. BMJ. 1997;314:705-710 
 402 
 
418. Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S. Cardiovascular 
and cancer mortality among canadians of european, south asian 
and chinese origin from 1979 to 1993: An analysis of 1.2 million 
deaths. CMAJ. 1999;161:132-138 
419. Hsu RT, Ardron ME, Brooks W, Cherry D, Taub NA, Botha JLT. The 
1996 leicestershire community stroke & ethnicity study: 
Differences and similarities between south asian and white strokes. 
International Journal of Epidemiology. 1999;28:853-858 
420. Fang J, Foo SH, Jeng JS, Yip PK, Alderman MH. Clinical 
characteristics of stroke among chinese in new york city. Ethn Dis. 
2004;14:378-383 
421. Feigin V, Carter K, Hackett M, et al. Ethnic disparities in incidence of 
stroke subtypes: Auckland regional community stroke study, 
2002–2003. Lancet Neurology. 2006;5:130-139 
422. Gunarathne A, Patel JV, Gammon B, Gill PS, Hughes EA, Lip GY. 
Ischemic stroke in south asians: A review of the epidemiology, 
pathophysiology and ethnicity-related clinical features. Stroke. 
2009;40:e415-e423 
423. Khan NA, Quan H, Hill MD, Pilote L, McAlister F, Palepu A, et al. Risk 
factors, quality of care and prognosis in south asian, east asian and 
white patients with stroke. BMC Neurology. 2013;13 
424. Qureshi AI, Giles WH, Croft JB. Racial differences in the incidence of 
intracerebral hemorrhage: Effects of blood pressure and education. 
Neurology. 1999;52:1617-1621 
425. van Asch C, Luitse M, Rinkel G, van der Tweel I, Algra A, Klijn C. 
Incidence, case fatality, and functional outcome of intracerebral 
haemorrhage overtime, according to age, sex, and ethnic origin: A 
systematic review and meta-analysis. Lancet Neurology. 
2010;9:167-176 
426. Qureshi AI, Suri MA, Safdar K, Ottenlips JR, Janssen RS, Frankel MR. 
Intracerebral hemorrhage in blacks. Risk factors, subtypes, and 
outcome. Stroke. 1997;28:961-964 
427. Ali M, Bath P, Brady M, David S, Diener H-C, Donnan G, et al. 
Development, expansion and use of a stroke clinical trials resource 
for novel exploratory analyses. International Journal of Stroke. 
2012;7:133-138 
428. Zahuranec DB, Wing JJ, Edwards DF, Menon RS, Fernandez SJ, 
Burgess RE. Poor long term blood pressure control after 
intracerebral hemorrhage. Stroke. 2012;43:2580-2585 
429. Fogelholm R, Avikainen S, Murros K. Prognostic value and 
determinants of first-day mean arterial pressure in spontaneous 
supratentorial intracerebral hemorrhage. Stroke. 1997;28:1396-
1400 
430. Passero S, Burgalassi L, D' Andrea P, Battistini N. Recurrence of 
bleeding in patients with primary intracerebral hemorrhage. 
Stroke. 1995;26:1189-1192 
431. Steiner T, Al-Shahi Salman R, Beer R, Christensen H, Cordonnier C, 
Csiba L, et al. European stroke organisation (eso) guidelines for the 
 403 
 
management of spontaneous intracerebral hemorrhage. 
International Journal of Stroke. 2014;9:840-855 
432. Hemphill J, Greenberg S, Anderson C, Becker K, Bendok B, Cushman 
M, et al. Guidelines for the management of spontaneous 
intracerebral hemorrhage. Stroke. 2015;46:2032-2060 
433. Gillum RF. Stroke mortality in blacks. Disturbing trends. Stroke. 
1999;30:1711-1715 
434. de Haan RJ, Limburg M, Van der Muelen JHP, Jacobs HM, Aaronson 
NK. Quality of life after stroke: Impact of stroke type and lesion 
location. Stroke. 1995;26:402-408 
435. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, 
Goodwin FK. The de facto mental and addictive disorders service 
system. Epidemiologic catchment area prospective 1-year 
prevalence rates of disorders and services. Archives of General 
Psychiatry. 1993;50:85-94 
436. Xian Y, Holloway RG, Smith EE, Schwamm L, Reeves MJ, Bhatt DL, et 
al. Racial/ethnic differences in process of care and outcomes 
among patients hospitalized with intracerebral hemorrhage. 
Stroke. 2014;45:3246-3250 
437. Ottenbacher KJ, Campbell J, Kuo YF, Deutsch A, Ostir GV, Granger 
CV. Racial and ethnic differences in postacute rehabilitation 
outcomes after stroke in the united states. Stroke. 2008;39:1514-
1519 
438. McNaughton H, Feigin V, Kerse N, Barber PA, Weatherall M, 
Bennett D, et al. Ethnicity and functional outcome after stroke. 
Stroke. 2010;42:960-964 
439. de Haan RJ, Limburg M, Van der Meulen JHP, Jacobs HM, Aaronson 
NK. Quality of life after stroke. Stroke. 1995;26:402-408 
440. Christensen MC, Mayer S, Ferran JM. Quality of life after 
intracerebral hemorrhage: Results of the factor seven for acute 
hemorrhagic stroke (fast) trial Stroke. 2009;40:1677-1682 
441. Pickle LW, Munigole M, Gilum RF. Geographic variation in stroke 
mortality in blacks and whites in the united states. Stroke. 
1997;28:1639-1647 
442. Lackland DT, Egan BM, Jones PJ. Impact of nativity and race on 
"stroke belt" mortality. Hypertension 1999;34:57-62 
443. Greenhalgh T. Papers that summarise other papers (systematic 
reviews and meta-analyses). BMJ. 1997;315:672-675 
444. Uman LS. Systematic reviews and meta-analyses. Journal of the 
Canadian Academy of Child and Adolescent Psychiatry. 2011;20:57-
59 
445. Crowther M, Lim W, Crowther MA. Systematic review and meta-
analysis methodology. Blood. 2010;116:3140-3146 
446. Higgins JPT, Green SG. Cochrane handbook for systematic reviews 
of interventions. 2011 
447. Higgins JPT, Altman DG, Sterne JAC, (editors). Chapter 8: Assessing 
risk of bias in included studies. . Cochrane Handbook for Systematic 
Reviews of Interventions Version 5.1.0 (updated March 2011). 2011 
 404 
 
448. Jadad AR, Moore RA, Caroll D, all. e. Assessing the quality of reports 
of randomized clinical trials: Is blinding necessary? Controlled 
Clinical Trials. 1996;17:1-12 
449. Ried K. Recommendations for examining and interpreting funnel 
plot asymmetry in meta-analyses of randomised controlled trials. . 
The Australian Family Physician. 2006;35 
450. Copas J, Qing JS. Meta-analysis, funnel plots and sensitivity analysis. 
Biostatistics. 2000;1:247-262 
451. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. 
Recommendations for examining and interpreting funnel plot 
asymmetry in meta-analyses of randomised controlled trials. BMJ. 
2011;343:d4002 
452. Sedgwick P. How to read a forest plot. BMJ. 2012;345:e8335 
453. Lewis S, Clarke M. Forest plots: Trying to see the wood and the 
trees. BMJ.322:1479-1480 
454. Britton M, de Faire U, Helmers C. Hazards of therapy for excessive 
hypertension in acute stroke. Acta Medical Scandinavia. 
1980;207:253-257 
455. Oppenheimer S, Hachinski V. Complications of acute stroke. Lancet. 
1992;339:721-724 
456. Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Tanaka R. Multivariate 
analysis of predictors of hematoma enlargement in spontaneous 
intracerebral hemorrhage. Stroke. 1998;29:1160-1166 
457. Geeganage CM, Bath PMW. Interventions for deliberately altering 
blood pressure in acute stroke. Stroke. 2009;40:390-391 
458. Sandset EC, Bath PM, Boysen G, Jatuzis D, Korv J, Luders S, et al. The 
angiotensin-receptor blocker candesartan for treatment of acute 
stroke (scast): A randomised, placebo-controlled, double-blind 
trial. Lancet. 2011;377:741-750 
459. Shaw L, Price C, McLure S, Howel D, McColl E, Younger P, et al. 
Paramedic initiated lisinopril for acute stroke treatment (pil-fast): 
Results from the pilot randomised controlled trial. Emerg Med J. 
2013 
460. Koch S, Romano JG, Forteza AM, Otero CM, Rabinstein AA. Rapid 
blood pressure reduction in acute intracerebral hemorrhage: 
Feasibility and safety. Neurocritical Care. 2008;8:316-321 
461. Higgins JPT, Green S. Cochrane handbook for systematic reviews of 
interventions 2011. 
462. Fagan SC, Gengo FM, Bates V, Levine SR, Kinkel WR. Effect of 
nimodipine on blood pressure in acute ischemic stroke in humans. 
Stroke. 1988;19:401-402 
463. Lisk DR, Grotta JC, Lamki LM, Tran HD, Taylor JW, Molony DA, et al. 
Should hypertension be treated after acute stroke? A randomized 
controlled trial using single photon emission computed 
tomography. Archives of Neurology. 1993;50:855-862 
464. Kenneth S. Butcher TJ, Michael Hill, Andrew M. Demchuk, Dariush 
Dowlatshahi, Shelagh B. Coutts, Bronwen Gould, Rebecca McCourt, 
Negar Asdaghi, J. Max Findlay, Derek Emery and Ashfaq Shuaib for 
 405 
 
the ICH ADAPT Investigators. The intracerebral hemorrhage 
acutely decreasing arterial pressure trial. Stroke. 2013;44:620-626 
465. Hillis AE, Ulatowski JA, Barker PB, Tobey M, Ziai W, Beauchamp NJ. 
A pilot randomised trial of induced blood pressure elevation: 
Effects on function and focal perfusion in acute and subacute 
stroke. Cerebrovascular  Diseases. 2003;16:236-248 
466. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. 
The access study: Evaluation of acute candesarten cilexetil therapy 
in stroke survivors. Stroke. 2003;34:1699-1703 
467. Eames PJ, Robinson TG, Panerai RB, Potter JF. Bendrofluazide fails 
to reduce elevated blood pressure levels in the immediate post-
stroke period. Cerebrovascular Diseases. 2005;19:253-259 
468. Eveson DJ, Robinson TG, Potter JF. Lisinopril for the treatment of 
hypertension within the first 24 hours of acute ischemic stroke and 
follow-up. American Journal of Hypertension. 2007;20:270-277 
469. Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, et al. 
Intensive blood pressure reduction in acute cerebral haemorrhage 
trial (interact): A randomised pilot trial. Lancet Neurol. 
2008;7:391-399 
470. He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, et al. Effects of 
immediate blood pressure reduction on death and major disability 
in patients with acute ischemic stroke: The catis randomized 
clinical trial. JAMA. 2013 
471. Bath PMW, Martin RH, Palesch Y, Cotton D, Yusuf S, Sacco R, et al. 
Effects of telmisartan on functional outcome, recurrence and blood 
pressure in patients with acute mild ischemic stroke: A profess 
subgroup analysis. Stroke. 2009;40:3541-3546 
472. Butcher KS, Jeerakathil T, Hill M, Demchuk AM, Dowlatshahi D, 
Coutts SB, et al. The intracerebral hemorrhage acutely decreasing 
arterial pressure trial. Stroke. 2013;44:620-626 
473. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. 
Rapid blood-pressure lowering in patients with acute intracerebral 
hemorrhage. N Engl J Med. 2013;368:2355-2365 
474. Sare GM, Ghadami A, Ankolekar S, England T, Hammonds F, Adrian 
M, et al. Effect of telmisartan on cerebral and systemic 
haemodynamics in patients with recent ischaemic stroke stroke: A 
randomised controlled trial. ISRN Stroke. 2013:1-9 
475. Uzuner N, Gucuyner D, Ozdemir G. The interaction between 
nimodipine and systemic blood pressure and pulse rate. Pan-
European consensus meeting on stroke management. 1995 
476. Dyker AG, Grosset DG, Lees K. Perindopril reduces blood pressure 
but not cerebral blood flow in patients with recent cerebral 
ischemic stroke. Stroke. 1997;28:580-583 
477. Willmot M, Ghadami A, Whysall B, Clarke W, Wardlaw J, Bath PMW. 
Transdermal glyceryl trinitrate lowers blood pressure and 
maintains cerebral blood flow in recent stroke. Hypertension. 
2006;47:1209-1215 
 406 
 
478. O'Brien. Acute candesartan cilexetil outcomes stroke trial (accost). 
2nd International Conference on Hypertension, Lipids, Diabetes and 
Stroke Prevention. 2008 
479. Bath PMW, Martin RH, Palesch Y, Cotton D, Yusuf S, Sacco R, et al. 
Effect of telmisartan on functional outcome, recurrence, and blood 
pressure in patients with acute mild ischemic stroke: A profess 
subgroup analysis. Stroke. 2009;40:3541-3546 
480. Yu K-H, Oh M-S, Hong K-S, Kang D-W, Park J-M, Bae H-J, et al. Safety 
and efficacy of modest blood pressure reduction with valsartan in 
acute ischemic stroke. International Stroke Conference Poster. 2013 
481. Bath PMW, Pathansali R, Bath F. The effect of transdermal glyceryl 
trinitrate, a nitric oxide donor on blood pressure and platelet 
function in acute stroke. Cerebrovascular  Diseases. 2000;11:265-
272 
482. Ankolekar S, Fuller M, Cross I, Renton C, Cox P, Sprigg N, et al. 
Feasibility of an ambulance-based stroke trial, and safety of 
glyceryl trinitrate in ultra-acute stroke the rapid intervention with 
glyceryl trinitrate in hypertensive stroke trial (right, 
isrctn66434824). Stroke; a journal of cerebral circulation. 
2013;44:3120-3128 
483. He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, et al. Effects of 
immediate blood pressure reduction on death and major disability 
in patients with acute ischemic stroke: The catis randomized 
clinical trial. JAMA. 2013;311:479-489 
484. Bath PMW, Pathansali R, Iddenden R, Bath FJ. The effect of nitric 
oxide, given as transdermal glyceryl trinitrate, on blood pressure in 
acute stroke. Cerebrovascular Diseases. 1999;9 Suppl 1:101 
485. Hosomi N, Sueda Y, Masugata H, Dobashi H, Murao K, Ueno M, et al. 
The optimal timing of antihypertensive medication administration 
for morning hypertension in patients with cerebral infarction. 
Hypertension Research. 2012;35:720-724 
486. Zanchetti A. Optimal blood pressure and cholesterol targets for 
preventing recurrent stroke in hypertensives esh-chl-shot. Clinical 
Trials. gov [NCT01563731]. 2013 
487. MAPAS trial investigators. Manipulation of arterial pressure in 
acute ischemic stroke. Clinical Trials. gov [NCT00848770]. 2009 
488. Stable ICAS investigators. Strategy for adequate blood pressure 
lowering in patients with intracranial atherosclerosis. Clinical 
Trials.gov [NCT011004311]. 2010 
489. Huang Y, Sharma VK, Robinson T, Lindley RI, Chen X, Kim JS, et al. 
Rationale, design, and progress of the enhanced control of 
hypertension and thrombolysis stroke study (enchanted) trial: An 
international multicenter 2 × 2 quasi-factorial randomized 
controlled trial of low- vs. Standard-dose rt-pa and early intensive 
vs. Guideline-recommended blood pressure lowering in patients 
with acute ischaemic stroke eligible for thrombolysis treatment. 
International Journal of Stroke. 2015;Epub ahead of print 
490. Sanossian N, on behalf of Field Administration of Stroke Therapy-
Blood Pressure Lowering (FAST-BP) investigators. Fast-bp: Field 
 407 
 
administration of stroke therapy- blood pressure lowering (fast-
bp). Clinical Trials. gov (NCT01811693). 2013 
491. Bang OY. Safety and efficacy of therapeutic induced hypertension in 
acute non-cardioembolic stroke. Clinical Trials. gov [NCT01600235]. 
2012 
492. Dyker AG, Grosset DG, Lees KR. Effect of perindopril in blood 
pressure and cerebral blood flow after ischaemic stroke. Heart 
Brain: Third Int.Conf.Stroke, Prague. 1995 
493. Bath P, Bath F, Rashid P, Weaver C. Large trial of effect of reducing 
blood pressure in acute stroke is being set up. BMJ. 2000;321:300 
494. Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JR. Low dose beta 
blockade in acute stroke ("best" trial): An evaluation. 
1988;296:737-741 
495. Jauch EC, Saver JL, Adams Jr HP, Connors B, Demaerschalk BM, 
Khatri P, et al. Guidelines for the early management of patients 
with acute ischemic stroke: A guideline for healthcare 
professionals from the american heart association/american stroke 
association. Stroke. 2013;44:870-947 
496. Morgensetern L, Hemphill J, Anderson C, Becker K, Broderick J, 
Connolly S, et al. Guidelines for the management of spontaneous 
intracerebral hemorrhage: A guideline for healthcare professionals 
from the american heart association/american stroke association. 
Stroke. 2010;41:2108-2129 
497. The European Stroke Organisation (ESO) Executive Committee and 
the ESO Writing Committee. Guidelines for management of 
ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc 
Dis. 2008;25:457-507 
498. Rodgers A, MacMahon S, Gamble G, Slattery J, Sandercock P, 
Warlow C, et al. Blood pressure and risk of stroke in patients with 
cerebrovascular disease. Br Med J. 1996;313:147 
499. MacMahon S, Neal B, Tzourio C, Rodgers A, Woodward M, Curler J, 
et al. Randomised trial of a perindopril-based blood-pressure-
lowering regimen among 6105 individuals with previous stroke or 
transient ischaemic attack. Lancet. 2001;358:1033-1041 
500. The Heart Outcomes Prevention Evaluation Study Investigators. 
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on 
cardiovascular events in high-risk patients. New Engl J Med. 
2000;342:145-153 
501. Willmot M, Leonardi-Bee J, Bath PMW. High blood pressure in 
acute stroke and subsequent outcome: A systematic review. 
Cerebrovascular Diseases. 2002;13 (suppl 3):95 (abstract) 
502. Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores S, 
Ehtisham Aa, et al. Effect of systolic blood pressure reduction on 
hematoma expansion, perihematomal edema, and 3-month 
outcome among patients with intracerebral hemorrhage results 
from the antihypertensive treatment of acute cerebral hemorrhage 
study. Archives of Neurology. 2010;67:570-576 
503. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale 
GM, Hope DT, et al. Early surgery versus initial conservative 
 408 
 
treatment in patients with spontaneous supratentorial 
intracerebral haematomas in the international surgical trial in 
intracerebral haemorrhage (stich): A randomised trial. Lancet. 
2005;365(9457):387-397 
504. Meretoja A, Churilov L, Campbell BC, Aviv RI, Yassi N, Barras C, et 
al. The spot sign and tranexamic acid on preventing ich growth-
australasia trial (stop-aust): Protocol of a phase ii randomized, 
placebo-controlled, double-blind, multicenter trial. International 
Journal of Stroke. 2014;9:519-524 
505. Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, 
hematoma expansion, and outcome of intracerebral hemorrhage. . 
Neurology. 2004:1059–1064. 
506. Vernooij MW, Haag MDM, van der Lugt A, Hofman A, Krestin GP, 
Stricker BH, et al. Use of antithrombotic drugs and the presence of 
cerebral microbleeds. The rotterdam scan study. Arch Neurol. 
2009;66:E1-7 
507. Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor 
blocker candesartan for treatment of acute stroke (scast): A 
randomised, placebo-controlled double-blind trial. Lancet. 
2011;377:741-750 
508. Manning LS, Mistri AK, Potter J, Rothwell PM, Robinson TG. Short-
term blood pressure variability in acute stroke: Post hoc analysis of 
the controlling hypertension and hypotension immediately post 
stroke and continue or stop post-stroke antihypertensives 
collaborative study trials. Stroke. 2015;[Epub ahead of print] 
509. Manning L, Hirakawa Y, Arima H, Wang X, Chalmers J, Wang J, et al. 
Blood pressure variability and outcome after acute intracerebral 
haemorrhage: A post-hoc analysis of interact2, a randomised 
controlled trial. The Lancet Neurology. 2014;13:364-373 
510. Sukhotinsky I, Dilekoz E, Moskowitz MA, Ayata C. Hypoxia and 
hypotension transform the blood flow response to cortical 
spreading depression from hyperemia into hypoperfusion in the 
rat. Journal of Cerebral Blood Flow and Metabolism. 2008;28:1369-
1376 
511. Sukhotinsky I, Yaseen MA, Sakadzic S, Ruvinskaya S, Sims JR, Boas 
DA, et al. Perfusion pressure-dependent recovery of cortical 
spreading depression is independent of tissue oxygenation over a 
wide physiologic range. Journal of Cerebral Blood Flow and 
Metabolism. 2010;30:1168-1177 
512. Wong AA, Davis JP, Schluter PJ, Henderson RD, O' Sullivan JD, Read 
SJ. The time course and determinants of blood pressure within the 
first 48 hours after ischaemic stroke. Cerebrovascular Diseases. 
2007;24:426-433 
513. Broderick JP, Diringer MN, Hill MD, Brun NC, Mayer SA, Steiner T, et 
al. Determinants of intracerebral hemorrhage growth: An 
exploratory analysis. Stroke. 2007;38:1072-1075 
514. Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, Molina CA, Silva 
Blas Y, Dzialowski I, et al. Prediction of haematoma growth and 
outcome in patients with intracerebral haemorrhage using the ct-
 409 
 
angiography spot sign (predict): A prospective observational study. 
Lancet Neurology. 2012;11:307-314 
515. Becker KJ, Baxter AB, Bybee HM, Tirschwell DL, Abouelsaad T, 
Cohen WA. Extravasation of radiographic contrast is an 
independent predictor of death in primary intracerebral 
hemorrhage. Stroke. 1999;30:20125-22032 
516. Wahlgren NG, Macmahon DG, Dekeyser J, Indredavik B, Ryman T. 
Intravenous nimodipine west european stroke trial (inwest) of 
nimodipine in the treatment of acute ischaemic stroke. 
Cerebrovascular Diseases. 1994;4:204-210 
517. The Intercollegiate Stroke working party of the Royal College of 
Physicians. National clinical guideline for stroke. 2012;4th Edition 
518. Nguyen-Huynh MN, Johnston SC. Regional variation in 
hospitalization for stroke among asians/pacific islanders in the 
united states: A nationwide retrospective cohort study. BMC 
Neurology. 2005;5 
519. Ayala C, Greenlund HJ, Croft JB, Keenan NL, Donehoo RS, Giles WH, 
et al. Racial/ethnic disparities in mortality by stroke subtype in the 
united states, 1995-1998. American Journal of Epidemiology. 
2001;154:1057-1063 
520. Gokhale S, Caplan LR, James ML. Sex differences in incidence, 
pathophysiology and outcome of primary intracerebral 
hemorrhage. Stroke. 2015;46:886-892 
521. T Inagawa NO, A Takechi, M Shibukawa, K Yahara. Primary 
intracerebral hemorrhage in izumo city, japan: Incidence rates and 
outcome in relation to the site of hemorrhage. Neurosurgery. 
2003:1283-1297 
522. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, et al. 
Trends in the incidence, mortality, and survival rate of 
cardiovascular disease in a japanese community: The hisayama 
study. Stroke. 2003;23:2349-2354 
523. Jiang B, Wang WZ, Chen H, Hong Z, Yang QD, Wu SP, et al. Incidence 
and trends of stroke and its subtypes in china: Results from three 
large cities. Stroke. 2006;37:63-68 
524. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, 
et al. Intensive blood-pressure lowering in patients with acute 
cerebral hemorrhage. New England Journal of Medicine. 2016;[Epub 
ahead of print] 
525. Bath PMW, on behalf of The Rapid Intervention with Glyceryl 
trinitrate in Hypertensive stroke investigators. Right 2: Rapid 
intervention with glyceryl trinitrate in hypertensive stroke trial-2.  
526. Hornslein AG, Sandset EC, Igland J, Terent A, Boysen G, Bath PM, et 
al. Effects of candesartan in acute stroke on vascular events during 
long-term follow-up: Results from the scandinavian candesartan 
acute stroke trial (scast). International Journal of Stroke. 
2015;10:830-835 
527. Huczynski J, Kostka-Trabka E, Sotowska W, Bieron K, Grodzinska L, 
Dembinska-Kiec A, et al. Double-blind controlled trial of the 
 410 
 
therapeutic effects of prostacyclin in patients with completed 
ischaemic stroke. Stroke. 1985;16:810-814 
 
 411 
 
APPENDIX I 
 
Flow chart of the number of CT scans from the ENOS trial used to assess intra and inter observer reliability 
 
 
 
*Only 23 of 548 scans were amenable to analysis using AVC 
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APPENDIX II 
 
This section lists the search terms used in Chapter 8 for a 
systematic review and meta-analysis of trials which 
deliberately altered blood pressure in acute stroke.  
 
MEDLINE search strategy 
 
1. blood pressure.tw.  
2. hypertension.tw  
3. acute/ 
4. stroke.tw. 
5. or/1-4 
6. and/1-4 
7. 1-4.kf. 
8.1-4.ti. 
9. trials 
10. 1-4 and 9 
11. 1-4 and 9.ti. 
12. ischaemic stroke.tw/ti. 
13. haemorrhagic stroke.tw/ti. 
14. intracerebral haemorrhage.tw./ti.  
15. blood pressure lowering/ 
16. blood pressure increase/ 
17. 1-4 or 12 
18. 1-4 or 13 
19. 1-4 or 14 
20. 1-4 and 15 
21.1-4 and 16 
22. cerebr 
23. 1-4 or 22 
24. vasoactive/ 
25. 12-16 or 24 
26. nitrate.tw. 
27. glyceryl trinitrate/GTN.tw 
28. nitric Oxide Donors.tw. 
29. 1-4 and/or 26-28 
30. 9, 12-13, 16 and/or 26-28 
31. thiazide.tw. 
32. bendrofluazide.tw. 
33. bendroflumethiazide.tw. 
34. hydrochrlothiazide/HCT.tw. 
35. 31-34 and/or 1-4 
36. 31-34 and/or 12-15 
37. beta blockers.tw 
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38. atenolol.tw. 
39. propanalol.tw. 
40. 37-39 and/or 1-4 
41. 37-39 and or 12-15 
42. calcium channel blockers.tw. 
43. nimodipine.tw. 
44. nicardipine.tw. 
45. amilodipine.tw. 
46. felodipine.tw. 
47. isradipine.tw. 
48. nifedipine.tw. 
49. nisolodipine.tw. 
50. 42-49 and or 1-4 
51. 42-49 and or 12-15 
52. angiotensin-converting enzyme inhibitors/ACE 
inhibitors.tw  
53. captopril.tw. 
54. enalapril.tw. 
55. lisinopril.tw. 
56. perindopril.tw. 
57. ramipril.tw. 
58. 52-57 and or 1-4 
59. 52-57 and or 12-15 
60. angiotensin receptor blockers/antagonists.tw. 
61. candesartan.tw 
62. losartan.tw. 
63. telmisartan.tw 
64. valsartan.tw. 
65. clonidine.tw. 
65. 60-65 and or 1-4 
66. 60-65 and or 12-15 
67. vasoconstrictors.tw. 
68. dopamine.tw. 
69. dobutamine.tw. 
70. noradrenaline.tw. 
71. phenylephrine.tw. 
72. 67-71 and or 3, 4, 9, 16 
73. cerebral blood flow 
74. autoregulation 
75. stroke outcome 
76. 73-75 and or 1-4 
77. 73-75 and or 12-16 
 
EMBASE search strategy 
 
1. blood pressure.tw.  
2. hypertension.tw  
 414 
 
3. acute/ 
4. stroke.tw. 
5. or/1-4 
6. and/1-4 
7. 1-4.kf. 
8.1-4.ti. 
9. trials 
10. 1-4 and 9 
11. 1-4 and 9.ti. 
12. ischaemic stroke.tw/ti. 
13. haemorrhagic stroke.tw/ti. 
14. intracerebral haemorrhage.tw./ti.  
15. blood pressure lowering/ 
16. blood pressure increase/ 
17. 1-4 or 12 
18. 1-4 or 13 
19. 1-4 or 14 
20. 1-4 and 15 
21.1-4 and 16 
22. cerebr 
23. 1-4 or 22 
24. vasoactive/ 
25. 12-16 or 24 
26. nitrate.tw. 
27. glyceryl trinitrate/GTN.tw  
28. nitric Oxide Donors.tw.  
29. 1-4 and/or 26-28 
30. 9, 12-13, 16 and/or 26-28  
31. thiazide.tw. 
32. bendrofluazide.tw. 
33. bendroflumethiazide.tw. 
34. hydrochrlothiazide/HCT.tw.  
35. 31-34 and/or 1-4 
36. 31-34 and/or 12-15  
37. beta blockers.tw  
38. atenolol.tw. 
39. propanalol.tw. 
40. 37-39 and/or 1-4 
41. 37-39 and or 12-15 
42. calcium channel blockers.tw. 
43. nimodipine.tw. 
44. nicardipine.tw. 
45. amilodipine.tw. 
46. felodipine.tw. 
47. isradipine.tw. 
48. nifedipine.tw. 
49. nisolodipine.tw. 
 415 
 
50. 42-49 and or 1-4 
51. 42-49 and or 12-15 
52. angiotensin-converting enzyme inhibitors/ACE 
inhibitors.tw  
53. captopril.tw. 
54. enalapril.tw. 
55. lisinopril.tw. 
56. perindopril.tw. 
57. ramipril.tw. 
58. 52-57 and or 1-4 
59. 52-57 and or 12-15 
60. angiotensin receptor blockers/antagonists.tw. 
61. candesartan.tw 
62. losartan.tw. 
63. telmisartan.tw 
64. valsartan.tw. 
65. clonidine.tw. 
65. 60-65 and or 1-4 
66. 60-65 and or 12-15 
67. vasoconstrictors.tw. 
68. dopamine.tw. 
69. dobutamine.tw. 
70. noradrenaline.tw. 
71. phenylephrine.tw. 
72. 67-71 and or 3, 4, 9, 16 
73. cerebral blood flow  
74. autoregulation 
75. stroke outcome 
76. 73-75 and or 1-4 77. 73-75 and or 12-16 
 
Science Citation Index search strategy 
1. blood pressure.TI.  
2. hypertension.TI  
3. acute/ 
4. stroke.TS. 
5. OR/1-4 
6. AND/1-4 
7. 1-4.TI. 
8.1-4.TI. 
9. trials 
10. 1-4 AND 9 
11. 1-4 AND 9.ti. 
12. ischaemic stroke.TI/TS. 
13. haemorrhagic stroke.TI/TS. 
14. intracerebral haemorrhage.TI./TS.  
15. blood pressure lowering/ 
16. blood pressure increase/ 
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17. 1-4 OR 12 
18. 1-4 OR 13 
19. 1-4 OR 14 
20. 1-4 AND 15 
21.1-4 AND 16 
22. cerebr 
23. 1-4 OR 22 
24. vasoactive/ 
25. 12-16 OR 24 
26. nitrate.TI./TS 
27. glyceryl trinitrate/GTN.TI/TS  
28. nitric Oxide Donors.TI./TS 
29. 1-4 AND/OR 26-28 
30. 9, 12-13, 16 AND/OR 26-28 
31. thiazide.TI. 
32. bendrofluazide.TI. 
33. bendroflumethiazide.TI. 
34. hydrochrlothiazide/HCT.TI. 
35. 31-34 AND/OR 1-4 
36. 31-34 AND/OR 12-15 
37. beta blockers.TI 
38. atenolol.TI. 
39. propanalol.TI. 
40. 37-39 AND/OR 1-4 
41. 37-39 AND/OR 12-15 
42. calcium channel blockers.TI. 
43. nimodipine.TI. 
44. nicardipine.TI. 
